[{"text": "Famotidine-associated delirium.", "entity_list": [{"name": "Famotidine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D015738", "tok_span": [0, 3]}, {"name": "delirium", "ent_type": "Disease", "char_span": [22, 30], "ent_id": "D003693", "tok_span": [5, 8]}], "relation_list": [{"subject": "Famotidine", "object": "delirium", "sbj_char_span": [0, 10], "obj_char_span": [22, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Although all of the currently available H2-receptor antagonists have shown the propensity to cause delirium, only two previously reported cases have been associated with famotidine.", "entity_list": [{"name": "famotidine", "ent_type": "Chemical", "char_span": [170, 180], "ent_id": "D015738", "tok_span": [30, 34]}, {"name": "delirium", "ent_type": "Disease", "char_span": [99, 107], "ent_id": "D003693", "tok_span": [17, 20]}], "relation_list": [{"subject": "famotidine", "object": "delirium", "sbj_char_span": [170, 180], "obj_char_span": [99, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "The authors report on six cases of famotidine-associated delirium in hospitalized patients who cleared completely upon removal of famotidine.", "entity_list": [{"name": "delirium", "ent_type": "Disease", "char_span": [57, 65], "ent_id": "D003693", "tok_span": [13, 16]}, {"name": "famotidine", "ent_type": "Chemical", "char_span": [35, 45], "ent_id": "D015738", "tok_span": [7, 11]}, {"name": "famotidine", "ent_type": "Chemical", "char_span": [130, 140], "ent_id": "D015738", "tok_span": [25, 29]}], "relation_list": [{"subject": "famotidine", "object": "delirium", "sbj_char_span": [130, 140], "obj_char_span": [57, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [13, 16]}, {"subject": "famotidine", "object": "delirium", "sbj_char_span": [35, 45], "obj_char_span": [57, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Indomethacin induced hypotension in sodium and volume depleted rats.", "entity_list": [{"name": "Indomethacin", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D007213", "tok_span": [0, 3]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [21, 32], "ent_id": "D007022", "tok_span": [4, 5]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [36, 42], "ent_id": "D012964", "tok_span": [6, 7]}], "relation_list": [{"subject": "Indomethacin", "object": "hypotension", "sbj_char_span": [0, 12], "obj_char_span": [21, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.", "entity_list": [{"name": "SSc", "ent_type": "Disease", "char_span": [113, 116], "ent_id": "D012595", "tok_span": [19, 21]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [83, 95], "ent_id": "D016572", "tok_span": [14, 16]}, {"name": "thrombotic microangiopathy", "ent_type": "Disease", "char_span": [40, 66], "ent_id": "D057049", "tok_span": [7, 12]}], "relation_list": [{"subject": "cyclosporine", "object": "thrombotic microangiopathy", "sbj_char_span": [83, 95], "obj_char_span": [40, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [7, 12]}], "umls_entity_list": []}, {"text": "The aim of this work is to call attention to the risk of tacrolimus use in patients with SSc.", "entity_list": [{"name": "tacrolimus", "ent_type": "Chemical", "char_span": [57, 67], "ent_id": "D016559", "tok_span": [13, 15]}, {"name": "SSc", "ent_type": "Disease", "char_span": [89, 92], "ent_id": "D012595", "tok_span": [19, 21]}], "relation_list": [{"subject": "tacrolimus", "object": "SSc", "sbj_char_span": [57, 67], "obj_char_span": [89, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia.", "entity_list": [{"name": "psychosis", "ent_type": "Disease", "char_span": [51, 60], "ent_id": "D011605", "tok_span": [9, 10]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [64, 79], "ent_id": "D008694", "tok_span": [11, 14]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [35, 50], "ent_id": "D008694", "tok_span": [6, 9]}], "relation_list": [{"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [64, 79], "obj_char_span": [51, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [9, 10]}, {"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [35, 50], "obj_char_span": [51, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "OBJECTIVE: The objective of this study was to determine the risk of lifetime and current methamphetamine-induced psychosis in patients with methamphetamine dependence.", "entity_list": [{"name": "psychosis", "ent_type": "Disease", "char_span": [113, 122], "ent_id": "D011605", "tok_span": [21, 22]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [89, 104], "ent_id": "D008694", "tok_span": [16, 19]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [140, 155], "ent_id": "D008694", "tok_span": [25, 28]}], "relation_list": [{"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [89, 104], "obj_char_span": [113, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [21, 22]}, {"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [140, 155], "obj_char_span": [113, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "The association between psychiatric co-morbidity and methamphetamine-induced psychosis was also studied.", "entity_list": [{"name": "psychosis", "ent_type": "Disease", "char_span": [77, 86], "ent_id": "D011605", "tok_span": [13, 14]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [53, 68], "ent_id": "D008694", "tok_span": [8, 11]}], "relation_list": [{"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [53, 68], "obj_char_span": [77, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Patients with the diagnosis of methamphetamine based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for methamphetamine-induced psychosis and other Axis I psychiatric disorders.", "entity_list": [{"name": "methamphetamine", "ent_type": "Chemical", "char_span": [151, 166], "ent_id": "D008694", "tok_span": [33, 36]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [31, 46], "ent_id": "D008694", "tok_span": [5, 8]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [175, 184], "ent_id": "D011605", "tok_span": [38, 39]}, {"name": "psychiatric disorders", "ent_type": "Disease", "char_span": [202, 223], "ent_id": "D001523", "tok_span": [44, 46]}], "relation_list": [{"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [31, 46], "obj_char_span": [175, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [38, 39]}, {"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [151, 166], "obj_char_span": [175, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [38, 39]}], "umls_entity_list": []}, {"text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "entity_list": [{"name": "bipolar disorder", "ent_type": "Disease", "char_span": [67, 83], "ent_id": "D001714", "tok_span": [29, 31]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [280, 289], "ent_id": "D011605", "tok_span": [93, 94]}, {"name": "depressive disorder", "ent_type": "Disease", "char_span": [16, 35], "ent_id": "D003866", "tok_span": [6, 8]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [256, 271], "ent_id": "D008694", "tok_span": [88, 91]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [191, 206], "ent_id": "D008694", "tok_span": [79, 82]}, {"name": "antisocial personality disorder", "ent_type": "Disease", "char_span": [117, 148], "ent_id": "D000987", "tok_span": [52, 56]}], "relation_list": [{"subject": "methamphetamine", "object": "antisocial personality disorder", "sbj_char_span": [191, 206], "obj_char_span": [117, 148], "rel_type": "chemical-induced disease", "sbj_tok_span": [79, 82], "obj_tok_span": [52, 56]}, {"subject": "methamphetamine", "object": "bipolar disorder", "sbj_char_span": [256, 271], "obj_char_span": [67, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [88, 91], "obj_tok_span": [29, 31]}, {"subject": "methamphetamine", "object": "bipolar disorder", "sbj_char_span": [191, 206], "obj_char_span": [67, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [79, 82], "obj_tok_span": [29, 31]}, {"subject": "methamphetamine", "object": "antisocial personality disorder", "sbj_char_span": [256, 271], "obj_char_span": [117, 148], "rel_type": "chemical-induced disease", "sbj_tok_span": [88, 91], "obj_tok_span": [52, 56]}, {"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [191, 206], "obj_char_span": [280, 289], "rel_type": "chemical-induced disease", "sbj_tok_span": [79, 82], "obj_tok_span": [93, 94]}, {"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [256, 271], "obj_char_span": [280, 289], "rel_type": "chemical-induced disease", "sbj_tok_span": [88, 91], "obj_tok_span": [93, 94]}], "umls_entity_list": []}, {"text": "CONCLUSION: There was a high risk of psychosis in patients with methamphetamine dependence.", "entity_list": [{"name": "psychosis", "ent_type": "Disease", "char_span": [37, 46], "ent_id": "D011605", "tok_span": [8, 9]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [64, 79], "ent_id": "D008694", "tok_span": [12, 15]}], "relation_list": [{"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [64, 79], "obj_char_span": [37, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "It was associated with co-morbid affective disorder, antisocial personality, and heavy methamphetamine use.", "entity_list": [{"name": "methamphetamine", "ent_type": "Chemical", "char_span": [87, 102], "ent_id": "D008694", "tok_span": [18, 21]}, {"name": "affective disorder", "ent_type": "Disease", "char_span": [33, 51], "ent_id": "D019964", "tok_span": [9, 11]}, {"name": "antisocial personality", "ent_type": "Disease", "char_span": [53, 75], "ent_id": "D000987", "tok_span": [12, 15]}], "relation_list": [{"subject": "methamphetamine", "object": "antisocial personality", "sbj_char_span": [87, 102], "obj_char_span": [53, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "It is recommended that all cases of methamphetamine dependence should be screened for psychotic symptoms.", "entity_list": [{"name": "methamphetamine", "ent_type": "Chemical", "char_span": [36, 51], "ent_id": "D008694", "tok_span": [7, 10]}, {"name": "psychotic symptoms", "ent_type": "Disease", "char_span": [86, 104], "ent_id": "D011605", "tok_span": [15, 18]}], "relation_list": [{"subject": "methamphetamine", "object": "psychotic symptoms", "sbj_char_span": [36, 51], "obj_char_span": [86, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and levodopa-induced dyskinesias (LIDs) is severely impaired.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [90, 98], "ent_id": "D007980", "tok_span": [21, 24]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [61, 80], "ent_id": "D010300", "tok_span": [13, 17]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [107, 118], "ent_id": "D004409", "tok_span": [26, 30]}, {"name": "PD", "ent_type": "Disease", "char_span": [82, 84], "ent_id": "D010300", "tok_span": [18, 19]}, {"name": "LIDs", "ent_type": "Disease", "char_span": [120, 124], "ent_id": "D004409", "tok_span": [31, 33]}], "relation_list": [{"subject": "levodopa", "object": "LIDs", "sbj_char_span": [90, 98], "obj_char_span": [120, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [31, 33]}, {"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [90, 98], "obj_char_span": [107, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide-induced cystitis in rats.", "entity_list": [{"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [62, 78], "ent_id": "D003520", "tok_span": [14, 17]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [87, 95], "ent_id": "D003556", "tok_span": [19, 21]}], "relation_list": [{"subject": "cyclophosphamide", "object": "cystitis", "sbj_char_span": [62, 78], "obj_char_span": [87, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (CYP)-induced cystitis in rats.", "entity_list": [{"name": "CYP", "ent_type": "Chemical", "char_span": [120, 123], "ent_id": "D003520", "tok_span": [27, 28]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [102, 118], "ent_id": "D003520", "tok_span": [23, 26]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [133, 141], "ent_id": "D003556", "tok_span": [31, 33]}], "relation_list": [{"subject": "cyclophosphamide", "object": "cystitis", "sbj_char_span": [102, 118], "obj_char_span": [133, 141], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [31, 33]}, {"subject": "CYP", "object": "cystitis", "sbj_char_span": [120, 123], "obj_char_span": [133, 141], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "Spontaneous pain behaviors following the administration of CYP were observed.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [12, 16], "ent_id": "D010146", "tok_span": [2, 3]}, {"name": "CYP", "ent_type": "Chemical", "char_span": [59, 62], "ent_id": "D003520", "tok_span": [8, 9]}], "relation_list": [{"subject": "CYP", "object": "pain", "sbj_char_span": [59, 62], "obj_char_span": [12, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "RESULTS: Cyclophosphamide treatment increased the spontaneous pain behaviors scores.", "entity_list": [{"name": "Cyclophosphamide", "ent_type": "Chemical", "char_span": [9, 25], "ent_id": "D003520", "tok_span": [2, 4]}, {"name": "pain", "ent_type": "Disease", "char_span": [62, 66], "ent_id": "D010146", "tok_span": [8, 9]}], "relation_list": [{"subject": "Cyclophosphamide", "object": "pain", "sbj_char_span": [9, 25], "obj_char_span": [62, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: In CYP-induced cystitis, the expression of P2X3 and NK1 receptors increased in urothelium and/or suburothelium.", "entity_list": [{"name": "CYP", "ent_type": "Chemical", "char_span": [16, 19], "ent_id": "D003520", "tok_span": [3, 4]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [28, 36], "ent_id": "D003556", "tok_span": [6, 8]}], "relation_list": [{"subject": "CYP", "object": "cystitis", "sbj_char_span": [16, 19], "obj_char_span": [28, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Acute hepatitis associated with clopidogrel: a case report and review of the literature.", "entity_list": [{"name": "clopidogrel", "ent_type": "Chemical", "char_span": [32, 43], "ent_id": "C055162", "tok_span": [4, 6]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [6, 15], "ent_id": "D056486", "tok_span": [1, 2]}], "relation_list": [{"subject": "clopidogrel", "object": "hepatitis", "sbj_char_span": [32, 43], "obj_char_span": [6, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "We describe a case of clopidogrel-related acute hepatitis.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [48, 57], "ent_id": "D056486", "tok_span": [10, 11]}, {"name": "clopidogrel", "ent_type": "Chemical", "char_span": [22, 33], "ent_id": "C055162", "tok_span": [5, 7]}], "relation_list": [{"subject": "clopidogrel", "object": "hepatitis", "sbj_char_span": [22, 33], "obj_char_span": [48, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Reports about cases of hepatotoxicity due to clopidogrel are increasing in the last few years, after the increased use of this drug.", "entity_list": [{"name": "clopidogrel", "ent_type": "Chemical", "char_span": [45, 56], "ent_id": "C055162", "tok_span": [8, 10]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [23, 37], "ent_id": "D056486", "tok_span": [4, 6]}], "relation_list": [{"subject": "clopidogrel", "object": "hepatotoxicity", "sbj_char_span": [45, 56], "obj_char_span": [23, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "In conclusion, we believe that physicians should carefully consider the risk of drug-induced hepatic injury when clopidogrel is prescribed.", "entity_list": [{"name": "hepatic injury", "ent_type": "Disease", "char_span": [93, 107], "ent_id": "D056486", "tok_span": [16, 18]}, {"name": "clopidogrel", "ent_type": "Chemical", "char_span": [113, 124], "ent_id": "C055162", "tok_span": [19, 21]}], "relation_list": [{"subject": "clopidogrel", "object": "hepatic injury", "sbj_char_span": [113, 124], "obj_char_span": [93, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Pubertal exposure to Bisphenol A increases anxiety-like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice.", "entity_list": [{"name": "anxiety", "ent_type": "Disease", "char_span": [43, 50], "ent_id": "D001008", "tok_span": [10, 11]}, {"name": "Bisphenol A", "ent_type": "Chemical", "char_span": [21, 32], "ent_id": "C006780", "tok_span": [5, 9]}], "relation_list": [{"subject": "Bisphenol A", "object": "anxiety", "sbj_char_span": [21, 32], "obj_char_span": [43, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Results from our behavioral phenotyping indicated that anxiety-like behavior was increased in mice exposed to BPA.", "entity_list": [{"name": "BPA", "ent_type": "Chemical", "char_span": [110, 113], "ent_id": "C006780", "tok_span": [18, 20]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [55, 62], "ent_id": "D001008", "tok_span": [8, 9]}], "relation_list": [{"subject": "BPA", "object": "anxiety", "sbj_char_span": [110, 113], "obj_char_span": [55, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "Our findings showed that pubertal BPA exposure increased anxiety-like behavior, which may be associated with decreased AChE activity of the hippocampus in adult male mice.", "entity_list": [{"name": "anxiety", "ent_type": "Disease", "char_span": [57, 64], "ent_id": "D001008", "tok_span": [10, 11]}, {"name": "BPA", "ent_type": "Chemical", "char_span": [34, 37], "ent_id": "C006780", "tok_span": [6, 8]}], "relation_list": [{"subject": "BPA", "object": "anxiety", "sbj_char_span": [34, 37], "obj_char_span": [57, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats.", "entity_list": [{"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [129, 143], "ent_id": "D066126", "tok_span": [27, 29]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [107, 120], "ent_id": "D007545", "tok_span": [21, 25]}], "relation_list": [{"subject": "isoproterenol", "object": "cardiotoxicity", "sbj_char_span": [107, 120], "obj_char_span": [129, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [48, 58], "ent_id": "D004409", "tok_span": [10, 14]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [31, 39], "ent_id": "D007980", "tok_span": [5, 8]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [93, 112], "ent_id": "D010300", "tok_span": [21, 25]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [31, 39], "obj_char_span": [48, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [115, 125], "ent_id": "D004409", "tok_span": [23, 27]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [18, 26], "ent_id": "D007980", "tok_span": [3, 6]}, {"name": "PD", "ent_type": "Disease", "char_span": [60, 62], "ent_id": "D010300", "tok_span": [13, 14]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [39, 58], "ent_id": "D010300", "tok_span": [8, 12]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [18, 26], "obj_char_span": [115, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [61, 71], "ent_id": "D004409", "tok_span": [12, 16]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [44, 52], "ent_id": "D007980", "tok_span": [7, 10]}, {"name": "PD", "ent_type": "Disease", "char_span": [114, 116], "ent_id": "D010300", "tok_span": [24, 25]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [44, 52], "obj_char_span": [61, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Dyskinesia was present in 44% (n = 42) with median levodopa therapy of 3 years.", "entity_list": [{"name": "Dyskinesia", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D004409", "tok_span": [0, 4]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [51, 59], "ent_id": "D007980", "tok_span": [16, 19]}], "relation_list": [{"subject": "levodopa", "object": "Dyskinesia", "sbj_char_span": [51, 59], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without dyskinesia.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [166, 174], "ent_id": "D007980", "tok_span": [50, 53]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [259, 269], "ent_id": "D004409", "tok_span": [81, 85]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [78, 86], "ent_id": "D007980", "tok_span": [22, 25]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [14, 24], "ent_id": "D004409", "tok_span": [2, 6]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [166, 174], "obj_char_span": [259, 269], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 53], "obj_tok_span": [81, 85]}, {"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [166, 174], "obj_char_span": [14, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 53], "obj_tok_span": [2, 6]}, {"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [78, 86], "obj_char_span": [14, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [2, 6]}, {"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [78, 86], "obj_char_span": [259, 269], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [81, 85]}], "umls_entity_list": []}, {"text": "The three significant predictors of dyskinesia were duration of levodopa therapy, onset age, and total daily levodopa dose.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [109, 117], "ent_id": "D007980", "tok_span": [23, 26]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [36, 46], "ent_id": "D004409", "tok_span": [5, 9]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [64, 72], "ent_id": "D007980", "tok_span": [12, 15]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [109, 117], "obj_char_span": [36, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [5, 9]}, {"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [64, 72], "obj_char_span": [36, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: The prevalence of levodopa-induced dyskinesia in our patients was 44%.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [48, 58], "ent_id": "D004409", "tok_span": [10, 14]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [31, 39], "ent_id": "D007980", "tok_span": [5, 8]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [31, 39], "obj_char_span": [48, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL amyloidosis.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [59, 70], "ent_id": "D011507", "tok_span": [10, 11]}, {"name": "everolimus", "ent_type": "Chemical", "char_span": [84, 94], "ent_id": "C107135", "tok_span": [13, 16]}, {"name": "amyloidosis", "ent_type": "Disease", "char_span": [99, 110], "ent_id": "D000686", "tok_span": [18, 20]}, {"name": "AL", "ent_type": "Disease", "char_span": [96, 98], "ent_id": "D000686", "tok_span": [17, 18]}], "relation_list": [{"subject": "everolimus", "object": "proteinuria", "sbj_char_span": [84, 94], "obj_char_span": [59, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [10, 11]}, {"subject": "everolimus", "object": "AL", "sbj_char_span": [84, 94], "obj_char_span": [96, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [17, 18]}, {"subject": "everolimus", "object": "amyloidosis", "sbj_char_span": [84, 94], "obj_char_span": [99, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [178, 189], "ent_id": "D011507", "tok_span": [31, 32]}, {"name": "amyloidosis", "ent_type": "Disease", "char_span": [51, 62], "ent_id": "D000686", "tok_span": [9, 11]}, {"name": "everolimus", "ent_type": "Chemical", "char_span": [226, 236], "ent_id": "C107135", "tok_span": [38, 41]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [212, 222], "ent_id": "D016559", "tok_span": [35, 37]}], "relation_list": [{"subject": "everolimus", "object": "proteinuria", "sbj_char_span": [226, 236], "obj_char_span": [178, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [31, 32]}, {"subject": "everolimus", "object": "amyloidosis", "sbj_char_span": [226, 236], "obj_char_span": [51, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.", "entity_list": [{"name": "glomerular dysfunction", "ent_type": "Disease", "char_span": [198, 220], "ent_id": "D007674", "tok_span": [47, 49]}, {"name": "TDF", "ent_type": "Chemical", "char_span": [68, 71], "ent_id": "C418563", "tok_span": [15, 17]}, {"name": "Fanconi syndrome", "ent_type": "Disease", "char_span": [238, 254], "ent_id": "D005198", "tok_span": [56, 60]}, {"name": "kidney disease", "ent_type": "Disease", "char_span": [80, 94], "ent_id": "D007674", "tok_span": [19, 21]}, {"name": "kidney tubular dysfunction", "ent_type": "Disease", "char_span": [130, 156], "ent_id": "D007674", "tok_span": [32, 35]}], "relation_list": [{"subject": "TDF", "object": "Fanconi syndrome", "sbj_char_span": [68, 71], "obj_char_span": [238, 254], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [56, 60]}], "umls_entity_list": []}, {"text": "The incidence of hospitalisation for TDF kidney adverse effects was high, particularly amongst patients with features of Fanconi syndrome.", "entity_list": [{"name": "Fanconi syndrome", "ent_type": "Disease", "char_span": [121, 137], "ent_id": "D005198", "tok_span": [20, 24]}, {"name": "TDF", "ent_type": "Chemical", "char_span": [37, 40], "ent_id": "C418563", "tok_span": [6, 8]}], "relation_list": [{"subject": "TDF", "object": "Fanconi syndrome", "sbj_char_span": [37, 40], "obj_char_span": [121, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02).", "entity_list": [{"name": "propofol", "ent_type": "Chemical", "char_span": [108, 116], "ent_id": "D015742", "tok_span": [24, 26]}, {"name": "thiopentone", "ent_type": "Chemical", "char_span": [11, 22], "ent_id": "D013874", "tok_span": [3, 7]}, {"name": "delirium", "ent_type": "Disease", "char_span": [87, 95], "ent_id": "D003693", "tok_span": [19, 22]}], "relation_list": [{"subject": "thiopentone", "object": "delirium", "sbj_char_span": [11, 22], "obj_char_span": [87, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.", "entity_list": [{"name": "neurotoxic", "ent_type": "Disease", "char_span": [9, 19], "ent_id": "D020258", "tok_span": [2, 4]}, {"name": "depressive", "ent_type": "Disease", "char_span": [67, 77], "ent_id": "D003866", "tok_span": [14, 15]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [28, 43], "ent_id": "D008694", "tok_span": [6, 9]}], "relation_list": [{"subject": "methamphetamine", "object": "depressive", "sbj_char_span": [28, 43], "obj_char_span": [67, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal.", "entity_list": [{"name": "METH", "ent_type": "Chemical", "char_span": [17, 21], "ent_id": "D008694", "tok_span": [4, 6]}, {"name": "Methamphetamine", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D008694", "tok_span": [0, 3]}, {"name": "METH", "ent_type": "Chemical", "char_span": [77, 81], "ent_id": "D008694", "tok_span": [16, 18]}, {"name": "depressive symptoms", "ent_type": "Disease", "char_span": [133, 152], "ent_id": "D003866", "tok_span": [25, 27]}], "relation_list": [{"subject": "METH", "object": "depressive symptoms", "sbj_char_span": [77, 81], "obj_char_span": [133, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [25, 27]}, {"subject": "METH", "object": "depressive symptoms", "sbj_char_span": [17, 21], "obj_char_span": [133, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [25, 27]}, {"subject": "Methamphetamine", "object": "depressive symptoms", "sbj_char_span": [0, 15], "obj_char_span": [133, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits.", "entity_list": [{"name": "METH", "ent_type": "Chemical", "char_span": [62, 66], "ent_id": "D008694", "tok_span": [12, 14]}, {"name": "depressive", "ent_type": "Disease", "char_span": [94, 104], "ent_id": "D003866", "tok_span": [20, 21]}], "relation_list": [{"subject": "METH", "object": "depressive", "sbj_char_span": [62, 66], "obj_char_span": [94, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.).", "entity_list": [{"name": "depressive", "ent_type": "Disease", "char_span": [26, 36], "ent_id": "D003866", "tok_span": [6, 7]}, {"name": "METH", "ent_type": "Chemical", "char_span": [115, 119], "ent_id": "D008694", "tok_span": [23, 25]}], "relation_list": [{"subject": "METH", "object": "depressive", "sbj_char_span": [115, 119], "obj_char_span": [26, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.", "entity_list": [{"name": "depressive", "ent_type": "Disease", "char_span": [5, 15], "ent_id": "D003866", "tok_span": [1, 2]}, {"name": "DOPAC", "ent_type": "Chemical", "char_span": [202, 207], "ent_id": "D015102", "tok_span": [37, 40]}, {"name": "HVA", "ent_type": "Chemical", "char_span": [212, 215], "ent_id": "D006719", "tok_span": [41, 43]}, {"name": "tyrosine", "ent_type": "Chemical", "char_span": [217, 225], "ent_id": "D014443", "tok_span": [44, 45]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [192, 200], "ent_id": "D004298", "tok_span": [35, 36]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [242, 251], "ent_id": "D012701", "tok_span": [48, 49]}, {"name": "METH", "ent_type": "Chemical", "char_span": [40, 44], "ent_id": "D008694", "tok_span": [7, 9]}], "relation_list": [{"subject": "METH", "object": "depressive", "sbj_char_span": [40, 44], "obj_char_span": [5, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "These findings demonstrate for the first time that a single high dose of METH induces long-lasting depressive-like behaviour in mice associated with a persistent disruption of frontostriatal dopaminergic and serotonergic homoeostasis.", "entity_list": [{"name": "METH", "ent_type": "Chemical", "char_span": [73, 77], "ent_id": "D008694", "tok_span": [13, 15]}, {"name": "depressive", "ent_type": "Disease", "char_span": [99, 109], "ent_id": "D003866", "tok_span": [19, 20]}], "relation_list": [{"subject": "METH", "object": "depressive", "sbj_char_span": [73, 77], "obj_char_span": [99, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "Linezolid-induced optic neuropathy.", "entity_list": [{"name": "Linezolid", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "C098010", "tok_span": [0, 3]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [18, 34], "ent_id": "D009901", "tok_span": [5, 7]}], "relation_list": [{"subject": "Linezolid", "object": "optic neuropathy", "sbj_char_span": [0, 9], "obj_char_span": [18, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "METHODS: Newborn piglets received levobupivacaine until cardiovascular collapse occurred.", "entity_list": [{"name": "levobupivacaine", "ent_type": "Chemical", "char_span": [34, 49], "ent_id": "C476513", "tok_span": [7, 13]}, {"name": "cardiovascular collapse", "ent_type": "Disease", "char_span": [56, 79], "ent_id": "D002318", "tok_span": [14, 16]}], "relation_list": [{"subject": "levobupivacaine", "object": "cardiovascular collapse", "sbj_char_span": [34, 49], "obj_char_span": [56, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 13], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Incidence of heparin-induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis.", "entity_list": [{"name": "thrombocytopenia type II", "ent_type": "Disease", "char_span": [29, 53], "ent_id": "D013921", "tok_span": [5, 9]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [13, 20], "ent_id": "D006493", "tok_span": [2, 3]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia type II", "sbj_char_span": [13, 20], "obj_char_span": [29, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "The impact of immune-mediated heparin-induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results.", "entity_list": [{"name": "thrombocytopenia type II", "ent_type": "Disease", "char_span": [46, 70], "ent_id": "D013921", "tok_span": [9, 13]}, {"name": "HIT type II", "ent_type": "Disease", "char_span": [72, 83], "ent_id": "D013921", "tok_span": [14, 18]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [30, 37], "ent_id": "D006493", "tok_span": [6, 7]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [99, 115], "ent_id": "D013921", "tok_span": [23, 25]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [30, 37], "obj_char_span": [99, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [23, 25]}, {"subject": "heparin", "object": "thrombocytopenia type II", "sbj_char_span": [30, 37], "obj_char_span": [46, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 13]}, {"subject": "heparin", "object": "HIT type II", "sbj_char_span": [30, 37], "obj_char_span": [72, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "For further reduction of HIT type II, the use of intravenous heparin should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight heparin after normalization of platelet count.", "entity_list": [{"name": "HIT type II", "ent_type": "Disease", "char_span": [25, 36], "ent_id": "D013921", "tok_span": [4, 8]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [61, 68], "ent_id": "D006493", "tok_span": [13, 14]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [170, 177], "ent_id": "D006493", "tok_span": [30, 31]}], "relation_list": [{"subject": "heparin", "object": "HIT type II", "sbj_char_span": [61, 68], "obj_char_span": [25, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [4, 8]}, {"subject": "heparin", "object": "HIT type II", "sbj_char_span": [170, 177], "obj_char_span": [25, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan.", "entity_list": [{"name": "apical ballooning syndrome", "ent_type": "Disease", "char_span": [23, 49], "ent_id": "D054549", "tok_span": [7, 11]}, {"name": "Zolmitriptan", "ent_type": "Chemical", "char_span": [64, 76], "ent_id": "C089750", "tok_span": [14, 19]}, {"name": "Takotsubo syndrome", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D054549", "tok_span": [0, 5]}], "relation_list": [{"subject": "Zolmitriptan", "object": "Takotsubo syndrome", "sbj_char_span": [64, 76], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [0, 5]}, {"subject": "Zolmitriptan", "object": "apical ballooning syndrome", "sbj_char_span": [64, 76], "obj_char_span": [23, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to zolmitriptan, but none of the cases were associated with TS.", "entity_list": [{"name": "TS", "ent_type": "Disease", "char_span": [151, 153], "ent_id": "D054549", "tok_span": [28, 29]}, {"name": "coronary artery vasospasm", "ent_type": "Disease", "char_span": [55, 80], "ent_id": "D003329", "tok_span": [7, 12]}, {"name": "zolmitriptan", "ent_type": "Chemical", "char_span": [94, 106], "ent_id": "C089750", "tok_span": [14, 19]}], "relation_list": [{"subject": "zolmitriptan", "object": "coronary artery vasospasm", "sbj_char_span": [94, 106], "obj_char_span": [55, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [7, 12]}, {"subject": "zolmitriptan", "object": "TS", "sbj_char_span": [94, 106], "obj_char_span": [151, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [28, 29]}], "umls_entity_list": []}, {"text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).", "entity_list": [{"name": "impulsiveness", "ent_type": "Disease", "char_span": [12, 25], "ent_id": "D010554", "tok_span": [2, 4]}, {"name": "3,4-methylenedioxymethamphetamine", "ent_type": "Chemical", "char_span": [83, 116], "ent_id": "D018817", "tok_span": [17, 28]}, {"name": "Depression", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D003866", "tok_span": [0, 1]}, {"name": "MDMA", "ent_type": "Chemical", "char_span": [118, 122], "ent_id": "D018817", "tok_span": [29, 31]}, {"name": "ecstasy", "ent_type": "Chemical", "char_span": [124, 131], "ent_id": "D018817", "tok_span": [32, 35]}], "relation_list": [{"subject": "MDMA", "object": "Depression", "sbj_char_span": [118, 122], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [0, 1]}, {"subject": "3,4-methylenedioxymethamphetamine", "object": "impulsiveness", "sbj_char_span": [83, 116], "obj_char_span": [12, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 28], "obj_tok_span": [2, 4]}, {"subject": "ecstasy", "object": "Depression", "sbj_char_span": [124, 131], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [0, 1]}, {"subject": "MDMA", "object": "impulsiveness", "sbj_char_span": [118, 122], "obj_char_span": [12, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [2, 4]}, {"subject": "ecstasy", "object": "impulsiveness", "sbj_char_span": [124, 131], "obj_char_span": [12, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [2, 4]}, {"subject": "3,4-methylenedioxymethamphetamine", "object": "Depression", "sbj_char_span": [83, 116], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 28], "obj_tok_span": [0, 1]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.", "entity_list": [{"name": "sleep disturbance", "ent_type": "Disease", "char_span": [118, 135], "ent_id": "D020920", "tok_span": [19, 21]}, {"name": "depression", "ent_type": "Disease", "char_span": [87, 97], "ent_id": "D003866", "tok_span": [13, 14]}, {"name": "ecstasy", "ent_type": "Chemical", "char_span": [181, 188], "ent_id": "D018817", "tok_span": [29, 32]}, {"name": "impulsiveness", "ent_type": "Disease", "char_span": [99, 112], "ent_id": "D010554", "tok_span": [15, 17]}, {"name": "impaired memory", "ent_type": "Disease", "char_span": [34, 49], "ent_id": "D008569", "tok_span": [6, 8]}], "relation_list": [{"subject": "ecstasy", "object": "impulsiveness", "sbj_char_span": [181, 188], "obj_char_span": [99, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [15, 17]}, {"subject": "ecstasy", "object": "sleep disturbance", "sbj_char_span": [181, 188], "obj_char_span": [118, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [19, 21]}, {"subject": "ecstasy", "object": "depression", "sbj_char_span": [181, 188], "obj_char_span": [87, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.", "entity_list": [{"name": "Levodopa", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D007980", "tok_span": [0, 3]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [55, 74], "ent_id": "D010300", "tok_span": [10, 14]}, {"name": "visual hallucinations", "ent_type": "Disease", "char_span": [179, 200], "ent_id": "D006212", "tok_span": [36, 40]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [164, 174], "ent_id": "D004409", "tok_span": [31, 35]}], "relation_list": [{"subject": "Levodopa", "object": "visual hallucinations", "sbj_char_span": [0, 8], "obj_char_span": [179, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [36, 40]}, {"subject": "Levodopa", "object": "dyskinesia", "sbj_char_span": [0, 8], "obj_char_span": [164, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.", "entity_list": [{"name": "hyperlipemia", "ent_type": "Disease", "char_span": [65, 77], "ent_id": "D006949", "tok_span": [13, 16]}, {"name": "diazinon", "ent_type": "Chemical", "char_span": [48, 56], "ent_id": "D003976", "tok_span": [8, 11]}, {"name": "Crocin", "ent_type": "Chemical", "char_span": [0, 6], "ent_id": "C029036", "tok_span": [0, 2]}], "relation_list": [{"subject": "diazinon", "object": "hyperlipemia", "sbj_char_span": [48, 56], "obj_char_span": [65, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.", "entity_list": [{"name": "Crocin", "ent_type": "Chemical", "char_span": [13, 19], "ent_id": "C029036", "tok_span": [2, 4]}, {"name": "diazinon", "ent_type": "Chemical", "char_span": [69, 77], "ent_id": "D003976", "tok_span": [13, 16]}, {"name": "hyperlipemia", "ent_type": "Disease", "char_span": [86, 98], "ent_id": "D006949", "tok_span": [18, 21]}], "relation_list": [{"subject": "diazinon", "object": "hyperlipemia", "sbj_char_span": [69, 77], "obj_char_span": [86, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users.", "entity_list": [{"name": "depression", "ent_type": "Disease", "char_span": [42, 52], "ent_id": "D003866", "tok_span": [7, 8]}, {"name": "ecstasy", "ent_type": "Chemical", "char_span": [108, 115], "ent_id": "D018817", "tok_span": [17, 20]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [30, 37], "ent_id": "D001008", "tok_span": [5, 6]}], "relation_list": [{"subject": "ecstasy", "object": "depression", "sbj_char_span": [108, 115], "obj_char_span": [42, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Incidence of contrast-induced nephropathy in hospitalised patients with cancer.", "entity_list": [{"name": "cancer", "ent_type": "Disease", "char_span": [72, 78], "ent_id": "D009369", "tok_span": [11, 12]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [30, 41], "ent_id": "D007674", "tok_span": [5, 6]}, {"name": "contrast", "ent_type": "Chemical", "char_span": [13, 21], "ent_id": "D003287", "tok_span": [2, 3]}], "relation_list": [{"subject": "contrast", "object": "nephropathy", "sbj_char_span": [13, 21], "obj_char_span": [30, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with cancer.", "entity_list": [{"name": "contrast", "ent_type": "Chemical", "char_span": [74, 82], "ent_id": "D003287", "tok_span": [12, 13]}, {"name": "cancer", "ent_type": "Disease", "char_span": [139, 145], "ent_id": "D009369", "tok_span": [24, 25]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [91, 102], "ent_id": "D007674", "tok_span": [15, 16]}], "relation_list": [{"subject": "contrast", "object": "nephropathy", "sbj_char_span": [74, 82], "obj_char_span": [91, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Contrast-induced nephropathy (CIN) is a concern for oncological patients undergoing CT. .", "entity_list": [{"name": "nephropathy", "ent_type": "Disease", "char_span": [17, 28], "ent_id": "D007674", "tok_span": [3, 4]}, {"name": "Contrast", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D003287", "tok_span": [0, 1]}], "relation_list": [{"subject": "Contrast", "object": "nephropathy", "sbj_char_span": [0, 8], "obj_char_span": [17, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine.", "entity_list": [{"name": "desvenlafaxine", "ent_type": "Chemical", "char_span": [73, 87], "ent_id": "C086816", "tok_span": [10, 16]}, {"name": "Syndrome of inappropriate antidiuretic hormone", "ent_type": "Disease", "char_span": [0, 46], "ent_id": "D007177", "tok_span": [0, 7]}], "relation_list": [{"subject": "desvenlafaxine", "object": "Syndrome of inappropriate antidiuretic hormone", "sbj_char_span": [73, 87], "obj_char_span": [0, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 16], "obj_tok_span": [0, 7]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To report a case of syndrome of inappropriate anti-diuretic hormone (SIADH) secretion associated with desvenlafaxine.", "entity_list": [{"name": "syndrome of inappropriate anti-diuretic hormone", "ent_type": "Disease", "char_span": [31, 78], "ent_id": "D007177", "tok_span": [7, 15]}, {"name": "SIADH", "ent_type": "Disease", "char_span": [80, 85], "ent_id": "D007177", "tok_span": [16, 19]}, {"name": "desvenlafaxine", "ent_type": "Chemical", "char_span": [113, 127], "ent_id": "C086816", "tok_span": [23, 29]}], "relation_list": [{"subject": "desvenlafaxine", "object": "SIADH", "sbj_char_span": [113, 127], "obj_char_span": [80, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 29], "obj_tok_span": [16, 19]}, {"subject": "desvenlafaxine", "object": "syndrome of inappropriate anti-diuretic hormone", "sbj_char_span": [113, 127], "obj_char_span": [31, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 29], "obj_tok_span": [7, 15]}], "umls_entity_list": []}, {"text": "Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion.", "entity_list": [{"name": "desvenlafaxine", "ent_type": "Chemical", "char_span": [25, 39], "ent_id": "C086816", "tok_span": [3, 9]}, {"name": "nausea", "ent_type": "Disease", "char_span": [63, 69], "ent_id": "D009325", "tok_span": [13, 14]}, {"name": "confusion", "ent_type": "Disease", "char_span": [83, 92], "ent_id": "D003221", "tok_span": [17, 18]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [71, 78], "ent_id": "D001008", "tok_span": [15, 16]}], "relation_list": [{"subject": "desvenlafaxine", "object": "confusion", "sbj_char_span": [25, 39], "obj_char_span": [83, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 9], "obj_tok_span": [17, 18]}, {"subject": "desvenlafaxine", "object": "anxiety", "sbj_char_span": [25, 39], "obj_char_span": [71, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 9], "obj_tok_span": [15, 16]}, {"subject": "desvenlafaxine", "object": "nausea", "sbj_char_span": [25, 39], "obj_char_span": [63, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 9], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "This case report suggests that desvenlafaxine might cause clinically significant hyponatremia.", "entity_list": [{"name": "desvenlafaxine", "ent_type": "Chemical", "char_span": [31, 45], "ent_id": "C086816", "tok_span": [5, 11]}, {"name": "hyponatremia", "ent_type": "Disease", "char_span": [81, 93], "ent_id": "D007010", "tok_span": [15, 19]}], "relation_list": [{"subject": "desvenlafaxine", "object": "hyponatremia", "sbj_char_span": [31, 45], "obj_char_span": [81, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 11], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [85, 96], "ent_id": "D004317", "tok_span": [14, 15]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [20, 34], "ent_id": "D066126", "tok_span": [4, 6]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiotoxicity", "sbj_char_span": [85, 96], "obj_char_span": [20, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "The mechanism of doxorubicin (DOX)-induced cardiotoxicity remains controversial.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [17, 28], "ent_id": "D004317", "tok_span": [3, 4]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [43, 57], "ent_id": "D066126", "tok_span": [9, 11]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [30, 33], "ent_id": "D004317", "tok_span": [5, 6]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiotoxicity", "sbj_char_span": [17, 28], "obj_char_span": [43, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [9, 11]}, {"subject": "DOX", "object": "cardiotoxicity", "sbj_char_span": [30, 33], "obj_char_span": [43, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Single dose of DOX was associated with increased cardiac disarrangement, necrosis, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP.", "entity_list": [{"name": "cardiac disarrangement", "ent_type": "Disease", "char_span": [49, 71], "ent_id": "D006331", "tok_span": [8, 12]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [15, 18], "ent_id": "D004317", "tok_span": [3, 4]}, {"name": "necrosis", "ent_type": "Disease", "char_span": [73, 81], "ent_id": "D009336", "tok_span": [13, 14]}], "relation_list": [{"subject": "DOX", "object": "necrosis", "sbj_char_span": [15, 18], "obj_char_span": [73, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Our results suggest that oxidative damage is associated with acute cardiotoxicity induced by a single dose of DOX only.", "entity_list": [{"name": "DOX", "ent_type": "Chemical", "char_span": [110, 113], "ent_id": "D004317", "tok_span": [18, 19]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [67, 81], "ent_id": "D066126", "tok_span": [10, 12]}], "relation_list": [{"subject": "DOX", "object": "cardiotoxicity", "sbj_char_span": [110, 113], "obj_char_span": [67, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Tacrolimus-related seizure after pediatric liver transplantation--a single-center experience.", "entity_list": [{"name": "seizure", "ent_type": "Disease", "char_span": [19, 26], "ent_id": "D012640", "tok_span": [6, 7]}, {"name": "Tacrolimus", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D016559", "tok_span": [0, 4]}], "relation_list": [{"subject": "Tacrolimus", "object": "seizure", "sbj_char_span": [0, 10], "obj_char_span": [19, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "All exhibited generalized tonic-clonic seizures within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.", "entity_list": [{"name": "end-stage liver disease", "ent_type": "Disease", "char_span": [202, 225], "ent_id": "D058625", "tok_span": [34, 39]}, {"name": "bilirubin", "ent_type": "Chemical", "char_span": [293, 302], "ent_id": "D001663", "tok_span": [53, 54]}, {"name": "TAC", "ent_type": "Chemical", "char_span": [329, 332], "ent_id": "D016559", "tok_span": [59, 60]}, {"name": "tonic-clonic seizures", "ent_type": "Disease", "char_span": [26, 47], "ent_id": "D004830", "tok_span": [3, 8]}, {"name": "seizures", "ent_type": "Disease", "char_span": [147, 155], "ent_id": "D012640", "tok_span": [26, 27]}], "relation_list": [{"subject": "TAC", "object": "seizures", "sbj_char_span": [329, 332], "obj_char_span": [147, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 60], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "Multivariate analysis showed that trough TAC level was the only independent risk factor associated with the seizures.", "entity_list": [{"name": "TAC", "ent_type": "Chemical", "char_span": [41, 44], "ent_id": "D016559", "tok_span": [5, 6]}, {"name": "seizures", "ent_type": "Disease", "char_span": [108, 116], "ent_id": "D012640", "tok_span": [16, 17]}], "relation_list": [{"subject": "TAC", "object": "seizures", "sbj_char_span": [41, 44], "obj_char_span": [108, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "High trough TAC level was the predominant factor that contributed to seizures in the early post-operative period after pediatric LT. High PELD and Child-Pugh scores before LT and high post-operative serum Tbil may be contributory risk factors for TAC-related seizures.", "entity_list": [{"name": "TAC", "ent_type": "Chemical", "char_span": [247, 250], "ent_id": "D016559", "tok_span": [49, 50]}, {"name": "seizures", "ent_type": "Disease", "char_span": [69, 77], "ent_id": "D012640", "tok_span": [11, 12]}, {"name": "seizures", "ent_type": "Disease", "char_span": [259, 267], "ent_id": "D012640", "tok_span": [52, 53]}, {"name": "TAC", "ent_type": "Chemical", "char_span": [12, 15], "ent_id": "D016559", "tok_span": [2, 3]}], "relation_list": [{"subject": "TAC", "object": "seizures", "sbj_char_span": [247, 250], "obj_char_span": [259, 267], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 50], "obj_tok_span": [52, 53]}, {"subject": "TAC", "object": "seizures", "sbj_char_span": [12, 15], "obj_char_span": [259, 267], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [52, 53]}, {"subject": "TAC", "object": "seizures", "sbj_char_span": [247, 250], "obj_char_span": [69, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 50], "obj_tok_span": [11, 12]}, {"subject": "TAC", "object": "seizures", "sbj_char_span": [12, 15], "obj_char_span": [69, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Furthermore, apigenin did not prevent the amnesia induced by scopolamine (1mg/kg, i.p., 30 min before the acquisition).", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [61, 72], "ent_id": "D012601", "tok_span": [14, 17]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [42, 49], "ent_id": "D000647", "tok_span": [9, 12]}, {"name": "apigenin", "ent_type": "Chemical", "char_span": [13, 21], "ent_id": "D047310", "tok_span": [2, 5]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [61, 72], "obj_char_span": [42, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [64, 72], "ent_id": "D009020", "tok_span": [12, 13]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [166, 174], "ent_id": "D009020", "tok_span": [32, 33]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [81, 88], "ent_id": "D000647", "tok_span": [15, 18]}, {"name": "CCK-8", "ent_type": "Chemical", "char_span": [33, 38], "ent_id": "D012844", "tok_span": [5, 9]}], "relation_list": [{"subject": "morphine", "object": "amnesia", "sbj_char_span": [64, 72], "obj_char_span": [81, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 18]}, {"subject": "morphine", "object": "amnesia", "sbj_char_span": [166, 174], "obj_char_span": [81, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats.", "entity_list": [{"name": "memory impairment", "ent_type": "Disease", "char_span": [97, 114], "ent_id": "D008569", "tok_span": [23, 25]}, {"name": "Streptozotocin", "ent_type": "Chemical", "char_span": [68, 82], "ent_id": "D013311", "tok_span": [14, 18]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [35, 48], "ent_id": "D020258", "tok_span": [7, 9]}], "relation_list": [{"subject": "Streptozotocin", "object": "memory impairment", "sbj_char_span": [68, 82], "obj_char_span": [97, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.", "entity_list": [{"name": "STZ", "ent_type": "Chemical", "char_span": [100, 103], "ent_id": "D013311", "tok_span": [21, 23]}, {"name": "Streptozotocin", "ent_type": "Chemical", "char_span": [84, 98], "ent_id": "D013311", "tok_span": [16, 20]}, {"name": "memory impaired", "ent_type": "Disease", "char_span": [113, 128], "ent_id": "D008569", "tok_span": [25, 27]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [68, 76], "ent_id": "D064420", "tok_span": [12, 13]}], "relation_list": [{"subject": "STZ", "object": "memory impaired", "sbj_char_span": [100, 103], "obj_char_span": [113, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [25, 27]}, {"subject": "Streptozotocin", "object": "memory impaired", "sbj_char_span": [84, 98], "obj_char_span": [113, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "In experiment set up 1: Memory deficit was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration.", "entity_list": [{"name": "STZ", "ent_type": "Chemical", "char_span": [95, 98], "ent_id": "D013311", "tok_span": [21, 23]}, {"name": "Memory deficit", "ent_type": "Disease", "char_span": [24, 38], "ent_id": "D008569", "tok_span": [6, 8]}], "relation_list": [{"subject": "STZ", "object": "Memory deficit", "sbj_char_span": [95, 98], "obj_char_span": [24, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation.", "entity_list": [{"name": "neuroinflammation", "ent_type": "Disease", "char_span": [89, 106], "ent_id": "D007249", "tok_span": [20, 24]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D013311", "tok_span": [0, 2]}], "relation_list": [{"subject": "STZ", "object": "neuroinflammation", "sbj_char_span": [0, 3], "obj_char_span": [89, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death.", "entity_list": [{"name": "STZ", "ent_type": "Chemical", "char_span": [108, 111], "ent_id": "D013311", "tok_span": [17, 19]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [71, 84], "ent_id": "D020258", "tok_span": [10, 12]}, {"name": "memory impairment", "ent_type": "Disease", "char_span": [120, 137], "ent_id": "D008569", "tok_span": [20, 22]}], "relation_list": [{"subject": "STZ", "object": "memory impairment", "sbj_char_span": [108, 111], "obj_char_span": [120, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Among a total of 60 patients included in the study, 16 patients developed acute renal failure (ARF) on the second day after contrast material was injected (26.6%).", "entity_list": [{"name": "ARF", "ent_type": "Disease", "char_span": [95, 98], "ent_id": "D058186", "tok_span": [18, 20]}, {"name": "contrast", "ent_type": "Chemical", "char_span": [124, 132], "ent_id": "D003287", "tok_span": [26, 27]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [74, 93], "ent_id": "D058186", "tok_span": [14, 17]}], "relation_list": [{"subject": "contrast", "object": "ARF", "sbj_char_span": [124, 132], "obj_char_span": [95, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [18, 20]}, {"subject": "contrast", "object": "acute renal failure", "sbj_char_span": [124, 132], "obj_char_span": [74, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Two hours after the sixth dose of TNA, she had an episode of generalized tonic clonic convulsions.", "entity_list": [{"name": "tonic clonic convulsions", "ent_type": "Disease", "char_span": [73, 97], "ent_id": "D004830", "tok_span": [16, 22]}, {"name": "TNA", "ent_type": "Chemical", "char_span": [34, 37], "ent_id": "D014148", "tok_span": [7, 9]}], "relation_list": [{"subject": "TNA", "object": "tonic clonic convulsions", "sbj_char_span": [34, 37], "obj_char_span": [73, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [16, 22]}], "umls_entity_list": []}, {"text": "BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.", "entity_list": [{"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [171, 185], "ent_id": "D066126", "tok_span": [37, 39]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [128, 136], "ent_id": "D015742", "tok_span": [27, 29]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [151, 162], "ent_id": "D002045", "tok_span": [31, 35]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [90, 101], "ent_id": "D002045", "tok_span": [17, 21]}], "relation_list": [{"subject": "bupivacaine", "object": "cardiotoxicity", "sbj_char_span": [90, 101], "obj_char_span": [171, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [37, 39]}, {"subject": "bupivacaine", "object": "cardiotoxicity", "sbj_char_span": [151, 162], "obj_char_span": [171, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 35], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.", "entity_list": [{"name": "bupivacaine", "ent_type": "Chemical", "char_span": [105, 116], "ent_id": "D002045", "tok_span": [23, 27]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [125, 139], "ent_id": "D066126", "tok_span": [29, 31]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [55, 63], "ent_id": "D015742", "tok_span": [11, 13]}], "relation_list": [{"subject": "bupivacaine", "object": "cardiotoxicity", "sbj_char_span": [105, 116], "obj_char_span": [125, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.", "entity_list": [{"name": "bupivacaine", "ent_type": "Chemical", "char_span": [184, 195], "ent_id": "D002045", "tok_span": [42, 46]}, {"name": "asystole", "ent_type": "Disease", "char_span": [155, 163], "ent_id": "D006323", "tok_span": [35, 38]}, {"name": "dysrhythmia", "ent_type": "Disease", "char_span": [26, 37], "ent_id": "D001145", "tok_span": [5, 9]}], "relation_list": [{"subject": "bupivacaine", "object": "asystole", "sbj_char_span": [184, 195], "obj_char_span": [155, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 46], "obj_tok_span": [35, 38]}], "umls_entity_list": []}, {"text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.", "entity_list": [{"name": "bupivacaine", "ent_type": "Chemical", "char_span": [15, 26], "ent_id": "D002045", "tok_span": [2, 6]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [475, 486], "ent_id": "D002045", "tok_span": [103, 107]}, {"name": "cardiotoxic", "ent_type": "Disease", "char_span": [429, 440], "ent_id": "D066126", "tok_span": [95, 97]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [354, 362], "ent_id": "D015742", "tok_span": [76, 78]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [316, 324], "ent_id": "D015742", "tok_span": [68, 70]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [409, 420], "ent_id": "D002045", "tok_span": [89, 93]}, {"name": "Bupivacaine", "ent_type": "Chemical", "char_span": [161, 172], "ent_id": "D002045", "tok_span": [35, 39]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [89, 100], "ent_id": "D002045", "tok_span": [19, 23]}], "relation_list": [{"subject": "bupivacaine", "object": "cardiotoxic", "sbj_char_span": [89, 100], "obj_char_span": [429, 440], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [95, 97]}, {"subject": "bupivacaine", "object": "cardiotoxic", "sbj_char_span": [475, 486], "obj_char_span": [429, 440], "rel_type": "chemical-induced disease", "sbj_tok_span": [103, 107], "obj_tok_span": [95, 97]}, {"subject": "Bupivacaine", "object": "cardiotoxic", "sbj_char_span": [161, 172], "obj_char_span": [429, 440], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [95, 97]}, {"subject": "bupivacaine", "object": "cardiotoxic", "sbj_char_span": [15, 26], "obj_char_span": [429, 440], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [95, 97]}, {"subject": "bupivacaine", "object": "cardiotoxic", "sbj_char_span": [409, 420], "obj_char_span": [429, 440], "rel_type": "chemical-induced disease", "sbj_tok_span": [89, 93], "obj_tok_span": [95, 97]}], "umls_entity_list": []}, {"text": "Drug-Induced Acute Liver Injury Within 12 Hours After Fluvastatin Therapy.", "entity_list": [{"name": "Fluvastatin", "ent_type": "Chemical", "char_span": [54, 65], "ent_id": "C065180", "tok_span": [12, 14]}, {"name": "Drug-Induced Acute Liver Injury", "ent_type": "Disease", "char_span": [0, 31], "ent_id": "D056486", "tok_span": [0, 7]}], "relation_list": [{"subject": "Fluvastatin", "object": "Drug-Induced Acute Liver Injury", "sbj_char_span": [54, 65], "obj_char_span": [0, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [0, 7]}], "umls_entity_list": []}, {"text": "A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with fluvastatin.", "entity_list": [{"name": "fluvastatin", "ent_type": "Chemical", "char_span": [109, 120], "ent_id": "C065180", "tok_span": [21, 23]}, {"name": "liver damage", "ent_type": "Disease", "char_span": [40, 52], "ent_id": "D056486", "tok_span": [10, 12]}], "relation_list": [{"subject": "fluvastatin", "object": "liver damage", "sbj_char_span": [109, 120], "obj_char_span": [40, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Fluconazole associated agranulocytosis and thrombocytopenia.", "entity_list": [{"name": "Fluconazole", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D015725", "tok_span": [0, 3]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [43, 59], "ent_id": "D013921", "tok_span": [10, 12]}, {"name": "agranulocytosis", "ent_type": "Disease", "char_span": [23, 38], "ent_id": "D000380", "tok_span": [4, 9]}], "relation_list": [{"subject": "Fluconazole", "object": "agranulocytosis", "sbj_char_span": [0, 11], "obj_char_span": [23, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 9]}, {"subject": "Fluconazole", "object": "thrombocytopenia", "sbj_char_span": [0, 11], "obj_char_span": [43, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "CASE: We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy.", "entity_list": [{"name": "agranulocytosis", "ent_type": "Disease", "char_span": [58, 73], "ent_id": "D000380", "tok_span": [12, 17]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [79, 95], "ent_id": "D013921", "tok_span": [18, 20]}, {"name": "fluconazole", "ent_type": "Chemical", "char_span": [35, 46], "ent_id": "D015725", "tok_span": [8, 11]}], "relation_list": [{"subject": "fluconazole", "object": "agranulocytosis", "sbj_char_span": [35, 46], "obj_char_span": [58, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [12, 17]}, {"subject": "fluconazole", "object": "thrombocytopenia", "sbj_char_span": [35, 46], "obj_char_span": [79, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "CONCLUSION: According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and thrombocytopenia occurred as a result of therapy with fluconazole is probable, with a total of six points.", "entity_list": [{"name": "agranulocytosis", "ent_type": "Disease", "char_span": [79, 94], "ent_id": "D000380", "tok_span": [17, 22]}, {"name": "fluconazole", "ent_type": "Chemical", "char_span": [153, 164], "ent_id": "D015725", "tok_span": [32, 35]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [99, 115], "ent_id": "D013921", "tok_span": [23, 25]}], "relation_list": [{"subject": "fluconazole", "object": "agranulocytosis", "sbj_char_span": [153, 164], "obj_char_span": [79, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [17, 22]}, {"subject": "fluconazole", "object": "thrombocytopenia", "sbj_char_span": [153, 164], "obj_char_span": [99, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.", "entity_list": [{"name": "epirubicine", "ent_type": "Chemical", "char_span": [157, 168], "ent_id": "D015251", "tok_span": [26, 30]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [135, 149], "ent_id": "D066126", "tok_span": [23, 25]}], "relation_list": [{"subject": "epirubicine", "object": "cardiotoxicity", "sbj_char_span": [157, 168], "obj_char_span": [135, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination?", "entity_list": [{"name": "midazolam", "ent_type": "Chemical", "char_span": [72, 81], "ent_id": "D008874", "tok_span": [20, 23]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [32, 41], "ent_id": "D009207", "tok_span": [7, 11]}, {"name": "etomidate", "ent_type": "Chemical", "char_span": [14, 23], "ent_id": "D005045", "tok_span": [2, 5]}, {"name": "Fentanyl", "ent_type": "Chemical", "char_span": [62, 70], "ent_id": "D005283", "tok_span": [16, 19]}], "relation_list": [{"subject": "etomidate", "object": "myoclonus", "sbj_char_span": [14, 23], "obj_char_span": [32, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.", "entity_list": [{"name": "fentanyl", "ent_type": "Chemical", "char_span": [136, 144], "ent_id": "D005283", "tok_span": [27, 30]}, {"name": "midazolam", "ent_type": "Chemical", "char_span": [149, 158], "ent_id": "D008874", "tok_span": [31, 34]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [188, 197], "ent_id": "D009207", "tok_span": [41, 45]}, {"name": "fentanyl", "ent_type": "Chemical", "char_span": [94, 102], "ent_id": "D005283", "tok_span": [15, 18]}, {"name": "midazolam", "ent_type": "Chemical", "char_span": [104, 113], "ent_id": "D008874", "tok_span": [19, 22]}, {"name": "etomidate", "ent_type": "Chemical", "char_span": [170, 179], "ent_id": "D005045", "tok_span": [36, 39]}], "relation_list": [{"subject": "etomidate", "object": "myoclonus", "sbj_char_span": [170, 179], "obj_char_span": [188, 197], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [41, 45]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.", "entity_list": [{"name": "etomidate", "ent_type": "Chemical", "char_span": [126, 135], "ent_id": "D005045", "tok_span": [24, 27]}, {"name": "fentanyl", "ent_type": "Chemical", "char_span": [48, 56], "ent_id": "D005283", "tok_span": [7, 10]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [144, 153], "ent_id": "D009207", "tok_span": [29, 33]}, {"name": "fentanyl", "ent_type": "Chemical", "char_span": [75, 83], "ent_id": "D005283", "tok_span": [13, 16]}, {"name": "midazolam", "ent_type": "Chemical", "char_span": [88, 97], "ent_id": "D008874", "tok_span": [17, 20]}], "relation_list": [{"subject": "etomidate", "object": "myoclonus", "sbj_char_span": [126, 135], "obj_char_span": [144, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "Cholestatic presentation of yellow phosphorus poisoning.", "entity_list": [{"name": "phosphorus", "ent_type": "Chemical", "char_span": [35, 45], "ent_id": "D010758", "tok_span": [7, 8]}, {"name": "Cholestatic", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D002779", "tok_span": [0, 4]}, {"name": "poisoning", "ent_type": "Disease", "char_span": [46, 55], "ent_id": "D011041", "tok_span": [8, 9]}], "relation_list": [{"subject": "phosphorus", "object": "Cholestatic", "sbj_char_span": [35, 45], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Poisoning with yellow phosphorus classically manifests with acute hepatitis leading to acute liver failure which may need liver transplantation.", "entity_list": [{"name": "Poisoning", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D011041", "tok_span": [0, 3]}, {"name": "acute hepatitis", "ent_type": "Disease", "char_span": [60, 75], "ent_id": "D006505", "tok_span": [11, 13]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [87, 106], "ent_id": "D017114", "tok_span": [15, 18]}, {"name": "phosphorus", "ent_type": "Chemical", "char_span": [22, 32], "ent_id": "D010758", "tok_span": [5, 6]}], "relation_list": [{"subject": "phosphorus", "object": "acute hepatitis", "sbj_char_span": [22, 32], "obj_char_span": [60, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [11, 13]}, {"subject": "phosphorus", "object": "acute liver failure", "sbj_char_span": [22, 32], "obj_char_span": [87, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "We present a case of yellow phosphorus poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow phosphorus hepatotoxicity.", "entity_list": [{"name": "phosphorus", "ent_type": "Chemical", "char_span": [28, 38], "ent_id": "D010758", "tok_span": [6, 7]}, {"name": "cholestasis", "ent_type": "Disease", "char_span": [111, 122], "ent_id": "D002779", "tok_span": [19, 22]}, {"name": "cholestasis", "ent_type": "Disease", "char_span": [150, 161], "ent_id": "D002779", "tok_span": [26, 29]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [218, 232], "ent_id": "D056486", "tok_span": [38, 40]}, {"name": "phosphorus", "ent_type": "Chemical", "char_span": [207, 217], "ent_id": "D010758", "tok_span": [37, 38]}, {"name": "poisoning", "ent_type": "Disease", "char_span": [39, 48], "ent_id": "D011041", "tok_span": [7, 8]}], "relation_list": [{"subject": "phosphorus", "object": "cholestasis", "sbj_char_span": [28, 38], "obj_char_span": [111, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [19, 22]}, {"subject": "phosphorus", "object": "cholestasis", "sbj_char_span": [207, 217], "obj_char_span": [150, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [26, 29]}, {"subject": "phosphorus", "object": "cholestasis", "sbj_char_span": [28, 38], "obj_char_span": [150, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [26, 29]}, {"subject": "phosphorus", "object": "cholestasis", "sbj_char_span": [207, 217], "obj_char_span": [111, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "Vasovagal syncope and severe bradycardia following intranasal dexmedetomidine for pediatric procedural sedation.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [29, 40], "ent_id": "D001919", "tok_span": [7, 11]}, {"name": "dexmedetomidine", "ent_type": "Chemical", "char_span": [62, 77], "ent_id": "D020927", "tok_span": [14, 19]}, {"name": "Vasovagal syncope", "ent_type": "Disease", "char_span": [0, 17], "ent_id": "D019462", "tok_span": [0, 5]}], "relation_list": [{"subject": "dexmedetomidine", "object": "Vasovagal syncope", "sbj_char_span": [62, 77], "obj_char_span": [0, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [0, 5]}, {"subject": "dexmedetomidine", "object": "bradycardia", "sbj_char_span": [62, 77], "obj_char_span": [29, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "We report syncope and bradycardia in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram.", "entity_list": [{"name": "syncope", "ent_type": "Disease", "char_span": [10, 17], "ent_id": "D013575", "tok_span": [2, 4]}, {"name": "dexmedetomidine", "ent_type": "Chemical", "char_span": [96, 111], "ent_id": "D020927", "tok_span": [22, 27]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [22, 33], "ent_id": "D001919", "tok_span": [5, 9]}], "relation_list": [{"subject": "dexmedetomidine", "object": "bradycardia", "sbj_char_span": [96, 111], "obj_char_span": [22, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder.", "entity_list": [{"name": "quetiapine", "ent_type": "Chemical", "char_span": [58, 68], "ent_id": "C069541", "tok_span": [14, 17]}, {"name": "schizo-affective disorder", "ent_type": "Disease", "char_span": [72, 97], "ent_id": "D011618", "tok_span": [18, 24]}, {"name": "agitation", "ent_type": "Disease", "char_span": [19, 28], "ent_id": "D011595", "tok_span": [4, 6]}], "relation_list": [{"subject": "quetiapine", "object": "agitation", "sbj_char_span": [58, 68], "obj_char_span": [19, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder.", "entity_list": [{"name": "agitation", "ent_type": "Disease", "char_span": [114, 123], "ent_id": "D011595", "tok_span": [25, 27]}, {"name": "aggressiveness", "ent_type": "Disease", "char_span": [207, 221], "ent_id": "D010554", "tok_span": [40, 42]}, {"name": "personality disorder", "ent_type": "Disease", "char_span": [225, 245], "ent_id": "D010554", "tok_span": [43, 45]}, {"name": "quetiapine", "ent_type": "Chemical", "char_span": [54, 64], "ent_id": "C069541", "tok_span": [9, 12]}], "relation_list": [{"subject": "quetiapine", "object": "agitation", "sbj_char_span": [54, 64], "obj_char_span": [114, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine.", "entity_list": [{"name": "quetiapine", "ent_type": "Chemical", "char_span": [168, 178], "ent_id": "C069541", "tok_span": [33, 36]}, {"name": "agitation", "ent_type": "Disease", "char_span": [142, 151], "ent_id": "D011595", "tok_span": [29, 31]}, {"name": "quetiapine", "ent_type": "Chemical", "char_span": [49, 59], "ent_id": "C069541", "tok_span": [9, 12]}, {"name": "agitation", "ent_type": "Disease", "char_span": [103, 112], "ent_id": "D011595", "tok_span": [21, 23]}], "relation_list": [{"subject": "quetiapine", "object": "agitation", "sbj_char_span": [168, 178], "obj_char_span": [103, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [21, 23]}, {"subject": "quetiapine", "object": "agitation", "sbj_char_span": [49, 59], "obj_char_span": [103, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [21, 23]}, {"subject": "quetiapine", "object": "agitation", "sbj_char_span": [168, 178], "obj_char_span": [142, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [29, 31]}, {"subject": "quetiapine", "object": "agitation", "sbj_char_span": [49, 59], "obj_char_span": [142, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.", "entity_list": [{"name": "dexamethasone", "ent_type": "Chemical", "char_span": [45, 58], "ent_id": "D003907", "tok_span": [10, 11]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [67, 79], "ent_id": "D006973", "tok_span": [13, 14]}], "relation_list": [{"subject": "dexamethasone", "object": "hypertension", "sbj_char_span": [45, 58], "obj_char_span": [67, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Dexamethasone- (Dex-) induced hypertension is associated with enhanced oxidative stress.", "entity_list": [{"name": "Dex", "ent_type": "Chemical", "char_span": [16, 19], "ent_id": "D003907", "tok_span": [4, 5]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [30, 42], "ent_id": "D006973", "tok_span": [8, 9]}, {"name": "Dexamethasone", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D003907", "tok_span": [0, 2]}], "relation_list": [{"subject": "Dexamethasone", "object": "hypertension", "sbj_char_span": [0, 13], "obj_char_span": [30, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [8, 9]}, {"subject": "Dex", "object": "hypertension", "sbj_char_span": [16, 19], "obj_char_span": [30, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration.", "entity_list": [{"name": "Dex", "ent_type": "Chemical", "char_span": [116, 119], "ent_id": "D003907", "tok_span": [19, 20]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [98, 110], "ent_id": "D006973", "tok_span": [17, 18]}], "relation_list": [{"subject": "Dex", "object": "hypertension", "sbj_char_span": [116, 119], "obj_char_span": [98, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex-induced hypertension.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [77, 89], "ent_id": "D006973", "tok_span": [25, 26]}, {"name": "Dex", "ent_type": "Chemical", "char_span": [65, 68], "ent_id": "D003907", "tok_span": [22, 23]}], "relation_list": [{"subject": "Dex", "object": "hypertension", "sbj_char_span": [65, 68], "obj_char_span": [77, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.", "entity_list": [{"name": "Dex", "ent_type": "Chemical", "char_span": [124, 127], "ent_id": "D003907", "tok_span": [18, 19]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [136, 148], "ent_id": "D006973", "tok_span": [21, 22]}], "relation_list": [{"subject": "Dex", "object": "hypertension", "sbj_char_span": [124, 127], "obj_char_span": [136, 148], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [55, 63], "ent_id": "D012640", "tok_span": [10, 11]}, {"name": "convulsive", "ent_type": "Disease", "char_span": [44, 54], "ent_id": "D012640", "tok_span": [8, 10]}, {"name": "tranexamic acid", "ent_type": "Chemical", "char_span": [24, 39], "ent_id": "D014148", "tok_span": [3, 7]}], "relation_list": [{"subject": "tranexamic acid", "object": "convulsive", "sbj_char_span": [24, 39], "obj_char_span": [44, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [8, 10]}, {"subject": "tranexamic acid", "object": "seizures", "sbj_char_span": [24, 39], "obj_char_span": [55, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.", "entity_list": [{"name": "tranexamic acid", "ent_type": "Chemical", "char_span": [229, 244], "ent_id": "D014148", "tok_span": [41, 45]}, {"name": "congestive heart failure", "ent_type": "Disease", "char_span": [131, 155], "ent_id": "D006333", "tok_span": [21, 26]}, {"name": "seizures", "ent_type": "Disease", "char_span": [40, 48], "ent_id": "D012640", "tok_span": [4, 5]}, {"name": "hypothermic", "ent_type": "Disease", "char_span": [162, 173], "ent_id": "D007035", "tok_span": [28, 30]}], "relation_list": [{"subject": "tranexamic acid", "object": "seizures", "sbj_char_span": [229, 244], "obj_char_span": [40, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "When tested in a multivariate regression analysis, tranexamic acid was a strong independent predictor of seizures (OR 14.3, 95% CI 5.5-36.7; p < 0.001).", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [105, 113], "ent_id": "D012640", "tok_span": [18, 19]}, {"name": "tranexamic acid", "ent_type": "Chemical", "char_span": [51, 66], "ent_id": "D014148", "tok_span": [8, 12]}], "relation_list": [{"subject": "tranexamic acid", "object": "seizures", "sbj_char_span": [51, 66], "obj_char_span": [105, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "As tranexamic acid is the only modifiable factor, its administration, particularly in doses exceeding 80 mg.kg(-1), should be weighed against the risk of postoperative seizures.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [168, 176], "ent_id": "D012640", "tok_span": [37, 38]}, {"name": "tranexamic acid", "ent_type": "Chemical", "char_span": [3, 18], "ent_id": "D014148", "tok_span": [1, 5]}], "relation_list": [{"subject": "tranexamic acid", "object": "seizures", "sbj_char_span": [3, 18], "obj_char_span": [168, 176], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 5], "obj_tok_span": [37, 38]}], "umls_entity_list": []}, {"text": "Dysfunctional overnight memory consolidation in ecstasy users.", "entity_list": [{"name": "Dysfunctional overnight memory", "ent_type": "Disease", "char_span": [0, 30], "ent_id": "D008569", "tok_span": [0, 4]}, {"name": "ecstasy", "ent_type": "Chemical", "char_span": [48, 55], "ent_id": "D018817", "tok_span": [6, 9]}], "relation_list": [{"subject": "ecstasy", "object": "Dysfunctional overnight memory", "sbj_char_span": [48, 55], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Previous studies indicate that ecstasy users have marked and persistent neurocognitive and sleep-related impairments.", "entity_list": [{"name": "ecstasy", "ent_type": "Chemical", "char_span": [31, 38], "ent_id": "D018817", "tok_span": [4, 7]}, {"name": "sleep-related impairments", "ent_type": "Disease", "char_span": [91, 116], "ent_id": "D012893", "tok_span": [15, 19]}], "relation_list": [{"subject": "ecstasy", "object": "sleep-related impairments", "sbj_char_span": [31, 38], "obj_char_span": [91, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Ecstasy users demonstrated impaired overnight memory consolidation, a finding that was more pronounced following associative interference.", "entity_list": [{"name": "Ecstasy", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D018817", "tok_span": [0, 3]}, {"name": "impaired overnight memory", "ent_type": "Disease", "char_span": [27, 52], "ent_id": "D008569", "tok_span": [5, 8]}], "relation_list": [{"subject": "Ecstasy", "object": "impaired overnight memory", "sbj_char_span": [0, 7], "obj_char_span": [27, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "We suggest that ecstasy-associated dysfunction in fronto-temporal circuitry may underlie overnight consolidation memory impairments in regular ecstasy users.", "entity_list": [{"name": "ecstasy", "ent_type": "Chemical", "char_span": [16, 23], "ent_id": "D018817", "tok_span": [3, 6]}, {"name": "memory impairments", "ent_type": "Disease", "char_span": [113, 131], "ent_id": "D008569", "tok_span": [19, 21]}, {"name": "ecstasy", "ent_type": "Chemical", "char_span": [143, 150], "ent_id": "D018817", "tok_span": [23, 26]}], "relation_list": [{"subject": "ecstasy", "object": "memory impairments", "sbj_char_span": [143, 150], "obj_char_span": [113, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [19, 21]}, {"subject": "ecstasy", "object": "memory impairments", "sbj_char_span": [16, 23], "obj_char_span": [113, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity_list": [{"name": "irritability", "ent_type": "Disease", "char_span": [225, 237], "ent_id": "D001523", "tok_span": [47, 49]}, {"name": "seizure", "ent_type": "Disease", "char_span": [242, 249], "ent_id": "D012640", "tok_span": [50, 51]}, {"name": "impaired renal and liver function", "ent_type": "Disease", "char_span": [17, 50], "ent_id": "D05143", "tok_span": [3, 8]}, {"name": "neurotoxic", "ent_type": "Disease", "char_span": [175, 185], "ent_id": "D020258", "tok_span": [35, 37]}, {"name": "pain", "ent_type": "Disease", "char_span": [81, 85], "ent_id": "D010146", "tok_span": [16, 17]}, {"name": "pethidine", "ent_type": "Chemical", "char_span": [95, 104], "ent_id": "D008614", "tok_span": [19, 23]}, {"name": "norpethidine", "ent_type": "Chemical", "char_span": [198, 210], "ent_id": "C002752", "tok_span": [39, 44]}], "relation_list": [{"subject": "norpethidine", "object": "seizure", "sbj_char_span": [198, 210], "obj_char_span": [242, 249], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 44], "obj_tok_span": [50, 51]}], "umls_entity_list": []}, {"text": "A 27-year-old male patient presented with a maculopapular eruption on the flexural areas and buttocks after using oral ketoconazole.", "entity_list": [{"name": "ketoconazole", "ent_type": "Chemical", "char_span": [119, 131], "ent_id": "D007654", "tok_span": [29, 32]}, {"name": "maculopapular eruption", "ent_type": "Disease", "char_span": [44, 66], "ent_id": "D003875", "tok_span": [11, 18]}], "relation_list": [{"subject": "ketoconazole", "object": "maculopapular eruption", "sbj_char_span": [119, 131], "obj_char_span": [44, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [11, 18]}], "umls_entity_list": []}, {"text": "A Case of Sudden Cardiac Death due to Pilsicainide-Induced Torsades de Pointes.", "entity_list": [{"name": "Sudden Cardiac Death", "ent_type": "Disease", "char_span": [10, 30], "ent_id": "D016757", "tok_span": [3, 7]}, {"name": "Pilsicainide", "ent_type": "Chemical", "char_span": [38, 50], "ent_id": "C042288", "tok_span": [9, 14]}, {"name": "Torsades de Pointes", "ent_type": "Disease", "char_span": [59, 78], "ent_id": "D016171", "tok_span": [17, 23]}], "relation_list": [{"subject": "Pilsicainide", "object": "Torsades de Pointes", "sbj_char_span": [38, 50], "obj_char_span": [59, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [17, 23]}, {"subject": "Pilsicainide", "object": "Sudden Cardiac Death", "sbj_char_span": [38, 50], "obj_char_span": [10, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "An 84-year-old male received oral pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later.", "entity_list": [{"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [133, 152], "ent_id": "D001281", "tok_span": [32, 34]}, {"name": "sudden cardiac death", "ent_type": "Disease", "char_span": [194, 214], "ent_id": "D016757", "tok_span": [42, 45]}, {"name": "pilsicainide", "ent_type": "Chemical", "char_span": [34, 46], "ent_id": "C042288", "tok_span": [9, 14]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [55, 61], "ent_id": "D012964", "tok_span": [17, 18]}], "relation_list": [{"subject": "pilsicainide", "object": "sudden cardiac death", "sbj_char_span": [34, 46], "obj_char_span": [194, 214], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [42, 45]}], "umls_entity_list": []}, {"text": "Although the patient's renal function was not highly impaired and the dose of pilsicainide was low, the plasma concentration of pilsicainide may have been high, which can produce torsades de pointes in the octogenarian.", "entity_list": [{"name": "pilsicainide", "ent_type": "Chemical", "char_span": [128, 140], "ent_id": "C042288", "tok_span": [27, 32]}, {"name": "pilsicainide", "ent_type": "Chemical", "char_span": [78, 90], "ent_id": "C042288", "tok_span": [15, 20]}, {"name": "torsades de pointes", "ent_type": "Disease", "char_span": [179, 198], "ent_id": "D016171", "tok_span": [40, 45]}], "relation_list": [{"subject": "pilsicainide", "object": "torsades de pointes", "sbj_char_span": [78, 90], "obj_char_span": [179, 198], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 20], "obj_tok_span": [40, 45]}, {"subject": "pilsicainide", "object": "torsades de pointes", "sbj_char_span": [128, 140], "obj_char_span": [179, 198], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 32], "obj_tok_span": [40, 45]}], "umls_entity_list": []}, {"text": "All-trans retinoic acid-induced inflammatory myositis in a patient with acute promyelocytic leukemia.", "entity_list": [{"name": "acute promyelocytic leukemia", "ent_type": "Disease", "char_span": [72, 100], "ent_id": "D015473", "tok_span": [16, 21]}, {"name": "All-trans retinoic acid", "ent_type": "Chemical", "char_span": [0, 23], "ent_id": "D014212", "tok_span": [0, 6]}, {"name": "myositis", "ent_type": "Disease", "char_span": [45, 53], "ent_id": "D009220", "tok_span": [9, 12]}], "relation_list": [{"subject": "All-trans retinoic acid", "object": "myositis", "sbj_char_span": [0, 23], "obj_char_span": [45, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 6], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Only a handful of cases of ATRA-induced myositis in children have been reported, and none in the radiology literature.", "entity_list": [{"name": "myositis", "ent_type": "Disease", "char_span": [40, 48], "ent_id": "D009220", "tok_span": [11, 14]}, {"name": "ATRA", "ent_type": "Chemical", "char_span": [27, 31], "ent_id": "D014212", "tok_span": [7, 9]}], "relation_list": [{"subject": "ATRA", "object": "myositis", "sbj_char_span": [27, 31], "obj_char_span": [40, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).", "entity_list": [{"name": "CTX", "ent_type": "Chemical", "char_span": [127, 130], "ent_id": "D003520", "tok_span": [28, 30]}, {"name": "CCNU", "ent_type": "Chemical", "char_span": [122, 126], "ent_id": "D008130", "tok_span": [24, 27]}, {"name": "Neutropenia", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D009503", "tok_span": [0, 4]}, {"name": "neutropenia", "ent_type": "Disease", "char_span": [81, 92], "ent_id": "D009503", "tok_span": [17, 19]}], "relation_list": [{"subject": "CTX", "object": "Neutropenia", "sbj_char_span": [127, 130], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [0, 4]}, {"subject": "CCNU", "object": "neutropenia", "sbj_char_span": [122, 126], "obj_char_span": [81, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [17, 19]}, {"subject": "CCNU", "object": "Neutropenia", "sbj_char_span": [122, 126], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [0, 4]}, {"subject": "CTX", "object": "neutropenia", "sbj_char_span": [127, 130], "obj_char_span": [81, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient.", "entity_list": [{"name": "Valproate", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D014635", "tok_span": [0, 3]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [33, 47], "ent_id": "D001927", "tok_span": [9, 11]}, {"name": "hyperammonemic", "ent_type": "Disease", "char_span": [18, 32], "ent_id": "D022124", "tok_span": [5, 9]}], "relation_list": [{"subject": "Valproate", "object": "hyperammonemic", "sbj_char_span": [0, 9], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Valproate-induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment.", "entity_list": [{"name": "valproate", "ent_type": "Chemical", "char_span": [85, 94], "ent_id": "D014635", "tok_span": [18, 21]}, {"name": "Valproate", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D014635", "tok_span": [0, 3]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [33, 47], "ent_id": "D001927", "tok_span": [9, 11]}, {"name": "hyperammonemic", "ent_type": "Disease", "char_span": [18, 32], "ent_id": "D022124", "tok_span": [5, 9]}], "relation_list": [{"subject": "valproate", "object": "hyperammonemic", "sbj_char_span": [85, 94], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [5, 9]}, {"subject": "Valproate", "object": "hyperammonemic", "sbj_char_span": [0, 9], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Here, we describe the case of a 15-year-old girl who was on a long-term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation.", "entity_list": [{"name": "epilepsy", "ent_type": "Disease", "char_span": [102, 110], "ent_id": "D004827", "tok_span": [28, 29]}, {"name": "valproate", "ent_type": "Chemical", "char_span": [85, 94], "ent_id": "D014635", "tok_span": [23, 26]}, {"name": "impaired consciousness", "ent_type": "Disease", "char_span": [124, 146], "ent_id": "D003244", "tok_span": [31, 33]}, {"name": "hyperammonemia", "ent_type": "Disease", "char_span": [152, 166], "ent_id": "D022124", "tok_span": [34, 38]}], "relation_list": [{"subject": "valproate", "object": "hyperammonemia", "sbj_char_span": [85, 94], "obj_char_span": [152, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [34, 38]}, {"subject": "valproate", "object": "impaired consciousness", "sbj_char_span": [85, 94], "obj_char_span": [124, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.", "entity_list": [{"name": "Waldenstrom macroglobulinaemia", "ent_type": "Disease", "char_span": [101, 131], "ent_id": "D008258", "tok_span": [22, 29]}, {"name": "Necrotising fasciitis", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D019115", "tok_span": [0, 6]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [43, 56], "ent_id": "D003907", "tok_span": [13, 14]}, {"name": "bortezomib", "ent_type": "Chemical", "char_span": [28, 38], "ent_id": "C400082", "tok_span": [7, 12]}], "relation_list": [{"subject": "bortezomib", "object": "Necrotising fasciitis", "sbj_char_span": [28, 38], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [0, 6]}, {"subject": "dexamethasone", "object": "Necrotising fasciitis", "sbj_char_span": [43, 56], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "entity_list": [{"name": "neutropenia", "ent_type": "Disease", "char_span": [117, 128], "ent_id": "D009503", "tok_span": [29, 31]}, {"name": "Waldenstrom macroglobulinaemia", "ent_type": "Disease", "char_span": [43, 73], "ent_id": "D008258", "tok_span": [13, 20]}, {"name": "bortezomib", "ent_type": "Chemical", "char_span": [166, 176], "ent_id": "C400082", "tok_span": [36, 41]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [188, 201], "ent_id": "D003907", "tok_span": [45, 46]}, {"name": "necrotising fasciitis", "ent_type": "Disease", "char_span": [87, 108], "ent_id": "D019115", "tok_span": [22, 28]}], "relation_list": [{"subject": "dexamethasone", "object": "necrotising fasciitis", "sbj_char_span": [188, 201], "obj_char_span": [87, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 46], "obj_tok_span": [22, 28]}, {"subject": "bortezomib", "object": "necrotising fasciitis", "sbj_char_span": [166, 176], "obj_char_span": [87, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 41], "obj_tok_span": [22, 28]}], "umls_entity_list": []}, {"text": "In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [59, 70], "ent_id": "D004317", "tok_span": [12, 13]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [328, 336], "ent_id": "D064420", "tok_span": [57, 58]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [85, 99], "ent_id": "D009202", "tok_span": [18, 19]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [72, 75], "ent_id": "D004317", "tok_span": [14, 15]}], "relation_list": [{"subject": "DOX", "object": "cardiomyopathy", "sbj_char_span": [72, 75], "obj_char_span": [85, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [18, 19]}, {"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [59, 70], "obj_char_span": [85, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Intradermal glutamate and capsaicin injections: intra- and interindividual variability of provoked hyperalgesia and allodynia.", "entity_list": [{"name": "allodynia", "ent_type": "Disease", "char_span": [116, 125], "ent_id": "D006930", "tok_span": [24, 27]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [12, 21], "ent_id": "D018698", "tok_span": [3, 4]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [26, 35], "ent_id": "D002211", "tok_span": [5, 8]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [99, 111], "ent_id": "D006930", "tok_span": [19, 23]}], "relation_list": [{"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [26, 35], "obj_char_span": [99, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [19, 23]}, {"subject": "capsaicin", "object": "allodynia", "sbj_char_span": [26, 35], "obj_char_span": [116, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.", "entity_list": [{"name": "glutamate", "ent_type": "Chemical", "char_span": [26, 35], "ent_id": "D018698", "tok_span": [5, 6]}, {"name": "allodynia", "ent_type": "Disease", "char_span": [131, 140], "ent_id": "D006930", "tok_span": [25, 28]}, {"name": "pain", "ent_type": "Disease", "char_span": [94, 98], "ent_id": "D010146", "tok_span": [17, 18]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [40, 49], "ent_id": "D002211", "tok_span": [7, 10]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [114, 126], "ent_id": "D006930", "tok_span": [20, 24]}, {"name": "pain disorders", "ent_type": "Disease", "char_span": [176, 190], "ent_id": "D013001", "tok_span": [33, 35]}], "relation_list": [{"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [40, 49], "obj_char_span": [114, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [20, 24]}, {"subject": "capsaicin", "object": "allodynia", "sbj_char_span": [40, 49], "obj_char_span": [131, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [25, 28]}], "umls_entity_list": []}, {"text": "For capsaicin, secondary pinprick hyperalgesia was detected with all von Frey gauges (P < 0.001).", "entity_list": [{"name": "hyperalgesia", "ent_type": "Disease", "char_span": [34, 46], "ent_id": "D006930", "tok_span": [9, 13]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [4, 13], "ent_id": "D002211", "tok_span": [1, 4]}], "relation_list": [{"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [4, 13], "obj_char_span": [34, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Capsaicin injection was reproducible for secondary hyperalgesia (ICC > 0.70) and allodynia (ICC > 0.71).", "entity_list": [{"name": "Capsaicin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D002211", "tok_span": [0, 3]}, {"name": "allodynia", "ent_type": "Disease", "char_span": [81, 90], "ent_id": "D006930", "tok_span": [20, 23]}, {"name": "secondary hyperalgesia", "ent_type": "Disease", "char_span": [41, 63], "ent_id": "D006930", "tok_span": [7, 12]}], "relation_list": [{"subject": "Capsaicin", "object": "secondary hyperalgesia", "sbj_char_span": [0, 9], "obj_char_span": [41, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [7, 12]}, {"subject": "Capsaicin", "object": "allodynia", "sbj_char_span": [0, 9], "obj_char_span": [81, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "In conclusion, glutamate and capsaicin yield reproducible hyperalgesic and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena.", "entity_list": [{"name": "glutamate", "ent_type": "Chemical", "char_span": [15, 24], "ent_id": "D018698", "tok_span": [3, 4]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [29, 38], "ent_id": "D002211", "tok_span": [5, 8]}, {"name": "allodynic", "ent_type": "Disease", "char_span": [75, 84], "ent_id": "D006930", "tok_span": [15, 18]}, {"name": "hyperalgesic", "ent_type": "Disease", "char_span": [58, 70], "ent_id": "D006930", "tok_span": [10, 14]}], "relation_list": [{"subject": "capsaicin", "object": "hyperalgesic", "sbj_char_span": [29, 38], "obj_char_span": [58, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 14]}, {"subject": "capsaicin", "object": "allodynic", "sbj_char_span": [29, 38], "obj_char_span": [75, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Treatment of WT mice with topical ocular 0.1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients.", "entity_list": [{"name": "glaucoma", "ent_type": "Disease", "char_span": [225, 233], "ent_id": "D005901", "tok_span": [40, 41]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [46, 59], "ent_id": "D003907", "tok_span": [11, 12]}, {"name": "axonal degeneration", "ent_type": "Disease", "char_span": [170, 189], "ent_id": "D009410", "tok_span": [33, 35]}, {"name": "retinal ganglion", "ent_type": "Disease", "char_span": [142, 158], "ent_id": "D012173", "tok_span": [28, 30]}], "relation_list": [{"subject": "dexamethasone", "object": "axonal degeneration", "sbj_char_span": [46, 59], "obj_char_span": [170, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [33, 35]}, {"subject": "dexamethasone", "object": "glaucoma", "sbj_char_span": [46, 59], "obj_char_span": [225, 233], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [40, 41]}], "umls_entity_list": []}, {"text": "Furthermore, dexamethasone-induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM).", "entity_list": [{"name": "dexamethasone", "ent_type": "Chemical", "char_span": [13, 26], "ent_id": "D003907", "tok_span": [2, 3]}, {"name": "ocular hypertension", "ent_type": "Disease", "char_span": [35, 54], "ent_id": "D009798", "tok_span": [5, 7]}], "relation_list": [{"subject": "dexamethasone", "object": "ocular hypertension", "sbj_char_span": [13, 26], "obj_char_span": [35, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced ocular hypertension.", "entity_list": [{"name": "dexamethasone", "ent_type": "Chemical", "char_span": [187, 200], "ent_id": "D003907", "tok_span": [34, 35]}, {"name": "ocular hypertension", "ent_type": "Disease", "char_span": [209, 228], "ent_id": "D009798", "tok_span": [37, 39]}, {"name": "Dexamethasone", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D003907", "tok_span": [0, 2]}], "relation_list": [{"subject": "Dexamethasone", "object": "ocular hypertension", "sbj_char_span": [0, 13], "obj_char_span": [209, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [37, 39]}, {"subject": "dexamethasone", "object": "ocular hypertension", "sbj_char_span": [187, 200], "obj_char_span": [209, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "Furthermore, reduction of ER stress in the TM with sodium 4-phenylbutyrate prevented dexamethasone-induced ocular hypertension in WT mice.", "entity_list": [{"name": "sodium 4-phenylbutyrate", "ent_type": "Chemical", "char_span": [51, 74], "ent_id": "C075773", "tok_span": [10, 16]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [85, 98], "ent_id": "D003907", "tok_span": [17, 18]}, {"name": "ocular hypertension", "ent_type": "Disease", "char_span": [107, 126], "ent_id": "D009798", "tok_span": [20, 22]}], "relation_list": [{"subject": "dexamethasone", "object": "ocular hypertension", "sbj_char_span": [85, 98], "obj_char_span": [107, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [62, 70], "ent_id": "D009020", "tok_span": [10, 11]}, {"name": "OIH", "ent_type": "Disease", "char_span": [0, 3], "ent_id": "D006930", "tok_span": [0, 2]}], "relation_list": [{"subject": "morphine", "object": "OIH", "sbj_char_span": [62, 70], "obj_char_span": [0, 3], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [20, 31], "ent_id": "D007022", "tok_span": [3, 4]}, {"name": "dexmedetomidine", "ent_type": "Chemical", "char_span": [119, 134], "ent_id": "D020927", "tok_span": [21, 26]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [36, 47], "ent_id": "D001919", "tok_span": [5, 9]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [138, 146], "ent_id": "D015742", "tok_span": [27, 29]}], "relation_list": [{"subject": "propofol", "object": "bradycardia", "sbj_char_span": [138, 146], "obj_char_span": [36, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [5, 9]}, {"subject": "propofol", "object": "hypotension", "sbj_char_span": [138, 146], "obj_char_span": [20, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [3, 4]}, {"subject": "dexmedetomidine", "object": "bradycardia", "sbj_char_span": [119, 134], "obj_char_span": [36, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 26], "obj_tok_span": [5, 9]}, {"subject": "dexmedetomidine", "object": "hypotension", "sbj_char_span": [119, 134], "obj_char_span": [20, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 26], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage.", "entity_list": [{"name": "Hydroxytyrosol", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "C005975", "tok_span": [0, 5]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [61, 72], "ent_id": "D004317", "tok_span": [11, 12]}, {"name": "cardiac disturbances", "ent_type": "Disease", "char_span": [28, 48], "ent_id": "D006331", "tok_span": [7, 9]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiac disturbances", "sbj_char_span": [61, 72], "obj_char_span": [28, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "This study demonstrates that hydroxytyrosol protect rat heart damage provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations.", "entity_list": [{"name": "heart damage", "ent_type": "Disease", "char_span": [56, 68], "ent_id": "D006331", "tok_span": [10, 12]}, {"name": "hydroxytyrosol", "ent_type": "Chemical", "char_span": [29, 43], "ent_id": "C005975", "tok_span": [4, 8]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [81, 92], "ent_id": "D004317", "tok_span": [15, 16]}], "relation_list": [{"subject": "doxorubicin", "object": "heart damage", "sbj_char_span": [81, 92], "obj_char_span": [56, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.", "entity_list": [{"name": "respiratory failure", "ent_type": "Disease", "char_span": [65, 84], "ent_id": "D012131", "tok_span": [19, 21]}, {"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [136, 155], "ent_id": "D001281", "tok_span": [32, 34]}, {"name": "hypothermia", "ent_type": "Disease", "char_span": [49, 60], "ent_id": "D007035", "tok_span": [16, 18]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [36, 47], "ent_id": "D001919", "tok_span": [11, 15]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [113, 123], "ent_id": "D000638", "tok_span": [26, 30]}], "relation_list": [{"subject": "amiodarone", "object": "hypothermia", "sbj_char_span": [113, 123], "obj_char_span": [49, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [16, 18]}, {"subject": "amiodarone", "object": "respiratory failure", "sbj_char_span": [113, 123], "obj_char_span": [65, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [19, 21]}, {"subject": "amiodarone", "object": "bradycardia", "sbj_char_span": [113, 123], "obj_char_span": [36, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.", "entity_list": [{"name": "argatroban", "ent_type": "Chemical", "char_span": [7, 17], "ent_id": "C031942", "tok_span": [2, 6]}, {"name": "thrombosis", "ent_type": "Disease", "char_span": [134, 144], "ent_id": "D013927", "tok_span": [28, 29]}, {"name": "thrombolysis", "ent_type": "Disease", "char_span": [40, 52], "ent_id": "D055499", "tok_span": [10, 12]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [112, 128], "ent_id": "D013921", "tok_span": [25, 27]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [96, 103], "ent_id": "D006493", "tok_span": [22, 23]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [96, 103], "obj_char_span": [112, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "entity_list": [{"name": "thrombosis", "ent_type": "Disease", "char_span": [93, 103], "ent_id": "D013927", "tok_span": [16, 17]}, {"name": "argatroban", "ent_type": "Chemical", "char_span": [132, 142], "ent_id": "C031942", "tok_span": [25, 29]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [71, 87], "ent_id": "D013921", "tok_span": [13, 15]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [55, 62], "ent_id": "D006493", "tok_span": [10, 11]}, {"name": "thrombolysis", "ent_type": "Disease", "char_span": [166, 178], "ent_id": "D055499", "tok_span": [33, 35]}, {"name": "HITT", "ent_type": "Disease", "char_span": [105, 109], "ent_id": "D01392", "tok_span": [18, 20]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [55, 62], "obj_char_span": [71, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.", "entity_list": [{"name": "pulmonary embolism", "ent_type": "Disease", "char_span": [227, 245], "ent_id": "D011655", "tok_span": [40, 42]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [275, 291], "ent_id": "D013921", "tok_span": [47, 49]}, {"name": "amyloidosis", "ent_type": "Disease", "char_span": [48, 59], "ent_id": "D000686", "tok_span": [12, 14]}, {"name": "upper-extremity deep venous thrombosis", "ent_type": "Disease", "char_span": [178, 216], "ent_id": "D056824", "tok_span": [29, 35]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [259, 266], "ent_id": "D006493", "tok_span": [44, 45]}, {"name": "DVT", "ent_type": "Disease", "char_span": [218, 221], "ent_id": "D020246", "tok_span": [36, 38]}], "relation_list": [{"subject": "heparin", "object": "pulmonary embolism", "sbj_char_span": [259, 266], "obj_char_span": [227, 245], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [40, 42]}, {"subject": "heparin", "object": "DVT", "sbj_char_span": [259, 266], "obj_char_span": [218, 221], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [36, 38]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [259, 266], "obj_char_span": [275, 291], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [47, 49]}], "umls_entity_list": []}, {"text": "Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice.", "entity_list": [{"name": "dehydroepiandrosterone", "ent_type": "Chemical", "char_span": [11, 33], "ent_id": "D003687", "tok_span": [2, 9]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [37, 48], "ent_id": "D000661", "tok_span": [10, 14]}, {"name": "schizophrenia", "ent_type": "Disease", "char_span": [57, 70], "ent_id": "D012559", "tok_span": [16, 17]}], "relation_list": [{"subject": "amphetamine", "object": "schizophrenia", "sbj_char_span": [37, 48], "obj_char_span": [57, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "entity_list": [{"name": "apomorphine", "ent_type": "Chemical", "char_span": [51, 62], "ent_id": "D001058", "tok_span": [16, 21]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [152, 161], "ent_id": "D002375", "tok_span": [52, 55]}, {"name": "hyper", "ent_type": "Disease", "char_span": [33, 38], "ent_id": "D006948", "tok_span": [13, 14]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [117, 128], "ent_id": "D006220", "tok_span": [39, 42]}, {"name": "Amphetamine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D000661", "tok_span": [0, 5]}, {"name": "schizophrenia", "ent_type": "Disease", "char_span": [198, 211], "ent_id": "D012559", "tok_span": [62, 63]}], "relation_list": [{"subject": "haloperidol", "object": "schizophrenia", "sbj_char_span": [117, 128], "obj_char_span": [198, 211], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [62, 63]}, {"subject": "apomorphine", "object": "schizophrenia", "sbj_char_span": [51, 62], "obj_char_span": [198, 211], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 21], "obj_tok_span": [62, 63]}, {"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [117, 128], "obj_char_span": [152, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [52, 55]}, {"subject": "Amphetamine", "object": "schizophrenia", "sbj_char_span": [0, 11], "obj_char_span": [198, 211], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [62, 63]}], "umls_entity_list": []}, {"text": "There was a significant difference between groups in the haloperidol-induced catalepsy test (p<0.05).", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [57, 68], "ent_id": "D006220", "tok_span": [9, 12]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [77, 86], "ent_id": "D002375", "tok_span": [14, 17]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [57, 68], "obj_char_span": [77, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD). hiPS-CMs using MEA system and FPDc can predict the effects of drug candidates on QT interval.", "entity_list": [{"name": "Torsade de Pointes", "ent_type": "Disease", "char_span": [83, 101], "ent_id": "D016171", "tok_span": [22, 28]}, {"name": "TdP", "ent_type": "Disease", "char_span": [103, 106], "ent_id": "D016171", "tok_span": [29, 32]}, {"name": "Citalopram", "ent_type": "Chemical", "char_span": [43, 53], "ent_id": "D015283", "tok_span": [12, 16]}, {"name": "Terfenadine", "ent_type": "Chemical", "char_span": [27, 38], "ent_id": "D016593", "tok_span": [7, 11]}], "relation_list": [{"subject": "Citalopram", "object": "Torsade de Pointes", "sbj_char_span": [43, 53], "obj_char_span": [83, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [22, 28]}, {"subject": "Terfenadine", "object": "TdP", "sbj_char_span": [27, 38], "obj_char_span": [103, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [29, 32]}, {"subject": "Terfenadine", "object": "Torsade de Pointes", "sbj_char_span": [27, 38], "obj_char_span": [83, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [22, 28]}, {"subject": "Citalopram", "object": "TdP", "sbj_char_span": [43, 53], "obj_char_span": [103, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "entity_list": [{"name": "ventricular septal defects", "ent_type": "Disease", "char_span": [114, 140], "ent_id": "D006345", "tok_span": [32, 35]}, {"name": "teratogenicity", "ent_type": "Disease", "char_span": [91, 105], "ent_id": "D064793", "tok_span": [26, 30]}, {"name": "S-53482", "ent_type": "Chemical", "char_span": [12, 19], "ent_id": "C106487", "tok_span": [2, 7]}, {"name": "growth retardation", "ent_type": "Disease", "char_span": [161, 179], "ent_id": "D005317", "tok_span": [43, 45]}, {"name": "S-23121", "ent_type": "Chemical", "char_span": [24, 31], "ent_id": "C083440", "tok_span": [8, 12]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [223, 231], "ent_id": "D064420", "tok_span": [51, 52]}, {"name": "embryolethality", "ent_type": "Disease", "char_span": [74, 89], "ent_id": "D020964", "tok_span": [21, 25]}], "relation_list": [{"subject": "S-53482", "object": "embryolethality", "sbj_char_span": [12, 19], "obj_char_span": [74, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [21, 25]}, {"subject": "S-53482", "object": "growth retardation", "sbj_char_span": [12, 19], "obj_char_span": [161, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [43, 45]}, {"subject": "S-23121", "object": "ventricular septal defects", "sbj_char_span": [24, 31], "obj_char_span": [114, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [32, 35]}, {"subject": "S-23121", "object": "growth retardation", "sbj_char_span": [24, 31], "obj_char_span": [161, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [43, 45]}, {"subject": "S-23121", "object": "teratogenicity", "sbj_char_span": [24, 31], "obj_char_span": [91, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [26, 30]}, {"subject": "S-53482", "object": "teratogenicity", "sbj_char_span": [12, 19], "obj_char_span": [91, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [26, 30]}, {"subject": "S-23121", "object": "embryolethality", "sbj_char_span": [24, 31], "obj_char_span": [74, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [21, 25]}, {"subject": "S-53482", "object": "ventricular septal defects", "sbj_char_span": [12, 19], "obj_char_span": [114, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "Dermal administration of S-23121 at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121.", "entity_list": [{"name": "S-23121", "ent_type": "Chemical", "char_span": [211, 218], "ent_id": "C083440", "tok_span": [41, 45]}, {"name": "embryonic death", "ent_type": "Disease", "char_span": [84, 99], "ent_id": "D020964", "tok_span": [19, 21]}, {"name": "ventricular septal defect", "ent_type": "Disease", "char_span": [104, 129], "ent_id": "D006345", "tok_span": [22, 25]}, {"name": "S-23121", "ent_type": "Chemical", "char_span": [25, 32], "ent_id": "C083440", "tok_span": [4, 8]}], "relation_list": [{"subject": "S-23121", "object": "ventricular septal defect", "sbj_char_span": [25, 32], "obj_char_span": [104, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [22, 25]}, {"subject": "S-23121", "object": "embryonic death", "sbj_char_span": [211, 218], "obj_char_span": [84, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [19, 21]}, {"subject": "S-23121", "object": "ventricular septal defect", "sbj_char_span": [211, 218], "obj_char_span": [104, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [22, 25]}, {"subject": "S-23121", "object": "embryonic death", "sbj_char_span": [25, 32], "obj_char_span": [84, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Based on the results, S-53482 and S-23121 were teratogenic when administered dermally to pregnant rats as were the compounds administered orally.", "entity_list": [{"name": "S-23121", "ent_type": "Chemical", "char_span": [47, 54], "ent_id": "C083440", "tok_span": [13, 17]}, {"name": "teratogenic", "ent_type": "Disease", "char_span": [60, 71], "ent_id": "D064793", "tok_span": [18, 21]}, {"name": "S-53482", "ent_type": "Chemical", "char_span": [35, 42], "ent_id": "C106487", "tok_span": [7, 12]}], "relation_list": [{"subject": "S-53482", "object": "teratogenic", "sbj_char_span": [35, 42], "obj_char_span": [60, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [18, 21]}, {"subject": "S-23121", "object": "teratogenic", "sbj_char_span": [47, 54], "obj_char_span": [60, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.", "entity_list": [{"name": "learning and memory impairments", "ent_type": "Disease", "char_span": [37, 68], "ent_id": "D00785", "tok_span": [6, 10]}, {"name": "seizures", "ent_type": "Disease", "char_span": [27, 35], "ent_id": "D012640", "tok_span": [4, 5]}, {"name": "pentylenetetrazole", "ent_type": "Chemical", "char_span": [101, 119], "ent_id": "D010433", "tok_span": [15, 20]}, {"name": "Metformin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D008687", "tok_span": [0, 2]}], "relation_list": [{"subject": "pentylenetetrazole", "object": "seizures", "sbj_char_span": [101, 119], "obj_char_span": [27, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 20], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.", "entity_list": [{"name": "pentylenetetrazole", "ent_type": "Chemical", "char_span": [155, 173], "ent_id": "D010433", "tok_span": [24, 29]}, {"name": "metformin", "ent_type": "Chemical", "char_span": [64, 73], "ent_id": "D008687", "tok_span": [11, 12]}, {"name": "seizures", "ent_type": "Disease", "char_span": [77, 85], "ent_id": "D012640", "tok_span": [13, 14]}, {"name": "cognitive impairment", "ent_type": "Disease", "char_span": [87, 107], "ent_id": "D003072", "tok_span": [15, 17]}], "relation_list": [{"subject": "pentylenetetrazole", "object": "seizures", "sbj_char_span": [155, 173], "obj_char_span": [77, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 29], "obj_tok_span": [13, 14]}, {"subject": "pentylenetetrazole", "object": "cognitive impairment", "sbj_char_span": [155, 173], "obj_char_span": [87, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 29], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Children are particularly sensitive to DOX-induced heart failure.", "entity_list": [{"name": "heart failure", "ent_type": "Disease", "char_span": [51, 64], "ent_id": "D006333", "tok_span": [8, 10]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [39, 42], "ent_id": "D004317", "tok_span": [5, 6]}], "relation_list": [{"subject": "DOX", "object": "heart failure", "sbj_char_span": [39, 42], "obj_char_span": [51, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Metronidazole-induced encephalopathy: an uncommon scenario.", "entity_list": [{"name": "Metronidazole", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D008795", "tok_span": [0, 5]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [22, 36], "ent_id": "D001927", "tok_span": [7, 9]}], "relation_list": [{"subject": "Metronidazole", "object": "encephalopathy", "sbj_char_span": [0, 13], "obj_char_span": [22, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "We present a case where a patient developed features of encephalopathy following prolonged metronidazole intake.", "entity_list": [{"name": "encephalopathy", "ent_type": "Disease", "char_span": [56, 70], "ent_id": "D001927", "tok_span": [10, 12]}, {"name": "metronidazole", "ent_type": "Chemical", "char_span": [91, 104], "ent_id": "D008795", "tok_span": [14, 19]}], "relation_list": [{"subject": "metronidazole", "object": "encephalopathy", "sbj_char_span": [91, 104], "obj_char_span": [56, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Aconitine-induced Ca2+ overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats.", "entity_list": [{"name": "Aconitine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D000157", "tok_span": [0, 3]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [39, 49], "ent_id": "D001145", "tok_span": [10, 12]}, {"name": "Ca", "ent_type": "Chemical", "char_span": [18, 20], "ent_id": "D002118", "tok_span": [5, 6]}], "relation_list": [{"subject": "Aconitine", "object": "arrhythmia", "sbj_char_span": [0, 9], "obj_char_span": [39, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the cardiotoxicity of aconitine.", "entity_list": [{"name": "Na", "ent_type": "Chemical", "char_span": [51, 53], "ent_id": "D012964", "tok_span": [7, 8]}, {"name": "aconitine", "ent_type": "Chemical", "char_span": [110, 119], "ent_id": "D000157", "tok_span": [20, 23]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [92, 106], "ent_id": "D066126", "tok_span": [17, 19]}], "relation_list": [{"subject": "aconitine", "object": "cardiotoxicity", "sbj_char_span": [110, 119], "obj_char_span": [92, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "However, no reports are available on the role of Ca(2+) in aconitine poisoning.", "entity_list": [{"name": "Ca", "ent_type": "Chemical", "char_span": [49, 51], "ent_id": "D002118", "tok_span": [10, 11]}, {"name": "aconitine", "ent_type": "Chemical", "char_span": [59, 68], "ent_id": "D000157", "tok_span": [16, 19]}, {"name": "poisoning", "ent_type": "Disease", "char_span": [69, 78], "ent_id": "D011041", "tok_span": [19, 20]}], "relation_list": [{"subject": "aconitine", "object": "poisoning", "sbj_char_span": [59, 68], "obj_char_span": [69, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo.", "entity_list": [{"name": "Ca", "ent_type": "Chemical", "char_span": [58, 60], "ent_id": "D002118", "tok_span": [10, 11]}, {"name": "poisoning", "ent_type": "Disease", "char_span": [88, 97], "ent_id": "D011041", "tok_span": [20, 21]}, {"name": "aconitine", "ent_type": "Chemical", "char_span": [78, 87], "ent_id": "D000157", "tok_span": [17, 20]}], "relation_list": [{"subject": "aconitine", "object": "poisoning", "sbj_char_span": [78, 87], "obj_char_span": [88, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "Hence, our results suggest that aconitine significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.", "entity_list": [{"name": "Ca", "ent_type": "Chemical", "char_span": [67, 69], "ent_id": "D002118", "tok_span": [12, 13]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [94, 104], "ent_id": "D001145", "tok_span": [20, 22]}, {"name": "aconitine", "ent_type": "Chemical", "char_span": [32, 41], "ent_id": "D000157", "tok_span": [6, 9]}], "relation_list": [{"subject": "aconitine", "object": "arrhythmia", "sbj_char_span": [32, 41], "obj_char_span": [94, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Isoproterenol (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce acute myocardial infarction.", "entity_list": [{"name": "acute myocardial infarction", "ent_type": "Disease", "char_span": [89, 116], "ent_id": "D009203", "tok_span": [24, 27]}, {"name": "Isoproterenol", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D007545", "tok_span": [0, 4]}], "relation_list": [{"subject": "Isoproterenol", "object": "acute myocardial infarction", "sbj_char_span": [0, 13], "obj_char_span": [89, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.", "entity_list": [{"name": "Neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [0, 30], "ent_id": "D009459", "tok_span": [0, 4]}, {"name": "tiapride", "ent_type": "Chemical", "char_span": [85, 93], "ent_id": "D063325", "tok_span": [13, 17]}, {"name": "breast cancer", "ent_type": "Disease", "char_span": [177, 190], "ent_id": "D001943", "tok_span": [34, 36]}, {"name": "Huntington's disease", "ent_type": "Disease", "char_span": [121, 141], "ent_id": "D006816", "tok_span": [22, 28]}, {"name": "tetrabenazine", "ent_type": "Chemical", "char_span": [67, 80], "ent_id": "D013747", "tok_span": [9, 12]}], "relation_list": [{"subject": "tiapride", "object": "Neuroleptic malignant syndrome", "sbj_char_span": [85, 93], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [0, 4]}, {"subject": "tetrabenazine", "object": "Neuroleptic malignant syndrome", "sbj_char_span": [67, 80], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease.", "entity_list": [{"name": "tiapride", "ent_type": "Chemical", "char_span": [168, 176], "ent_id": "D063325", "tok_span": [32, 36]}, {"name": "Huntington's disease", "ent_type": "Disease", "char_span": [225, 245], "ent_id": "D006816", "tok_span": [55, 61]}, {"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [66, 96], "ent_id": "D009459", "tok_span": [15, 21]}, {"name": "tetrabenazine", "ent_type": "Chemical", "char_span": [193, 206], "ent_id": "D013747", "tok_span": [43, 46]}], "relation_list": [{"subject": "tetrabenazine", "object": "neuroleptic malignant syndrome", "sbj_char_span": [193, 206], "obj_char_span": [66, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [15, 21]}, {"subject": "tiapride", "object": "neuroleptic malignant syndrome", "sbj_char_span": [168, 176], "obj_char_span": [66, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 36], "obj_tok_span": [15, 21]}], "umls_entity_list": []}, {"text": "To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported.", "entity_list": [{"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [48, 78], "ent_id": "D009459", "tok_span": [10, 16]}, {"name": "tetrabenazine", "ent_type": "Chemical", "char_span": [111, 124], "ent_id": "D013747", "tok_span": [21, 24]}, {"name": "tiapride", "ent_type": "Chemical", "char_span": [129, 137], "ent_id": "D063325", "tok_span": [25, 29]}], "relation_list": [{"subject": "tetrabenazine", "object": "neuroleptic malignant syndrome", "sbj_char_span": [111, 124], "obj_char_span": [48, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [10, 16]}, {"subject": "tiapride", "object": "neuroleptic malignant syndrome", "sbj_char_span": [129, 137], "obj_char_span": [48, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [10, 16]}], "umls_entity_list": []}, {"text": "A metoprolol-terbinafine combination induced bradycardia.", "entity_list": [{"name": "metoprolol", "ent_type": "Chemical", "char_span": [2, 12], "ent_id": "D008790", "tok_span": [1, 4]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [45, 56], "ent_id": "D001919", "tok_span": [11, 15]}, {"name": "terbinafine", "ent_type": "Chemical", "char_span": [13, 24], "ent_id": "C041359", "tok_span": [5, 9]}], "relation_list": [{"subject": "metoprolol", "object": "bradycardia", "sbj_char_span": [2, 12], "obj_char_span": [45, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [11, 15]}, {"subject": "terbinafine", "object": "bradycardia", "sbj_char_span": [13, 24], "obj_char_span": [45, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Ethambutol is known to cause optic neuropathy and, more rarely, axonal polyneuropathy.", "entity_list": [{"name": "optic neuropathy", "ent_type": "Disease", "char_span": [29, 45], "ent_id": "D009901", "tok_span": [8, 10]}, {"name": "Ethambutol", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D004977", "tok_span": [0, 4]}, {"name": "polyneuropathy", "ent_type": "Disease", "char_span": [71, 85], "ent_id": "D011115", "tok_span": [16, 19]}], "relation_list": [{"subject": "Ethambutol", "object": "polyneuropathy", "sbj_char_span": [0, 10], "obj_char_span": [71, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [16, 19]}, {"subject": "Ethambutol", "object": "optic neuropathy", "sbj_char_span": [0, 10], "obj_char_span": [29, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed visual loss and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ethambutol.", "entity_list": [{"name": "ethambutol", "ent_type": "Chemical", "char_span": [197, 207], "ent_id": "D004977", "tok_span": [42, 46]}, {"name": "visual loss", "ent_type": "Disease", "char_span": [111, 122], "ent_id": "D014786", "tok_span": [23, 25]}, {"name": "paresthesias", "ent_type": "Disease", "char_span": [127, 139], "ent_id": "D010292", "tok_span": [26, 30]}], "relation_list": [{"subject": "ethambutol", "object": "paresthesias", "sbj_char_span": [197, 207], "obj_char_span": [127, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 46], "obj_tok_span": [26, 30]}, {"subject": "ethambutol", "object": "visual loss", "sbj_char_span": [197, 207], "obj_char_span": [111, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 46], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Testosterone ameliorates streptozotocin-induced memory impairment in male rats.", "entity_list": [{"name": "memory impairment", "ent_type": "Disease", "char_span": [48, 65], "ent_id": "D008569", "tok_span": [10, 12]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [25, 39], "ent_id": "D013311", "tok_span": [4, 8]}, {"name": "Testosterone", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D013739", "tok_span": [0, 2]}], "relation_list": [{"subject": "streptozotocin", "object": "memory impairment", "sbj_char_span": [25, 39], "obj_char_span": [48, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.", "entity_list": [{"name": "memory impairment", "ent_type": "Disease", "char_span": [74, 91], "ent_id": "D008569", "tok_span": [19, 21]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [45, 59], "ent_id": "D013311", "tok_span": [9, 13]}, {"name": "testosterone", "ent_type": "Chemical", "char_span": [29, 41], "ent_id": "D013739", "tok_span": [7, 8]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [61, 64], "ent_id": "D013311", "tok_span": [14, 16]}], "relation_list": [{"subject": "streptozotocin", "object": "memory impairment", "sbj_char_span": [45, 59], "obj_char_span": [74, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [19, 21]}, {"subject": "STZ", "object": "memory impairment", "sbj_char_span": [61, 64], "obj_char_span": [74, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity_list": [{"name": "flutamide", "ent_type": "Chemical", "char_span": [18, 27], "ent_id": "D005485", "tok_span": [2, 6]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [173, 176], "ent_id": "D013311", "tok_span": [29, 31]}, {"name": "tamoxifen", "ent_type": "Chemical", "char_span": [42, 51], "ent_id": "D013629", "tok_span": [12, 13]}, {"name": "memory impairment", "ent_type": "Disease", "char_span": [201, 218], "ent_id": "D008569", "tok_span": [38, 40]}, {"name": "letrozole", "ent_type": "Chemical", "char_span": [29, 38], "ent_id": "C067431", "tok_span": [7, 11]}, {"name": "impaired the memory", "ent_type": "Disease", "char_span": [66, 85], "ent_id": "D008569", "tok_span": [14, 17]}, {"name": "testosterone", "ent_type": "Chemical", "char_span": [135, 147], "ent_id": "D013739", "tok_span": [25, 26]}], "relation_list": [{"subject": "letrozole", "object": "impaired the memory", "sbj_char_span": [29, 38], "obj_char_span": [66, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [14, 17]}, {"subject": "tamoxifen", "object": "memory impairment", "sbj_char_span": [42, 51], "obj_char_span": [201, 218], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [38, 40]}, {"subject": "STZ", "object": "memory impairment", "sbj_char_span": [173, 176], "obj_char_span": [201, 218], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [38, 40]}, {"subject": "STZ", "object": "impaired the memory", "sbj_char_span": [173, 176], "obj_char_span": [66, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [14, 17]}, {"subject": "flutamide", "object": "memory impairment", "sbj_char_span": [18, 27], "obj_char_span": [201, 218], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [38, 40]}, {"subject": "flutamide", "object": "impaired the memory", "sbj_char_span": [18, 27], "obj_char_span": [66, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [14, 17]}, {"subject": "tamoxifen", "object": "impaired the memory", "sbj_char_span": [42, 51], "obj_char_span": [66, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [14, 17]}, {"subject": "letrozole", "object": "memory impairment", "sbj_char_span": [29, 38], "obj_char_span": [201, 218], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [38, 40]}], "umls_entity_list": []}, {"text": "CONCLUSION: Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats.", "entity_list": [{"name": "Testosterone", "ent_type": "Chemical", "char_span": [12, 24], "ent_id": "D013739", "tok_span": [2, 4]}, {"name": "memory impairment", "ent_type": "Disease", "char_span": [80, 97], "ent_id": "D008569", "tok_span": [16, 18]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [52, 55], "ent_id": "D013311", "tok_span": [7, 9]}], "relation_list": [{"subject": "STZ", "object": "memory impairment", "sbj_char_span": [52, 55], "obj_char_span": [80, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [84, 95], "ent_id": "D010862", "tok_span": [17, 20]}, {"name": "garcinielliptone FC", "ent_type": "Chemical", "char_span": [61, 80], "ent_id": "C573355", "tok_span": [9, 16]}, {"name": "seizures", "ent_type": "Disease", "char_span": [104, 112], "ent_id": "D012640", "tok_span": [22, 23]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [84, 95], "obj_char_span": [104, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.", "entity_list": [{"name": "GFC", "ent_type": "Chemical", "char_span": [26, 29], "ent_id": "C573355", "tok_span": [4, 6]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [108, 119], "ent_id": "D010862", "tok_span": [21, 24]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [128, 146], "ent_id": "D013226", "tok_span": [26, 29]}, {"name": "seizure", "ent_type": "Disease", "char_span": [196, 203], "ent_id": "D012640", "tok_span": [38, 39]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [108, 119], "obj_char_span": [196, 203], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [38, 39]}, {"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [108, 119], "obj_char_span": [128, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "entity_list": [{"name": "hepatitis C virus infected", "ent_type": "Disease", "char_span": [20, 46], "ent_id": "D006526", "tok_span": [6, 10]}, {"name": "Rhabdomyolysis", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D012206", "tok_span": [0, 4]}, {"name": "simvastatin", "ent_type": "Chemical", "char_span": [83, 94], "ent_id": "D019821", "tok_span": [18, 20]}, {"name": "telaprevir", "ent_type": "Chemical", "char_span": [68, 78], "ent_id": "C486464", "tok_span": [13, 17]}], "relation_list": [{"subject": "simvastatin", "object": "Rhabdomyolysis", "sbj_char_span": [83, 94], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [0, 4]}, {"subject": "telaprevir", "object": "Rhabdomyolysis", "sbj_char_span": [68, 78], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "entity_list": [{"name": "statin", "ent_type": "Chemical", "char_span": [72, 78], "ent_id": "D019821", "tok_span": [11, 12]}, {"name": "muscle toxicity", "ent_type": "Disease", "char_span": [87, 102], "ent_id": "D009135", "tok_span": [13, 15]}, {"name": "statin", "ent_type": "Chemical", "char_span": [142, 148], "ent_id": "D019821", "tok_span": [22, 23]}, {"name": "Simvastatin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D019821", "tok_span": [0, 2]}], "relation_list": [{"subject": "Simvastatin", "object": "muscle toxicity", "sbj_char_span": [0, 11], "obj_char_span": [87, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [13, 15]}, {"subject": "statin", "object": "muscle toxicity", "sbj_char_span": [72, 78], "obj_char_span": [87, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [13, 15]}, {"subject": "statin", "object": "muscle toxicity", "sbj_char_span": [142, 148], "obj_char_span": [87, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.", "entity_list": [{"name": "nephropathy", "ent_type": "Disease", "char_span": [57, 68], "ent_id": "D007674", "tok_span": [11, 12]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [36, 48], "ent_id": "D016572", "tok_span": [7, 9]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [14, 23], "ent_id": "D020123", "tok_span": [3, 5]}], "relation_list": [{"subject": "cyclosporine", "object": "nephropathy", "sbj_char_span": [36, 48], "obj_char_span": [57, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.", "entity_list": [{"name": "cyclosporin A", "ent_type": "Chemical", "char_span": [29, 42], "ent_id": "D016572", "tok_span": [5, 8]}, {"name": "CsA", "ent_type": "Chemical", "char_span": [44, 47], "ent_id": "D016572", "tok_span": [9, 11]}, {"name": "CsA", "ent_type": "Chemical", "char_span": [140, 143], "ent_id": "D016572", "tok_span": [29, 31]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [52, 61], "ent_id": "D020123", "tok_span": [13, 15]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [152, 163], "ent_id": "D007674", "tok_span": [33, 34]}, {"name": "SRL", "ent_type": "Chemical", "char_span": [63, 66], "ent_id": "D020123", "tok_span": [16, 18]}], "relation_list": [{"subject": "CsA", "object": "nephropathy", "sbj_char_span": [44, 47], "obj_char_span": [152, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [33, 34]}, {"subject": "CsA", "object": "nephropathy", "sbj_char_span": [140, 143], "obj_char_span": [152, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [33, 34]}, {"subject": "cyclosporin A", "object": "nephropathy", "sbj_char_span": [29, 42], "obj_char_span": [152, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [33, 34]}], "umls_entity_list": []}, {"text": "SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [27, 38], "ent_id": "D011507", "tok_span": [6, 7]}, {"name": "renal impairment", "ent_type": "Disease", "char_span": [91, 107], "ent_id": "D007674", "tok_span": [20, 22]}, {"name": "SRL", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D020123", "tok_span": [0, 2]}], "relation_list": [{"subject": "SRL", "object": "proteinuria", "sbj_char_span": [0, 3], "obj_char_span": [27, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.", "entity_list": [{"name": "CsA", "ent_type": "Chemical", "char_span": [6, 9], "ent_id": "D016572", "tok_span": [1, 3]}, {"name": "kidney lesions", "ent_type": "Disease", "char_span": [52, 66], "ent_id": "D007674", "tok_span": [9, 11]}], "relation_list": [{"subject": "CsA", "object": "kidney lesions", "sbj_char_span": [6, 9], "obj_char_span": [52, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 3], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.", "entity_list": [{"name": "renal damage", "ent_type": "Disease", "char_span": [34, 46], "ent_id": "D007674", "tok_span": [8, 10]}, {"name": "CsA", "ent_type": "Chemical", "char_span": [10, 13], "ent_id": "D016572", "tok_span": [3, 5]}], "relation_list": [{"subject": "CsA", "object": "renal damage", "sbj_char_span": [10, 13], "obj_char_span": [34, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.", "entity_list": [{"name": "renal damage", "ent_type": "Disease", "char_span": [40, 52], "ent_id": "D007674", "tok_span": [10, 12]}, {"name": "CsA", "ent_type": "Chemical", "char_span": [28, 31], "ent_id": "D016572", "tok_span": [6, 8]}, {"name": "SRL", "ent_type": "Chemical", "char_span": [179, 182], "ent_id": "D020123", "tok_span": [40, 42]}, {"name": "SRL", "ent_type": "Chemical", "char_span": [14, 17], "ent_id": "D020123", "tok_span": [3, 5]}, {"name": "CsA", "ent_type": "Chemical", "char_span": [160, 163], "ent_id": "D016572", "tok_span": [36, 38]}], "relation_list": [{"subject": "CsA", "object": "renal damage", "sbj_char_span": [160, 163], "obj_char_span": [40, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 38], "obj_tok_span": [10, 12]}, {"subject": "CsA", "object": "renal damage", "sbj_char_span": [28, 31], "obj_char_span": [40, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.", "entity_list": [{"name": "cisplatin", "ent_type": "Chemical", "char_span": [52, 61], "ent_id": "D002945", "tok_span": [11, 12]}, {"name": "acute renal injury", "ent_type": "Disease", "char_span": [70, 88], "ent_id": "D058186", "tok_span": [14, 17]}], "relation_list": [{"subject": "cisplatin", "object": "acute renal injury", "sbj_char_span": [52, 61], "obj_char_span": [70, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity_list": [{"name": "acute kidney injury", "ent_type": "Disease", "char_span": [91, 110], "ent_id": "D058186", "tok_span": [20, 23]}, {"name": "acute tubular necrosis", "ent_type": "Disease", "char_span": [222, 244], "ent_id": "D007683", "tok_span": [42, 45]}, {"name": "urea", "ent_type": "Chemical", "char_span": [203, 207], "ent_id": "D014508", "tok_span": [38, 39]}, {"name": "Cisplatin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D002945", "tok_span": [0, 3]}, {"name": "creatinine", "ent_type": "Chemical", "char_span": [188, 198], "ent_id": "D003404", "tok_span": [36, 37]}], "relation_list": [{"subject": "Cisplatin", "object": "acute tubular necrosis", "sbj_char_span": [0, 9], "obj_char_span": [222, 244], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [42, 45]}, {"subject": "Cisplatin", "object": "acute kidney injury", "sbj_char_span": [0, 9], "obj_char_span": [91, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "To examine the role of the kinin B2 receptor in cisplatin-induced acute kidney injury, kinin B2 receptor knockout mice were challenged with cisplatin.", "entity_list": [{"name": "cisplatin", "ent_type": "Chemical", "char_span": [48, 57], "ent_id": "D002945", "tok_span": [12, 13]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [140, 149], "ent_id": "D002945", "tok_span": [29, 30]}, {"name": "acute kidney injury", "ent_type": "Disease", "char_span": [66, 85], "ent_id": "D058186", "tok_span": [15, 18]}], "relation_list": [{"subject": "cisplatin", "object": "acute kidney injury", "sbj_char_span": [48, 57], "obj_char_span": [66, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 18]}, {"subject": "cisplatin", "object": "acute kidney injury", "sbj_char_span": [140, 149], "obj_char_span": [66, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function.", "entity_list": [{"name": "necrotic", "ent_type": "Disease", "char_span": [120, 128], "ent_id": "D009336", "tok_span": [24, 25]}, {"name": "acute kidney injury", "ent_type": "Disease", "char_span": [83, 102], "ent_id": "D058186", "tok_span": [18, 21]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [65, 74], "ent_id": "D002945", "tok_span": [15, 16]}], "relation_list": [{"subject": "cisplatin", "object": "acute kidney injury", "sbj_char_span": [65, 74], "obj_char_span": [83, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.", "entity_list": [{"name": "rocuronium", "ent_type": "Chemical", "char_span": [30, 40], "ent_id": "C061870", "tok_span": [7, 10]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [89, 104], "ent_id": "D013390", "tok_span": [20, 23]}, {"name": "myalgia", "ent_type": "Disease", "char_span": [71, 78], "ent_id": "D063806", "tok_span": [16, 19]}, {"name": "fasciculation", "ent_type": "Disease", "char_span": [53, 66], "ent_id": "D005207", "tok_span": [12, 15]}], "relation_list": [{"subject": "succinylcholine", "object": "fasciculation", "sbj_char_span": [89, 104], "obj_char_span": [53, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [12, 15]}, {"subject": "succinylcholine", "object": "myalgia", "sbj_char_span": [89, 104], "obj_char_span": [71, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "BACKGROUND: Succinylcholine commonly produces frequent adverse effects, including muscle fasciculation and myalgia.", "entity_list": [{"name": "Succinylcholine", "ent_type": "Chemical", "char_span": [12, 27], "ent_id": "D013390", "tok_span": [2, 6]}, {"name": "muscle fasciculation", "ent_type": "Disease", "char_span": [82, 102], "ent_id": "D005207", "tok_span": [13, 17]}, {"name": "myalgia", "ent_type": "Disease", "char_span": [107, 114], "ent_id": "D063806", "tok_span": [18, 21]}], "relation_list": [{"subject": "Succinylcholine", "object": "muscle fasciculation", "sbj_char_span": [12, 27], "obj_char_span": [82, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [13, 17]}, {"subject": "Succinylcholine", "object": "myalgia", "sbj_char_span": [12, 27], "obj_char_span": [107, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "entity_list": [{"name": "myalgia", "ent_type": "Disease", "char_span": [113, 120], "ent_id": "D063806", "tok_span": [22, 25]}, {"name": "rocuronium", "ent_type": "Chemical", "char_span": [49, 59], "ent_id": "C061870", "tok_span": [8, 11]}, {"name": "fasciculation", "ent_type": "Disease", "char_span": [95, 108], "ent_id": "D005207", "tok_span": [18, 21]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [197, 212], "ent_id": "D013390", "tok_span": [40, 43]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [71, 86], "ent_id": "D013390", "tok_span": [13, 16]}, {"name": "rocuronium", "ent_type": "Chemical", "char_span": [152, 162], "ent_id": "C061870", "tok_span": [30, 33]}], "relation_list": [{"subject": "succinylcholine", "object": "myalgia", "sbj_char_span": [71, 86], "obj_char_span": [113, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [22, 25]}, {"subject": "succinylcholine", "object": "fasciculation", "sbj_char_span": [71, 86], "obj_char_span": [95, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 21]}, {"subject": "succinylcholine", "object": "myalgia", "sbj_char_span": [197, 212], "obj_char_span": [113, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 43], "obj_tok_span": [22, 25]}, {"subject": "succinylcholine", "object": "fasciculation", "sbj_char_span": [197, 212], "obj_char_span": [95, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 43], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "All patients received succinylcholine 1.5 mg/kg at 2 minutes after the precurarization, and were assessed the incidence and severity of fasciculations, while myalgia was assessed at 24 hours after surgery.", "entity_list": [{"name": "succinylcholine", "ent_type": "Chemical", "char_span": [22, 37], "ent_id": "D013390", "tok_span": [3, 6]}, {"name": "myalgia", "ent_type": "Disease", "char_span": [158, 165], "ent_id": "D063806", "tok_span": [35, 38]}, {"name": "fasciculations", "ent_type": "Disease", "char_span": [136, 150], "ent_id": "D005207", "tok_span": [30, 33]}], "relation_list": [{"subject": "succinylcholine", "object": "fasciculations", "sbj_char_span": [22, 37], "obj_char_span": [136, 150], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [30, 33]}, {"subject": "succinylcholine", "object": "myalgia", "sbj_char_span": [22, 37], "obj_char_span": [158, 165], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [35, 38]}], "umls_entity_list": []}, {"text": "Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus.", "entity_list": [{"name": "nephrogenic diabetes insipidus", "ent_type": "Disease", "char_span": [48, 78], "ent_id": "D018500", "tok_span": [11, 18]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [32, 39], "ent_id": "D008094", "tok_span": [8, 9]}], "relation_list": [{"subject": "lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [32, 39], "obj_char_span": [48, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [11, 18]}], "umls_entity_list": []}, {"text": "Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus (NDI) in  40% of patients.", "entity_list": [{"name": "NDI", "ent_type": "Disease", "char_span": [77, 80], "ent_id": "D018500", "tok_span": [17, 19]}, {"name": "nephrogenic diabetes insipidus", "ent_type": "Disease", "char_span": [45, 75], "ent_id": "D018500", "tok_span": [9, 16]}, {"name": "Lithium", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D008094", "tok_span": [0, 2]}], "relation_list": [{"subject": "Lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [0, 7], "obj_char_span": [45, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [9, 16]}, {"subject": "Lithium", "object": "NDI", "sbj_char_span": [0, 7], "obj_char_span": [77, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium-induced polyuria.", "entity_list": [{"name": "polyuria", "ent_type": "Disease", "char_span": [131, 139], "ent_id": "D011141", "tok_span": [24, 26]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [115, 122], "ent_id": "D008094", "tok_span": [21, 22]}], "relation_list": [{"subject": "lithium", "object": "polyuria", "sbj_char_span": [115, 122], "obj_char_span": [131, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.", "entity_list": [{"name": "NDI", "ent_type": "Disease", "char_span": [116, 119], "ent_id": "D018500", "tok_span": [24, 26]}, {"name": "polyuria", "ent_type": "Disease", "char_span": [164, 172], "ent_id": "D011141", "tok_span": [34, 36]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [100, 107], "ent_id": "D008094", "tok_span": [21, 22]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [189, 196], "ent_id": "D008094", "tok_span": [38, 39]}], "relation_list": [{"subject": "lithium", "object": "NDI", "sbj_char_span": [100, 107], "obj_char_span": [116, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [24, 26]}, {"subject": "lithium", "object": "polyuria", "sbj_char_span": [100, 107], "obj_char_span": [164, 172], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [34, 36]}, {"subject": "lithium", "object": "polyuria", "sbj_char_span": [189, 196], "obj_char_span": [164, 172], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 39], "obj_tok_span": [34, 36]}, {"subject": "lithium", "object": "NDI", "sbj_char_span": [189, 196], "obj_char_span": [116, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 39], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Is Dysguesia Going to be a Rare or a Common Side-effect of Amlodipine?", "entity_list": [{"name": "Amlodipine", "ent_type": "Chemical", "char_span": [59, 69], "ent_id": "D017311", "tok_span": [19, 23]}, {"name": "Dysguesia", "ent_type": "Disease", "char_span": [3, 12], "ent_id": "D004408", "tok_span": [1, 4]}], "relation_list": [{"subject": "Amlodipine", "object": "Dysguesia", "sbj_char_span": [59, 69], "obj_char_span": [3, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "A very rare side-effect of amlodipine is dysguesia.", "entity_list": [{"name": "amlodipine", "ent_type": "Chemical", "char_span": [27, 37], "ent_id": "D017311", "tok_span": [7, 11]}, {"name": "dysguesia", "ent_type": "Disease", "char_span": [41, 50], "ent_id": "D004408", "tok_span": [12, 15]}], "relation_list": [{"subject": "amlodipine", "object": "dysguesia", "sbj_char_span": [27, 37], "obj_char_span": [41, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "We conclude that amlodipine can cause dysguesia.", "entity_list": [{"name": "amlodipine", "ent_type": "Chemical", "char_span": [17, 27], "ent_id": "D017311", "tok_span": [3, 7]}, {"name": "dysguesia", "ent_type": "Disease", "char_span": [38, 47], "ent_id": "D004408", "tok_span": [9, 12]}], "relation_list": [{"subject": "amlodipine", "object": "dysguesia", "sbj_char_span": [17, 27], "obj_char_span": [38, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Here, we describe the clinical presentation and review the relevant literature on amlodipine and dysguesia.", "entity_list": [{"name": "dysguesia", "ent_type": "Disease", "char_span": [97, 106], "ent_id": "D004408", "tok_span": [18, 21]}, {"name": "amlodipine", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D017311", "tok_span": [13, 17]}], "relation_list": [{"subject": "amlodipine", "object": "dysguesia", "sbj_char_span": [82, 92], "obj_char_span": [97, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.", "entity_list": [{"name": "clarithromycin", "ent_type": "Chemical", "char_span": [71, 85], "ent_id": "D017291", "tok_span": [13, 16]}, {"name": "Rhabdomyolysis", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D012206", "tok_span": [0, 4]}, {"name": "simvastatin", "ent_type": "Chemical", "char_span": [35, 46], "ent_id": "D019821", "tok_span": [7, 9]}], "relation_list": [{"subject": "clarithromycin", "object": "Rhabdomyolysis", "sbj_char_span": [71, 85], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [0, 4]}, {"subject": "simvastatin", "object": "Rhabdomyolysis", "sbj_char_span": [35, 46], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "This particular case is of interest as rhabdomyolysis only occurred after an increase in the dose of clarithromycin.", "entity_list": [{"name": "clarithromycin", "ent_type": "Chemical", "char_span": [101, 115], "ent_id": "D017291", "tok_span": [20, 23]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [39, 53], "ent_id": "D012206", "tok_span": [7, 11]}], "relation_list": [{"subject": "clarithromycin", "object": "rhabdomyolysis", "sbj_char_span": [101, 115], "obj_char_span": [39, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Our case suggests that troponin elevation could be associated with statin induced rhabdomyolysis, which may warrant further studies.", "entity_list": [{"name": "statin", "ent_type": "Chemical", "char_span": [67, 73], "ent_id": "D019821", "tok_span": [11, 12]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [82, 96], "ent_id": "D012206", "tok_span": [13, 17]}], "relation_list": [{"subject": "statin", "object": "rhabdomyolysis", "sbj_char_span": [67, 73], "obj_char_span": [82, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Characterization of a novel BCHE \"silent\" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.", "entity_list": [{"name": "suxamethonium", "ent_type": "Chemical", "char_span": [128, 141], "ent_id": "D013390", "tok_span": [30, 35]}, {"name": "apnea", "ent_type": "Disease", "char_span": [117, 122], "ent_id": "D001049", "tok_span": [28, 29]}], "relation_list": [{"subject": "suxamethonium", "object": "apnea", "sbj_char_span": [128, 141], "obj_char_span": [117, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [28, 29]}], "umls_entity_list": []}, {"text": "Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.", "entity_list": [{"name": "suxamethonium", "ent_type": "Chemical", "char_span": [104, 117], "ent_id": "D013390", "tok_span": [20, 25]}, {"name": "apnea", "ent_type": "Disease", "char_span": [63, 68], "ent_id": "D001049", "tok_span": [11, 12]}, {"name": "Butyrylcholinesterase deficiency", "ent_type": "Disease", "char_span": [0, 32], "ent_id": "C537417", "tok_span": [0, 7]}, {"name": "mivacurium", "ent_type": "Chemical", "char_span": [121, 131], "ent_id": "C049430", "tok_span": [26, 29]}], "relation_list": [{"subject": "suxamethonium", "object": "apnea", "sbj_char_span": [104, 117], "obj_char_span": [63, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [11, 12]}, {"subject": "mivacurium", "object": "apnea", "sbj_char_span": [121, 131], "obj_char_span": [63, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [11, 12]}, {"subject": "mivacurium", "object": "Butyrylcholinesterase deficiency", "sbj_char_span": [121, 131], "obj_char_span": [0, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [0, 7]}, {"subject": "suxamethonium", "object": "Butyrylcholinesterase deficiency", "sbj_char_span": [104, 117], "obj_char_span": [0, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [0, 7]}], "umls_entity_list": []}, {"text": "Cases of delayed hemolytic anemia have been described after treatment with injectable artesunate, the current World Health Organization (WHO)-recommended first-line drug for the treatment of severe malaria.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [17, 33], "ent_id": "D000743", "tok_span": [3, 6]}, {"name": "artesunate", "ent_type": "Chemical", "char_span": [86, 96], "ent_id": "C039726", "tok_span": [14, 18]}, {"name": "malaria", "ent_type": "Disease", "char_span": [198, 205], "ent_id": "D008288", "tok_span": [38, 39]}], "relation_list": [{"subject": "artesunate", "object": "hemolytic anemia", "sbj_char_span": [86, 96], "obj_char_span": [17, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days.", "entity_list": [{"name": "myocardial ischemic injury", "ent_type": "Disease", "char_span": [6, 32], "ent_id": "D017202", "tok_span": [1, 4]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [82, 95], "ent_id": "D007545", "tok_span": [12, 16]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial ischemic injury", "sbj_char_span": [82, 95], "obj_char_span": [6, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.", "entity_list": [{"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [96, 115], "ent_id": "D017202", "tok_span": [18, 20]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [68, 81], "ent_id": "D007545", "tok_span": [11, 15]}, {"name": "betaine", "ent_type": "Chemical", "char_span": [36, 43], "ent_id": "D001622", "tok_span": [7, 9]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial ischemia", "sbj_char_span": [68, 81], "obj_char_span": [96, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma.", "entity_list": [{"name": "bipolar", "ent_type": "Disease", "char_span": [36, 43], "ent_id": "D001714", "tok_span": [9, 10]}, {"name": "Quetiapine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "C069541", "tok_span": [0, 3]}, {"name": "hepatocellular carcinoma", "ent_type": "Disease", "char_span": [57, 81], "ent_id": "D006528", "tok_span": [12, 14]}, {"name": "neutropenia", "ent_type": "Disease", "char_span": [19, 30], "ent_id": "D009503", "tok_span": [5, 7]}], "relation_list": [{"subject": "Quetiapine", "object": "neutropenia", "sbj_char_span": [0, 10], "obj_char_span": [19, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.", "entity_list": [{"name": "blood dyscrasias", "ent_type": "Disease", "char_span": [117, 133], "ent_id": "D006402", "tok_span": [27, 32]}, {"name": "neutropenia", "ent_type": "Disease", "char_span": [146, 157], "ent_id": "D009503", "tok_span": [34, 36]}, {"name": "Quetiapine", "ent_type": "Chemical", "char_span": [11, 21], "ent_id": "C069541", "tok_span": [2, 5]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [68, 77], "ent_id": "D003024", "tok_span": [16, 19]}], "relation_list": [{"subject": "Quetiapine", "object": "neutropenia", "sbj_char_span": [11, 21], "obj_char_span": [146, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here.", "entity_list": [{"name": "neutropenia", "ent_type": "Disease", "char_span": [65, 76], "ent_id": "D009503", "tok_span": [10, 12]}, {"name": "quetiapine", "ent_type": "Chemical", "char_span": [98, 108], "ent_id": "C069541", "tok_span": [15, 18]}, {"name": "hepatocellular carcinoma", "ent_type": "Disease", "char_span": [25, 49], "ent_id": "D006528", "tok_span": [6, 8]}], "relation_list": [{"subject": "quetiapine", "object": "neutropenia", "sbj_char_span": [98, 108], "obj_char_span": [65, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "She developed leucopenia after being treated with quetiapine.", "entity_list": [{"name": "leucopenia", "ent_type": "Disease", "char_span": [14, 24], "ent_id": "D007970", "tok_span": [2, 4]}, {"name": "quetiapine", "ent_type": "Chemical", "char_span": [50, 60], "ent_id": "C069541", "tok_span": [8, 11]}], "relation_list": [{"subject": "quetiapine", "object": "leucopenia", "sbj_char_span": [50, 60], "obj_char_span": [14, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Although neutropenia is not a common side effect of quetiapine, physicians should be cautious about its presentation and associated risk factors.", "entity_list": [{"name": "neutropenia", "ent_type": "Disease", "char_span": [22, 33], "ent_id": "D009503", "tok_span": [3, 5]}, {"name": "quetiapine", "ent_type": "Chemical", "char_span": [65, 75], "ent_id": "C069541", "tok_span": [12, 15]}], "relation_list": [{"subject": "quetiapine", "object": "neutropenia", "sbj_char_span": [65, 75], "obj_char_span": [22, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Hepatic dysfunction may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine.", "entity_list": [{"name": "Hepatic dysfunction", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D008107", "tok_span": [0, 3]}, {"name": "fever", "ent_type": "Disease", "char_span": [77, 82], "ent_id": "D005334", "tok_span": [14, 15]}, {"name": "quetiapine", "ent_type": "Chemical", "char_span": [134, 144], "ent_id": "C069541", "tok_span": [24, 27]}], "relation_list": [{"subject": "quetiapine", "object": "fever", "sbj_char_span": [134, 144], "obj_char_span": [77, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "MATERIAL AND METHOD: A 40-year-old woman presented with decreased sensation and paresthesia over her right lateral forearm; the paresthesia had occurred after a steroid injection in the right lateral epicondyle 3 months before.", "entity_list": [{"name": "paresthesia", "ent_type": "Disease", "char_span": [128, 139], "ent_id": "D010292", "tok_span": [27, 30]}, {"name": "paresthesia", "ent_type": "Disease", "char_span": [80, 91], "ent_id": "D010292", "tok_span": [17, 20]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [161, 168], "ent_id": "D013256", "tok_span": [34, 35]}], "relation_list": [{"subject": "steroid", "object": "paresthesia", "sbj_char_span": [161, 168], "obj_char_span": [128, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [27, 30]}, {"subject": "steroid", "object": "paresthesia", "sbj_char_span": [161, 168], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [34, 48], "ent_id": "D007674", "tok_span": [7, 10]}, {"name": "oxygen", "ent_type": "Chemical", "char_span": [119, 125], "ent_id": "D010100", "tok_span": [20, 21]}, {"name": "maleate", "ent_type": "Chemical", "char_span": [18, 25], "ent_id": "C030272", "tok_span": [3, 5]}, {"name": "Curcumin", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D003474", "tok_span": [0, 2]}], "relation_list": [{"subject": "maleate", "object": "nephrotoxicity", "sbj_char_span": [18, 25], "obj_char_span": [34, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity_list": [{"name": "renal injury", "ent_type": "Disease", "char_span": [107, 119], "ent_id": "D007674", "tok_span": [23, 25]}, {"name": "maleate", "ent_type": "Chemical", "char_span": [131, 138], "ent_id": "C030272", "tok_span": [27, 29]}, {"name": "curcumin", "ent_type": "Chemical", "char_span": [59, 67], "ent_id": "D003474", "tok_span": [8, 9]}], "relation_list": [{"subject": "maleate", "object": "renal injury", "sbj_char_span": [131, 138], "obj_char_span": [107, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [8, 19], "ent_id": "D011507", "tok_span": [3, 4]}, {"name": "maleate", "ent_type": "Chemical", "char_span": [79, 86], "ent_id": "C030272", "tok_span": [14, 16]}], "relation_list": [{"subject": "maleate", "object": "proteinuria", "sbj_char_span": [79, 86], "obj_char_span": [8, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "entity_list": [{"name": "kidney injury", "ent_type": "Disease", "char_span": [246, 259], "ent_id": "D007674", "tok_span": [56, 58]}, {"name": "glucose", "ent_type": "Chemical", "char_span": [123, 130], "ent_id": "D005947", "tok_span": [21, 22]}, {"name": "necrosis", "ent_type": "Disease", "char_span": [343, 351], "ent_id": "D009336", "tok_span": [80, 81]}, {"name": "renal injury", "ent_type": "Disease", "char_span": [16, 28], "ent_id": "D007674", "tok_span": [4, 6]}, {"name": "Maleate", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "C030272", "tok_span": [0, 2]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [132, 138], "ent_id": "D012964", "tok_span": [23, 24]}], "relation_list": [{"subject": "Maleate", "object": "necrosis", "sbj_char_span": [0, 7], "obj_char_span": [343, 351], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [80, 81]}, {"subject": "Maleate", "object": "kidney injury", "sbj_char_span": [0, 7], "obj_char_span": [246, 259], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [56, 58]}, {"subject": "Maleate", "object": "renal injury", "sbj_char_span": [0, 7], "obj_char_span": [16, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "It is concluded that curcumin is able to attenuate in vivo maleate-induced nephropathy and in vitro cell damage.", "entity_list": [{"name": "curcumin", "ent_type": "Chemical", "char_span": [21, 29], "ent_id": "D003474", "tok_span": [4, 5]}, {"name": "maleate", "ent_type": "Chemical", "char_span": [59, 66], "ent_id": "C030272", "tok_span": [11, 13]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [75, 86], "ent_id": "D007674", "tok_span": [15, 16]}], "relation_list": [{"subject": "maleate", "object": "nephropathy", "sbj_char_span": [59, 66], "obj_char_span": [75, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.", "entity_list": [{"name": "organophosphate", "ent_type": "Chemical", "char_span": [30, 45], "ent_id": "D010755", "tok_span": [8, 10]}, {"name": "lung cancer", "ent_type": "Disease", "char_span": [116, 127], "ent_id": "D008175", "tok_span": [21, 23]}, {"name": "diazinon", "ent_type": "Chemical", "char_span": [227, 235], "ent_id": "D003976", "tok_span": [41, 44]}, {"name": "cancer", "ent_type": "Disease", "char_span": [247, 253], "ent_id": "D009369", "tok_span": [46, 47]}, {"name": "Diazinon", "ent_type": "Chemical", "char_span": [11, 19], "ent_id": "D003976", "tok_span": [2, 5]}], "relation_list": [{"subject": "diazinon", "object": "lung cancer", "sbj_char_span": [227, 235], "obj_char_span": [116, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 44], "obj_tok_span": [21, 23]}, {"subject": "Diazinon", "object": "lung cancer", "sbj_char_span": [11, 19], "obj_char_span": [116, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "RESULTS: We observed elevated lung cancer risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of diazinon use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08).", "entity_list": [{"name": "diazinon", "ent_type": "Chemical", "char_span": [164, 172], "ent_id": "D003976", "tok_span": [53, 56]}, {"name": "lung cancer", "ent_type": "Disease", "char_span": [30, 41], "ent_id": "D008175", "tok_span": [5, 7]}], "relation_list": [{"subject": "diazinon", "object": "lung cancer", "sbj_char_span": [164, 172], "obj_char_span": [30, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 56], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Our updated evaluation of diazinon provides additional evidence of an association with lung cancer risk.", "entity_list": [{"name": "lung cancer", "ent_type": "Disease", "char_span": [100, 111], "ent_id": "D008175", "tok_span": [16, 18]}, {"name": "diazinon", "ent_type": "Chemical", "char_span": [39, 47], "ent_id": "D003976", "tok_span": [6, 9]}], "relation_list": [{"subject": "diazinon", "object": "lung cancer", "sbj_char_span": [39, 47], "obj_char_span": [100, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study.", "entity_list": [{"name": "Parkinson's Disease", "ent_type": "Disease", "char_span": [52, 71], "ent_id": "D010300", "tok_span": [13, 17]}, {"name": "Ozone", "ent_type": "Chemical", "char_span": [16, 21], "ent_id": "D010126", "tok_span": [3, 5]}], "relation_list": [{"subject": "Ozone", "object": "Parkinson's Disease", "sbj_char_span": [16, 21], "obj_char_span": [52, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "OBJECTIVE: This study describes associations of ozone and fine particulate matter with Parkinson's disease observed among farmers in North Carolina and Iowa.", "entity_list": [{"name": "ozone", "ent_type": "Chemical", "char_span": [48, 53], "ent_id": "D010126", "tok_span": [7, 8]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [87, 106], "ent_id": "D010300", "tok_span": [13, 17]}, {"name": "particulate matter", "ent_type": "Chemical", "char_span": [63, 81], "ent_id": "D052638", "tok_span": [10, 12]}], "relation_list": [{"subject": "particulate matter", "object": "Parkinson's disease", "sbj_char_span": [63, 81], "obj_char_span": [87, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [13, 17]}, {"subject": "ozone", "object": "Parkinson's disease", "sbj_char_span": [48, 53], "obj_char_span": [87, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "RESULTS: We observed positive associations of Parkinson's disease with ozone (odds ratio = 1.39; 95% CI: 0.98 to 1.98) and fine particulate matter (odds ratio = 1.34; 95% CI: 0.93 to 1.93) in North Carolina but not in Iowa.", "entity_list": [{"name": "ozone", "ent_type": "Chemical", "char_span": [71, 76], "ent_id": "D010126", "tok_span": [12, 13]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [46, 65], "ent_id": "D010300", "tok_span": [7, 11]}, {"name": "particulate matter", "ent_type": "Chemical", "char_span": [128, 146], "ent_id": "D052638", "tok_span": [35, 37]}], "relation_list": [{"subject": "ozone", "object": "Parkinson's disease", "sbj_char_span": [71, 76], "obj_char_span": [46, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [7, 11]}, {"subject": "particulate matter", "object": "Parkinson's disease", "sbj_char_span": [128, 146], "obj_char_span": [46, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 37], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring.", "entity_list": [{"name": "caffeine", "ent_type": "Chemical", "char_span": [59, 67], "ent_id": "D002110", "tok_span": [12, 13]}, {"name": "intrauterine growth retardation", "ent_type": "Disease", "char_span": [96, 127], "ent_id": "D005317", "tok_span": [20, 24]}, {"name": "IUGR", "ent_type": "Disease", "char_span": [129, 133], "ent_id": "D005317", "tok_span": [25, 27]}], "relation_list": [{"subject": "caffeine", "object": "intrauterine growth retardation", "sbj_char_span": [59, 67], "obj_char_span": [96, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [20, 24]}, {"subject": "caffeine", "object": "IUGR", "sbj_char_span": [59, 67], "obj_char_span": [129, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "UNASSIGNED: Metolachlor, a widely used herbicide, is classified as a Group C carcinogen by the U.S. Environmental Protection Agency based on increased liver neoplasms in female rats.", "entity_list": [{"name": "Metolachlor", "ent_type": "Chemical", "char_span": [12, 23], "ent_id": "C051786", "tok_span": [5, 8]}, {"name": "liver neoplasms", "ent_type": "Disease", "char_span": [151, 166], "ent_id": "D008113", "tok_span": [35, 37]}], "relation_list": [{"subject": "Metolachlor", "object": "liver neoplasms", "sbj_char_span": [12, 23], "obj_char_span": [151, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "This suggestion of an association between metolachlor and liver cancer among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies.", "entity_list": [{"name": "liver neoplasms", "ent_type": "Disease", "char_span": [154, 169], "ent_id": "D008113", "tok_span": [26, 28]}, {"name": "liver cancer", "ent_type": "Disease", "char_span": [58, 70], "ent_id": "D008113", "tok_span": [10, 12]}, {"name": "metolachlor", "ent_type": "Chemical", "char_span": [42, 53], "ent_id": "C051786", "tok_span": [6, 9]}], "relation_list": [{"subject": "metolachlor", "object": "liver neoplasms", "sbj_char_span": [42, 53], "obj_char_span": [154, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [26, 28]}, {"subject": "metolachlor", "object": "liver cancer", "sbj_char_span": [42, 53], "obj_char_span": [58, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "However, our findings for both liver cancer and follicular cell lymphoma warrant follow-up to better differentiate effects of metolachlor use from other factors.", "entity_list": [{"name": "lymphoma", "ent_type": "Disease", "char_span": [64, 72], "ent_id": "D008223", "tok_span": [11, 12]}, {"name": "metolachlor", "ent_type": "Chemical", "char_span": [126, 137], "ent_id": "C051786", "tok_span": [21, 24]}, {"name": "liver cancer", "ent_type": "Disease", "char_span": [31, 43], "ent_id": "D008113", "tok_span": [6, 8]}], "relation_list": [{"subject": "metolachlor", "object": "liver cancer", "sbj_char_span": [126, 137], "obj_char_span": [31, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "There is considerable interest in identifying the molecular mechanisms that relate early-life iAs exposure to the development of these latent diseases, particularly in relationship to cancer.", "entity_list": [{"name": "cancer", "ent_type": "Disease", "char_span": [184, 190], "ent_id": "D009369", "tok_span": [29, 30]}, {"name": "iAs", "ent_type": "Chemical", "char_span": [94, 97], "ent_id": "D001152", "tok_span": [14, 16]}], "relation_list": [{"subject": "iAs", "object": "cancer", "sbj_char_span": [94, 97], "obj_char_span": [184, 190], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "OBJECTIVES: This work summarizes research on the molecular mechanisms that underlie the increased risk of cancer development in adulthood that is associated with early-life iAs exposure.", "entity_list": [{"name": "iAs", "ent_type": "Chemical", "char_span": [173, 176], "ent_id": "D001152", "tok_span": [27, 29]}, {"name": "cancer", "ent_type": "Disease", "char_span": [106, 112], "ent_id": "D009369", "tok_span": [16, 17]}], "relation_list": [{"subject": "iAs", "object": "cancer", "sbj_char_span": [173, 176], "obj_char_span": [106, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "DISCUSSION: Epigenetic reprogramming that imparts functional changes in gene expression, the development of cancer stem cells, and immunomodulation are plausible underlying mechanisms by which early-life iAs exposure elicits latent carcinogenic effects.", "entity_list": [{"name": "cancer", "ent_type": "Disease", "char_span": [108, 114], "ent_id": "D009369", "tok_span": [18, 19]}, {"name": "iAs", "ent_type": "Chemical", "char_span": [204, 207], "ent_id": "D001152", "tok_span": [34, 36]}], "relation_list": [{"subject": "iAs", "object": "cancer", "sbj_char_span": [204, 207], "obj_char_span": [108, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Evidence is mounting that relates early-life iAs exposure and cancer development later in life.", "entity_list": [{"name": "cancer", "ent_type": "Disease", "char_span": [75, 81], "ent_id": "D009369", "tok_span": [14, 15]}, {"name": "iAs", "ent_type": "Chemical", "char_span": [58, 61], "ent_id": "D001152", "tok_span": [10, 12]}], "relation_list": [{"subject": "iAs", "object": "cancer", "sbj_char_span": [58, 61], "obj_char_span": [75, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Four types of experimental arrhythmia are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.", "entity_list": [{"name": "adrenaline", "ent_type": "Chemical", "char_span": [76, 86], "ent_id": "D004837", "tok_span": [18, 20]}, {"name": "BaCl2", "ent_type": "Chemical", "char_span": [53, 58], "ent_id": "C024986", "tok_span": [11, 14]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [27, 37], "ent_id": "D001145", "tok_span": [4, 6]}, {"name": "aconitine", "ent_type": "Chemical", "char_span": [117, 126], "ent_id": "D000157", "tok_span": [29, 32]}, {"name": "strophantine G", "ent_type": "Chemical", "char_span": [93, 107], "ent_id": "D010042", "tok_span": [22, 27]}, {"name": "chloroform", "ent_type": "Chemical", "char_span": [65, 75], "ent_id": "D002725", "tok_span": [16, 17]}], "relation_list": [{"subject": "aconitine", "object": "arrhythmia", "sbj_char_span": [117, 126], "obj_char_span": [27, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [4, 6]}, {"subject": "strophantine G", "object": "arrhythmia", "sbj_char_span": [93, 107], "obj_char_span": [27, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [4, 6]}, {"subject": "BaCl2", "object": "arrhythmia", "sbj_char_span": [53, 58], "obj_char_span": [27, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [4, 6]}, {"subject": "chloroform", "object": "arrhythmia", "sbj_char_span": [65, 75], "obj_char_span": [27, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [4, 6]}, {"subject": "adrenaline", "object": "arrhythmia", "sbj_char_span": [76, 86], "obj_char_span": [27, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).", "entity_list": [{"name": "chloroform", "ent_type": "Chemical", "char_span": [151, 161], "ent_id": "D002725", "tok_span": [27, 28]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [162, 172], "ent_id": "D004837", "tok_span": [29, 31]}, {"name": "BaCl2", "ent_type": "Chemical", "char_span": [199, 204], "ent_id": "C024986", "tok_span": [39, 42]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [129, 139], "ent_id": "D001145", "tok_span": [23, 25]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [77, 87], "ent_id": "D001145", "tok_span": [14, 16]}], "relation_list": [{"subject": "BaCl2", "object": "arrhythmia", "sbj_char_span": [199, 204], "obj_char_span": [77, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [14, 16]}, {"subject": "chloroform", "object": "arrhythmia", "sbj_char_span": [151, 161], "obj_char_span": [77, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [14, 16]}, {"subject": "adrenaline", "object": "arrhythmia", "sbj_char_span": [162, 172], "obj_char_span": [129, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [23, 25]}, {"subject": "chloroform", "object": "arrhythmia", "sbj_char_span": [151, 161], "obj_char_span": [129, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [23, 25]}, {"subject": "adrenaline", "object": "arrhythmia", "sbj_char_span": [162, 172], "obj_char_span": [77, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [14, 16]}, {"subject": "BaCl2", "object": "arrhythmia", "sbj_char_span": [199, 204], "obj_char_span": [129, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "The authors induced myodystrophy in the rat by giving it a diet lacking in vitamin E. The pharmacological characteristics of vitamin E and the degenerative changes brought about by its deficiency, especially in the muscles, are illustrated.", "entity_list": [{"name": "vitamin E", "ent_type": "Chemical", "char_span": [125, 134], "ent_id": "D014810", "tok_span": [25, 27]}, {"name": "myodystrophy", "ent_type": "Disease", "char_span": [20, 32], "ent_id": "D009136", "tok_span": [3, 8]}, {"name": "vitamin E", "ent_type": "Chemical", "char_span": [75, 84], "ent_id": "D014810", "tok_span": [18, 20]}], "relation_list": [{"subject": "vitamin E", "object": "myodystrophy", "sbj_char_span": [75, 84], "obj_char_span": [20, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [3, 8]}, {"subject": "vitamin E", "object": "myodystrophy", "sbj_char_span": [125, 134], "obj_char_span": [20, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 27], "obj_tok_span": [3, 8]}], "umls_entity_list": []}, {"text": "The baby showed warfarin-induced embryopathy with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata).", "entity_list": [{"name": "stippled epiphyses", "ent_type": "Disease", "char_span": [71, 89], "ent_id": "D002806", "tok_span": [13, 19]}, {"name": "chondrodysplasia punctata", "ent_type": "Disease", "char_span": [91, 116], "ent_id": "D002806", "tok_span": [20, 26]}, {"name": "nasal hypoplasia", "ent_type": "Disease", "char_span": [50, 66], "ent_id": "-1", "tok_span": [9, 12]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [16, 24], "ent_id": "D014859", "tok_span": [3, 4]}, {"name": "embryopathy", "ent_type": "Disease", "char_span": [33, 44], "ent_id": "D005315", "tok_span": [6, 8]}], "relation_list": [{"subject": "warfarin", "object": "chondrodysplasia punctata", "sbj_char_span": [16, 24], "obj_char_span": [91, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [20, 26]}, {"subject": "warfarin", "object": "stippled epiphyses", "sbj_char_span": [16, 24], "obj_char_span": [71, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [13, 19]}], "umls_entity_list": []}, {"text": "Nasal hypoplasia with or without stippled epiphyses has now been reported in 11 infants born to mothers treated with warfarin during the first trimester, and a causal association is probable.", "entity_list": [{"name": "stippled epiphyses", "ent_type": "Disease", "char_span": [33, 51], "ent_id": "D002806", "tok_span": [7, 13]}, {"name": "Nasal hypoplasia", "ent_type": "Disease", "char_span": [0, 16], "ent_id": "-1", "tok_span": [0, 4]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [117, 125], "ent_id": "D014859", "tok_span": [25, 26]}], "relation_list": [{"subject": "warfarin", "object": "stippled epiphyses", "sbj_char_span": [117, 125], "obj_char_span": [33, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [7, 13]}], "umls_entity_list": []}, {"text": "The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.", "entity_list": [{"name": "dizziness", "ent_type": "Disease", "char_span": [37, 46], "ent_id": "D004244", "tok_span": [8, 11]}, {"name": "flushing", "ent_type": "Disease", "char_span": [64, 72], "ent_id": "D005483", "tok_span": [15, 18]}, {"name": "palpitation", "ent_type": "Disease", "char_span": [48, 59], "ent_id": "-1", "tok_span": [12, 14]}, {"name": "headache", "ent_type": "Disease", "char_span": [27, 35], "ent_id": "D006261", "tok_span": [6, 7]}, {"name": "isradipine", "ent_type": "Chemical", "char_span": [142, 152], "ent_id": "D017275", "tok_span": [30, 33]}], "relation_list": [{"subject": "isradipine", "object": "flushing", "sbj_char_span": [142, 152], "obj_char_span": [64, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [15, 18]}, {"subject": "isradipine", "object": "headache", "sbj_char_span": [142, 152], "obj_char_span": [27, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [6, 7]}, {"subject": "isradipine", "object": "dizziness", "sbj_char_span": [142, 152], "obj_char_span": [37, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.", "entity_list": [{"name": "restlessness", "ent_type": "Disease", "char_span": [117, 129], "ent_id": "D011595", "tok_span": [24, 27]}, {"name": "tremors", "ent_type": "Disease", "char_span": [135, 142], "ent_id": "D014202", "tok_span": [29, 31]}, {"name": "palpitations", "ent_type": "Disease", "char_span": [103, 115], "ent_id": "-1", "tok_span": [21, 23]}, {"name": "nausea", "ent_type": "Disease", "char_span": [95, 101], "ent_id": "D009325", "tok_span": [19, 20]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [67, 74], "ent_id": "D001008", "tok_span": [12, 13]}, {"name": "Caffeine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D002110", "tok_span": [0, 4]}], "relation_list": [{"subject": "Caffeine", "object": "anxiety", "sbj_char_span": [0, 8], "obj_char_span": [67, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [12, 13]}, {"subject": "Caffeine", "object": "nausea", "sbj_char_span": [0, 8], "obj_char_span": [95, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [19, 20]}, {"subject": "Caffeine", "object": "tremors", "sbj_char_span": [0, 8], "obj_char_span": [135, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "Patients with anxiety disorders may benefit by avoiding caffeine-containing foods and beverages.", "entity_list": [{"name": "anxiety disorders", "ent_type": "Disease", "char_span": [14, 31], "ent_id": "D001008", "tok_span": [2, 4]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [56, 64], "ent_id": "D002110", "tok_span": [8, 9]}], "relation_list": [{"subject": "caffeine", "object": "anxiety disorders", "sbj_char_span": [56, 64], "obj_char_span": [14, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "In the first, cobalt cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05).", "entity_list": [{"name": "cobalt", "ent_type": "Chemical", "char_span": [14, 20], "ent_id": "D003035", "tok_span": [4, 5]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [21, 35], "ent_id": "D009202", "tok_span": [5, 6]}], "relation_list": [{"subject": "cobalt", "object": "cardiomyopathy", "sbj_char_span": [14, 20], "obj_char_span": [21, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05).", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [17, 28], "ent_id": "D004317", "tok_span": [4, 5]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [37, 50], "ent_id": "D006333", "tok_span": [7, 9]}], "relation_list": [{"subject": "doxorubicin", "object": "heart failure", "sbj_char_span": [17, 28], "obj_char_span": [37, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Five phenotypic characteristics--locomotor activity, righting ability, clonic seizure induction, stress-induced lethality, death without external stress--were scored at various caffeine doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions.", "entity_list": [{"name": "caffeine", "ent_type": "Chemical", "char_span": [177, 185], "ent_id": "D002110", "tok_span": [33, 34]}, {"name": "clonic seizure", "ent_type": "Disease", "char_span": [71, 85], "ent_id": "D012640", "tok_span": [12, 15]}], "relation_list": [{"subject": "caffeine", "object": "clonic seizure", "sbj_char_span": [177, 185], "obj_char_span": [71, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis.", "entity_list": [{"name": "hydroureteronephrosis", "ent_type": "Disease", "char_span": [31, 52], "ent_id": "D006869", "tok_span": [9, 15]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [156, 172], "ent_id": "D003520", "tok_span": [35, 38]}, {"name": "hematuria", "ent_type": "Disease", "char_span": [106, 115], "ent_id": "D006417", "tok_span": [25, 27]}, {"name": "cerebral vasculitis", "ent_type": "Disease", "char_span": [177, 196], "ent_id": "D020293", "tok_span": [39, 42]}], "relation_list": [{"subject": "cyclophosphamide", "object": "hematuria", "sbj_char_span": [156, 172], "obj_char_span": [106, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.", "entity_list": [{"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [24, 40], "ent_id": "D003520", "tok_span": [4, 7]}, {"name": "carcinoma of the urinary tract", "ent_type": "Disease", "char_span": [226, 256], "ent_id": "D014571", "tok_span": [38, 43]}, {"name": "hemorrhagic cystitis", "ent_type": "Disease", "char_span": [50, 70], "ent_id": "D00647", "tok_span": [9, 12]}, {"name": "carcinoma", "ent_type": "Disease", "char_span": [139, 148], "ent_id": "D002277", "tok_span": [22, 23]}], "relation_list": [{"subject": "cyclophosphamide", "object": "carcinoma", "sbj_char_span": [24, 40], "obj_char_span": [139, 148], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine-associated chest pain.", "entity_list": [{"name": "chest pain", "ent_type": "Disease", "char_span": [134, 144], "ent_id": "D002637", "tok_span": [23, 25]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [115, 122], "ent_id": "D003042", "tok_span": [20, 21]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [38, 48], "ent_id": "D004280", "tok_span": [8, 11]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [115, 122], "obj_char_span": [134, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "STUDY OBJECTIVE: Chest pain in the setting of cocaine use poses a diagnostic dilemma.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [46, 53], "ent_id": "D003042", "tok_span": [9, 10]}, {"name": "Chest pain", "ent_type": "Disease", "char_span": [17, 27], "ent_id": "D002637", "tok_span": [3, 5]}], "relation_list": [{"subject": "cocaine", "object": "Chest pain", "sbj_char_span": [46, 53], "obj_char_span": [17, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain.", "entity_list": [{"name": "chest pain", "ent_type": "Disease", "char_span": [217, 227], "ent_id": "D002637", "tok_span": [38, 40]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [198, 205], "ent_id": "D003042", "tok_span": [35, 36]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [63, 73], "ent_id": "D004280", "tok_span": [8, 11]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [92, 99], "ent_id": "D003042", "tok_span": [15, 16]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [198, 205], "obj_char_span": [217, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 36], "obj_tok_span": [38, 40]}, {"subject": "cocaine", "object": "chest pain", "sbj_char_span": [92, 99], "obj_char_span": [217, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [38, 40]}], "umls_entity_list": []}, {"text": "Patients were eligible for DSE if they had used cocaine within 24 hours preceding the onset of chest pain and had a normal ECG and tropinin I level.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [48, 55], "ent_id": "D003042", "tok_span": [10, 11]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [95, 105], "ent_id": "D002637", "tok_span": [18, 20]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [48, 55], "obj_char_span": [95, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine-related chest pain.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [110, 117], "ent_id": "D003042", "tok_span": [19, 20]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [65, 75], "ent_id": "D004280", "tok_span": [11, 14]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [126, 136], "ent_id": "D002637", "tok_span": [22, 24]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [110, 117], "obj_char_span": [126, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Amiodarone-induced torsade de pointes during bladder irrigation: an unusual presentation--a case report.", "entity_list": [{"name": "Amiodarone", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D000638", "tok_span": [0, 4]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [19, 37], "ent_id": "D016171", "tok_span": [6, 11]}], "relation_list": [{"subject": "Amiodarone", "object": "torsade de pointes", "sbj_char_span": [0, 10], "obj_char_span": [19, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "The authors present a case of early (within 4 days) development of torsade de pointes (TdP) associated with oral amiodarone therapy.", "entity_list": [{"name": "TdP", "ent_type": "Disease", "char_span": [87, 90], "ent_id": "D016171", "tok_span": [20, 23]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [113, 123], "ent_id": "D000638", "tok_span": [27, 31]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [67, 85], "ent_id": "D016171", "tok_span": [14, 19]}], "relation_list": [{"subject": "amiodarone", "object": "torsade de pointes", "sbj_char_span": [113, 123], "obj_char_span": [67, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [14, 19]}, {"subject": "amiodarone", "object": "TdP", "sbj_char_span": [113, 123], "obj_char_span": [87, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "In the absence of amiodarone therapy, a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia.", "entity_list": [{"name": "TdP", "ent_type": "Disease", "char_span": [81, 84], "ent_id": "D016171", "tok_span": [17, 20]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [18, 28], "ent_id": "D000638", "tok_span": [4, 8]}, {"name": "hypokalemia", "ent_type": "Disease", "char_span": [93, 104], "ent_id": "D007008", "tok_span": [21, 25]}, {"name": "hypomagnesemia", "ent_type": "Disease", "char_span": [109, 123], "ent_id": "C537153", "tok_span": [26, 30]}], "relation_list": [{"subject": "amiodarone", "object": "TdP", "sbj_char_span": [18, 28], "obj_char_span": [81, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.", "entity_list": [{"name": "Acute renal insufficiency", "ent_type": "Disease", "char_span": [0, 25], "ent_id": "D058186", "tok_span": [0, 3]}, {"name": "melphalan", "ent_type": "Chemical", "char_span": [42, 51], "ent_id": "D008558", "tok_span": [7, 10]}, {"name": "primary systemic amyloidosis", "ent_type": "Disease", "char_span": [69, 97], "ent_id": "C531616", "tok_span": [13, 17]}], "relation_list": [{"subject": "melphalan", "object": "Acute renal insufficiency", "sbj_char_span": [42, 51], "obj_char_span": [0, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "The authors have noted the development of acute renal insufficiency immediately after melphalan conditioning.", "entity_list": [{"name": "acute renal insufficiency", "ent_type": "Disease", "char_span": [42, 67], "ent_id": "D058186", "tok_span": [7, 10]}, {"name": "melphalan", "ent_type": "Chemical", "char_span": [86, 95], "ent_id": "D008558", "tok_span": [12, 15]}], "relation_list": [{"subject": "melphalan", "object": "acute renal insufficiency", "sbj_char_span": [86, 95], "obj_char_span": [42, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.", "entity_list": [{"name": "Acute renal insufficiency", "ent_type": "Disease", "char_span": [0, 25], "ent_id": "D058186", "tok_span": [0, 3]}, {"name": "melphalan", "ent_type": "Chemical", "char_span": [48, 57], "ent_id": "D008558", "tok_span": [11, 14]}, {"name": "creatinine", "ent_type": "Chemical", "char_span": [134, 144], "ent_id": "D003404", "tok_span": [38, 39]}, {"name": "ARI", "ent_type": "Disease", "char_span": [27, 30], "ent_id": "D058186", "tok_span": [4, 6]}], "relation_list": [{"subject": "melphalan", "object": "Acute renal insufficiency", "sbj_char_span": [48, 57], "obj_char_span": [0, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [0, 3]}, {"subject": "melphalan", "object": "ARI", "sbj_char_span": [48, 57], "obj_char_span": [27, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "RESULTS: Of the 80 patients studied, ARI developed in 18.8% of the patients after high-dose melphalan.", "entity_list": [{"name": "ARI", "ent_type": "Disease", "char_span": [37, 40], "ent_id": "D058186", "tok_span": [8, 10]}, {"name": "melphalan", "ent_type": "Chemical", "char_span": [92, 101], "ent_id": "D008558", "tok_span": [23, 26]}], "relation_list": [{"subject": "melphalan", "object": "ARI", "sbj_char_span": [92, 101], "obj_char_span": [37, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Patients who had ARI after high-dose melphalan underwent dialysis more often (P = 0.007), and had a worse 1-year survival (P = 0.03).", "entity_list": [{"name": "ARI", "ent_type": "Disease", "char_span": [17, 20], "ent_id": "D058186", "tok_span": [3, 5]}, {"name": "melphalan", "ent_type": "Chemical", "char_span": [37, 46], "ent_id": "D008558", "tok_span": [9, 12]}], "relation_list": [{"subject": "melphalan", "object": "ARI", "sbj_char_span": [37, 46], "obj_char_span": [17, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "CONCLUSION: The timing of renal injury strongly suggests melphalan as the causative agent.", "entity_list": [{"name": "melphalan", "ent_type": "Chemical", "char_span": [57, 66], "ent_id": "D008558", "tok_span": [9, 12]}, {"name": "renal injury", "ent_type": "Disease", "char_span": [26, 38], "ent_id": "D058186", "tok_span": [5, 7]}], "relation_list": [{"subject": "melphalan", "object": "renal injury", "sbj_char_span": [57, 66], "obj_char_span": [26, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Ongoing tubular injury may be a prerequisite for renal injury by melphalan as evidenced by the active urinary sediment.", "entity_list": [{"name": "tubular injury", "ent_type": "Disease", "char_span": [8, 22], "ent_id": "-1", "tok_span": [2, 4]}, {"name": "renal injury", "ent_type": "Disease", "char_span": [49, 61], "ent_id": "D058186", "tok_span": [9, 11]}, {"name": "melphalan", "ent_type": "Chemical", "char_span": [65, 74], "ent_id": "D008558", "tok_span": [12, 15]}], "relation_list": [{"subject": "melphalan", "object": "renal injury", "sbj_char_span": [65, 74], "obj_char_span": [49, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Impaired fear recognition in regular recreational cocaine users.", "entity_list": [{"name": "Impaired fear recognition", "ent_type": "Disease", "char_span": [0, 25], "ent_id": "D001925", "tok_span": [0, 4]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [50, 57], "ent_id": "D003042", "tok_span": [8, 9]}], "relation_list": [{"subject": "cocaine", "object": "Impaired fear recognition", "sbj_char_span": [50, 57], "obj_char_span": [0, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "The selective deficit in fear recognition accuracy manifested by the RC group cannot be explained by the subacute effects of cocaine, or ecstasy, because recent and less recent users of these drugs within this group were similarly impaired.", "entity_list": [{"name": "ecstasy", "ent_type": "Chemical", "char_span": [137, 144], "ent_id": "D018817", "tok_span": [24, 27]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [125, 132], "ent_id": "D003042", "tok_span": [21, 22]}, {"name": "deficit in fear recognition", "ent_type": "Disease", "char_span": [14, 41], "ent_id": "D001925", "tok_span": [2, 6]}], "relation_list": [{"subject": "cocaine", "object": "deficit in fear recognition", "sbj_char_span": [125, 132], "obj_char_span": [14, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Corneal ulcers associated with aerosolized crack cocaine use.", "entity_list": [{"name": "crack cocaine", "ent_type": "Chemical", "char_span": [43, 56], "ent_id": "D016578", "tok_span": [8, 10]}, {"name": "Corneal ulcers", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D003320", "tok_span": [0, 4]}], "relation_list": [{"subject": "crack cocaine", "object": "Corneal ulcers", "sbj_char_span": [43, 56], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "RESULTS: Four patients with corneal ulcers associated with crack cocaine use were reviewed.", "entity_list": [{"name": "crack cocaine", "ent_type": "Chemical", "char_span": [59, 72], "ent_id": "D016578", "tok_span": [9, 11]}, {"name": "corneal ulcers", "ent_type": "Disease", "char_span": [28, 42], "ent_id": "D003320", "tok_span": [5, 7]}], "relation_list": [{"subject": "crack cocaine", "object": "corneal ulcers", "sbj_char_span": [59, 72], "obj_char_span": [28, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Aerosolized crack cocaine use can be associated with the development of corneal ulcers.", "entity_list": [{"name": "corneal ulcers", "ent_type": "Disease", "char_span": [85, 99], "ent_id": "D003320", "tok_span": [15, 17]}, {"name": "crack cocaine", "ent_type": "Chemical", "char_span": [25, 38], "ent_id": "D016578", "tok_span": [5, 7]}], "relation_list": [{"subject": "crack cocaine", "object": "corneal ulcers", "sbj_char_span": [25, 38], "obj_char_span": [85, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [127, 134], "ent_id": "D003042", "tok_span": [28, 29]}, {"name": "alcohol", "ent_type": "Chemical", "char_span": [104, 111], "ent_id": "D000431", "tok_span": [24, 25]}, {"name": "ischemia of the globus pallidus", "ent_type": "Disease", "char_span": [56, 87], "ent_id": "D002545", "tok_span": [14, 22]}], "relation_list": [{"subject": "cocaine", "object": "ischemia of the globus pallidus", "sbj_char_span": [127, 134], "obj_char_span": [56, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [14, 22]}], "umls_entity_list": []}, {"text": "Drug-related globus pallidus infarctions are most often associated with heroin.", "entity_list": [{"name": "heroin", "ent_type": "Chemical", "char_span": [72, 78], "ent_id": "D003932", "tok_span": [15, 17]}, {"name": "globus pallidus infarctions", "ent_type": "Disease", "char_span": [13, 40], "ent_id": "D020520", "tok_span": [3, 10]}], "relation_list": [{"subject": "heroin", "object": "globus pallidus infarctions", "sbj_char_span": [72, 78], "obj_char_span": [13, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [3, 10]}], "umls_entity_list": []}, {"text": "Bilateral basal ganglia infarcts after the use of cocaine, without concurrent heroin use, have never been reported.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [50, 57], "ent_id": "D003042", "tok_span": [10, 11]}, {"name": "heroin", "ent_type": "Chemical", "char_span": [78, 84], "ent_id": "D003932", "tok_span": [14, 16]}, {"name": "basal ganglia infarcts", "ent_type": "Disease", "char_span": [10, 32], "ent_id": "D020520", "tok_span": [2, 6]}], "relation_list": [{"subject": "heroin", "object": "basal ganglia infarcts", "sbj_char_span": [78, 84], "obj_char_span": [10, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Acute renal failure after high-dose methotrexate therapy in a patient with ileostomy.", "entity_list": [{"name": "Acute renal failure", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D058186", "tok_span": [0, 3]}, {"name": "methotrexate", "ent_type": "Chemical", "char_span": [36, 48], "ent_id": "D008727", "tok_span": [7, 9]}], "relation_list": [{"subject": "methotrexate", "object": "Acute renal failure", "sbj_char_span": [36, 48], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "We report a case of acute renal failure after HD-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.", "entity_list": [{"name": "MTX", "ent_type": "Chemical", "char_span": [49, 52], "ent_id": "D008727", "tok_span": [11, 12]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [20, 39], "ent_id": "D058186", "tok_span": [5, 8]}, {"name": "biliary atresia", "ent_type": "Disease", "char_span": [194, 209], "ent_id": "D001656", "tok_span": [41, 45]}], "relation_list": [{"subject": "MTX", "object": "acute renal failure", "sbj_char_span": [49, 52], "obj_char_span": [20, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Subsequent HD-MTX therapy caused acute renal failure that required continuous hemodialysis.", "entity_list": [{"name": "MTX", "ent_type": "Chemical", "char_span": [14, 17], "ent_id": "D008727", "tok_span": [3, 4]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [33, 52], "ent_id": "D058186", "tok_span": [6, 9]}], "relation_list": [{"subject": "MTX", "object": "acute renal failure", "sbj_char_span": [14, 17], "obj_char_span": [33, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "entity_list": [{"name": "ICH", "ent_type": "Disease", "char_span": [38, 41], "ent_id": "D002543", "tok_span": [9, 11]}, {"name": "TIA", "ent_type": "Disease", "char_span": [94, 97], "ent_id": "D002546", "tok_span": [29, 31]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [288, 296], "ent_id": "D014859", "tok_span": [100, 101]}, {"name": "MB", "ent_type": "Disease", "char_span": [59, 61], "ent_id": "-1", "tok_span": [19, 20]}, {"name": "ICH", "ent_type": "Disease", "char_span": [84, 87], "ent_id": "D002543", "tok_span": [24, 26]}, {"name": "TIA", "ent_type": "Disease", "char_span": [54, 57], "ent_id": "D002546", "tok_span": [16, 18]}, {"name": "IS", "ent_type": "Disease", "char_span": [51, 53], "ent_id": "D002544", "tok_span": [14, 15]}, {"name": "IS", "ent_type": "Disease", "char_span": [91, 93], "ent_id": "D002544", "tok_span": [27, 28]}], "relation_list": [{"subject": "warfarin", "object": "ICH", "sbj_char_span": [288, 296], "obj_char_span": [38, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [100, 101], "obj_tok_span": [9, 11]}, {"subject": "warfarin", "object": "ICH", "sbj_char_span": [288, 296], "obj_char_span": [84, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [100, 101], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "entity_list": [{"name": "TIA", "ent_type": "Disease", "char_span": [141, 144], "ent_id": "D002546", "tok_span": [50, 52]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [34, 42], "ent_id": "D014859", "tok_span": [8, 9]}, {"name": "IS", "ent_type": "Disease", "char_span": [138, 140], "ent_id": "D002544", "tok_span": [48, 49]}, {"name": "ICH", "ent_type": "Disease", "char_span": [66, 69], "ent_id": "D002543", "tok_span": [14, 16]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [118, 126], "ent_id": "D014859", "tok_span": [45, 46]}, {"name": "MB", "ent_type": "Disease", "char_span": [28, 30], "ent_id": "-1", "tok_span": [6, 7]}], "relation_list": [{"subject": "warfarin", "object": "ICH", "sbj_char_span": [34, 42], "obj_char_span": [66, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [14, 16]}, {"subject": "warfarin", "object": "ICH", "sbj_char_span": [118, 126], "obj_char_span": [66, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 46], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.", "entity_list": [{"name": "ICH", "ent_type": "Disease", "char_span": [53, 56], "ent_id": "D002543", "tok_span": [10, 12]}, {"name": "ICH", "ent_type": "Disease", "char_span": [140, 143], "ent_id": "D002543", "tok_span": [26, 28]}, {"name": "MB", "ent_type": "Disease", "char_span": [27, 29], "ent_id": "-1", "tok_span": [5, 6]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [120, 128], "ent_id": "D014859", "tok_span": [23, 24]}, {"name": "MB", "ent_type": "Disease", "char_span": [96, 98], "ent_id": "-1", "tok_span": [18, 19]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [33, 41], "ent_id": "D014859", "tok_span": [7, 8]}], "relation_list": [{"subject": "warfarin", "object": "ICH", "sbj_char_span": [33, 41], "obj_char_span": [53, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [10, 12]}, {"subject": "warfarin", "object": "ICH", "sbj_char_span": [120, 128], "obj_char_span": [140, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [26, 28]}, {"subject": "warfarin", "object": "ICH", "sbj_char_span": [120, 128], "obj_char_span": [53, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [10, 12]}, {"subject": "warfarin", "object": "ICH", "sbj_char_span": [33, 41], "obj_char_span": [140, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "entity_list": [{"name": "macroprolactinemia", "ent_type": "Disease", "char_span": [165, 183], "ent_id": "D015175", "tok_span": [53, 57]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [257, 268], "ent_id": "D018967", "tok_span": [89, 92]}, {"name": "macroprolactinoma", "ent_type": "Disease", "char_span": [93, 110], "ent_id": "D015175", "tok_span": [23, 27]}, {"name": "microprolactinoma", "ent_type": "Disease", "char_span": [128, 145], "ent_id": "D015175", "tok_span": [38, 42]}, {"name": "pseudoprolactinoma", "ent_type": "Disease", "char_span": [215, 233], "ent_id": "-1", "tok_span": [71, 75]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [277, 295], "ent_id": "D006966", "tok_span": [94, 98]}, {"name": "Verapamil", "ent_type": "Chemical", "char_span": [9, 18], "ent_id": "D014700", "tok_span": [2, 5]}], "relation_list": [{"subject": "risperidone", "object": "hyperprolactinemia", "sbj_char_span": [257, 268], "obj_char_span": [277, 295], "rel_type": "chemical-induced disease", "sbj_tok_span": [89, 92], "obj_tok_span": [94, 98]}], "umls_entity_list": []}, {"text": "ROC curve analysis revealed that unresponsiveness to verapamil defined as PRL <7%, discriminated anatomical or functional stalk effect (sensitivity: 74%, specificity: 73%, AUC: 0.855+/-0.04, P <0.001, CI: 0.768-0.942) associated with pseudoprolactinoma or risperidone-induced hyperprolactinemia, respectively.", "entity_list": [{"name": "pseudoprolactinoma", "ent_type": "Disease", "char_span": [234, 252], "ent_id": "-1", "tok_span": [72, 76]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [256, 267], "ent_id": "D018967", "tok_span": [77, 80]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [276, 294], "ent_id": "D006966", "tok_span": [82, 86]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [53, 62], "ent_id": "D014700", "tok_span": [9, 12]}], "relation_list": [{"subject": "risperidone", "object": "hyperprolactinemia", "sbj_char_span": [256, 267], "obj_char_span": [276, 294], "rel_type": "chemical-induced disease", "sbj_tok_span": [77, 80], "obj_tok_span": [82, 86]}], "umls_entity_list": []}, {"text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.", "entity_list": [{"name": "fentanyl", "ent_type": "Chemical", "char_span": [99, 107], "ent_id": "D005283", "tok_span": [24, 27]}, {"name": "naphazoline", "ent_type": "Chemical", "char_span": [25, 36], "ent_id": "D009278", "tok_span": [6, 10]}, {"name": "codine", "ent_type": "Chemical", "char_span": [163, 169], "ent_id": "D003061", "tok_span": [40, 42]}, {"name": "clonidine", "ent_type": "Chemical", "char_span": [14, 23], "ent_id": "D003000", "tok_span": [3, 5]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [80, 88], "ent_id": "D009020", "tok_span": [19, 20]}, {"name": "codeine", "ent_type": "Chemical", "char_span": [90, 97], "ent_id": "D003061", "tok_span": [21, 23]}, {"name": "pentazocine", "ent_type": "Chemical", "char_span": [112, 123], "ent_id": "D010423", "tok_span": [28, 31]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [153, 161], "ent_id": "D009020", "tok_span": [38, 39]}, {"name": "cataleptic", "ent_type": "Disease", "char_span": [132, 142], "ent_id": "D002375", "tok_span": [34, 36]}, {"name": "xylometazoline", "ent_type": "Chemical", "char_span": [41, 55], "ent_id": "C009695", "tok_span": [11, 15]}, {"name": "fentanyl", "ent_type": "Chemical", "char_span": [174, 182], "ent_id": "D005283", "tok_span": [43, 46]}], "relation_list": [{"subject": "naphazoline", "object": "cataleptic", "sbj_char_span": [25, 36], "obj_char_span": [132, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [34, 36]}, {"subject": "clonidine", "object": "cataleptic", "sbj_char_span": [14, 23], "obj_char_span": [132, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [34, 36]}, {"subject": "morphine", "object": "cataleptic", "sbj_char_span": [80, 88], "obj_char_span": [132, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [34, 36]}, {"subject": "xylometazoline", "object": "cataleptic", "sbj_char_span": [41, 55], "obj_char_span": [132, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [34, 36]}, {"subject": "fentanyl", "object": "cataleptic", "sbj_char_span": [174, 182], "obj_char_span": [132, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [34, 36]}, {"subject": "fentanyl", "object": "cataleptic", "sbj_char_span": [99, 107], "obj_char_span": [132, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [34, 36]}, {"subject": "codeine", "object": "cataleptic", "sbj_char_span": [90, 97], "obj_char_span": [132, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [34, 36]}, {"subject": "codine", "object": "cataleptic", "sbj_char_span": [163, 169], "obj_char_span": [132, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 42], "obj_tok_span": [34, 36]}, {"subject": "morphine", "object": "cataleptic", "sbj_char_span": [153, 161], "obj_char_span": [132, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 39], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [147, 156], "ent_id": "D002375", "tok_span": [28, 31]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [168, 176], "ent_id": "D009020", "tok_span": [33, 34]}, {"name": "fentanyl", "ent_type": "Chemical", "char_span": [181, 189], "ent_id": "D005283", "tok_span": [35, 38]}, {"name": "NA", "ent_type": "Chemical", "char_span": [50, 52], "ent_id": "D009638", "tok_span": [8, 9]}], "relation_list": [{"subject": "morphine", "object": "catalepsy", "sbj_char_span": [168, 176], "obj_char_span": [147, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [28, 31]}, {"subject": "fentanyl", "object": "catalepsy", "sbj_char_span": [181, 189], "obj_char_span": [147, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.", "entity_list": [{"name": "clonidine", "ent_type": "Chemical", "char_span": [35, 44], "ent_id": "D003000", "tok_span": [8, 10]}, {"name": "xylometazoline", "ent_type": "Chemical", "char_span": [78, 92], "ent_id": "C009695", "tok_span": [18, 22]}, {"name": "naphazoline", "ent_type": "Chemical", "char_span": [62, 73], "ent_id": "D009278", "tok_span": [13, 17]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [8, 17], "ent_id": "D002375", "tok_span": [2, 5]}, {"name": "Codeine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D003061", "tok_span": [0, 2]}], "relation_list": [{"subject": "naphazoline", "object": "catalepsy", "sbj_char_span": [62, 73], "obj_char_span": [8, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [2, 5]}, {"subject": "clonidine", "object": "catalepsy", "sbj_char_span": [35, 44], "obj_char_span": [8, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [2, 5]}, {"subject": "xylometazoline", "object": "catalepsy", "sbj_char_span": [78, 92], "obj_char_span": [8, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [2, 5]}, {"subject": "Codeine", "object": "catalepsy", "sbj_char_span": [0, 7], "obj_char_span": [8, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen.", "entity_list": [{"name": "progestagen", "ent_type": "Chemical", "char_span": [75, 86], "ent_id": "D011372", "tok_span": [14, 17]}, {"name": "hyperplasia", "ent_type": "Disease", "char_span": [7, 18], "ent_id": "D006965", "tok_span": [2, 3]}, {"name": "oestrogen", "ent_type": "Chemical", "char_span": [49, 58], "ent_id": "D004967", "tok_span": [9, 12]}], "relation_list": [{"subject": "oestrogen", "object": "hyperplasia", "sbj_char_span": [49, 58], "obj_char_span": [7, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.", "entity_list": [{"name": "hyperplasia", "ent_type": "Disease", "char_span": [352, 363], "ent_id": "D006965", "tok_span": [63, 64]}, {"name": "oestrogen", "ent_type": "Chemical", "char_span": [290, 299], "ent_id": "D004967", "tok_span": [53, 56]}, {"name": "malignancy", "ent_type": "Disease", "char_span": [369, 379], "ent_id": "D009369", "tok_span": [65, 66]}, {"name": "endometrial carcinoma", "ent_type": "Disease", "char_span": [174, 195], "ent_id": "D016889", "tok_span": [38, 40]}, {"name": "hyperplasia", "ent_type": "Disease", "char_span": [150, 161], "ent_id": "D006965", "tok_span": [33, 34]}, {"name": "norethisterone", "ent_type": "Chemical", "char_span": [31, 45], "ent_id": "D009640", "tok_span": [8, 12]}, {"name": "hyperplasia", "ent_type": "Disease", "char_span": [105, 116], "ent_id": "D006965", "tok_span": [24, 25]}], "relation_list": [{"subject": "oestrogen", "object": "hyperplasia", "sbj_char_span": [290, 299], "obj_char_span": [352, 363], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 56], "obj_tok_span": [63, 64]}, {"subject": "oestrogen", "object": "hyperplasia", "sbj_char_span": [290, 299], "obj_char_span": [150, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 56], "obj_tok_span": [33, 34]}, {"subject": "oestrogen", "object": "hyperplasia", "sbj_char_span": [290, 299], "obj_char_span": [105, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 56], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin.", "entity_list": [{"name": "lymphadenopathy", "ent_type": "Disease", "char_span": [44, 59], "ent_id": "D008206", "tok_span": [10, 12]}, {"name": "Pure red cell aplasia", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D012010", "tok_span": [0, 6]}, {"name": "toxic dermatitis", "ent_type": "Disease", "char_span": [23, 39], "ent_id": "D003875", "tok_span": [7, 9]}, {"name": "diphenylhydantoin", "ent_type": "Chemical", "char_span": [80, 97], "ent_id": "D010672", "tok_span": [16, 22]}], "relation_list": [{"subject": "diphenylhydantoin", "object": "lymphadenopathy", "sbj_char_span": [80, 97], "obj_char_span": [44, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 22], "obj_tok_span": [10, 12]}, {"subject": "diphenylhydantoin", "object": "Pure red cell aplasia", "sbj_char_span": [80, 97], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 22], "obj_tok_span": [0, 6]}, {"subject": "diphenylhydantoin", "object": "toxic dermatitis", "sbj_char_span": [80, 97], "obj_char_span": [23, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 22], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "A patient taking diphenylhydantoin for 3 weeks developed a generalized skin rash, lymphadenopathy and pure red cell aplasia.", "entity_list": [{"name": "diphenylhydantoin", "ent_type": "Chemical", "char_span": [17, 34], "ent_id": "D010672", "tok_span": [3, 9]}, {"name": "lymphadenopathy", "ent_type": "Disease", "char_span": [82, 97], "ent_id": "D008206", "tok_span": [19, 21]}, {"name": "skin rash", "ent_type": "Disease", "char_span": [71, 80], "ent_id": "D005076", "tok_span": [15, 18]}, {"name": "pure red cell aplasia", "ent_type": "Disease", "char_span": [102, 123], "ent_id": "D012010", "tok_span": [22, 28]}], "relation_list": [{"subject": "diphenylhydantoin", "object": "lymphadenopathy", "sbj_char_span": [17, 34], "obj_char_span": [82, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 9], "obj_tok_span": [19, 21]}, {"subject": "diphenylhydantoin", "object": "pure red cell aplasia", "sbj_char_span": [17, 34], "obj_char_span": [102, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 9], "obj_tok_span": [22, 28]}], "umls_entity_list": []}, {"text": "Skin rash is a well-known complication of diphenylhydantoin treatment as is benign and malignant lymphadenopathy.", "entity_list": [{"name": "diphenylhydantoin", "ent_type": "Chemical", "char_span": [42, 59], "ent_id": "D010672", "tok_span": [10, 16]}, {"name": "Skin rash", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D005076", "tok_span": [0, 3]}, {"name": "lymphadenopathy", "ent_type": "Disease", "char_span": [97, 112], "ent_id": "D008206", "tok_span": [22, 24]}], "relation_list": [{"subject": "diphenylhydantoin", "object": "lymphadenopathy", "sbj_char_span": [42, 59], "obj_char_span": [97, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 16], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Pure red cell aplasia associated with diphenylhydantoin medication has been reported in 3 patients.", "entity_list": [{"name": "Pure red cell aplasia", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D012010", "tok_span": [0, 6]}, {"name": "diphenylhydantoin", "ent_type": "Chemical", "char_span": [38, 55], "ent_id": "D010672", "tok_span": [8, 14]}], "relation_list": [{"subject": "diphenylhydantoin", "object": "Pure red cell aplasia", "sbj_char_span": [38, 55], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 14], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "In this patient the time relation between the ingestion of diphenylhydantoin and the occurrence of the skin rash, lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection.", "entity_list": [{"name": "lymphadenopathy", "ent_type": "Disease", "char_span": [114, 129], "ent_id": "D008206", "tok_span": [25, 27]}, {"name": "diphenylhydantoin", "ent_type": "Chemical", "char_span": [59, 76], "ent_id": "D010672", "tok_span": [10, 16]}, {"name": "skin rash", "ent_type": "Disease", "char_span": [103, 112], "ent_id": "D005076", "tok_span": [21, 24]}, {"name": "pure red cell aplasia", "ent_type": "Disease", "char_span": [134, 155], "ent_id": "D012010", "tok_span": [28, 34]}], "relation_list": [{"subject": "diphenylhydantoin", "object": "lymphadenopathy", "sbj_char_span": [59, 76], "obj_char_span": [114, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 16], "obj_tok_span": [25, 27]}, {"subject": "diphenylhydantoin", "object": "pure red cell aplasia", "sbj_char_span": [59, 76], "obj_char_span": [134, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 16], "obj_tok_span": [28, 34]}], "umls_entity_list": []}, {"text": "Azotemia was not related to duration of therapy or serum tobramycin concentration.", "entity_list": [{"name": "Azotemia", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D053099", "tok_span": [0, 3]}, {"name": "tobramycin", "ent_type": "Chemical", "char_span": [57, 67], "ent_id": "D014031", "tok_span": [12, 15]}], "relation_list": [{"subject": "tobramycin", "object": "Azotemia", "sbj_char_span": [57, 67], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH).", "entity_list": [{"name": "Epsilon aminocaproic acid", "ent_type": "Chemical", "char_span": [0, 25], "ent_id": "D015119", "tok_span": [0, 8]}, {"name": "SAH", "ent_type": "Disease", "char_span": [111, 114], "ent_id": "D013345", "tok_span": [30, 32]}, {"name": "EACA", "ent_type": "Chemical", "char_span": [27, 31], "ent_id": "D015119", "tok_span": [9, 11]}, {"name": "subarachnoid hemorrhage", "ent_type": "Disease", "char_span": [86, 109], "ent_id": "D013345", "tok_span": [23, 29]}], "relation_list": [{"subject": "Epsilon aminocaproic acid", "object": "subarachnoid hemorrhage", "sbj_char_span": [0, 25], "obj_char_span": [86, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 8], "obj_tok_span": [23, 29]}, {"subject": "EACA", "object": "subarachnoid hemorrhage", "sbj_char_span": [27, 31], "obj_char_span": [86, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [23, 29]}, {"subject": "Epsilon aminocaproic acid", "object": "SAH", "sbj_char_span": [0, 25], "obj_char_span": [111, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 8], "obj_tok_span": [30, 32]}, {"subject": "EACA", "object": "SAH", "sbj_char_span": [27, 31], "obj_char_span": [111, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy.", "entity_list": [{"name": "EACA", "ent_type": "Chemical", "char_span": [122, 126], "ent_id": "D015119", "tok_span": [20, 22]}, {"name": "thrombotic", "ent_type": "Disease", "char_span": [94, 104], "ent_id": "D013927", "tok_span": [16, 18]}], "relation_list": [{"subject": "EACA", "object": "thrombotic", "sbj_char_span": [122, 126], "obj_char_span": [94, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.", "entity_list": [{"name": "thrombi", "ent_type": "Disease", "char_span": [148, 155], "ent_id": "D013927", "tok_span": [21, 23]}, {"name": "EACA", "ent_type": "Chemical", "char_span": [209, 213], "ent_id": "D015119", "tok_span": [31, 33]}, {"name": "intracranial vascular thrombosis", "ent_type": "Disease", "char_span": [61, 93], "ent_id": "D020767", "tok_span": [7, 10]}, {"name": "SAH", "ent_type": "Disease", "char_span": [111, 114], "ent_id": "D013345", "tok_span": [13, 15]}, {"name": "thromboembolic phenomena", "ent_type": "Disease", "char_span": [224, 248], "ent_id": "D013923", "tok_span": [36, 39]}], "relation_list": [{"subject": "EACA", "object": "intracranial vascular thrombosis", "sbj_char_span": [209, 213], "obj_char_span": [61, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [7, 10]}, {"subject": "EACA", "object": "SAH", "sbj_char_span": [209, 213], "obj_char_span": [111, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [13, 15]}, {"subject": "EACA", "object": "thrombi", "sbj_char_span": [209, 213], "obj_char_span": [148, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\"", "entity_list": [{"name": "disseminated intravascular coagulation", "ent_type": "Disease", "char_span": [180, 218], "ent_id": "D004211", "tok_span": [32, 36]}, {"name": "thrombi", "ent_type": "Disease", "char_span": [27, 34], "ent_id": "D013927", "tok_span": [4, 6]}, {"name": "consumption coagulopathies", "ent_type": "Disease", "char_span": [229, 255], "ent_id": "D004211", "tok_span": [39, 43]}, {"name": "thrombi", "ent_type": "Disease", "char_span": [155, 162], "ent_id": "D013927", "tok_span": [27, 29]}, {"name": "EACA", "ent_type": "Chemical", "char_span": [95, 99], "ent_id": "D015119", "tok_span": [16, 18]}], "relation_list": [{"subject": "EACA", "object": "thrombi", "sbj_char_span": [95, 99], "obj_char_span": [155, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [27, 29]}, {"subject": "EACA", "object": "thrombi", "sbj_char_span": [95, 99], "obj_char_span": [27, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH.", "entity_list": [{"name": "EACA", "ent_type": "Chemical", "char_span": [30, 34], "ent_id": "D015119", "tok_span": [4, 6]}, {"name": "SAH", "ent_type": "Disease", "char_span": [114, 117], "ent_id": "D013345", "tok_span": [19, 21]}, {"name": "SAH", "ent_type": "Disease", "char_span": [61, 64], "ent_id": "D013345", "tok_span": [11, 13]}], "relation_list": [{"subject": "EACA", "object": "SAH", "sbj_char_span": [30, 34], "obj_char_span": [61, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [11, 13]}, {"subject": "EACA", "object": "SAH", "sbj_char_span": [30, 34], "obj_char_span": [114, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "In 1 patient, marked hypertension was induced by propranolol and the drug had to be withdrawn.", "entity_list": [{"name": "propranolol", "ent_type": "Chemical", "char_span": [49, 60], "ent_id": "D011433", "tok_span": [9, 13]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [21, 33], "ent_id": "D006973", "tok_span": [5, 6]}], "relation_list": [{"subject": "propranolol", "object": "hypertension", "sbj_char_span": [49, 60], "obj_char_span": [21, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "It is considered unlikely that etomidate will prove to be the hypnotic of choice for a totally intravenous anesthetic technique in adults because of the high incidence of myoclonia after prolonged administration.", "entity_list": [{"name": "etomidate", "ent_type": "Chemical", "char_span": [31, 40], "ent_id": "D005045", "tok_span": [5, 8]}, {"name": "myoclonia", "ent_type": "Disease", "char_span": [171, 180], "ent_id": "D009207", "tok_span": [32, 35]}], "relation_list": [{"subject": "etomidate", "object": "myoclonia", "sbj_char_span": [31, 40], "obj_char_span": [171, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "After the end of fenoterol-hydrobromide infusion, tremor amplitudes decreased significantly faster than those following ritodrin-HCl infusion.", "entity_list": [{"name": "fenoterol-hydrobromide", "ent_type": "Chemical", "char_span": [17, 39], "ent_id": "D005280", "tok_span": [4, 12]}, {"name": "ritodrin-HCl", "ent_type": "Chemical", "char_span": [120, 132], "ent_id": "D012312", "tok_span": [23, 28]}, {"name": "tremor", "ent_type": "Disease", "char_span": [50, 56], "ent_id": "D014202", "tok_span": [14, 16]}], "relation_list": [{"subject": "ritodrin-HCl", "object": "tremor", "sbj_char_span": [120, 132], "obj_char_span": [50, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 28], "obj_tok_span": [14, 16]}, {"subject": "fenoterol-hydrobromide", "object": "tremor", "sbj_char_span": [17, 39], "obj_char_span": [50, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 12], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [199, 208], "ent_id": "D008012", "tok_span": [37, 39]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [210, 221], "ent_id": "D004837", "tok_span": [40, 43]}, {"name": "retinal artery and choriocapillaris occlusions", "ent_type": "Disease", "char_span": [39, 85], "ent_id": "D015356", "tok_span": [7, 17]}, {"name": "methylprednisolone acetate", "ent_type": "Chemical", "char_span": [152, 178], "ent_id": "C000873", "tok_span": [29, 34]}, {"name": "penicillin", "ent_type": "Chemical", "char_span": [226, 236], "ent_id": "D010406", "tok_span": [45, 46]}, {"name": "blindness", "ent_type": "Disease", "char_span": [91, 100], "ent_id": "D001766", "tok_span": [18, 20]}], "relation_list": [{"subject": "methylprednisolone acetate", "object": "retinal artery and choriocapillaris occlusions", "sbj_char_span": [152, 178], "obj_char_span": [39, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 34], "obj_tok_span": [7, 17]}], "umls_entity_list": []}, {"text": "Cephalothin-induced immune hemolytic anemia.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [27, 43], "ent_id": "D000743", "tok_span": [7, 10]}, {"name": "Cephalothin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D002512", "tok_span": [0, 4]}], "relation_list": [{"subject": "Cephalothin", "object": "hemolytic anemia", "sbj_char_span": [0, 11], "obj_char_span": [27, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "A patient with renal disease developed Coombs-positive hemolytic anemia while receiving cephalothin therapy.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [55, 71], "ent_id": "D000743", "tok_span": [11, 14]}, {"name": "renal disease", "ent_type": "Disease", "char_span": [15, 28], "ent_id": "D007674", "tok_span": [3, 5]}, {"name": "cephalothin", "ent_type": "Chemical", "char_span": [88, 99], "ent_id": "D002512", "tok_span": [16, 19]}], "relation_list": [{"subject": "cephalothin", "object": "hemolytic anemia", "sbj_char_span": [88, 99], "obj_char_span": [55, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Hypokalemia, sometimes severe, was observed in some L-dopa-treated parkinsonian patients.", "entity_list": [{"name": "L-dopa", "ent_type": "Chemical", "char_span": [52, 58], "ent_id": "D007980", "tok_span": [12, 16]}, {"name": "Hypokalemia", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D007008", "tok_span": [0, 4]}, {"name": "parkinsonian", "ent_type": "Disease", "char_span": [67, 79], "ent_id": "D010300", "tok_span": [18, 21]}], "relation_list": [{"subject": "L-dopa", "object": "Hypokalemia", "sbj_char_span": [52, 58], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "entity_list": [{"name": "sodium", "ent_type": "Chemical", "char_span": [289, 295], "ent_id": "D012964", "tok_span": [56, 57]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [239, 245], "ent_id": "D012964", "tok_span": [47, 48]}, {"name": "potassium", "ent_type": "Chemical", "char_span": [278, 287], "ent_id": "D011188", "tok_span": [54, 55]}, {"name": "hypokalemia", "ent_type": "Disease", "char_span": [91, 102], "ent_id": "D007008", "tok_span": [19, 23]}, {"name": "potassium", "ent_type": "Chemical", "char_span": [50, 59], "ent_id": "D011188", "tok_span": [12, 13]}, {"name": "L-dopa", "ent_type": "Chemical", "char_span": [17, 23], "ent_id": "D007980", "tok_span": [3, 7]}, {"name": "potassium", "ent_type": "Chemical", "char_span": [225, 234], "ent_id": "D011188", "tok_span": [45, 46]}, {"name": "aldosterone", "ent_type": "Chemical", "char_span": [300, 311], "ent_id": "D000450", "tok_span": [58, 60]}], "relation_list": [{"subject": "L-dopa", "object": "hypokalemia", "sbj_char_span": [17, 23], "obj_char_span": [91, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Phenytoin encephalopathy as probable idiosyncratic reaction: case report.", "entity_list": [{"name": "Phenytoin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D010672", "tok_span": [0, 3]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [10, 24], "ent_id": "D001927", "tok_span": [3, 5]}], "relation_list": [{"subject": "Phenytoin", "object": "encephalopathy", "sbj_char_span": [0, 9], "obj_char_span": [10, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "A case of phenytoin (DPH) encephalopathy with increasing seizures and EEG and mental changes is described.", "entity_list": [{"name": "phenytoin", "ent_type": "Chemical", "char_span": [10, 19], "ent_id": "D010672", "tok_span": [3, 6]}, {"name": "seizures", "ent_type": "Disease", "char_span": [57, 65], "ent_id": "D012640", "tok_span": [14, 15]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [26, 40], "ent_id": "D001927", "tok_span": [10, 12]}, {"name": "DPH", "ent_type": "Chemical", "char_span": [21, 24], "ent_id": "D010672", "tok_span": [7, 9]}], "relation_list": [{"subject": "DPH", "object": "encephalopathy", "sbj_char_span": [21, 24], "obj_char_span": [26, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [10, 12]}, {"subject": "phenytoin", "object": "encephalopathy", "sbj_char_span": [10, 19], "obj_char_span": [26, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Effects of exercise on the severity of isoproterenol-induced myocardial infarction.", "entity_list": [{"name": "isoproterenol", "ent_type": "Chemical", "char_span": [39, 52], "ent_id": "D007545", "tok_span": [7, 11]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [61, 82], "ent_id": "D009203", "tok_span": [13, 15]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [39, 52], "obj_char_span": [61, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "The effect of exercise on the severity of isoproterenol-induced myocardial infarction was studied in male rats.", "entity_list": [{"name": "isoproterenol", "ent_type": "Chemical", "char_span": [42, 55], "ent_id": "D007545", "tok_span": [8, 12]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [64, 85], "ent_id": "D009203", "tok_span": [14, 16]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [42, 55], "obj_char_span": [64, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only.", "entity_list": [{"name": "Dehydrated", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D003681", "tok_span": [0, 3]}, {"name": "aminoglycoside", "ent_type": "Chemical", "char_span": [84, 98], "ent_id": "D000617", "tok_span": [13, 16]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [34, 53], "ent_id": "D058186", "tok_span": [6, 9]}], "relation_list": [{"subject": "aminoglycoside", "object": "acute renal failure", "sbj_char_span": [84, 98], "obj_char_span": [34, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "Paraplegia following intrathecal methotrexate: report of a case and review of the literature.", "entity_list": [{"name": "methotrexate", "ent_type": "Chemical", "char_span": [33, 45], "ent_id": "D008727", "tok_span": [8, 10]}, {"name": "Paraplegia", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D010264", "tok_span": [0, 4]}], "relation_list": [{"subject": "methotrexate", "object": "Paraplegia", "sbj_char_span": [33, 45], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "A patient who developed paraplegia following the intrathecal instillation of methotrexate is discribed.", "entity_list": [{"name": "paraplegia", "ent_type": "Disease", "char_span": [24, 34], "ent_id": "D010264", "tok_span": [4, 7]}, {"name": "methotrexate", "ent_type": "Chemical", "char_span": [77, 89], "ent_id": "D008727", "tok_span": [16, 18]}], "relation_list": [{"subject": "methotrexate", "object": "paraplegia", "sbj_char_span": [77, 89], "obj_char_span": [24, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).", "entity_list": [{"name": "propranolol", "ent_type": "Chemical", "char_span": [218, 229], "ent_id": "D011433", "tok_span": [65, 69]}, {"name": "carbachol", "ent_type": "Chemical", "char_span": [335, 344], "ent_id": "D002217", "tok_span": [94, 97]}, {"name": "enlargement of pulse pressure", "ent_type": "Disease", "char_span": [270, 299], "ent_id": "D006973", "tok_span": [82, 86]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [308, 319], "ent_id": "D013610", "tok_span": [88, 89]}, {"name": "hexamethonium", "ent_type": "Chemical", "char_span": [100, 113], "ent_id": "D018738", "tok_span": [24, 28]}, {"name": "phentolamine", "ent_type": "Chemical", "char_span": [125, 137], "ent_id": "D010646", "tok_span": [33, 36]}, {"name": "desmethylimipramine", "ent_type": "Chemical", "char_span": [182, 201], "ent_id": "D003891", "tok_span": [52, 57]}, {"name": "guanethidine", "ent_type": "Chemical", "char_span": [79, 91], "ent_id": "D006145", "tok_span": [16, 19]}], "relation_list": [{"subject": "carbachol", "object": "tachycardia", "sbj_char_span": [335, 344], "obj_char_span": [308, 319], "rel_type": "chemical-induced disease", "sbj_tok_span": [94, 97], "obj_tok_span": [88, 89]}, {"subject": "carbachol", "object": "enlargement of pulse pressure", "sbj_char_span": [335, 344], "obj_char_span": [270, 299], "rel_type": "chemical-induced disease", "sbj_tok_span": [94, 97], "obj_tok_span": [82, 86]}, {"subject": "desmethylimipramine", "object": "enlargement of pulse pressure", "sbj_char_span": [182, 201], "obj_char_span": [270, 299], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 57], "obj_tok_span": [82, 86]}], "umls_entity_list": []}, {"text": "Hyperglycemic effect of amino compounds structurally related to caproate in rats.", "entity_list": [{"name": "caproate", "ent_type": "Chemical", "char_span": [64, 72], "ent_id": "C037652", "tok_span": [10, 13]}, {"name": "Hyperglycemic", "ent_type": "Disease", "char_span": [0, 13], "ent_id": "D006943", "tok_span": [0, 3]}, {"name": "amino", "ent_type": "Chemical", "char_span": [24, 29], "ent_id": "D015119", "tok_span": [5, 6]}], "relation_list": [{"subject": "amino", "object": "Hyperglycemic", "sbj_char_span": [24, 29], "obj_char_span": [0, 13], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.", "entity_list": [{"name": "glucosuria", "ent_type": "Disease", "char_span": [184, 194], "ent_id": "D006030", "tok_span": [38, 41]}, {"name": "caproate", "ent_type": "Chemical", "char_span": [93, 101], "ent_id": "C037652", "tok_span": [22, 25]}, {"name": "amino", "ent_type": "Chemical", "char_span": [72, 77], "ent_id": "D015119", "tok_span": [19, 20]}, {"name": "hyperglycemia", "ent_type": "Disease", "char_span": [114, 127], "ent_id": "D006943", "tok_span": [27, 28]}, {"name": "glucose", "ent_type": "Chemical", "char_span": [141, 148], "ent_id": "D005947", "tok_span": [31, 32]}], "relation_list": [{"subject": "amino", "object": "hyperglycemia", "sbj_char_span": [72, 77], "obj_char_span": [114, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "Fatty liver induced by tetracycline in the rat.", "entity_list": [{"name": "Fatty liver", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D005234", "tok_span": [0, 3]}, {"name": "tetracycline", "ent_type": "Chemical", "char_span": [23, 35], "ent_id": "D013752", "tok_span": [5, 7]}], "relation_list": [{"subject": "tetracycline", "object": "Fatty liver", "sbj_char_span": [23, 35], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Dose-response relationships, biochemical mechanisms, and sex differences in the experimental fatty liver induced by tetracycline were studied in the intact rat and with the isolated perfused rat liver in vitro.", "entity_list": [{"name": "fatty liver", "ent_type": "Disease", "char_span": [93, 104], "ent_id": "D005234", "tok_span": [14, 16]}, {"name": "tetracycline", "ent_type": "Chemical", "char_span": [116, 128], "ent_id": "D013752", "tok_span": [18, 20]}], "relation_list": [{"subject": "tetracycline", "object": "fatty liver", "sbj_char_span": [116, 128], "obj_char_span": [93, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.", "entity_list": [{"name": "triglyceride", "ent_type": "Chemical", "char_span": [31, 43], "ent_id": "D014280", "tok_span": [5, 6]}, {"name": "triglyceride", "ent_type": "Chemical", "char_span": [96, 108], "ent_id": "D014280", "tok_span": [16, 17]}, {"name": "tetracycline", "ent_type": "Chemical", "char_span": [235, 247], "ent_id": "D013752", "tok_span": [38, 40]}, {"name": "fatty liver", "ent_type": "Disease", "char_span": [208, 219], "ent_id": "D005234", "tok_span": [33, 35]}, {"name": "triglyceride", "ent_type": "Chemical", "char_span": [190, 202], "ent_id": "D014280", "tok_span": [30, 31]}], "relation_list": [{"subject": "tetracycline", "object": "fatty liver", "sbj_char_span": [235, 247], "obj_char_span": [208, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 40], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "Fatal myeloencephalopathy due to intrathecal vincristine administration.", "entity_list": [{"name": "vincristine", "ent_type": "Chemical", "char_span": [45, 56], "ent_id": "D014750", "tok_span": [11, 15]}, {"name": "myeloencephalopathy", "ent_type": "Disease", "char_span": [6, 25], "ent_id": "D001927", "tok_span": [2, 6]}], "relation_list": [{"subject": "vincristine", "object": "myeloencephalopathy", "sbj_char_span": [45, 56], "obj_char_span": [6, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Vincristine was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by encephalopathy and death.", "entity_list": [{"name": "encephalopathy", "ent_type": "Disease", "char_span": [128, 142], "ent_id": "D001927", "tok_span": [26, 28]}, {"name": "leukaemia", "ent_type": "Disease", "char_span": [65, 74], "ent_id": "D007938", "tok_span": [16, 18]}, {"name": "Vincristine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D014750", "tok_span": [0, 4]}, {"name": "sensory and motor dysfunction", "ent_type": "Disease", "char_span": [86, 115], "ent_id": "D007049", "tok_span": [20, 24]}], "relation_list": [{"subject": "Vincristine", "object": "encephalopathy", "sbj_char_span": [0, 11], "obj_char_span": [128, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [26, 28]}, {"subject": "Vincristine", "object": "sensory and motor dysfunction", "sbj_char_span": [0, 11], "obj_char_span": [86, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become arrhythmic), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.", "entity_list": [{"name": "arrhythmic", "ent_type": "Disease", "char_span": [141, 151], "ent_id": "D001145", "tok_span": [32, 34]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [61, 72], "ent_id": "D002045", "tok_span": [13, 17]}, {"name": "progesterone", "ent_type": "Chemical", "char_span": [189, 201], "ent_id": "D011374", "tok_span": [44, 45]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [22, 33], "ent_id": "D002045", "tok_span": [3, 7]}, {"name": "HCl", "ent_type": "Chemical", "char_span": [202, 205], "ent_id": "D006851", "tok_span": [45, 46]}], "relation_list": [{"subject": "progesterone", "object": "arrhythmic", "sbj_char_span": [189, 201], "obj_char_span": [141, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [32, 34]}, {"subject": "bupivacaine", "object": "arrhythmic", "sbj_char_span": [22, 33], "obj_char_span": [141, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [32, 34]}, {"subject": "bupivacaine", "object": "arrhythmic", "sbj_char_span": [61, 72], "obj_char_span": [141, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [32, 34]}], "umls_entity_list": []}, {"text": "Potentiation of bupivacaine arrhythmia in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level.", "entity_list": [{"name": "arrhythmia", "ent_type": "Disease", "char_span": [28, 38], "ent_id": "D001145", "tok_span": [8, 10]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [16, 27], "ent_id": "D002045", "tok_span": [4, 8]}], "relation_list": [{"subject": "bupivacaine", "object": "arrhythmia", "sbj_char_span": [16, 27], "obj_char_span": [28, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Neuroleptic-associated hyperprolactinemia.", "entity_list": [{"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [23, 41], "ent_id": "D006966", "tok_span": [4, 8]}, {"name": "Neuroleptic", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D014150", "tok_span": [0, 2]}], "relation_list": [{"subject": "Neuroleptic", "object": "hyperprolactinemia", "sbj_char_span": [0, 11], "obj_char_span": [23, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.", "entity_list": [{"name": "amenorrhea", "ent_type": "Disease", "char_span": [63, 73], "ent_id": "D000568", "tok_span": [11, 14]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [153, 166], "ent_id": "D001971", "tok_span": [30, 34]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [40, 58], "ent_id": "D006966", "tok_span": [6, 10]}, {"name": "neuroleptic medications", "ent_type": "Chemical", "char_span": [111, 134], "ent_id": "D014150", "tok_span": [22, 27]}, {"name": "oligomenorrhea", "ent_type": "Disease", "char_span": [74, 88], "ent_id": "D009839", "tok_span": [15, 19]}], "relation_list": [{"subject": "neuroleptic medications", "object": "hyperprolactinemia", "sbj_char_span": [111, 134], "obj_char_span": [40, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [6, 10]}, {"subject": "neuroleptic medications", "object": "amenorrhea", "sbj_char_span": [111, 134], "obj_char_span": [63, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [11, 14]}, {"subject": "neuroleptic medications", "object": "oligomenorrhea", "sbj_char_span": [111, 134], "obj_char_span": [74, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "One woman, however, developed worsened psychiatric symptoms while taking bromocriptine, and it was discontinued.", "entity_list": [{"name": "bromocriptine", "ent_type": "Chemical", "char_span": [73, 86], "ent_id": "D001971", "tok_span": [12, 16]}, {"name": "psychiatric symptoms", "ent_type": "Disease", "char_span": [39, 59], "ent_id": "D011618", "tok_span": [8, 10]}], "relation_list": [{"subject": "bromocriptine", "object": "psychiatric symptoms", "sbj_char_span": [73, 86], "obj_char_span": [39, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/galactorrhea.", "entity_list": [{"name": "neuroleptic", "ent_type": "Chemical", "char_span": [86, 97], "ent_id": "D014150", "tok_span": [15, 19]}, {"name": "amenorrhea", "ent_type": "Disease", "char_span": [132, 142], "ent_id": "D000568", "tok_span": [26, 29]}, {"name": "galactorrhea", "ent_type": "Disease", "char_span": [143, 155], "ent_id": "D005687", "tok_span": [30, 33]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [19, 32], "ent_id": "D001971", "tok_span": [3, 7]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [109, 127], "ent_id": "D006966", "tok_span": [21, 25]}], "relation_list": [{"subject": "neuroleptic", "object": "amenorrhea", "sbj_char_span": [86, 97], "obj_char_span": [132, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [26, 29]}, {"subject": "neuroleptic", "object": "hyperprolactinemia", "sbj_char_span": [86, 97], "obj_char_span": [109, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "Ethacrynic acid-induced convulsions and brain neurotransmitters in mice.", "entity_list": [{"name": "Ethacrynic acid", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D004976", "tok_span": [0, 5]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [24, 35], "ent_id": "D012640", "tok_span": [7, 10]}], "relation_list": [{"subject": "Ethacrynic acid", "object": "convulsions", "sbj_char_span": [0, 15], "obj_char_span": [24, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "entity_list": [{"name": "gamma-aminobutyric acid", "ent_type": "Chemical", "char_span": [193, 216], "ent_id": "D005680", "tok_span": [47, 54]}, {"name": "5-HT", "ent_type": "Chemical", "char_span": [155, 159], "ent_id": "D012701", "tok_span": [38, 41]}, {"name": "5-hydroxytryptamine", "ent_type": "Chemical", "char_span": [134, 153], "ent_id": "D012701", "tok_span": [31, 37]}, {"name": "ethacrynic acid", "ent_type": "Chemical", "char_span": [37, 52], "ent_id": "D004976", "tok_span": [7, 12]}, {"name": "convulsive", "ent_type": "Disease", "char_span": [58, 68], "ent_id": "D012640", "tok_span": [15, 17]}, {"name": "acetylcholine", "ent_type": "Chemical", "char_span": [221, 234], "ent_id": "D000109", "tok_span": [55, 56]}], "relation_list": [{"subject": "ethacrynic acid", "object": "convulsive", "sbj_char_span": [37, 52], "obj_char_span": [58, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "In ethacrynic acid-induced convulsions, these neurotransmitter systems may be differentially modulated, probably through activation of glutaminergic neurons in the brain.", "entity_list": [{"name": "ethacrynic acid", "ent_type": "Chemical", "char_span": [3, 18], "ent_id": "D004976", "tok_span": [1, 6]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [27, 38], "ent_id": "D012640", "tok_span": [8, 11]}], "relation_list": [{"subject": "ethacrynic acid", "object": "convulsions", "sbj_char_span": [3, 18], "obj_char_span": [27, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 6], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the convulsions induced by isoniazid (200 mg/kg s.c.).", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [103, 114], "ent_id": "D012640", "tok_span": [28, 31]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [126, 135], "ent_id": "D007538", "tok_span": [33, 37]}, {"name": "beta-carboline", "ent_type": "Chemical", "char_span": [29, 43], "ent_id": "D002243", "tok_span": [10, 14]}, {"name": "[35S]TBPS", "ent_type": "Chemical", "char_span": [77, 86], "ent_id": "C037476", "tok_span": [19, 25]}], "relation_list": [{"subject": "isoniazid", "object": "convulsions", "sbj_char_span": [126, 135], "obj_char_span": [103, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 37], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "Recurrent myocardial infarction in a postpartum patient receiving bromocriptine.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [10, 31], "ent_id": "D009203", "tok_span": [2, 4]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [66, 79], "ent_id": "D001971", "tok_span": [9, 13]}], "relation_list": [{"subject": "bromocriptine", "object": "myocardial infarction", "sbj_char_span": [66, 79], "obj_char_span": [10, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Bromocriptine has been implicated in several previous case reports of myocardial infarction in the puerperium.", "entity_list": [{"name": "Bromocriptine", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D001971", "tok_span": [0, 4]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [70, 91], "ent_id": "D009203", "tok_span": [13, 15]}], "relation_list": [{"subject": "Bromocriptine", "object": "myocardial infarction", "sbj_char_span": [0, 13], "obj_char_span": [70, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "entity_list": [{"name": "neurotoxicity", "ent_type": "Disease", "char_span": [57, 70], "ent_id": "D020258", "tok_span": [12, 14]}, {"name": "CBZ", "ent_type": "Chemical", "char_span": [197, 200], "ent_id": "D002220", "tok_span": [40, 42]}, {"name": "asterixis", "ent_type": "Disease", "char_span": [12, 21], "ent_id": "D020820", "tok_span": [2, 5]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [158, 167], "ent_id": "D003024", "tok_span": [32, 35]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [147, 154], "ent_id": "D008094", "tok_span": [30, 31]}], "relation_list": [{"subject": "clozapine", "object": "asterixis", "sbj_char_span": [158, 167], "obj_char_span": [12, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [2, 5]}, {"subject": "lithium", "object": "asterixis", "sbj_char_span": [147, 154], "obj_char_span": [12, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.", "entity_list": [{"name": "parkinsonian", "ent_type": "Disease", "char_span": [58, 70], "ent_id": "D010300", "tok_span": [12, 15]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [46, 54], "ent_id": "D007980", "tok_span": [8, 11]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [24, 35], "ent_id": "D007022", "tok_span": [4, 6]}], "relation_list": [{"subject": "levodopa", "object": "hypotensive", "sbj_char_span": [46, 54], "obj_char_span": [24, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [43, 51], "ent_id": "D007980", "tok_span": [8, 11]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [21, 32], "ent_id": "D007022", "tok_span": [4, 6]}], "relation_list": [{"subject": "levodopa", "object": "hypotensive", "sbj_char_span": [43, 51], "obj_char_span": [21, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.", "entity_list": [{"name": "hypotensive", "ent_type": "Disease", "char_span": [131, 142], "ent_id": "D007022", "tok_span": [29, 31]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [175, 183], "ent_id": "D007980", "tok_span": [38, 41]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [64, 72], "ent_id": "D007980", "tok_span": [15, 18]}, {"name": "Phenylalanine", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D010649", "tok_span": [0, 3]}, {"name": "amino acid", "ent_type": "Chemical", "char_span": [31, 41], "ent_id": "D000596", "tok_span": [7, 9]}], "relation_list": [{"subject": "levodopa", "object": "hypotensive", "sbj_char_span": [175, 183], "obj_char_span": [131, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [29, 31]}, {"subject": "levodopa", "object": "hypotensive", "sbj_char_span": [64, 72], "obj_char_span": [131, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "We conclude that levodopa has a central hypotensive action that parallels the motor effects in fluctuating patients.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [17, 25], "ent_id": "D007980", "tok_span": [3, 6]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [40, 51], "ent_id": "D007022", "tok_span": [9, 11]}], "relation_list": [{"subject": "levodopa", "object": "hypotensive", "sbj_char_span": [17, 25], "obj_char_span": [40, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine.", "entity_list": [{"name": "vincristine", "ent_type": "Chemical", "char_span": [77, 88], "ent_id": "D014750", "tok_span": [12, 16]}, {"name": "Syndrome of inappropriate secretion of antidiuretic hormone", "ent_type": "Disease", "char_span": [0, 59], "ent_id": "D007177", "tok_span": [0, 9]}], "relation_list": [{"subject": "vincristine", "object": "Syndrome of inappropriate secretion of antidiuretic hormone", "sbj_char_span": [77, 88], "obj_char_span": [0, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 9]}], "umls_entity_list": []}, {"text": "Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion.", "entity_list": [{"name": "syndrome of inappropriate secretion of antidiuretic hormone", "ent_type": "Disease", "char_span": [24, 83], "ent_id": "D007177", "tok_span": [3, 12]}, {"name": "vincristine", "ent_type": "Chemical", "char_span": [113, 124], "ent_id": "D014750", "tok_span": [18, 22]}], "relation_list": [{"subject": "vincristine", "object": "syndrome of inappropriate secretion of antidiuretic hormone", "sbj_char_span": [113, 124], "obj_char_span": [24, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [3, 12]}], "umls_entity_list": []}, {"text": "Also, digoxin has undesirable effects such as increasing peripheral resistance and myocardial demands, and causing arrhythmias.", "entity_list": [{"name": "digoxin", "ent_type": "Chemical", "char_span": [6, 13], "ent_id": "D004077", "tok_span": [2, 4]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [115, 126], "ent_id": "D001145", "tok_span": [18, 19]}], "relation_list": [{"subject": "digoxin", "object": "arrhythmias", "sbj_char_span": [6, 13], "obj_char_span": [115, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Intravascular hemolysis and acute renal failure following intermittent rifampin therapy.", "entity_list": [{"name": "hemolysis", "ent_type": "Disease", "char_span": [14, 23], "ent_id": "D006461", "tok_span": [2, 4]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [28, 47], "ent_id": "D058186", "tok_span": [5, 8]}, {"name": "rifampin", "ent_type": "Chemical", "char_span": [71, 79], "ent_id": "D012293", "tok_span": [10, 13]}], "relation_list": [{"subject": "rifampin", "object": "hemolysis", "sbj_char_span": [71, 79], "obj_char_span": [14, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [2, 4]}, {"subject": "rifampin", "object": "acute renal failure", "sbj_char_span": [71, 79], "obj_char_span": [28, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Intravascular hemolysis leading to acute renal failure following rifampin therapy is extremely rare.", "entity_list": [{"name": "hemolysis", "ent_type": "Disease", "char_span": [14, 23], "ent_id": "D006461", "tok_span": [2, 4]}, {"name": "rifampin", "ent_type": "Chemical", "char_span": [65, 73], "ent_id": "D012293", "tok_span": [10, 13]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [35, 54], "ent_id": "D058186", "tok_span": [6, 9]}], "relation_list": [{"subject": "rifampin", "object": "acute renal failure", "sbj_char_span": [65, 73], "obj_char_span": [35, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [6, 9]}, {"subject": "rifampin", "object": "hemolysis", "sbj_char_span": [65, 73], "obj_char_span": [14, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Two patients with leprosy who developed hemolysis and acute renal failure following rifampin are reported.", "entity_list": [{"name": "leprosy", "ent_type": "Disease", "char_span": [18, 25], "ent_id": "D007918", "tok_span": [3, 6]}, {"name": "hemolysis", "ent_type": "Disease", "char_span": [40, 49], "ent_id": "D006461", "tok_span": [8, 10]}, {"name": "rifampin", "ent_type": "Chemical", "char_span": [84, 92], "ent_id": "D012293", "tok_span": [15, 18]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [54, 73], "ent_id": "D058186", "tok_span": [11, 14]}], "relation_list": [{"subject": "rifampin", "object": "hemolysis", "sbj_char_span": [84, 92], "obj_char_span": [40, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [8, 10]}, {"subject": "rifampin", "object": "acute renal failure", "sbj_char_span": [84, 92], "obj_char_span": [54, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Zidovudine-induced hepatitis.", "entity_list": [{"name": "Zidovudine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D015215", "tok_span": [0, 5]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [19, 28], "ent_id": "D056486", "tok_span": [7, 8]}], "relation_list": [{"subject": "Zidovudine", "object": "hepatitis", "sbj_char_span": [0, 10], "obj_char_span": [19, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "A case of acute hepatitis induced by zidovudine in a 38-year-old patient with AIDS is presented.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [16, 25], "ent_id": "D056486", "tok_span": [4, 5]}, {"name": "AIDS", "ent_type": "Disease", "char_span": [78, 82], "ent_id": "D000163", "tok_span": [21, 22]}, {"name": "zidovudine", "ent_type": "Chemical", "char_span": [37, 47], "ent_id": "D015215", "tok_span": [7, 12]}], "relation_list": [{"subject": "zidovudine", "object": "hepatitis", "sbj_char_span": [37, 47], "obj_char_span": [16, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Thoracic hematomyelia secondary to coumadin anticoagulant therapy: a case report.", "entity_list": [{"name": "coumadin", "ent_type": "Chemical", "char_span": [35, 43], "ent_id": "D014859", "tok_span": [7, 10]}, {"name": "Thoracic hematomyelia", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D020758", "tok_span": [0, 5]}], "relation_list": [{"subject": "coumadin", "object": "Thoracic hematomyelia", "sbj_char_span": [35, 43], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "Mania associated with fluoxetine treatment in adolescents.", "entity_list": [{"name": "fluoxetine", "ent_type": "Chemical", "char_span": [22, 32], "ent_id": "D005473", "tok_span": [4, 7]}, {"name": "Mania", "ent_type": "Disease", "char_span": [0, 5], "ent_id": "D001714", "tok_span": [0, 2]}], "relation_list": [{"subject": "fluoxetine", "object": "Mania", "sbj_char_span": [22, 32], "obj_char_span": [0, 5], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania.", "entity_list": [{"name": "mania", "ent_type": "Disease", "char_span": [84, 89], "ent_id": "D001714", "tok_span": [16, 18]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [45, 55], "ent_id": "D005473", "tok_span": [8, 11]}], "relation_list": [{"subject": "fluoxetine", "object": "mania", "sbj_char_span": [45, 55], "obj_char_span": [84, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here.", "entity_list": [{"name": "mania", "ent_type": "Disease", "char_span": [75, 80], "ent_id": "D001714", "tok_span": [16, 18]}, {"name": "depressed", "ent_type": "Disease", "char_span": [18, 27], "ent_id": "D003866", "tok_span": [4, 5]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [109, 119], "ent_id": "D005473", "tok_span": [22, 25]}], "relation_list": [{"subject": "fluoxetine", "object": "mania", "sbj_char_span": [109, 119], "obj_char_span": [75, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "entity_list": [{"name": "fluoxetine", "ent_type": "Chemical", "char_span": [71, 81], "ent_id": "D005473", "tok_span": [14, 17]}, {"name": "affective disorder", "ent_type": "Disease", "char_span": [271, 289], "ent_id": "D019964", "tok_span": [47, 49]}, {"name": "depression", "ent_type": "Disease", "char_span": [215, 225], "ent_id": "D003866", "tok_span": [37, 38]}, {"name": "psychotic", "ent_type": "Disease", "char_span": [231, 240], "ent_id": "D011618", "tok_span": [39, 41]}, {"name": "bipolar disorder", "ent_type": "Disease", "char_span": [302, 318], "ent_id": "D001714", "tok_span": [51, 53]}, {"name": "hypomania", "ent_type": "Disease", "char_span": [54, 63], "ent_id": "D001714", "tok_span": [10, 13]}, {"name": "bipolar disorder", "ent_type": "Disease", "char_span": [339, 355], "ent_id": "D001714", "tok_span": [58, 60]}, {"name": "attention-deficit hyperactivity disorder", "ent_type": "Disease", "char_span": [141, 181], "ent_id": "D001289", "tok_span": [26, 32]}, {"name": "mania", "ent_type": "Disease", "char_span": [45, 50], "ent_id": "D001714", "tok_span": [7, 9]}], "relation_list": [{"subject": "fluoxetine", "object": "bipolar disorder", "sbj_char_span": [71, 81], "obj_char_span": [339, 355], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [58, 60]}, {"subject": "fluoxetine", "object": "bipolar disorder", "sbj_char_span": [71, 81], "obj_char_span": [302, 318], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [51, 53]}, {"subject": "fluoxetine", "object": "mania", "sbj_char_span": [71, 81], "obj_char_span": [45, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [7, 9]}, {"subject": "fluoxetine", "object": "hypomania", "sbj_char_span": [71, 81], "obj_char_span": [54, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents.", "entity_list": [{"name": "mania", "ent_type": "Disease", "char_span": [146, 151], "ent_id": "D001714", "tok_span": [23, 25]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [127, 137], "ent_id": "D005473", "tok_span": [19, 22]}], "relation_list": [{"subject": "fluoxetine", "object": "mania", "sbj_char_span": [127, 137], "obj_char_span": [146, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Hepatocellular carcinoma in Fanconi's anemia treated with androgen and corticosteroid.", "entity_list": [{"name": "androgen", "ent_type": "Chemical", "char_span": [58, 66], "ent_id": "D000728", "tok_span": [12, 13]}, {"name": "Hepatocellular carcinoma", "ent_type": "Disease", "char_span": [0, 24], "ent_id": "D006528", "tok_span": [0, 3]}, {"name": "Fanconi's anemia", "ent_type": "Disease", "char_span": [28, 44], "ent_id": "D005199", "tok_span": [4, 10]}, {"name": "corticosteroid", "ent_type": "Chemical", "char_span": [71, 85], "ent_id": "D000305", "tok_span": [14, 15]}], "relation_list": [{"subject": "corticosteroid", "object": "Hepatocellular carcinoma", "sbj_char_span": [71, 85], "obj_char_span": [0, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [0, 3]}, {"subject": "androgen", "object": "Hepatocellular carcinoma", "sbj_char_span": [58, 66], "obj_char_span": [0, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.", "entity_list": [{"name": "hepatic neoplasms", "ent_type": "Disease", "char_span": [74, 91], "ent_id": "D008113", "tok_span": [13, 15]}, {"name": "Fanconi's anemia", "ent_type": "Disease", "char_span": [171, 187], "ent_id": "D005199", "tok_span": [29, 35]}, {"name": "peliosis", "ent_type": "Disease", "char_span": [96, 104], "ent_id": "D010382", "tok_span": [16, 18]}, {"name": "androgen", "ent_type": "Chemical", "char_span": [134, 142], "ent_id": "D000728", "tok_span": [23, 24]}, {"name": "corticosteroid", "ent_type": "Chemical", "char_span": [148, 162], "ent_id": "D000305", "tok_span": [26, 27]}], "relation_list": [{"subject": "androgen", "object": "peliosis", "sbj_char_span": [134, 142], "obj_char_span": [96, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [16, 18]}, {"subject": "corticosteroid", "object": "peliosis", "sbj_char_span": [148, 162], "obj_char_span": [96, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "The trimethaphan-induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion.", "entity_list": [{"name": "tachycardia", "ent_type": "Disease", "char_span": [135, 146], "ent_id": "D013610", "tok_span": [34, 35]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [25, 36], "ent_id": "D007022", "tok_span": [7, 8]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [70, 81], "ent_id": "D001919", "tok_span": [13, 17]}, {"name": "trimethaphan", "ent_type": "Chemical", "char_span": [4, 16], "ent_id": "D014294", "tok_span": [1, 5]}], "relation_list": [{"subject": "trimethaphan", "object": "tachycardia", "sbj_char_span": [4, 16], "obj_char_span": [135, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 5], "obj_tok_span": [34, 35]}, {"subject": "trimethaphan", "object": "hypotension", "sbj_char_span": [4, 16], "obj_char_span": [25, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 5], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Damage of substantia nigra pars reticulata during pilocarpine-induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation.", "entity_list": [{"name": "Damage of substantia nigra pars reticulata", "ent_type": "Disease", "char_span": [0, 42], "ent_id": "D001930", "tok_span": [0, 12]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [70, 88], "ent_id": "D013226", "tok_span": [18, 21]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [50, 61], "ent_id": "D010862", "tok_span": [13, 16]}], "relation_list": [{"subject": "pilocarpine", "object": "Damage of substantia nigra pars reticulata", "sbj_char_span": [50, 61], "obj_char_span": [0, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [0, 12]}, {"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [50, 61], "obj_char_span": [70, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "In this study, status epilepticus was induced by systemic injection of pilocarpine in rats.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [15, 33], "ent_id": "D013226", "tok_span": [4, 7]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [71, 82], "ent_id": "D010862", "tok_span": [13, 16]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [71, 82], "obj_char_span": [15, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.", "entity_list": [{"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [8, 22], "ent_id": "D066126", "tok_span": [1, 3]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [26, 37], "ent_id": "D004317", "tok_span": [4, 5]}, {"name": "N-(2-hydroxypropyl)methacrylamide", "ent_type": "Chemical", "char_span": [59, 92], "ent_id": "C032976", "tok_span": [10, 21]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiotoxicity", "sbj_char_span": [26, 37], "obj_char_span": [8, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "entity_list": [{"name": "N-(2-hydroxypropyl)methacrylamide", "ent_type": "Chemical", "char_span": [167, 200], "ent_id": "C032976", "tok_span": [36, 47]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [51, 59], "ent_id": "D064420", "tok_span": [10, 11]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [99, 110], "ent_id": "D004317", "tok_span": [21, 22]}, {"name": "HPMA", "ent_type": "Chemical", "char_span": [202, 206], "ent_id": "C032976", "tok_span": [48, 50]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [73, 87], "ent_id": "D066126", "tok_span": [14, 16]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [112, 115], "ent_id": "D004317", "tok_span": [23, 24]}], "relation_list": [{"subject": "DOX", "object": "cardiotoxicity", "sbj_char_span": [112, 115], "obj_char_span": [73, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [14, 16]}, {"subject": "doxorubicin", "object": "cardiotoxicity", "sbj_char_span": [99, 110], "obj_char_span": [73, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "entity_list": [{"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [292, 306], "ent_id": "D066126", "tok_span": [53, 55]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [168, 171], "ent_id": "D004317", "tok_span": [32, 33]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [280, 283], "ent_id": "D004317", "tok_span": [50, 51]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [122, 125], "ent_id": "D004317", "tok_span": [22, 23]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [51, 65], "ent_id": "D066126", "tok_span": [11, 13]}, {"name": "HPMA", "ent_type": "Chemical", "char_span": [144, 148], "ent_id": "C032976", "tok_span": [27, 29]}], "relation_list": [{"subject": "DOX", "object": "cardiotoxicity", "sbj_char_span": [280, 283], "obj_char_span": [51, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 51], "obj_tok_span": [11, 13]}, {"subject": "DOX", "object": "cardiotoxicity", "sbj_char_span": [168, 171], "obj_char_span": [292, 306], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [53, 55]}, {"subject": "DOX", "object": "cardiotoxicity", "sbj_char_span": [122, 125], "obj_char_span": [51, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [11, 13]}, {"subject": "DOX", "object": "cardiotoxicity", "sbj_char_span": [122, 125], "obj_char_span": [292, 306], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [53, 55]}, {"subject": "DOX", "object": "cardiotoxicity", "sbj_char_span": [168, 171], "obj_char_span": [51, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [11, 13]}, {"subject": "DOX", "object": "cardiotoxicity", "sbj_char_span": [280, 283], "obj_char_span": [292, 306], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 51], "obj_tok_span": [53, 55]}], "umls_entity_list": []}, {"text": "Nineteen patients (48.7%) substantially improved after the 8-week trial; 5 (12.8%) discontinued therapy due to side-effects such as intolerable capsaicin-induced burning sensations (4) or mastitis (1); 15 (38.5%) reported no benefit.", "entity_list": [{"name": "mastitis", "ent_type": "Disease", "char_span": [188, 196], "ent_id": "D008413", "tok_span": [49, 51]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [144, 153], "ent_id": "D002211", "tok_span": [37, 40]}], "relation_list": [{"subject": "capsaicin", "object": "mastitis", "sbj_char_span": [144, 153], "obj_char_span": [188, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [49, 51]}], "umls_entity_list": []}, {"text": "Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.", "entity_list": [{"name": "paranoid", "ent_type": "Disease", "char_span": [14, 22], "ent_id": "D010259", "tok_span": [3, 6]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [45, 54], "ent_id": "D012701", "tok_span": [10, 11]}, {"name": "amitriptyline", "ent_type": "Chemical", "char_span": [90, 103], "ent_id": "D000639", "tok_span": [19, 24]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [75, 85], "ent_id": "D005473", "tok_span": [15, 18]}], "relation_list": [{"subject": "fluoxetine", "object": "paranoid", "sbj_char_span": [75, 85], "obj_char_span": [14, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [3, 6]}, {"subject": "amitriptyline", "object": "paranoid", "sbj_char_span": [90, 103], "obj_char_span": [14, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 24], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Five cases of encephalitis during treatment of loiasis with diethylcarbamazine.", "entity_list": [{"name": "loiasis", "ent_type": "Disease", "char_span": [47, 54], "ent_id": "D008118", "tok_span": [8, 10]}, {"name": "diethylcarbamazine", "ent_type": "Chemical", "char_span": [60, 78], "ent_id": "D004049", "tok_span": [11, 17]}, {"name": "encephalitis", "ent_type": "Disease", "char_span": [14, 26], "ent_id": "D004660", "tok_span": [3, 5]}], "relation_list": [{"subject": "diethylcarbamazine", "object": "encephalitis", "sbj_char_span": [60, 78], "obj_char_span": [14, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 17], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Five cases of encephalitis following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.", "entity_list": [{"name": "filariasis", "ent_type": "Disease", "char_span": [126, 136], "ent_id": "D005368", "tok_span": [29, 32]}, {"name": "encephalitis", "ent_type": "Disease", "char_span": [14, 26], "ent_id": "D004660", "tok_span": [3, 5]}, {"name": "diethylcarbamazine", "ent_type": "Chemical", "char_span": [52, 70], "ent_id": "D004049", "tok_span": [8, 14]}, {"name": "DEC", "ent_type": "Chemical", "char_span": [72, 75], "ent_id": "D004049", "tok_span": [15, 16]}], "relation_list": [{"subject": "diethylcarbamazine", "object": "encephalitis", "sbj_char_span": [52, 70], "obj_char_span": [14, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 14], "obj_tok_span": [3, 5]}, {"subject": "DEC", "object": "encephalitis", "sbj_char_span": [72, 75], "obj_char_span": [14, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Delirium in an elderly woman possibly associated with administration of misoprostol.", "entity_list": [{"name": "Delirium", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D003693", "tok_span": [0, 3]}, {"name": "misoprostol", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D016595", "tok_span": [12, 15]}], "relation_list": [{"subject": "misoprostol", "object": "Delirium", "sbj_char_span": [72, 83], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Her delirium significantly improved after misoprostol was discontinued and her mental status returned to normal within a week.", "entity_list": [{"name": "delirium", "ent_type": "Disease", "char_span": [4, 12], "ent_id": "D003693", "tok_span": [1, 4]}, {"name": "misoprostol", "ent_type": "Chemical", "char_span": [42, 53], "ent_id": "D016595", "tok_span": [7, 10]}], "relation_list": [{"subject": "misoprostol", "object": "delirium", "sbj_char_span": [42, 53], "obj_char_span": [4, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "Because no other factors related to this patient changed significantly, the delirium experienced by this patient possibly resulted from misoprostol therapy.", "entity_list": [{"name": "misoprostol", "ent_type": "Chemical", "char_span": [136, 147], "ent_id": "D016595", "tok_span": [22, 25]}, {"name": "delirium", "ent_type": "Disease", "char_span": [76, 84], "ent_id": "D003693", "tok_span": [12, 15]}], "relation_list": [{"subject": "misoprostol", "object": "delirium", "sbj_char_span": [136, 147], "obj_char_span": [76, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "We conclude that an H1 antagonist may be useful in preventing hypotension caused by iv cimetidine, since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor.", "entity_list": [{"name": "cimetidine", "ent_type": "Chemical", "char_span": [134, 144], "ent_id": "D002927", "tok_span": [26, 29]}, {"name": "cimetidine", "ent_type": "Chemical", "char_span": [87, 97], "ent_id": "D002927", "tok_span": [16, 19]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [62, 73], "ent_id": "D007022", "tok_span": [12, 13]}], "relation_list": [{"subject": "cimetidine", "object": "hypotension", "sbj_char_span": [134, 144], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [12, 13]}, {"subject": "cimetidine", "object": "hypotension", "sbj_char_span": [87, 97], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "Acute renal failure due to rifampicin.", "entity_list": [{"name": "Acute renal failure", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D058186", "tok_span": [0, 3]}, {"name": "rifampicin", "ent_type": "Chemical", "char_span": [27, 37], "ent_id": "D012293", "tok_span": [5, 8]}], "relation_list": [{"subject": "rifampicin", "object": "Acute renal failure", "sbj_char_span": [27, 37], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.", "entity_list": [{"name": "polyneuropathy", "ent_type": "Disease", "char_span": [7, 21], "ent_id": "D011115", "tok_span": [1, 4]}, {"name": "thiotepa", "ent_type": "Chemical", "char_span": [55, 63], "ent_id": "D013852", "tok_span": [11, 14]}], "relation_list": [{"subject": "thiotepa", "object": "polyneuropathy", "sbj_char_span": [55, 63], "obj_char_span": [7, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "Two cases of severe delayed neurologic toxicity related to the administration of intrathecal (IT) combination chemotherapy including thiotepa (TSPA) are presented.", "entity_list": [{"name": "TSPA", "ent_type": "Chemical", "char_span": [143, 147], "ent_id": "D013852", "tok_span": [25, 27]}, {"name": "thiotepa", "ent_type": "Chemical", "char_span": [133, 141], "ent_id": "D013852", "tok_span": [21, 24]}, {"name": "neurologic toxicity", "ent_type": "Disease", "char_span": [28, 47], "ent_id": "D020258", "tok_span": [5, 7]}], "relation_list": [{"subject": "thiotepa", "object": "neurologic toxicity", "sbj_char_span": [133, 141], "obj_char_span": [28, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [5, 7]}, {"subject": "TSPA", "object": "neurologic toxicity", "sbj_char_span": [143, 147], "obj_char_span": [28, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 27], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Neurologic toxicities have been described with IT-methotrexate, IT-cytosine arabinoside and IT-TSPA.", "entity_list": [{"name": "TSPA", "ent_type": "Chemical", "char_span": [95, 99], "ent_id": "D013852", "tok_span": [23, 25]}, {"name": "cytosine arabinoside", "ent_type": "Chemical", "char_span": [67, 87], "ent_id": "D003561", "tok_span": [15, 20]}, {"name": "Neurologic toxicities", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D020258", "tok_span": [0, 4]}, {"name": "methotrexate", "ent_type": "Chemical", "char_span": [50, 62], "ent_id": "D008727", "tok_span": [10, 12]}], "relation_list": [{"subject": "methotrexate", "object": "Neurologic toxicities", "sbj_char_span": [50, 62], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [0, 4]}, {"subject": "cytosine arabinoside", "object": "Neurologic toxicities", "sbj_char_span": [67, 87], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 20], "obj_tok_span": [0, 4]}, {"subject": "TSPA", "object": "Neurologic toxicities", "sbj_char_span": [95, 99], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "In spite of the fact that TSPA is a useful IT agent, its combination with MTX, ara-C and radiotherapy could cause severe neurotoxicity.", "entity_list": [{"name": "ara-C", "ent_type": "Chemical", "char_span": [79, 84], "ent_id": "D003561", "tok_span": [19, 23]}, {"name": "MTX", "ent_type": "Chemical", "char_span": [74, 77], "ent_id": "D008727", "tok_span": [17, 18]}, {"name": "TSPA", "ent_type": "Chemical", "char_span": [26, 30], "ent_id": "D013852", "tok_span": [6, 8]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [121, 134], "ent_id": "D020258", "tok_span": [28, 30]}], "relation_list": [{"subject": "MTX", "object": "neurotoxicity", "sbj_char_span": [74, 77], "obj_char_span": [121, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [28, 30]}, {"subject": "TSPA", "object": "neurotoxicity", "sbj_char_span": [26, 30], "obj_char_span": [121, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [28, 30]}, {"subject": "ara-C", "object": "neurotoxicity", "sbj_char_span": [79, 84], "obj_char_span": [121, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [53, 64], "ent_id": "D007022", "tok_span": [10, 11]}, {"name": "cromakalim", "ent_type": "Chemical", "char_span": [76, 86], "ent_id": "D019806", "tok_span": [13, 17]}, {"name": "pinacidil", "ent_type": "Chemical", "char_span": [91, 100], "ent_id": "D020110", "tok_span": [18, 21]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [204, 215], "ent_id": "D013610", "tok_span": [40, 41]}, {"name": "beta adrenergic and muscarinic receptors blockade", "ent_type": "Chemical", "char_span": [137, 186], "ent_id": "D00031", "tok_span": [27, 36]}], "relation_list": [{"subject": "cromakalim", "object": "tachycardia", "sbj_char_span": [76, 86], "obj_char_span": [204, 215], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [40, 41]}, {"subject": "pinacidil", "object": "tachycardia", "sbj_char_span": [91, 100], "obj_char_span": [204, 215], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [40, 41]}, {"subject": "pinacidil", "object": "hypotension", "sbj_char_span": [91, 100], "obj_char_span": [53, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [10, 11]}, {"subject": "cromakalim", "object": "hypotension", "sbj_char_span": [76, 86], "obj_char_span": [53, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Mefenamic acid-induced neutropenia and renal failure in elderly females with hypothyroidism.", "entity_list": [{"name": "renal failure", "ent_type": "Disease", "char_span": [39, 52], "ent_id": "D051437", "tok_span": [9, 11]}, {"name": "Mefenamic acid", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D008528", "tok_span": [0, 4]}, {"name": "neutropenia", "ent_type": "Disease", "char_span": [23, 34], "ent_id": "D009503", "tok_span": [6, 8]}, {"name": "hypothyroidism", "ent_type": "Disease", "char_span": [77, 91], "ent_id": "D007037", "tok_span": [15, 17]}], "relation_list": [{"subject": "Mefenamic acid", "object": "neutropenia", "sbj_char_span": [0, 14], "obj_char_span": [23, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 8]}, {"subject": "Mefenamic acid", "object": "renal failure", "sbj_char_span": [0, 14], "obj_char_span": [39, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "We report mefenamic acid-induced non-oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females.", "entity_list": [{"name": "mefenamic acid", "ent_type": "Chemical", "char_span": [10, 24], "ent_id": "D008528", "tok_span": [2, 6]}, {"name": "neutropenia", "ent_type": "Disease", "char_span": [71, 82], "ent_id": "D009503", "tok_span": [16, 18]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [46, 59], "ent_id": "D051437", "tok_span": [12, 14]}], "relation_list": [{"subject": "mefenamic acid", "object": "neutropenia", "sbj_char_span": [10, 24], "obj_char_span": [71, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [16, 18]}, {"subject": "mefenamic acid", "object": "renal failure", "sbj_char_span": [10, 24], "obj_char_span": [46, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy.", "entity_list": [{"name": "hypercalcemia", "ent_type": "Disease", "char_span": [12, 25], "ent_id": "D006934", "tok_span": [3, 6]}, {"name": "calcium carbonate", "ent_type": "Chemical", "char_span": [54, 71], "ent_id": "D002119", "tok_span": [10, 12]}], "relation_list": [{"subject": "calcium carbonate", "object": "hypercalcemia", "sbj_char_span": [54, 71], "obj_char_span": [12, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Fourteen of 39 dialysis patients (36%) became hypercalcemic after switching to calcium carbonate as their principal phosphate binder.", "entity_list": [{"name": "hypercalcemic", "ent_type": "Disease", "char_span": [46, 59], "ent_id": "D006934", "tok_span": [11, 14]}, {"name": "calcium carbonate", "ent_type": "Chemical", "char_span": [79, 96], "ent_id": "D002119", "tok_span": [17, 19]}, {"name": "phosphate", "ent_type": "Chemical", "char_span": [116, 125], "ent_id": "D010710", "tok_span": [22, 23]}], "relation_list": [{"subject": "calcium carbonate", "object": "hypercalcemic", "sbj_char_span": [79, 96], "obj_char_span": [46, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Methyldopa-induced hemolytic anemia in a 15 year old presenting as near-syncope.", "entity_list": [{"name": "Methyldopa", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D008750", "tok_span": [0, 3]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [19, 35], "ent_id": "D000743", "tok_span": [5, 8]}, {"name": "syncope", "ent_type": "Disease", "char_span": [72, 79], "ent_id": "D013575", "tok_span": [17, 19]}], "relation_list": [{"subject": "Methyldopa", "object": "hemolytic anemia", "sbj_char_span": [0, 10], "obj_char_span": [19, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope.", "entity_list": [{"name": "emergency department", "ent_type": "Disease", "char_span": [98, 118], "ent_id": "D004630", "tok_span": [25, 27]}, {"name": "syncope", "ent_type": "Disease", "char_span": [129, 136], "ent_id": "D013575", "tok_span": [30, 32]}, {"name": "methyldopa", "ent_type": "Chemical", "char_span": [20, 30], "ent_id": "D008750", "tok_span": [5, 8]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [39, 55], "ent_id": "D000743", "tok_span": [10, 13]}], "relation_list": [{"subject": "methyldopa", "object": "hemolytic anemia", "sbj_char_span": [20, 30], "obj_char_span": [39, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "There was a direct relationship between CHP concentration and patients' ratings of pain on an analogue scale.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [83, 87], "ent_id": "D010146", "tok_span": [14, 15]}, {"name": "CHP", "ent_type": "Chemical", "char_span": [40, 43], "ent_id": "C048279", "tok_span": [6, 8]}], "relation_list": [{"subject": "CHP", "object": "pain", "sbj_char_span": [40, 43], "obj_char_span": [83, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "The 0.25 per cent CHP cream was closest to AgSD in pain tolerance; however, none of the treatments differed statistically from AgSD or from each other.", "entity_list": [{"name": "AgSD", "ent_type": "Chemical", "char_span": [43, 47], "ent_id": "D012837", "tok_span": [13, 15]}, {"name": "AgSD", "ent_type": "Chemical", "char_span": [127, 131], "ent_id": "D012837", "tok_span": [28, 30]}, {"name": "CHP", "ent_type": "Chemical", "char_span": [18, 21], "ent_id": "C048279", "tok_span": [6, 8]}, {"name": "pain", "ent_type": "Disease", "char_span": [51, 55], "ent_id": "D010146", "tok_span": [16, 17]}], "relation_list": [{"subject": "CHP", "object": "pain", "sbj_char_span": [18, 21], "obj_char_span": [51, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "Ninety-six patients were not given anticonvulsive prophylaxis; 7 (7.5%) developed seizures during the 4 days of the busulfan course or within 24 h after the last dosing.", "entity_list": [{"name": "busulfan", "ent_type": "Chemical", "char_span": [116, 124], "ent_id": "D002066", "tok_span": [29, 32]}, {"name": "seizures", "ent_type": "Disease", "char_span": [82, 90], "ent_id": "D012640", "tok_span": [22, 23]}], "relation_list": [{"subject": "busulfan", "object": "seizures", "sbj_char_span": [116, 124], "obj_char_span": [82, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "Histamine antagonists and d-tubocurarine-induced hypotension in cardiac surgical patients.", "entity_list": [{"name": "d-tubocurarine", "ent_type": "Chemical", "char_span": [26, 40], "ent_id": "D014403", "tok_span": [4, 10]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [49, 60], "ent_id": "D007022", "tok_span": [12, 13]}, {"name": "Histamine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D006632", "tok_span": [0, 2]}], "relation_list": [{"subject": "d-tubocurarine", "object": "hypotension", "sbj_char_span": [26, 40], "obj_char_span": [49, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 10], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [189, 197], "ent_id": "D012640", "tok_span": [39, 40]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [127, 135], "ent_id": "D004298", "tok_span": [27, 28]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [25, 32], "ent_id": "D001556", "tok_span": [5, 8]}, {"name": "GABA", "ent_type": "Chemical", "char_span": [121, 125], "ent_id": "D005680", "tok_span": [25, 26]}], "relation_list": [{"subject": "lindane", "object": "seizures", "sbj_char_span": [25, 32], "obj_char_span": [189, 197], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [39, 40]}], "umls_entity_list": []}, {"text": "All animals suffered tonic convulsions at 18.3 +/- 1.4 min after lindane administration.", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [27, 38], "ent_id": "D012640", "tok_span": [4, 7]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [65, 72], "ent_id": "D001556", "tok_span": [19, 22]}], "relation_list": [{"subject": "lindane", "object": "convulsions", "sbj_char_span": [65, 72], "obj_char_span": [27, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [47, 56], "ent_id": "D056486", "tok_span": [11, 12]}, {"name": "lupus-like syndrome", "ent_type": "Disease", "char_span": [167, 186], "ent_id": "D008180", "tok_span": [36, 40]}, {"name": "hepatocellular necrosis", "ent_type": "Disease", "char_span": [99, 122], "ent_id": "D047508", "tok_span": [23, 25]}, {"name": "propylthiouracil", "ent_type": "Chemical", "char_span": [139, 155], "ent_id": "D011441", "tok_span": [29, 34]}, {"name": "propylthiouracil", "ent_type": "Chemical", "char_span": [13, 29], "ent_id": "D011441", "tok_span": [3, 8]}, {"name": "methimazole", "ent_type": "Chemical", "char_span": [76, 87], "ent_id": "D008713", "tok_span": [17, 21]}], "relation_list": [{"subject": "methimazole", "object": "hepatocellular necrosis", "sbj_char_span": [76, 87], "obj_char_span": [99, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [23, 25]}, {"subject": "propylthiouracil", "object": "hepatitis", "sbj_char_span": [13, 29], "obj_char_span": [47, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [11, 12]}, {"subject": "propylthiouracil", "object": "lupus-like syndrome", "sbj_char_span": [13, 29], "obj_char_span": [167, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [36, 40]}, {"subject": "propylthiouracil", "object": "lupus-like syndrome", "sbj_char_span": [139, 155], "obj_char_span": [167, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 34], "obj_tok_span": [36, 40]}, {"subject": "propylthiouracil", "object": "hepatitis", "sbj_char_span": [139, 155], "obj_char_span": [47, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 34], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [69, 87], "ent_id": "D013226", "tok_span": [20, 23]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [48, 59], "ent_id": "D010862", "tok_span": [15, 18]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [26, 32], "ent_id": "D016291", "tok_span": [7, 11]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [40, 47], "ent_id": "D008094", "tok_span": [13, 14]}], "relation_list": [{"subject": "lithium", "object": "status epilepticus", "sbj_char_span": [40, 47], "obj_char_span": [69, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [20, 23]}, {"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [48, 59], "obj_char_span": [69, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [79, 90], "ent_id": "D010862", "tok_span": [14, 17]}, {"name": "seizures", "ent_type": "Disease", "char_span": [47, 55], "ent_id": "D012640", "tok_span": [9, 10]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [137, 148], "ent_id": "D010862", "tok_span": [27, 30]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [192, 210], "ent_id": "D013226", "tok_span": [38, 41]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [67, 74], "ent_id": "D008094", "tok_span": [12, 13]}, {"name": "seizures", "ent_type": "Disease", "char_span": [242, 250], "ent_id": "D012640", "tok_span": [48, 49]}], "relation_list": [{"subject": "lithium", "object": "status epilepticus", "sbj_char_span": [67, 74], "obj_char_span": [192, 210], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [38, 41]}, {"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [137, 148], "obj_char_span": [192, 210], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [38, 41]}, {"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [79, 90], "obj_char_span": [192, 210], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [38, 41]}], "umls_entity_list": []}, {"text": "Administration of MK-801 30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate.", "entity_list": [{"name": "MK-801", "ent_type": "Chemical", "char_span": [18, 24], "ent_id": "D016291", "tok_span": [2, 6]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [44, 55], "ent_id": "D010862", "tok_span": [11, 14]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [70, 88], "ent_id": "D013226", "tok_span": [21, 24]}, {"name": "seizure", "ent_type": "Disease", "char_span": [134, 141], "ent_id": "D012640", "tok_span": [30, 31]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [44, 55], "obj_char_span": [70, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.", "entity_list": [{"name": "NMDA", "ent_type": "Chemical", "char_span": [41, 45], "ent_id": "D016202", "tok_span": [6, 7]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [134, 145], "ent_id": "D010862", "tok_span": [23, 26]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [126, 133], "ent_id": "D008094", "tok_span": [21, 22]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [83, 101], "ent_id": "D013226", "tok_span": [13, 16]}, {"name": "brain damage", "ent_type": "Disease", "char_span": [106, 118], "ent_id": "D001930", "tok_span": [17, 19]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [134, 145], "obj_char_span": [83, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [13, 16]}, {"subject": "lithium", "object": "status epilepticus", "sbj_char_span": [126, 133], "obj_char_span": [83, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "This was further supported by results showing that nonconvulsive doses of NMDA and pilocarpine were synergistic, resulting in status epilepticus and subsequent mortality.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [126, 144], "ent_id": "D013226", "tok_span": [24, 27]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [74, 78], "ent_id": "D016202", "tok_span": [14, 15]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [83, 94], "ent_id": "D010862", "tok_span": [16, 19]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [83, 94], "obj_char_span": [126, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Nifedipine induced bradycardia in a patient with autonomic neuropathy.", "entity_list": [{"name": "Nifedipine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D009543", "tok_span": [0, 3]}, {"name": "autonomic neuropathy", "ent_type": "Disease", "char_span": [49, 69], "ent_id": "D009422", "tok_span": [12, 14]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [19, 30], "ent_id": "D001919", "tok_span": [4, 8]}], "relation_list": [{"subject": "Nifedipine", "object": "bradycardia", "sbj_char_span": [0, 10], "obj_char_span": [19, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "This is inconsistent with the well-established finding that nifedipine induces tachycardia in normally innervated hearts.", "entity_list": [{"name": "nifedipine", "ent_type": "Chemical", "char_span": [60, 70], "ent_id": "D009543", "tok_span": [10, 13]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [79, 90], "ent_id": "D013610", "tok_span": [14, 15]}], "relation_list": [{"subject": "nifedipine", "object": "tachycardia", "sbj_char_span": [60, 70], "obj_char_span": [79, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Haloperidol failed to prevent amphetamine-induced seizures, but did lower the mortality rate at most doses tested.", "entity_list": [{"name": "Haloperidol", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D006220", "tok_span": [0, 3]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [30, 41], "ent_id": "D000661", "tok_span": [6, 10]}, {"name": "seizures", "ent_type": "Disease", "char_span": [50, 58], "ent_id": "D012640", "tok_span": [12, 13]}], "relation_list": [{"subject": "amphetamine", "object": "seizures", "sbj_char_span": [30, 41], "obj_char_span": [50, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "Haloperidol decreased the incidence of cocaine-induced seizures at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose.", "entity_list": [{"name": "Haloperidol", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D006220", "tok_span": [0, 3]}, {"name": "seizures", "ent_type": "Disease", "char_span": [55, 63], "ent_id": "D012640", "tok_span": [10, 11]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [39, 46], "ent_id": "D003042", "tok_span": [7, 8]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [39, 46], "obj_char_span": [55, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [70, 81], "ent_id": "D006220", "tok_span": [11, 14]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [53, 61], "ent_id": "D004298", "tok_span": [9, 10]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [111, 122], "ent_id": "D000661", "tok_span": [20, 24]}, {"name": "seizures", "ent_type": "Disease", "char_span": [166, 174], "ent_id": "D012640", "tok_span": [30, 31]}], "relation_list": [{"subject": "amphetamine", "object": "seizures", "sbj_char_span": [111, 122], "obj_char_span": [166, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [30, 31]}], "umls_entity_list": []}, {"text": "In contrast, haloperidol demonstrated an ability to reduce cocaine-induced seizures without significantly reducing mortality.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [13, 24], "ent_id": "D006220", "tok_span": [3, 6]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [59, 66], "ent_id": "D003042", "tok_span": [11, 12]}, {"name": "seizures", "ent_type": "Disease", "char_span": [75, 83], "ent_id": "D012640", "tok_span": [14, 15]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [59, 66], "obj_char_span": [75, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas.", "entity_list": [{"name": "diethylstilbesterol", "ent_type": "Chemical", "char_span": [65, 84], "ent_id": "D004054", "tok_span": [11, 18]}, {"name": "estrogen", "ent_type": "Chemical", "char_span": [29, 37], "ent_id": "D004967", "tok_span": [5, 6]}, {"name": "renal carcinomas", "ent_type": "Disease", "char_span": [101, 117], "ent_id": "D002292", "tok_span": [21, 23]}], "relation_list": [{"subject": "diethylstilbesterol", "object": "renal carcinomas", "sbj_char_span": [65, 84], "obj_char_span": [101, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 18], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters.", "entity_list": [{"name": "renal carcinomas", "ent_type": "Disease", "char_span": [127, 143], "ent_id": "D002292", "tok_span": [25, 27]}, {"name": "diethylstilbesterol", "ent_type": "Chemical", "char_span": [99, 118], "ent_id": "D004054", "tok_span": [17, 24]}, {"name": "Estrogen", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D004967", "tok_span": [0, 2]}], "relation_list": [{"subject": "diethylstilbesterol", "object": "renal carcinomas", "sbj_char_span": [99, 118], "obj_char_span": [127, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 24], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Bradycardia due to biperiden.", "entity_list": [{"name": "biperiden", "ent_type": "Chemical", "char_span": [19, 28], "ent_id": "D001712", "tok_span": [4, 7]}, {"name": "Bradycardia", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D001919", "tok_span": [0, 2]}], "relation_list": [{"subject": "biperiden", "object": "Bradycardia", "sbj_char_span": [19, 28], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.", "entity_list": [{"name": "muscarine", "ent_type": "Chemical", "char_span": [133, 142], "ent_id": "D009116", "tok_span": [30, 33]}, {"name": "biperiden", "ent_type": "Chemical", "char_span": [23, 32], "ent_id": "D001712", "tok_span": [4, 7]}, {"name": "atropine", "ent_type": "Chemical", "char_span": [110, 118], "ent_id": "D001285", "tok_span": [23, 26]}, {"name": "Bradycardia", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D001919", "tok_span": [0, 2]}], "relation_list": [{"subject": "biperiden", "object": "Bradycardia", "sbj_char_span": [23, 32], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.", "entity_list": [{"name": "enflurane", "ent_type": "Chemical", "char_span": [60, 69], "ent_id": "D004737", "tok_span": [14, 17]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [73, 83], "ent_id": "D007530", "tok_span": [18, 20]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [11, 22], "ent_id": "D007022", "tok_span": [3, 4]}, {"name": "labetalol", "ent_type": "Chemical", "char_span": [34, 43], "ent_id": "D007741", "tok_span": [6, 9]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [49, 58], "ent_id": "D006221", "tok_span": [10, 13]}], "relation_list": [{"subject": "enflurane", "object": "hypotension", "sbj_char_span": [60, 69], "obj_char_span": [11, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [3, 4]}, {"subject": "halothane", "object": "hypotension", "sbj_char_span": [49, 58], "obj_char_span": [11, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [3, 4]}, {"subject": "labetalol", "object": "hypotension", "sbj_char_span": [34, 43], "obj_char_span": [11, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [3, 4]}, {"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [73, 83], "obj_char_span": [11, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.", "entity_list": [{"name": "hypotensive", "ent_type": "Disease", "char_span": [87, 98], "ent_id": "D007022", "tok_span": [21, 23]}, {"name": "labetalol", "ent_type": "Chemical", "char_span": [25, 34], "ent_id": "D007741", "tok_span": [4, 7]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [150, 159], "ent_id": "D006221", "tok_span": [31, 34]}, {"name": "enflurane", "ent_type": "Chemical", "char_span": [161, 170], "ent_id": "D004737", "tok_span": [35, 38]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [174, 184], "ent_id": "D007530", "tok_span": [39, 41]}], "relation_list": [{"subject": "halothane", "object": "hypotensive", "sbj_char_span": [150, 159], "obj_char_span": [87, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [21, 23]}, {"subject": "labetalol", "object": "hypotensive", "sbj_char_span": [25, 34], "obj_char_span": [87, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [21, 23]}, {"subject": "enflurane", "object": "hypotensive", "sbj_char_span": [161, 170], "obj_char_span": [87, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [21, 23]}, {"subject": "isoflurane", "object": "hypotensive", "sbj_char_span": [174, 184], "obj_char_span": [87, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 41], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "The mean H concentration during hypotension in the inspiratory gas was 0.7 +/- 0.1 vol%, the mean E concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%.", "entity_list": [{"name": "E", "ent_type": "Chemical", "char_span": [98, 99], "ent_id": "D004737", "tok_span": [26, 27]}, {"name": "I", "ent_type": "Chemical", "char_span": [145, 146], "ent_id": "D007530", "tok_span": [43, 44]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [32, 43], "ent_id": "D007022", "tok_span": [5, 6]}, {"name": "H", "ent_type": "Chemical", "char_span": [9, 10], "ent_id": "D006221", "tok_span": [2, 3]}], "relation_list": [{"subject": "H", "object": "hypotension", "sbj_char_span": [9, 10], "obj_char_span": [32, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [5, 6]}, {"subject": "I", "object": "hypotension", "sbj_char_span": [145, 146], "obj_char_span": [32, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 44], "obj_tok_span": [5, 6]}, {"subject": "E", "object": "hypotension", "sbj_char_span": [98, 99], "obj_char_span": [32, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group.", "entity_list": [{"name": "creatinine", "ent_type": "Chemical", "char_span": [30, 40], "ent_id": "D003404", "tok_span": [5, 6]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [205, 215], "ent_id": "D007530", "tok_span": [31, 33]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [7, 18], "ent_id": "D007022", "tok_span": [1, 2]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [111, 122], "ent_id": "D007022", "tok_span": [16, 17]}], "relation_list": [{"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [205, 215], "obj_char_span": [7, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [1, 2]}, {"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [205, 215], "obj_char_span": [111, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension.", "entity_list": [{"name": "labetalol", "ent_type": "Chemical", "char_span": [28, 37], "ent_id": "D007741", "tok_span": [4, 7]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [64, 75], "ent_id": "D007022", "tok_span": [10, 11]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [97, 108], "ent_id": "D013610", "tok_span": [13, 14]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [121, 133], "ent_id": "D006973", "tok_span": [17, 18]}], "relation_list": [{"subject": "labetalol", "object": "hypotension", "sbj_char_span": [28, 37], "obj_char_span": [64, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Tonic-clonic seizures followed intravenous fluorescein injection for fundus angiography in a 47-year-old male.", "entity_list": [{"name": "Tonic-clonic seizures", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D004830", "tok_span": [0, 6]}, {"name": "fluorescein", "ent_type": "Chemical", "char_span": [43, 54], "ent_id": "D019793", "tok_span": [8, 9]}], "relation_list": [{"subject": "fluorescein", "object": "Tonic-clonic seizures", "sbj_char_span": [43, 54], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ventricular tachycardia in anesthetized dogs.", "entity_list": [{"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [91, 114], "ent_id": "D017180", "tok_span": [22, 24]}, {"name": "ouabain", "ent_type": "Chemical", "char_span": [75, 82], "ent_id": "D010042", "tok_span": [17, 20]}, {"name": "ACC-9653", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "C043114", "tok_span": [0, 4]}, {"name": "phenytoin sodium", "ent_type": "Chemical", "char_span": [13, 29], "ent_id": "C043114", "tok_span": [5, 9]}], "relation_list": [{"subject": "ouabain", "object": "ventricular tachycardia", "sbj_char_span": [75, 82], "obj_char_span": [91, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Only phenytoin sodium displayed in vitro antiarrhythmic activity against strophanthidin-induced arrhythmias in guinea pig right atria.", "entity_list": [{"name": "strophanthidin", "ent_type": "Chemical", "char_span": [73, 87], "ent_id": "D013327", "tok_span": [14, 18]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [96, 107], "ent_id": "D001145", "tok_span": [20, 21]}, {"name": "phenytoin sodium", "ent_type": "Chemical", "char_span": [5, 21], "ent_id": "C043114", "tok_span": [1, 5]}], "relation_list": [{"subject": "strophanthidin", "object": "arrhythmias", "sbj_char_span": [73, 87], "obj_char_span": [96, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "A 61 year old female developed fatal hepatic failure after phenytoin administration.", "entity_list": [{"name": "phenytoin", "ent_type": "Chemical", "char_span": [59, 68], "ent_id": "D010672", "tok_span": [10, 13]}, {"name": "hepatic failure", "ent_type": "Disease", "char_span": [37, 52], "ent_id": "D017093", "tok_span": [7, 9]}], "relation_list": [{"subject": "phenytoin", "object": "hepatic failure", "sbj_char_span": [59, 68], "obj_char_span": [37, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion.", "entity_list": [{"name": "adrenaline", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D004837", "tok_span": [2, 4]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [85, 95], "ent_id": "D004837", "tok_span": [16, 18]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [23, 35], "ent_id": "D006973", "tok_span": [5, 6]}], "relation_list": [{"subject": "adrenaline", "object": "hypertension", "sbj_char_span": [12, 22], "obj_char_span": [23, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [5, 6]}, {"subject": "adrenaline", "object": "hypertension", "sbj_char_span": [85, 95], "obj_char_span": [23, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "These findings are strong support for the adrenaline-hypertension hypothesis in man.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [53, 65], "ent_id": "D006973", "tok_span": [10, 11]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [42, 52], "ent_id": "D004837", "tok_span": [7, 9]}], "relation_list": [{"subject": "adrenaline", "object": "hypertension", "sbj_char_span": [42, 52], "obj_char_span": [53, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Effect of alkylxanthines on gentamicin-induced acute renal failure in the rat.", "entity_list": [{"name": "alkylxanthines", "ent_type": "Chemical", "char_span": [10, 24], "ent_id": "-1", "tok_span": [2, 6]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [47, 66], "ent_id": "D058186", "tok_span": [11, 14]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [28, 38], "ent_id": "D005839", "tok_span": [7, 9]}], "relation_list": [{"subject": "gentamicin", "object": "acute renal failure", "sbj_char_span": [28, 38], "obj_char_span": [47, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).", "entity_list": [{"name": "theophylline", "ent_type": "Chemical", "char_span": [130, 142], "ent_id": "D013806", "tok_span": [27, 30]}, {"name": "adenosine", "ent_type": "Chemical", "char_span": [86, 95], "ent_id": "D000241", "tok_span": [18, 19]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [242, 252], "ent_id": "D005839", "tok_span": [49, 51]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [194, 213], "ent_id": "D058186", "tok_span": [41, 44]}, {"name": "enprofylline", "ent_type": "Chemical", "char_span": [147, 159], "ent_id": "C034347", "tok_span": [31, 35]}, {"name": "alkylxanthines", "ent_type": "Chemical", "char_span": [43, 57], "ent_id": "-1", "tok_span": [9, 13]}, {"name": "8-phenyltheophylline", "ent_type": "Chemical", "char_span": [108, 128], "ent_id": "C028322", "tok_span": [20, 26]}], "relation_list": [{"subject": "gentamicin", "object": "acute renal failure", "sbj_char_span": [242, 252], "obj_char_span": [194, 213], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 51], "obj_tok_span": [41, 44]}], "umls_entity_list": []}, {"text": "The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in gentamicin-induced ARF.", "entity_list": [{"name": "alkylxanthines", "ent_type": "Chemical", "char_span": [60, 74], "ent_id": "-1", "tok_span": [10, 14]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [177, 187], "ent_id": "D005839", "tok_span": [32, 34]}, {"name": "adenosine", "ent_type": "Chemical", "char_span": [118, 127], "ent_id": "D000241", "tok_span": [21, 22]}, {"name": "ARF", "ent_type": "Disease", "char_span": [196, 199], "ent_id": "D058186", "tok_span": [36, 38]}], "relation_list": [{"subject": "gentamicin", "object": "ARF", "sbj_char_span": [177, 187], "obj_char_span": [196, 199], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 34], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "Both anti-asthmatic and tremorgenic effects of procaterol were dose-related.", "entity_list": [{"name": "procaterol", "ent_type": "Chemical", "char_span": [47, 57], "ent_id": "D017265", "tok_span": [11, 14]}, {"name": "asthmatic", "ent_type": "Disease", "char_span": [10, 19], "ent_id": "D001249", "tok_span": [3, 5]}, {"name": "tremorgenic", "ent_type": "Disease", "char_span": [24, 35], "ent_id": "D014202", "tok_span": [6, 9]}], "relation_list": [{"subject": "procaterol", "object": "tremorgenic", "sbj_char_span": [47, 57], "obj_char_span": [24, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "Subacute effects of propranolol and B 24/76 on isoproterenol-induced rat heart hypertrophy in correlation with blood pressure.", "entity_list": [{"name": "isoproterenol", "ent_type": "Chemical", "char_span": [47, 60], "ent_id": "D007545", "tok_span": [14, 18]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [20, 31], "ent_id": "D011433", "tok_span": [4, 8]}, {"name": "heart hypertrophy", "ent_type": "Disease", "char_span": [73, 90], "ent_id": "D006332", "tok_span": [21, 23]}], "relation_list": [{"subject": "isoproterenol", "object": "heart hypertrophy", "sbj_char_span": [47, 60], "obj_char_span": [73, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "The studies were performed using an experimental model of isoproterenol-induced heart hypertrophy in rats.", "entity_list": [{"name": "isoproterenol", "ent_type": "Chemical", "char_span": [58, 71], "ent_id": "D007545", "tok_span": [9, 13]}, {"name": "heart hypertrophy", "ent_type": "Disease", "char_span": [80, 97], "ent_id": "D006332", "tok_span": [15, 17]}], "relation_list": [{"subject": "isoproterenol", "object": "heart hypertrophy", "sbj_char_span": [58, 71], "obj_char_span": [80, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Thus, the investigations did not provide any evidence that the beta-receptor blockers propranolol and B 24/76 have the potency to prevent isoproterenol from producing heart hypertrophy.", "entity_list": [{"name": "propranolol", "ent_type": "Chemical", "char_span": [86, 97], "ent_id": "D011433", "tok_span": [15, 19]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [138, 151], "ent_id": "D007545", "tok_span": [29, 33]}, {"name": "heart hypertrophy", "ent_type": "Disease", "char_span": [167, 184], "ent_id": "D006332", "tok_span": [35, 37]}], "relation_list": [{"subject": "isoproterenol", "object": "heart hypertrophy", "sbj_char_span": [138, 151], "obj_char_span": [167, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 33], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.", "entity_list": [{"name": "tremors", "ent_type": "Disease", "char_span": [109, 116], "ent_id": "D014202", "tok_span": [21, 23]}, {"name": "vomiting", "ent_type": "Disease", "char_span": [96, 104], "ent_id": "D014839", "tok_span": [19, 20]}, {"name": "theophylline", "ent_type": "Chemical", "char_span": [123, 135], "ent_id": "D013806", "tok_span": [24, 27]}, {"name": "oxitropium", "ent_type": "Chemical", "char_span": [36, 46], "ent_id": "C017590", "tok_span": [6, 10]}, {"name": "nausea", "ent_type": "Disease", "char_span": [88, 94], "ent_id": "D009325", "tok_span": [17, 18]}], "relation_list": [{"subject": "theophylline", "object": "tremors", "sbj_char_span": [123, 135], "obj_char_span": [109, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [21, 23]}, {"subject": "theophylline", "object": "vomiting", "sbj_char_span": [123, 135], "obj_char_span": [96, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [19, 20]}, {"subject": "theophylline", "object": "nausea", "sbj_char_span": [123, 135], "obj_char_span": [88, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Penicillin anaphylaxis.", "entity_list": [{"name": "anaphylaxis", "ent_type": "Disease", "char_span": [11, 22], "ent_id": "D000707", "tok_span": [2, 5]}, {"name": "Penicillin", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D010406", "tok_span": [0, 2]}], "relation_list": [{"subject": "Penicillin", "object": "anaphylaxis", "sbj_char_span": [0, 10], "obj_char_span": [11, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "A case of oral penicillin anaphylaxis is described, and the terminology, occurrence, clinical manifestations, pathogenesis, prevention, and treatment of anaphylaxis are reviewed.", "entity_list": [{"name": "anaphylaxis", "ent_type": "Disease", "char_span": [153, 164], "ent_id": "D000707", "tok_span": [27, 30]}, {"name": "anaphylaxis", "ent_type": "Disease", "char_span": [26, 37], "ent_id": "D000707", "tok_span": [5, 8]}, {"name": "penicillin", "ent_type": "Chemical", "char_span": [15, 25], "ent_id": "D010406", "tok_span": [4, 5]}], "relation_list": [{"subject": "penicillin", "object": "anaphylaxis", "sbj_char_span": [15, 25], "obj_char_span": [26, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [5, 8]}, {"subject": "penicillin", "object": "anaphylaxis", "sbj_char_span": [15, 25], "obj_char_span": [153, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "Emergency physicians should be aware of oral penicillin anaphylaxis in order to prevent its occurrence by prescribing the antibiotic judiciously and knowledgeably and to offer optimal medical therapy once this life-threatening reaction has begun.", "entity_list": [{"name": "penicillin", "ent_type": "Chemical", "char_span": [45, 55], "ent_id": "D010406", "tok_span": [7, 8]}, {"name": "anaphylaxis", "ent_type": "Disease", "char_span": [56, 67], "ent_id": "D000707", "tok_span": [8, 11]}], "relation_list": [{"subject": "penicillin", "object": "anaphylaxis", "sbj_char_span": [45, 55], "obj_char_span": [56, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Reversible valproic acid-induced dementia: a case report.", "entity_list": [{"name": "valproic acid", "ent_type": "Chemical", "char_span": [11, 24], "ent_id": "D014635", "tok_span": [2, 6]}, {"name": "dementia", "ent_type": "Disease", "char_span": [33, 41], "ent_id": "D003704", "tok_span": [8, 9]}], "relation_list": [{"subject": "valproic acid", "object": "dementia", "sbj_char_span": [11, 24], "obj_char_span": [33, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "entity_list": [{"name": "valproic acid", "ent_type": "Chemical", "char_span": [11, 24], "ent_id": "D014635", "tok_span": [2, 6]}, {"name": "epilepsy", "ent_type": "Disease", "char_span": [83, 91], "ent_id": "D004827", "tok_span": [20, 21]}, {"name": "dementia", "ent_type": "Disease", "char_span": [33, 41], "ent_id": "D003704", "tok_span": [8, 9]}], "relation_list": [{"subject": "valproic acid", "object": "dementia", "sbj_char_span": [11, 24], "obj_char_span": [33, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "entity_list": [{"name": "valproic acid", "ent_type": "Chemical", "char_span": [268, 281], "ent_id": "D014635", "tok_span": [50, 54]}, {"name": "hyperammonemia", "ent_type": "Disease", "char_span": [290, 304], "ent_id": "D022124", "tok_span": [56, 60]}, {"name": "valproic acid", "ent_type": "Chemical", "char_span": [145, 158], "ent_id": "D014635", "tok_span": [25, 29]}], "relation_list": [{"subject": "valproic acid", "object": "hyperammonemia", "sbj_char_span": [268, 281], "obj_char_span": [290, 304], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 54], "obj_tok_span": [56, 60]}, {"subject": "valproic acid", "object": "hyperammonemia", "sbj_char_span": [145, 158], "obj_char_span": [290, 304], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [56, 60]}], "umls_entity_list": []}, {"text": "Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training naloxone.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [12, 23], "ent_id": "D012601", "tok_span": [3, 6]}, {"name": "naloxone", "ent_type": "Chemical", "char_span": [87, 95], "ent_id": "D009270", "tok_span": [21, 24]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [32, 39], "ent_id": "D000647", "tok_span": [8, 11]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [12, 23], "obj_char_span": [32, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Scopolamine, but not methyl scopolamine (1 and 3 mg/kg), induced an amnesia as measured by latency and duration parameters.", "entity_list": [{"name": "Scopolamine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D012601", "tok_span": [0, 3]}, {"name": "methyl scopolamine", "ent_type": "Chemical", "char_span": [21, 39], "ent_id": "D019832", "tok_span": [6, 10]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [68, 75], "ent_id": "D000647", "tok_span": [21, 24]}], "relation_list": [{"subject": "Scopolamine", "object": "amnesia", "sbj_char_span": [0, 11], "obj_char_span": [68, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced amnesia.", "entity_list": [{"name": "naloxone", "ent_type": "Chemical", "char_span": [32, 40], "ent_id": "D009270", "tok_span": [5, 8]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [102, 113], "ent_id": "D012601", "tok_span": [25, 28]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [122, 129], "ent_id": "D000647", "tok_span": [30, 33]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [102, 113], "obj_char_span": [122, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna.", "entity_list": [{"name": "mesna", "ent_type": "Chemical", "char_span": [134, 139], "ent_id": "D015080", "tok_span": [22, 24]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [43, 59], "ent_id": "D003520", "tok_span": [5, 8]}, {"name": "lesions of the urinary bladder", "ent_type": "Disease", "char_span": [68, 98], "ent_id": "D001745", "tok_span": [10, 15]}], "relation_list": [{"subject": "cyclophosphamide", "object": "lesions of the urinary bladder", "sbj_char_span": [43, 59], "obj_char_span": [68, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 15]}], "umls_entity_list": []}, {"text": "Increase in intragastric pressure during suxamethonium-induced muscle fasciculations in children: inhibition by alfentanil.", "entity_list": [{"name": "suxamethonium", "ent_type": "Chemical", "char_span": [41, 54], "ent_id": "D013390", "tok_span": [8, 13]}, {"name": "alfentanil", "ent_type": "Chemical", "char_span": [112, 122], "ent_id": "D015760", "tok_span": [24, 28]}, {"name": "muscle fasciculations", "ent_type": "Disease", "char_span": [63, 84], "ent_id": "D005207", "tok_span": [15, 19]}], "relation_list": [{"subject": "suxamethonium", "object": "muscle fasciculations", "sbj_char_span": [41, 54], "obj_char_span": [63, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "The incidence and intensity of muscle fasciculations caused by suxamethonium were significantly greater in the control than in the alfentanil group.", "entity_list": [{"name": "muscle fasciculations", "ent_type": "Disease", "char_span": [31, 52], "ent_id": "D005207", "tok_span": [5, 9]}, {"name": "suxamethonium", "ent_type": "Chemical", "char_span": [63, 76], "ent_id": "D013390", "tok_span": [11, 16]}, {"name": "alfentanil", "ent_type": "Chemical", "char_span": [131, 141], "ent_id": "D015760", "tok_span": [25, 29]}], "relation_list": [{"subject": "suxamethonium", "object": "muscle fasciculations", "sbj_char_span": [63, 76], "obj_char_span": [31, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 16], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "It is concluded that intragastric pressure increases significantly during muscle fasciculations caused by suxamethonium in healthy children.", "entity_list": [{"name": "suxamethonium", "ent_type": "Chemical", "char_span": [106, 119], "ent_id": "D013390", "tok_span": [17, 22]}, {"name": "muscle fasciculations", "ent_type": "Disease", "char_span": [74, 95], "ent_id": "D005207", "tok_span": [11, 15]}], "relation_list": [{"subject": "suxamethonium", "object": "muscle fasciculations", "sbj_char_span": [106, 119], "obj_char_span": [74, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 22], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Alfentanil 50 micrograms kg-1 effectively inhibits the incidence and intensity of suxamethonium-induced muscle fasciculations; moreover, intragastric pressure remains at its control value.", "entity_list": [{"name": "suxamethonium", "ent_type": "Chemical", "char_span": [82, 95], "ent_id": "D013390", "tok_span": [17, 22]}, {"name": "Alfentanil", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D015760", "tok_span": [0, 4]}, {"name": "muscle fasciculations", "ent_type": "Disease", "char_span": [104, 125], "ent_id": "D005207", "tok_span": [24, 28]}], "relation_list": [{"subject": "suxamethonium", "object": "muscle fasciculations", "sbj_char_span": [82, 95], "obj_char_span": [104, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 22], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.", "entity_list": [{"name": "streptozotocin", "ent_type": "Chemical", "char_span": [96, 110], "ent_id": "D013311", "tok_span": [18, 22]}, {"name": "cardiotoxic", "ent_type": "Disease", "char_span": [57, 68], "ent_id": "D066126", "tok_span": [9, 11]}, {"name": "diabetic", "ent_type": "Disease", "char_span": [111, 119], "ent_id": "D003920", "tok_span": [22, 23]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [79, 92], "ent_id": "D007545", "tok_span": [13, 17]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetic", "sbj_char_span": [96, 110], "obj_char_span": [111, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "A morphometric study of isoproterenol induced myocardial fibrosis.", "entity_list": [{"name": "fibrosis", "ent_type": "Disease", "char_span": [57, 65], "ent_id": "D005355", "tok_span": [11, 12]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [24, 37], "ent_id": "D007545", "tok_span": [5, 9]}], "relation_list": [{"subject": "isoproterenol", "object": "fibrosis", "sbj_char_span": [24, 37], "obj_char_span": [57, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.", "entity_list": [{"name": "ISO", "ent_type": "Chemical", "char_span": [170, 173], "ent_id": "D007545", "tok_span": [32, 33]}, {"name": "diabetes", "ent_type": "Disease", "char_span": [98, 106], "ent_id": "D003920", "tok_span": [17, 18]}, {"name": "cardiotoxic", "ent_type": "Disease", "char_span": [119, 130], "ent_id": "D066126", "tok_span": [20, 22]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [83, 97], "ent_id": "D013311", "tok_span": [13, 17]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [155, 168], "ent_id": "D007545", "tok_span": [27, 31]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetes", "sbj_char_span": [83, 97], "obj_char_span": [98, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.", "entity_list": [{"name": "ISO", "ent_type": "Chemical", "char_span": [62, 65], "ent_id": "D007545", "tok_span": [11, 12]}, {"name": "ISO", "ent_type": "Chemical", "char_span": [100, 103], "ent_id": "D007545", "tok_span": [18, 19]}, {"name": "fibrosis", "ent_type": "Disease", "char_span": [112, 120], "ent_id": "D005355", "tok_span": [20, 21]}, {"name": "glucose", "ent_type": "Chemical", "char_span": [274, 281], "ent_id": "D005947", "tok_span": [59, 60]}], "relation_list": [{"subject": "ISO", "object": "fibrosis", "sbj_char_span": [100, 103], "obj_char_span": [112, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [20, 21]}, {"subject": "ISO", "object": "fibrosis", "sbj_char_span": [62, 65], "obj_char_span": [112, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in diabetic rats.", "entity_list": [{"name": "streptozotocin", "ent_type": "Chemical", "char_span": [74, 88], "ent_id": "D013311", "tok_span": [12, 16]}, {"name": "diabetic", "ent_type": "Disease", "char_span": [211, 219], "ent_id": "D003920", "tok_span": [35, 36]}, {"name": "ISO", "ent_type": "Chemical", "char_span": [110, 113], "ent_id": "D007545", "tok_span": [20, 21]}, {"name": "catecholamine", "ent_type": "Chemical", "char_span": [182, 195], "ent_id": "D002395", "tok_span": [31, 33]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetic", "sbj_char_span": [74, 88], "obj_char_span": [211, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [35, 36]}], "umls_entity_list": []}, {"text": "Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [86, 97], "ent_id": "D010862", "tok_span": [15, 18]}, {"name": "seizures", "ent_type": "Disease", "char_span": [65, 73], "ent_id": "D012640", "tok_span": [12, 13]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [86, 97], "obj_char_span": [65, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "The muscarinic cholinergic agonist pilocarpine induces in rats seizures and status epilepticus followed by widespread damage to the forebrain.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [76, 94], "ent_id": "D013226", "tok_span": [14, 17]}, {"name": "seizures", "ent_type": "Disease", "char_span": [63, 71], "ent_id": "D012640", "tok_span": [12, 13]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [35, 46], "ent_id": "D010862", "tok_span": [6, 9]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [35, 46], "obj_char_span": [63, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [12, 13]}, {"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [35, 46], "obj_char_span": [76, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [183, 191], "ent_id": "D012640", "tok_span": [44, 45]}, {"name": "ibuprofen", "ent_type": "Chemical", "char_span": [150, 159], "ent_id": "D007052", "tok_span": [33, 37]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [204, 215], "ent_id": "D010862", "tok_span": [47, 50]}, {"name": "indomethacin", "ent_type": "Chemical", "char_span": [136, 148], "ent_id": "D007213", "tok_span": [29, 32]}, {"name": "phenylbutazone", "ent_type": "Chemical", "char_span": [120, 134], "ent_id": "D010653", "tok_span": [25, 28]}, {"name": "sodium salicylate", "ent_type": "Chemical", "char_span": [101, 118], "ent_id": "D012980", "tok_span": [20, 24]}, {"name": "mefenamic acid", "ent_type": "Chemical", "char_span": [164, 178], "ent_id": "D008528", "tok_span": [38, 42]}], "relation_list": [{"subject": "sodium salicylate", "object": "seizures", "sbj_char_span": [101, 118], "obj_char_span": [183, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [44, 45]}, {"subject": "phenylbutazone", "object": "seizures", "sbj_char_span": [120, 134], "obj_char_span": [183, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [44, 45]}, {"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [204, 215], "obj_char_span": [183, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 50], "obj_tok_span": [44, 45]}], "umls_entity_list": []}, {"text": "Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine.", "entity_list": [{"name": "Indomethacin", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D007213", "tok_span": [0, 3]}, {"name": "ibuprofen", "ent_type": "Chemical", "char_span": [30, 39], "ent_id": "D007052", "tok_span": [12, 16]}, {"name": "seizures", "ent_type": "Disease", "char_span": [74, 82], "ent_id": "D012640", "tok_span": [27, 28]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [95, 106], "ent_id": "D010862", "tok_span": [30, 33]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [95, 106], "obj_char_span": [74, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.", "entity_list": [{"name": "seizure", "ent_type": "Disease", "char_span": [77, 84], "ent_id": "D012640", "tok_span": [21, 22]}, {"name": "seizures", "ent_type": "Disease", "char_span": [44, 52], "ent_id": "D012640", "tok_span": [16, 17]}, {"name": "brain damage", "ent_type": "Disease", "char_span": [93, 105], "ent_id": "D001930", "tok_span": [24, 26]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [117, 128], "ent_id": "D010862", "tok_span": [28, 31]}, {"name": "Mefenamic acid", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D008528", "tok_span": [0, 4]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [117, 128], "obj_char_span": [44, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [16, 17]}, {"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [117, 128], "obj_char_span": [77, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "These results indicate that non-steroidal anti-inflammatory drugs differentially modulate the threshold for pilocarpine-induced seizures.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [108, 119], "ent_id": "D010862", "tok_span": [17, 20]}, {"name": "seizures", "ent_type": "Disease", "char_span": [128, 136], "ent_id": "D012640", "tok_span": [22, 23]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [108, 119], "obj_char_span": [128, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity_list": [{"name": "anorexia", "ent_type": "Disease", "char_span": [146, 154], "ent_id": "D000855", "tok_span": [31, 34]}, {"name": "calcium channel blockers", "ent_type": "Chemical", "char_span": [32, 56], "ent_id": "D002121", "tok_span": [8, 11]}, {"name": "headache", "ent_type": "Disease", "char_span": [90, 98], "ent_id": "D006261", "tok_span": [17, 18]}, {"name": "palpitations", "ent_type": "Disease", "char_span": [117, 129], "ent_id": "-1", "tok_span": [24, 26]}, {"name": "nausea", "ent_type": "Disease", "char_span": [138, 144], "ent_id": "D009325", "tok_span": [29, 30]}, {"name": "flushing", "ent_type": "Disease", "char_span": [107, 115], "ent_id": "D005483", "tok_span": [20, 23]}, {"name": "edema", "ent_type": "Disease", "char_span": [131, 136], "ent_id": "D004487", "tok_span": [27, 28]}, {"name": "dizziness", "ent_type": "Disease", "char_span": [160, 169], "ent_id": "D004244", "tok_span": [36, 39]}, {"name": "dihydropyridine", "ent_type": "Chemical", "char_span": [16, 31], "ent_id": "C038806", "tok_span": [4, 8]}], "relation_list": [{"subject": "calcium channel blockers", "object": "edema", "sbj_char_span": [32, 56], "obj_char_span": [131, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [27, 28]}, {"subject": "calcium channel blockers", "object": "anorexia", "sbj_char_span": [32, 56], "obj_char_span": [146, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [31, 34]}, {"subject": "calcium channel blockers", "object": "dizziness", "sbj_char_span": [32, 56], "obj_char_span": [160, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [36, 39]}, {"subject": "calcium channel blockers", "object": "flushing", "sbj_char_span": [32, 56], "obj_char_span": [107, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [20, 23]}, {"subject": "calcium channel blockers", "object": "nausea", "sbj_char_span": [32, 56], "obj_char_span": [138, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [29, 30]}, {"subject": "calcium channel blockers", "object": "headache", "sbj_char_span": [32, 56], "obj_char_span": [90, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).", "entity_list": [{"name": "FSGS", "ent_type": "Disease", "char_span": [63, 67], "ent_id": "D005923", "tok_span": [9, 11]}, {"name": "puromycin-aminonucleoside", "ent_type": "Chemical", "char_span": [125, 150], "ent_id": "D011692", "tok_span": [21, 27]}, {"name": "AMNS", "ent_type": "Chemical", "char_span": [152, 156], "ent_id": "D011692", "tok_span": [28, 30]}, {"name": "focal segmental glomerular sclerosis", "ent_type": "Disease", "char_span": [25, 61], "ent_id": "D005923", "tok_span": [4, 8]}, {"name": "protamine sulfate", "ent_type": "Chemical", "char_span": [162, 179], "ent_id": "D011479", "tok_span": [32, 35]}, {"name": "PS", "ent_type": "Chemical", "char_span": [181, 183], "ent_id": "D011479", "tok_span": [36, 37]}], "relation_list": [{"subject": "puromycin-aminonucleoside", "object": "FSGS", "sbj_char_span": [125, 150], "obj_char_span": [63, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 27], "obj_tok_span": [9, 11]}, {"subject": "AMNS", "object": "focal segmental glomerular sclerosis", "sbj_char_span": [152, 156], "obj_char_span": [25, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [4, 8]}, {"subject": "puromycin-aminonucleoside", "object": "focal segmental glomerular sclerosis", "sbj_char_span": [125, 150], "obj_char_span": [25, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 27], "obj_tok_span": [4, 8]}, {"subject": "AMNS", "object": "FSGS", "sbj_char_span": [152, 156], "obj_char_span": [63, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.", "entity_list": [{"name": "end-stage renal disease", "ent_type": "Disease", "char_span": [168, 191], "ent_id": "D007676", "tok_span": [31, 36]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [70, 78], "ent_id": "D064420", "tok_span": [12, 13]}, {"name": "PS", "ent_type": "Chemical", "char_span": [54, 56], "ent_id": "D011479", "tok_span": [9, 10]}, {"name": "FSGS", "ent_type": "Disease", "char_span": [138, 142], "ent_id": "D005923", "tok_span": [24, 26]}, {"name": "AMNS", "ent_type": "Chemical", "char_span": [82, 86], "ent_id": "D011692", "tok_span": [14, 16]}], "relation_list": [{"subject": "AMNS", "object": "FSGS", "sbj_char_span": [82, 86], "obj_char_span": [138, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [24, 26]}, {"subject": "AMNS", "object": "end-stage renal disease", "sbj_char_span": [82, 86], "obj_char_span": [168, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [31, 36]}], "umls_entity_list": []}, {"text": "Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal seizures which occurred after 28 and 30 minutes respectively.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [154, 162], "ent_id": "D012640", "tok_span": [33, 34]}, {"name": "aminophylline", "ent_type": "Chemical", "char_span": [117, 130], "ent_id": "D000628", "tok_span": [26, 29]}], "relation_list": [{"subject": "aminophylline", "object": "seizures", "sbj_char_span": [117, 130], "obj_char_span": [154, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [33, 34]}], "umls_entity_list": []}, {"text": "Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.", "entity_list": [{"name": "fludrocortisone", "ent_type": "Chemical", "char_span": [66, 81], "ent_id": "D005438", "tok_span": [17, 22]}, {"name": "naproxen", "ent_type": "Chemical", "char_span": [41, 49], "ent_id": "D009288", "tok_span": [10, 14]}, {"name": "Hyperkalemia", "ent_type": "Disease", "char_span": [0, 12], "ent_id": "D006947", "tok_span": [0, 4]}, {"name": "indomethacin", "ent_type": "Chemical", "char_span": [24, 36], "ent_id": "D007213", "tok_span": [6, 9]}], "relation_list": [{"subject": "naproxen", "object": "Hyperkalemia", "sbj_char_span": [41, 49], "obj_char_span": [0, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 4]}, {"subject": "indomethacin", "object": "Hyperkalemia", "sbj_char_span": [24, 36], "obj_char_span": [0, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity_list": [{"name": "nephropathy", "ent_type": "Disease", "char_span": [93, 104], "ent_id": "D007674", "tok_span": [17, 18]}, {"name": "mefenamic acid", "ent_type": "Chemical", "char_span": [78, 92], "ent_id": "D008528", "tok_span": [13, 17]}, {"name": "hypoaldosteronism", "ent_type": "Disease", "char_span": [144, 161], "ent_id": "D006994", "tok_span": [26, 31]}, {"name": "indomethacin", "ent_type": "Chemical", "char_span": [182, 194], "ent_id": "D007213", "tok_span": [35, 38]}, {"name": "hyperkalemia", "ent_type": "Disease", "char_span": [113, 125], "ent_id": "D006947", "tok_span": [20, 24]}, {"name": "rheumatoid arthritis", "ent_type": "Disease", "char_span": [40, 60], "ent_id": "D001172", "tok_span": [7, 9]}, {"name": "naproxen", "ent_type": "Chemical", "char_span": [199, 207], "ent_id": "D009288", "tok_span": [39, 43]}], "relation_list": [{"subject": "mefenamic acid", "object": "nephropathy", "sbj_char_span": [78, 92], "obj_char_span": [93, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [17, 18]}, {"subject": "indomethacin", "object": "hypoaldosteronism", "sbj_char_span": [182, 194], "obj_char_span": [144, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [26, 31]}, {"subject": "indomethacin", "object": "hyperkalemia", "sbj_char_span": [182, 194], "obj_char_span": [113, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [20, 24]}, {"subject": "naproxen", "object": "hypoaldosteronism", "sbj_char_span": [199, 207], "obj_char_span": [144, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 43], "obj_tok_span": [26, 31]}, {"subject": "naproxen", "object": "hyperkalemia", "sbj_char_span": [199, 207], "obj_char_span": [113, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 43], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, fludrocortisone was added, correcting the hyperkalemia and allowing indomethacin therapy to be continued safely.", "entity_list": [{"name": "indomethacin", "ent_type": "Chemical", "char_span": [150, 162], "ent_id": "D007213", "tok_span": [32, 35]}, {"name": "fludrocortisone", "ent_type": "Chemical", "char_span": [82, 97], "ent_id": "D005438", "tok_span": [16, 21]}, {"name": "hyperkalemia", "ent_type": "Disease", "char_span": [124, 136], "ent_id": "D006947", "tok_span": [26, 30]}], "relation_list": [{"subject": "indomethacin", "object": "hyperkalemia", "sbj_char_span": [150, 162], "obj_char_span": [124, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.", "entity_list": [{"name": "cisplatin", "ent_type": "Chemical", "char_span": [77, 86], "ent_id": "D002945", "tok_span": [12, 13]}, {"name": "5-fluorouracil", "ent_type": "Chemical", "char_span": [91, 105], "ent_id": "D005472", "tok_span": [14, 19]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [34, 48], "ent_id": "D066126", "tok_span": [6, 8]}, {"name": "Hypotension", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D007022", "tok_span": [0, 2]}], "relation_list": [{"subject": "5-fluorouracil", "object": "Hypotension", "sbj_char_span": [91, 105], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [0, 2]}, {"subject": "cisplatin", "object": "Hypotension", "sbj_char_span": [77, 86], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "entity_list": [{"name": "5-fluorouracil", "ent_type": "Chemical", "char_span": [150, 164], "ent_id": "D005472", "tok_span": [24, 29]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [129, 138], "ent_id": "D002945", "tok_span": [18, 19]}, {"name": "colorectal carcinoma", "ent_type": "Disease", "char_span": [83, 103], "ent_id": "D015179", "tok_span": [12, 14]}, {"name": "CDDP", "ent_type": "Chemical", "char_span": [140, 144], "ent_id": "D002945", "tok_span": [20, 22]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [28, 39], "ent_id": "D007022", "tok_span": [4, 5]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [166, 170], "ent_id": "D005472", "tok_span": [30, 33]}], "relation_list": [{"subject": "5-fluorouracil", "object": "hypotension", "sbj_char_span": [150, 164], "obj_char_span": [28, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 29], "obj_tok_span": [4, 5]}, {"subject": "5-FU", "object": "hypotension", "sbj_char_span": [166, 170], "obj_char_span": [28, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [4, 5]}, {"subject": "cisplatin", "object": "hypotension", "sbj_char_span": [129, 138], "obj_char_span": [28, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [4, 5]}, {"subject": "CDDP", "object": "hypotension", "sbj_char_span": [140, 144], "obj_char_span": [28, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Fatal aplastic anemia in a patient treated with carbamazepine.", "entity_list": [{"name": "carbamazepine", "ent_type": "Chemical", "char_span": [48, 61], "ent_id": "D002220", "tok_span": [10, 14]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [6, 21], "ent_id": "D000741", "tok_span": [2, 5]}], "relation_list": [{"subject": "carbamazepine", "object": "aplastic anemia", "sbj_char_span": [48, 61], "obj_char_span": [6, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "A case of fatal aplastic anemia due to carbamazepine treatment in an epileptic woman is reported.", "entity_list": [{"name": "aplastic anemia", "ent_type": "Disease", "char_span": [16, 31], "ent_id": "D000741", "tok_span": [4, 7]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [39, 52], "ent_id": "D002220", "tok_span": [9, 13]}, {"name": "epileptic", "ent_type": "Disease", "char_span": [69, 78], "ent_id": "D004827", "tok_span": [16, 17]}], "relation_list": [{"subject": "carbamazepine", "object": "aplastic anemia", "sbj_char_span": [39, 52], "obj_char_span": [16, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine-induced hypotension and bradycardia.", "entity_list": [{"name": "clonidine", "ent_type": "Chemical", "char_span": [72, 81], "ent_id": "D003000", "tok_span": [15, 17]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [106, 117], "ent_id": "D001919", "tok_span": [21, 25]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [90, 101], "ent_id": "D007022", "tok_span": [19, 20]}], "relation_list": [{"subject": "clonidine", "object": "bradycardia", "sbj_char_span": [72, 81], "obj_char_span": [106, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [21, 25]}, {"subject": "clonidine", "object": "hypotension", "sbj_char_span": [72, 81], "obj_char_span": [90, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "The clonidine-induced hypotension was antagonized by prior spinal transection, but not bilateral vagotomy.", "entity_list": [{"name": "clonidine", "ent_type": "Chemical", "char_span": [4, 13], "ent_id": "D003000", "tok_span": [1, 3]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [22, 33], "ent_id": "D007022", "tok_span": [5, 6]}], "relation_list": [{"subject": "clonidine", "object": "hypotension", "sbj_char_span": [4, 13], "obj_char_span": [22, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 3], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "On the other hand, the clonidine-induced bradycardia was antagonized by prior bilateral vagotomy, but not spinal transection.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [41, 52], "ent_id": "D001919", "tok_span": [10, 14]}, {"name": "clonidine", "ent_type": "Chemical", "char_span": [23, 32], "ent_id": "D003000", "tok_span": [6, 8]}], "relation_list": [{"subject": "clonidine", "object": "bradycardia", "sbj_char_span": [23, 32], "obj_char_span": [41, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Furthermore, selective destruction of the spinal 5-HT nerves, produced by bilateral spinal injection of 5,7-dihydroxytryptamine, reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats.", "entity_list": [{"name": "5,7-dihydroxytryptamine", "ent_type": "Chemical", "char_span": [104, 127], "ent_id": "D015116", "tok_span": [18, 27]}, {"name": "clonidine", "ent_type": "Chemical", "char_span": [205, 214], "ent_id": "D003000", "tok_span": [45, 47]}, {"name": "5-HT", "ent_type": "Chemical", "char_span": [49, 53], "ent_id": "D012701", "tok_span": [7, 10]}, {"name": "bradycardiac", "ent_type": "Disease", "char_span": [179, 191], "ent_id": "D001919", "tok_span": [39, 43]}], "relation_list": [{"subject": "clonidine", "object": "bradycardiac", "sbj_char_span": [205, 214], "obj_char_span": [179, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 47], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine-induced hypotension and bradycardia.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [122, 133], "ent_id": "D001919", "tok_span": [22, 26]}, {"name": "clonidine", "ent_type": "Chemical", "char_span": [88, 97], "ent_id": "D003000", "tok_span": [16, 18]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [106, 117], "ent_id": "D007022", "tok_span": [20, 21]}], "relation_list": [{"subject": "clonidine", "object": "hypotension", "sbj_char_span": [88, 97], "obj_char_span": [106, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [20, 21]}, {"subject": "clonidine", "object": "bradycardia", "sbj_char_span": [88, 97], "obj_char_span": [122, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Hypertension in neuroblastoma induced by imipramine.", "entity_list": [{"name": "neuroblastoma", "ent_type": "Disease", "char_span": [16, 29], "ent_id": "D009447", "tok_span": [2, 4]}, {"name": "imipramine", "ent_type": "Chemical", "char_span": [41, 51], "ent_id": "D007099", "tok_span": [6, 10]}, {"name": "Hypertension", "ent_type": "Disease", "char_span": [0, 12], "ent_id": "D006973", "tok_span": [0, 1]}], "relation_list": [{"subject": "imipramine", "object": "Hypertension", "sbj_char_span": [41, 51], "obj_char_span": [0, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [0, 1]}], "umls_entity_list": []}, {"text": "We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a behavior disorder.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [35, 47], "ent_id": "D006973", "tok_span": [6, 7]}, {"name": "Imipramine", "ent_type": "Chemical", "char_span": [127, 137], "ent_id": "D007099", "tok_span": [28, 32]}, {"name": "behavior disorder", "ent_type": "Disease", "char_span": [151, 168], "ent_id": "D002653", "tok_span": [35, 37]}, {"name": "neuroblastoma", "ent_type": "Disease", "char_span": [99, 112], "ent_id": "D009447", "tok_span": [23, 25]}], "relation_list": [{"subject": "Imipramine", "object": "hypertension", "sbj_char_span": [127, 137], "obj_char_span": [35, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 32], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her hypertension.", "entity_list": [{"name": "Imipramine", "ent_type": "Chemical", "char_span": [105, 115], "ent_id": "D007099", "tok_span": [16, 20]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [228, 240], "ent_id": "D006973", "tok_span": [43, 44]}], "relation_list": [{"subject": "Imipramine", "object": "hypertension", "sbj_char_span": [105, 115], "obj_char_span": [228, 240], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [43, 44]}], "umls_entity_list": []}, {"text": "Rechallenge of patients who developed oral candidiasis or hoarseness with beclomethasone dipropionate.", "entity_list": [{"name": "oral candidiasis", "ent_type": "Disease", "char_span": [38, 54], "ent_id": "D002180", "tok_span": [8, 11]}, {"name": "hoarseness", "ent_type": "Disease", "char_span": [58, 68], "ent_id": "D006685", "tok_span": [12, 15]}, {"name": "beclomethasone dipropionate", "ent_type": "Chemical", "char_span": [74, 101], "ent_id": "D001507", "tok_span": [16, 25]}], "relation_list": [{"subject": "beclomethasone dipropionate", "object": "oral candidiasis", "sbj_char_span": [74, 101], "obj_char_span": [38, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 25], "obj_tok_span": [8, 11]}, {"subject": "beclomethasone dipropionate", "object": "hoarseness", "sbj_char_span": [74, 101], "obj_char_span": [58, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 25], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "Of 158 asthmatic patients who were placed on inhaled beclomethasone, 15 (9.5%) developed either hoarseness (8), oral thrush (6), or both (1).", "entity_list": [{"name": "asthmatic", "ent_type": "Disease", "char_span": [7, 16], "ent_id": "D001249", "tok_span": [2, 4]}, {"name": "hoarseness", "ent_type": "Disease", "char_span": [96, 106], "ent_id": "D006685", "tok_span": [25, 28]}, {"name": "thrush", "ent_type": "Disease", "char_span": [117, 123], "ent_id": "D002180", "tok_span": [33, 35]}, {"name": "beclomethasone", "ent_type": "Chemical", "char_span": [53, 67], "ent_id": "D001507", "tok_span": [10, 15]}], "relation_list": [{"subject": "beclomethasone", "object": "hoarseness", "sbj_char_span": [53, 67], "obj_char_span": [96, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [25, 28]}, {"subject": "beclomethasone", "object": "thrush", "sbj_char_span": [53, 67], "obj_char_span": [117, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated; however, because of the high recurrence rate, patients who develop hoarseness should not be re-challenged.", "entity_list": [{"name": "hoarseness", "ent_type": "Disease", "char_span": [163, 173], "ent_id": "D006685", "tok_span": [32, 35]}, {"name": "beclomethasone", "ent_type": "Chemical", "char_span": [54, 68], "ent_id": "D001507", "tok_span": [11, 16]}], "relation_list": [{"subject": "beclomethasone", "object": "hoarseness", "sbj_char_span": [54, 68], "obj_char_span": [163, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 16], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.", "entity_list": [{"name": "candidiasis", "ent_type": "Disease", "char_span": [112, 123], "ent_id": "D002177", "tok_span": [25, 27]}, {"name": "hoarseness", "ent_type": "Disease", "char_span": [98, 108], "ent_id": "D006685", "tok_span": [21, 24]}, {"name": "prednisone", "ent_type": "Chemical", "char_span": [24, 34], "ent_id": "D011241", "tok_span": [6, 8]}, {"name": "beclomethasone", "ent_type": "Chemical", "char_span": [47, 61], "ent_id": "D001507", "tok_span": [10, 15]}], "relation_list": [{"subject": "beclomethasone", "object": "hoarseness", "sbj_char_span": [47, 61], "obj_char_span": [98, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "Studies of risk factors for aminoglycoside nephrotoxicity.", "entity_list": [{"name": "aminoglycoside", "ent_type": "Chemical", "char_span": [28, 42], "ent_id": "D000617", "tok_span": [5, 8]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [43, 57], "ent_id": "D007674", "tok_span": [8, 11]}], "relation_list": [{"subject": "aminoglycoside", "object": "nephrotoxicity", "sbj_char_span": [28, 42], "obj_char_span": [43, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "The epidemiology of aminoglycoside-induced nephrotoxicity is not fully understood.", "entity_list": [{"name": "aminoglycoside", "ent_type": "Chemical", "char_span": [20, 34], "ent_id": "D000617", "tok_span": [3, 6]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [43, 57], "ent_id": "D007674", "tok_span": [8, 11]}], "relation_list": [{"subject": "aminoglycoside", "object": "nephrotoxicity", "sbj_char_span": [20, 34], "obj_char_span": [43, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Experimental studies in healthy human volunteers indicate aminoglycosides cause proximal tubular damage in most patients, but rarely, if ever, cause glomerular or tubular dysfunction.", "entity_list": [{"name": "aminoglycosides", "ent_type": "Chemical", "char_span": [58, 73], "ent_id": "D000617", "tok_span": [7, 10]}, {"name": "glomerular or tubular dysfunction", "ent_type": "Disease", "char_span": [149, 182], "ent_id": "D007674", "tok_span": [25, 29]}], "relation_list": [{"subject": "aminoglycosides", "object": "glomerular or tubular dysfunction", "sbj_char_span": [58, 73], "obj_char_span": [149, 182], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.", "entity_list": [{"name": "creatinine", "ent_type": "Chemical", "char_span": [152, 162], "ent_id": "D003404", "tok_span": [27, 28]}, {"name": "aminoglycoside", "ent_type": "Chemical", "char_span": [77, 91], "ent_id": "D000617", "tok_span": [13, 16]}, {"name": "liver disease", "ent_type": "Disease", "char_span": [100, 113], "ent_id": "D008107", "tok_span": [18, 20]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [228, 242], "ent_id": "D007674", "tok_span": [40, 43]}], "relation_list": [{"subject": "aminoglycoside", "object": "nephrotoxicity", "sbj_char_span": [77, 91], "obj_char_span": [228, 242], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [40, 43]}], "umls_entity_list": []}, {"text": "These models may also be useful in developing insights into the pathophysiology of aminoglycoside-induced nephrotoxicity.", "entity_list": [{"name": "aminoglycoside", "ent_type": "Chemical", "char_span": [83, 97], "ent_id": "D000617", "tok_span": [13, 16]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [106, 120], "ent_id": "D007674", "tok_span": [18, 21]}], "relation_list": [{"subject": "aminoglycoside", "object": "nephrotoxicity", "sbj_char_span": [83, 97], "obj_char_span": [106, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.", "entity_list": [{"name": "flurothyl", "ent_type": "Chemical", "char_span": [79, 88], "ent_id": "D005481", "tok_span": [14, 17]}, {"name": "hypothermia", "ent_type": "Disease", "char_span": [128, 139], "ent_id": "D007035", "tok_span": [24, 26]}, {"name": "seizure", "ent_type": "Disease", "char_span": [143, 150], "ent_id": "D012640", "tok_span": [27, 28]}, {"name": "hypothermia", "ent_type": "Disease", "char_span": [25, 36], "ent_id": "D007035", "tok_span": [5, 7]}, {"name": "Flurothyl", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D005481", "tok_span": [0, 3]}, {"name": "ether", "ent_type": "Chemical", "char_span": [10, 15], "ent_id": "D004986", "tok_span": [3, 4]}], "relation_list": [{"subject": "Flurothyl", "object": "hypothermia", "sbj_char_span": [0, 9], "obj_char_span": [128, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [24, 26]}, {"subject": "flurothyl", "object": "hypothermia", "sbj_char_span": [79, 88], "obj_char_span": [128, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [24, 26]}, {"subject": "Flurothyl", "object": "hypothermia", "sbj_char_span": [0, 9], "obj_char_span": [25, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}, {"subject": "flurothyl", "object": "hypothermia", "sbj_char_span": [79, 88], "obj_char_span": [25, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [39, 50], "ent_id": "D010862", "tok_span": [7, 10]}, {"name": "seizures", "ent_type": "Disease", "char_span": [18, 26], "ent_id": "D012640", "tok_span": [4, 5]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [83, 92], "ent_id": "D007538", "tok_span": [16, 20]}, {"name": "gamma-vinyl-GABA", "ent_type": "Chemical", "char_span": [96, 112], "ent_id": "D020888", "tok_span": [21, 27]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [39, 50], "obj_char_span": [18, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain.", "entity_list": [{"name": "Pilocarpine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D010862", "tok_span": [0, 3]}, {"name": "convulsive", "ent_type": "Disease", "char_span": [189, 199], "ent_id": "D012640", "tok_span": [34, 36]}, {"name": "seizures", "ent_type": "Disease", "char_span": [273, 281], "ent_id": "D012640", "tok_span": [46, 47]}, {"name": "temporal lobe epilepsy", "ent_type": "Disease", "char_span": [91, 113], "ent_id": "D004833", "tok_span": [18, 21]}], "relation_list": [{"subject": "Pilocarpine", "object": "convulsive", "sbj_char_span": [0, 11], "obj_char_span": [189, 199], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [34, 36]}, {"subject": "Pilocarpine", "object": "seizures", "sbj_char_span": [0, 11], "obj_char_span": [273, 281], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [46, 47]}], "umls_entity_list": []}, {"text": "In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [182, 193], "ent_id": "D010862", "tok_span": [37, 40]}, {"name": "GABA", "ent_type": "Chemical", "char_span": [95, 99], "ent_id": "D005680", "tok_span": [21, 22]}, {"name": "seizures", "ent_type": "Disease", "char_span": [161, 169], "ent_id": "D012640", "tok_span": [34, 35]}, {"name": "gamma-aminobutyric acid", "ent_type": "Chemical", "char_span": [70, 93], "ent_id": "D005680", "tok_span": [13, 20]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [182, 193], "obj_char_span": [161, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [34, 35]}], "umls_entity_list": []}, {"text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [325, 343], "ent_id": "D013226", "tok_span": [82, 85]}, {"name": "seizures", "ent_type": "Disease", "char_span": [312, 320], "ent_id": "D012640", "tok_span": [80, 81]}, {"name": "L-glutamic acid", "ent_type": "Chemical", "char_span": [131, 146], "ent_id": "D018698", "tok_span": [29, 34]}, {"name": "GABA", "ent_type": "Chemical", "char_span": [105, 109], "ent_id": "D005680", "tok_span": [23, 24]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [46, 55], "ent_id": "D007538", "tok_span": [8, 12]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [248, 259], "ent_id": "D010862", "tok_span": [63, 66]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [248, 259], "obj_char_span": [312, 320], "rel_type": "chemical-induced disease", "sbj_tok_span": [63, 66], "obj_tok_span": [80, 81]}], "umls_entity_list": []}, {"text": "Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine-induced convulsions.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [101, 112], "ent_id": "D010862", "tok_span": [14, 17]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [121, 132], "ent_id": "D012640", "tok_span": [19, 22]}], "relation_list": [{"subject": "pilocarpine", "object": "convulsions", "sbj_char_span": [101, 112], "obj_char_span": [121, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "Morphological analysis of frontal forebrain sections with light microscopy revealed seizure-related damage to the hippocampal formation, thalamus, amygdala, olfactory cortex, substantia nigra and neocortex, which is typically observed with pilocarpine in doses exceeding 350 mg/kg.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [240, 251], "ent_id": "D010862", "tok_span": [42, 45]}, {"name": "seizure", "ent_type": "Disease", "char_span": [84, 91], "ent_id": "D012640", "tok_span": [12, 13]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [240, 251], "obj_char_span": [84, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 45], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [85, 96], "ent_id": "D010862", "tok_span": [18, 21]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [38, 47], "ent_id": "D007538", "tok_span": [8, 12]}, {"name": "seizures", "ent_type": "Disease", "char_span": [64, 72], "ent_id": "D012640", "tok_span": [15, 16]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [85, 96], "obj_char_span": [64, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg.", "entity_list": [{"name": "GABA", "ent_type": "Chemical", "char_span": [44, 48], "ent_id": "D005680", "tok_span": [6, 7]}, {"name": "gamma-vinyl-GABA", "ent_type": "Chemical", "char_span": [63, 79], "ent_id": "D020888", "tok_span": [10, 16]}, {"name": "seizures", "ent_type": "Disease", "char_span": [212, 220], "ent_id": "D012640", "tok_span": [53, 54]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [233, 244], "ent_id": "D010862", "tok_span": [56, 59]}, {"name": "D,L-4-amino-hex-5-enoic acid", "ent_type": "Chemical", "char_span": [81, 109], "ent_id": "D020888", "tok_span": [17, 32]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [233, 244], "obj_char_span": [212, 220], "rel_type": "chemical-induced disease", "sbj_tok_span": [56, 59], "obj_tok_span": [53, 54]}], "umls_entity_list": []}, {"text": "Microinjections of gamma-vinyl-GABA, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by pilocarpine, 380 mg/kg.", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [127, 138], "ent_id": "D012640", "tok_span": [29, 32]}, {"name": "gamma-vinyl-GABA", "ent_type": "Chemical", "char_span": [19, 35], "ent_id": "D020888", "tok_span": [4, 10]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [151, 162], "ent_id": "D010862", "tok_span": [34, 37]}], "relation_list": [{"subject": "pilocarpine", "object": "convulsions", "sbj_char_span": [151, 162], "obj_char_span": [127, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 37], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "The results demonstrate that the threshold for pilocarpine-induced seizures in rats is subjected to the regulation of the GABA-mediated synaptic inhibition within the substantia nigra.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [47, 58], "ent_id": "D010862", "tok_span": [7, 10]}, {"name": "GABA", "ent_type": "Chemical", "char_span": [122, 126], "ent_id": "D005680", "tok_span": [22, 23]}, {"name": "seizures", "ent_type": "Disease", "char_span": [67, 75], "ent_id": "D012640", "tok_span": [12, 13]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [47, 58], "obj_char_span": [67, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "The data suggest that the dipyridamole-induced myocardial ischemia is caused by the inhomogenous distribution of myocardial blood flow.", "entity_list": [{"name": "dipyridamole", "ent_type": "Chemical", "char_span": [26, 38], "ent_id": "D004176", "tok_span": [5, 10]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [47, 66], "ent_id": "D017202", "tok_span": [12, 14]}], "relation_list": [{"subject": "dipyridamole", "object": "myocardial ischemia", "sbj_char_span": [26, 38], "obj_char_span": [47, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Bradycardia after high-dose intravenous methylprednisolone therapy.", "entity_list": [{"name": "methylprednisolone", "ent_type": "Chemical", "char_span": [40, 58], "ent_id": "D008775", "tok_span": [7, 11]}, {"name": "Bradycardia", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D001919", "tok_span": [0, 2]}], "relation_list": [{"subject": "methylprednisolone", "object": "Bradycardia", "sbj_char_span": [40, 58], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine.", "entity_list": [{"name": "oscillopsia", "ent_type": "Disease", "char_span": [36, 47], "ent_id": "D015835", "tok_span": [11, 14]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [64, 77], "ent_id": "D002220", "tok_span": [16, 20]}, {"name": "downbeat nystagmus", "ent_type": "Disease", "char_span": [13, 31], "ent_id": "D009759", "tok_span": [3, 10]}], "relation_list": [{"subject": "carbamazepine", "object": "oscillopsia", "sbj_char_span": [64, 77], "obj_char_span": [36, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Improvement by denopamine (TA-064) of pentobarbital-induced cardiac failure in the dog heart-lung preparation.", "entity_list": [{"name": "denopamine", "ent_type": "Chemical", "char_span": [15, 25], "ent_id": "C037293", "tok_span": [2, 6]}, {"name": "TA-064", "ent_type": "Chemical", "char_span": [27, 33], "ent_id": "C037293", "tok_span": [7, 11]}, {"name": "pentobarbital", "ent_type": "Chemical", "char_span": [38, 51], "ent_id": "D010424", "tok_span": [13, 15]}, {"name": "cardiac failure", "ent_type": "Disease", "char_span": [60, 75], "ent_id": "D006333", "tok_span": [17, 19]}], "relation_list": [{"subject": "pentobarbital", "object": "cardiac failure", "sbj_char_span": [38, 51], "obj_char_span": [60, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "entity_list": [{"name": "prostaglandin", "ent_type": "Chemical", "char_span": [21, 34], "ent_id": "D011453", "tok_span": [4, 5]}, {"name": "hematuria", "ent_type": "Disease", "char_span": [181, 190], "ent_id": "D006417", "tok_span": [32, 34]}, {"name": "creatinine", "ent_type": "Chemical", "char_span": [227, 237], "ent_id": "D003404", "tok_span": [45, 46]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [93, 100], "ent_id": "D001241", "tok_span": [14, 15]}, {"name": "renal damage", "ent_type": "Disease", "char_span": [77, 89], "ent_id": "D007674", "tok_span": [11, 13]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [371, 378], "ent_id": "D001241", "tok_span": [80, 81]}], "relation_list": [{"subject": "aspirin", "object": "renal damage", "sbj_char_span": [371, 378], "obj_char_span": [77, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [80, 81], "obj_tok_span": [11, 13]}, {"subject": "aspirin", "object": "renal damage", "sbj_char_span": [93, 100], "obj_char_span": [77, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [269, 278], "ent_id": "D008012", "tok_span": [53, 55]}, {"name": "asystole", "ent_type": "Disease", "char_span": [237, 245], "ent_id": "D006323", "tok_span": [44, 47]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [118, 127], "ent_id": "D008012", "tok_span": [21, 23]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [135, 146], "ent_id": "D007022", "tok_span": [25, 26]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [198, 207], "ent_id": "D008012", "tok_span": [36, 38]}], "relation_list": [{"subject": "lidocaine", "object": "hypotension", "sbj_char_span": [198, 207], "obj_char_span": [135, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 38], "obj_tok_span": [25, 26]}, {"subject": "lidocaine", "object": "hypotension", "sbj_char_span": [118, 127], "obj_char_span": [135, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [25, 26]}, {"subject": "lidocaine", "object": "hypotension", "sbj_char_span": [269, 278], "obj_char_span": [135, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 55], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Evidence for a cholinergic role in haloperidol-induced catalepsy.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [55, 64], "ent_id": "D002375", "tok_span": [11, 14]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [35, 46], "ent_id": "D006220", "tok_span": [6, 9]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [35, 46], "obj_char_span": [55, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Large doses of the cholinomimetic, pilocarpine, could induce catalepsy when peripheral cholinergic receptors were blocked.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [61, 70], "ent_id": "D002375", "tok_span": [15, 18]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [35, 46], "ent_id": "D010862", "tok_span": [9, 12]}], "relation_list": [{"subject": "pilocarpine", "object": "catalepsy", "sbj_char_span": [35, 46], "obj_char_span": [61, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Low doses of pilocarpine caused a pronounced enhancement of the catalepsy that was induced by the dopaminergic blocker, haloperidol.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [13, 24], "ent_id": "D010862", "tok_span": [3, 6]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [120, 131], "ent_id": "D006220", "tok_span": [23, 26]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [64, 73], "ent_id": "D002375", "tok_span": [12, 15]}], "relation_list": [{"subject": "pilocarpine", "object": "catalepsy", "sbj_char_span": [13, 24], "obj_char_span": [64, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [12, 15]}, {"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [120, 131], "obj_char_span": [64, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "A muscarinic receptor blocker, atropine, disrupted haloperidol-induced catalepsy.", "entity_list": [{"name": "atropine", "ent_type": "Chemical", "char_span": [31, 39], "ent_id": "D001285", "tok_span": [7, 10]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [71, 80], "ent_id": "D002375", "tok_span": [17, 20]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [51, 62], "ent_id": "D006220", "tok_span": [12, 15]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [51, 62], "obj_char_span": [71, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Intracranial injection of an acetylcholine-synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol.", "entity_list": [{"name": "hemicholinium", "ent_type": "Chemical", "char_span": [64, 77], "ent_id": "D006426", "tok_span": [12, 16]}, {"name": "acetylcholine", "ent_type": "Chemical", "char_span": [29, 42], "ent_id": "D000109", "tok_span": [7, 8]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [93, 102], "ent_id": "D002375", "tok_span": [19, 22]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [130, 141], "ent_id": "D006220", "tok_span": [27, 30]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [130, 141], "obj_char_span": [93, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "These findings suggest the hypothesis that the catalepsy that is produced by neuroleptics such as haloperidol is actually mediated by intrinsic central cholinergic systems.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [47, 56], "ent_id": "D002375", "tok_span": [7, 10]}, {"name": "neuroleptics", "ent_type": "Chemical", "char_span": [77, 89], "ent_id": "D014150", "tok_span": [14, 18]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [98, 109], "ent_id": "D006220", "tok_span": [20, 23]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [98, 109], "obj_char_span": [47, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Propranolol antagonism of phenylpropanolamine-induced hypertension.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [54, 66], "ent_id": "D006973", "tok_span": [13, 14]}, {"name": "Propranolol", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D011433", "tok_span": [0, 4]}, {"name": "phenylpropanolamine", "ent_type": "Chemical", "char_span": [26, 45], "ent_id": "D010665", "tok_span": [7, 11]}], "relation_list": [{"subject": "phenylpropanolamine", "object": "hypertension", "sbj_char_span": [26, 45], "obj_char_span": [54, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.", "entity_list": [{"name": "overdose", "ent_type": "Disease", "char_span": [26, 34], "ent_id": "D062787", "tok_span": [9, 11]}, {"name": "PPA", "ent_type": "Chemical", "char_span": [21, 24], "ent_id": "D010665", "tok_span": [6, 8]}, {"name": "intracerebral hemorrhage", "ent_type": "Disease", "char_span": [66, 90], "ent_id": "D002543", "tok_span": [16, 20]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [52, 64], "ent_id": "D006973", "tok_span": [14, 15]}, {"name": "Phenylpropanolamine", "ent_type": "Chemical", "char_span": [0, 19], "ent_id": "D010665", "tok_span": [0, 5]}], "relation_list": [{"subject": "PPA", "object": "hypertension", "sbj_char_span": [21, 24], "obj_char_span": [52, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [14, 15]}, {"subject": "Phenylpropanolamine", "object": "hypertension", "sbj_char_span": [0, 19], "obj_char_span": [52, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "We studied the efficacy and safety of propranolol in the treatment of PPA-induced hypertension.", "entity_list": [{"name": "PPA", "ent_type": "Chemical", "char_span": [70, 73], "ent_id": "D010665", "tok_span": [15, 17]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [38, 49], "ent_id": "D011433", "tok_span": [7, 11]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [82, 94], "ent_id": "D006973", "tok_span": [19, 20]}], "relation_list": [{"subject": "PPA", "object": "hypertension", "sbj_char_span": [70, 73], "obj_char_span": [82, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal carbon (CC) intravenously.", "entity_list": [{"name": "proteinuric", "ent_type": "Disease", "char_span": [41, 52], "ent_id": "D011507", "tok_span": [8, 10]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [18, 21], "ent_id": "D011692", "tok_span": [4, 5]}, {"name": "carbon", "ent_type": "Chemical", "char_span": [110, 116], "ent_id": "D002244", "tok_span": [28, 29]}], "relation_list": [{"subject": "PAN", "object": "proteinuric", "sbj_char_span": [18, 21], "obj_char_span": [41, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Relationship between nicotine-induced seizures and hippocampal nicotinic receptors.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [38, 46], "ent_id": "D012640", "tok_span": [5, 6]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [21, 29], "ent_id": "D009538", "tok_span": [2, 3]}], "relation_list": [{"subject": "nicotine", "object": "seizures", "sbj_char_span": [21, 29], "obj_char_span": [38, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "Using mice derived from a classical F2 and backcross genetic design, a relationship between nicotine-induced seizures and alpha-bungarotoxin nicotinic receptor concentration was found.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [109, 117], "ent_id": "D012640", "tok_span": [20, 21]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [92, 100], "ent_id": "D009538", "tok_span": [17, 18]}], "relation_list": [{"subject": "nicotine", "object": "seizures", "sbj_char_span": [92, 100], "obj_char_span": [109, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "Mice sensitive to the convulsant effects of nicotine had greater alpha-bungarotoxin binding in the hippocampus than seizure insensitive mice.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [44, 52], "ent_id": "D009538", "tok_span": [9, 10]}, {"name": "seizure", "ent_type": "Disease", "char_span": [116, 123], "ent_id": "D012640", "tok_span": [23, 24]}], "relation_list": [{"subject": "nicotine", "object": "seizure", "sbj_char_span": [44, 52], "obj_char_span": [116, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "Acetaminophen (APAP) produces proximal tubular necrosis in Fischer 344 (F344) rats.", "entity_list": [{"name": "APAP", "ent_type": "Chemical", "char_span": [15, 19], "ent_id": "D000082", "tok_span": [4, 6]}, {"name": "Acetaminophen", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D000082", "tok_span": [0, 3]}, {"name": "tubular necrosis", "ent_type": "Disease", "char_span": [39, 55], "ent_id": "D007683", "tok_span": [9, 11]}], "relation_list": [{"subject": "Acetaminophen", "object": "tubular necrosis", "sbj_char_span": [0, 13], "obj_char_span": [39, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 11]}, {"subject": "APAP", "object": "tubular necrosis", "sbj_char_span": [15, 19], "obj_char_span": [39, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "It is concluded that PAP formation, in vivo, accounts, at least in part, for APAP-induced renal tubular necrosis.", "entity_list": [{"name": "renal tubular necrosis", "ent_type": "Disease", "char_span": [90, 112], "ent_id": "D007683", "tok_span": [22, 25]}, {"name": "PAP", "ent_type": "Chemical", "char_span": [21, 24], "ent_id": "C026729", "tok_span": [4, 5]}, {"name": "APAP", "ent_type": "Chemical", "char_span": [77, 81], "ent_id": "D000082", "tok_span": [18, 20]}], "relation_list": [{"subject": "APAP", "object": "renal tubular necrosis", "sbj_char_span": [77, 81], "obj_char_span": [90, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [22, 25]}, {"subject": "PAP", "object": "renal tubular necrosis", "sbj_char_span": [21, 24], "obj_char_span": [90, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "Morphine-induced seizures in newborn infants.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [17, 25], "ent_id": "D012640", "tok_span": [4, 5]}, {"name": "Morphine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D009020", "tok_span": [0, 2]}], "relation_list": [{"subject": "Morphine", "object": "seizures", "sbj_char_span": [0, 8], "obj_char_span": [17, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Two neonates suffered from generalized seizures during the course of intravenous morphine sulfate for post-operative analgesia.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [39, 47], "ent_id": "D012640", "tok_span": [5, 6]}, {"name": "morphine sulfate", "ent_type": "Chemical", "char_span": [81, 97], "ent_id": "D009020", "tok_span": [11, 13]}], "relation_list": [{"subject": "morphine sulfate", "object": "seizures", "sbj_char_span": [81, 97], "obj_char_span": [39, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "They received morphine in doses of 32 micrograms/kg/hr and 40 micrograms/kg/hr larger than a group of 10 neonates who received 6-24 micrograms/kg/hr and had no seizures.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [14, 22], "ent_id": "D009020", "tok_span": [2, 3]}, {"name": "seizures", "ent_type": "Disease", "char_span": [160, 168], "ent_id": "D012640", "tok_span": [42, 43]}], "relation_list": [{"subject": "morphine", "object": "seizures", "sbj_char_span": [14, 22], "obj_char_span": [160, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [42, 43]}], "umls_entity_list": []}, {"text": "Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [24, 32], "ent_id": "D012640", "tok_span": [4, 5]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [107, 115], "ent_id": "D009020", "tok_span": [20, 21]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [56, 67], "ent_id": "D012640", "tok_span": [10, 13]}], "relation_list": [{"subject": "morphine", "object": "seizures", "sbj_char_span": [107, 115], "obj_char_span": [24, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [4, 5]}, {"subject": "morphine", "object": "convulsions", "sbj_char_span": [107, 115], "obj_char_span": [56, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Effect of vincristine sulfate on Pseudomonas infections in monkeys.", "entity_list": [{"name": "vincristine sulfate", "ent_type": "Chemical", "char_span": [10, 29], "ent_id": "D014750", "tok_span": [2, 7]}, {"name": "Pseudomonas infections", "ent_type": "Disease", "char_span": [33, 55], "ent_id": "D011552", "tok_span": [8, 10]}], "relation_list": [{"subject": "vincristine sulfate", "object": "Pseudomonas infections", "sbj_char_span": [10, 29], "obj_char_span": [33, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Intravenous or intratracheal inoculation of 2.0 to 2.5 mg of vincristine sulfate was followed by leukopenia in 4 to 5 days.", "entity_list": [{"name": "vincristine sulfate", "ent_type": "Chemical", "char_span": [61, 80], "ent_id": "D014750", "tok_span": [19, 24]}, {"name": "leukopenia", "ent_type": "Disease", "char_span": [97, 107], "ent_id": "D007970", "tok_span": [27, 29]}], "relation_list": [{"subject": "vincristine sulfate", "object": "leukopenia", "sbj_char_span": [61, 80], "obj_char_span": [97, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 24], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions.", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [121, 132], "ent_id": "D012640", "tok_span": [29, 32]}, {"name": "muscle tremors", "ent_type": "Disease", "char_span": [102, 116], "ent_id": "D014202", "tok_span": [25, 28]}, {"name": "toxocity", "ent_type": "Disease", "char_span": [13, 21], "ent_id": "D064420", "tok_span": [6, 9]}, {"name": "salivation", "ent_type": "Disease", "char_span": [49, 59], "ent_id": "D012798", "tok_span": [13, 15]}, {"name": "FZP", "ent_type": "Chemical", "char_span": [9, 12], "ent_id": "D005479", "tok_span": [3, 6]}], "relation_list": [{"subject": "FZP", "object": "convulsions", "sbj_char_span": [9, 12], "obj_char_span": [121, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "As a function of dose, FZP first protected against convulsions and death.", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [51, 62], "ent_id": "D012640", "tok_span": [12, 15]}, {"name": "FZP", "ent_type": "Chemical", "char_span": [23, 26], "ent_id": "D005479", "tok_span": [6, 9]}], "relation_list": [{"subject": "FZP", "object": "convulsions", "sbj_char_span": [23, 26], "obj_char_span": [51, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "These doses of FZP were lower than those that would alone cause convulsions.", "entity_list": [{"name": "FZP", "ent_type": "Chemical", "char_span": [15, 18], "ent_id": "D005479", "tok_span": [3, 6]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [64, 75], "ent_id": "D012640", "tok_span": [14, 17]}], "relation_list": [{"subject": "FZP", "object": "convulsions", "sbj_char_span": [15, 18], "obj_char_span": [64, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced tachycardia in two experiments involving nine normal subjects.", "entity_list": [{"name": "propranolol", "ent_type": "Chemical", "char_span": [83, 94], "ent_id": "D011433", "tok_span": [22, 26]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [145, 158], "ent_id": "D007545", "tok_span": [39, 43]}, {"name": "atenolol", "ent_type": "Chemical", "char_span": [49, 57], "ent_id": "D001262", "tok_span": [10, 14]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [167, 178], "ent_id": "D013610", "tok_span": [45, 46]}], "relation_list": [{"subject": "isoproterenol", "object": "tachycardia", "sbj_char_span": [145, 158], "obj_char_span": [167, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 43], "obj_tok_span": [45, 46]}], "umls_entity_list": []}, {"text": "The effects on isoproterenol tachycardia were determined before and after atropine (0.04 mg/kg IV).", "entity_list": [{"name": "tachycardia", "ent_type": "Disease", "char_span": [29, 40], "ent_id": "D013610", "tok_span": [7, 8]}, {"name": "atropine", "ent_type": "Chemical", "char_span": [74, 82], "ent_id": "D001285", "tok_span": [13, 16]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [15, 28], "ent_id": "D007545", "tok_span": [3, 7]}], "relation_list": [{"subject": "isoproterenol", "object": "tachycardia", "sbj_char_span": [15, 28], "obj_char_span": [29, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "These data are consistent with the hypothesis that exercise-induced tachycardia results largely from beta 1-receptor activation that is blocked by both cardioselective and nonselective drugs, whereas isoproterenol activates both beta 1- and beta 2-receptors so that after cardioselective blockade there remains a beta 2-component that can be blocked with a nonselective drug.", "entity_list": [{"name": "tachycardia", "ent_type": "Disease", "char_span": [68, 79], "ent_id": "D013610", "tok_span": [11, 12]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [200, 213], "ent_id": "D007545", "tok_span": [35, 39]}], "relation_list": [{"subject": "isoproterenol", "object": "tachycardia", "sbj_char_span": [200, 213], "obj_char_span": [68, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Early infections in kidney, heart, and liver transplant recipients on cyclosporine.", "entity_list": [{"name": "cyclosporine", "ent_type": "Chemical", "char_span": [70, 82], "ent_id": "D016572", "tok_span": [12, 14]}, {"name": "infections", "ent_type": "Disease", "char_span": [6, 16], "ent_id": "D007239", "tok_span": [1, 2]}], "relation_list": [{"subject": "cyclosporine", "object": "infections", "sbj_char_span": [70, 82], "obj_char_span": [6, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients.", "entity_list": [{"name": "Aza", "ent_type": "Chemical", "char_span": [15, 18], "ent_id": "D001379", "tok_span": [2, 4]}, {"name": "infections", "ent_type": "Disease", "char_span": [93, 103], "ent_id": "D007239", "tok_span": [21, 22]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [143, 155], "ent_id": "D016572", "tok_span": [33, 35]}, {"name": "infections", "ent_type": "Disease", "char_span": [45, 55], "ent_id": "D007239", "tok_span": [8, 9]}], "relation_list": [{"subject": "Aza", "object": "infections", "sbj_char_span": [15, 18], "obj_char_span": [45, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [8, 9]}, {"subject": "cyclosporine", "object": "infections", "sbj_char_span": [143, 155], "obj_char_span": [45, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 35], "obj_tok_span": [8, 9]}, {"subject": "cyclosporine", "object": "infections", "sbj_char_span": [143, 155], "obj_char_span": [93, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 35], "obj_tok_span": [21, 22]}, {"subject": "Aza", "object": "infections", "sbj_char_span": [15, 18], "obj_char_span": [93, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients.", "entity_list": [{"name": "Aza", "ent_type": "Chemical", "char_span": [108, 111], "ent_id": "D001379", "tok_span": [17, 19]}, {"name": "infections", "ent_type": "Disease", "char_span": [34, 44], "ent_id": "D007239", "tok_span": [6, 7]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [50, 62], "ent_id": "D016572", "tok_span": [8, 10]}, {"name": "infections", "ent_type": "Disease", "char_span": [88, 98], "ent_id": "D007239", "tok_span": [14, 15]}], "relation_list": [{"subject": "cyclosporine", "object": "infections", "sbj_char_span": [50, 62], "obj_char_span": [88, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [14, 15]}, {"subject": "cyclosporine", "object": "infections", "sbj_char_span": [50, 62], "obj_char_span": [34, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [6, 7]}, {"subject": "Aza", "object": "infections", "sbj_char_span": [108, 111], "obj_char_span": [34, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [6, 7]}, {"subject": "Aza", "object": "infections", "sbj_char_span": [108, 111], "obj_char_span": [88, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "entity_list": [{"name": "Aza", "ent_type": "Chemical", "char_span": [80, 83], "ent_id": "D001379", "tok_span": [13, 15]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [64, 76], "ent_id": "D016572", "tok_span": [10, 12]}, {"name": "infection", "ent_type": "Disease", "char_span": [89, 98], "ent_id": "D007239", "tok_span": [17, 18]}], "relation_list": [{"subject": "Aza", "object": "infection", "sbj_char_span": [80, 83], "obj_char_span": [89, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [17, 18]}, {"subject": "cyclosporine", "object": "infection", "sbj_char_span": [64, 76], "obj_char_span": [89, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Pulmonary infections were less common in cyclosporine-treated renal patients than in Aza-treated patients (P less than 0.05).", "entity_list": [{"name": "Aza", "ent_type": "Chemical", "char_span": [85, 88], "ent_id": "D001379", "tok_span": [14, 16]}, {"name": "infections", "ent_type": "Disease", "char_span": [10, 20], "ent_id": "D007239", "tok_span": [1, 2]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [41, 53], "ent_id": "D016572", "tok_span": [6, 8]}], "relation_list": [{"subject": "cyclosporine", "object": "infections", "sbj_char_span": [41, 53], "obj_char_span": [10, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [1, 2]}, {"subject": "Aza", "object": "infections", "sbj_char_span": [85, 88], "obj_char_span": [10, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "Structure-activity and dose-effect relationships of the antagonism of picrotoxin-induced seizures by cholecystokinin, fragments and analogues of cholecystokinin in mice.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [89, 97], "ent_id": "D012640", "tok_span": [18, 19]}, {"name": "picrotoxin", "ent_type": "Chemical", "char_span": [70, 80], "ent_id": "D010852", "tok_span": [13, 16]}, {"name": "cholecystokinin", "ent_type": "Chemical", "char_span": [101, 116], "ent_id": "D002766", "tok_span": [20, 24]}, {"name": "cholecystokinin", "ent_type": "Chemical", "char_span": [145, 160], "ent_id": "D002766", "tok_span": [29, 33]}], "relation_list": [{"subject": "picrotoxin", "object": "seizures", "sbj_char_span": [70, 80], "obj_char_span": [89, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice.", "entity_list": [{"name": "cholecystokinin octapeptide", "ent_type": "Chemical", "char_span": [34, 61], "ent_id": "D012844", "tok_span": [5, 13]}, {"name": "CCK-8", "ent_type": "Chemical", "char_span": [134, 139], "ent_id": "D012844", "tok_span": [37, 41]}, {"name": "picrotoxin", "ent_type": "Chemical", "char_span": [188, 198], "ent_id": "D010852", "tok_span": [51, 54]}, {"name": "cholecystokinin octapeptide", "ent_type": "Chemical", "char_span": [105, 132], "ent_id": "D012844", "tok_span": [28, 36]}, {"name": "CCK-8", "ent_type": "Chemical", "char_span": [78, 83], "ent_id": "D012844", "tok_span": [16, 20]}, {"name": "seizures", "ent_type": "Disease", "char_span": [168, 176], "ent_id": "D012640", "tok_span": [48, 49]}], "relation_list": [{"subject": "picrotoxin", "object": "seizures", "sbj_char_span": [188, 198], "obj_char_span": [168, 176], "rel_type": "chemical-induced disease", "sbj_tok_span": [51, 54], "obj_tok_span": [48, 49]}], "umls_entity_list": []}, {"text": "The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin-induced seizures and mortality.", "entity_list": [{"name": "picrotoxin", "ent_type": "Chemical", "char_span": [169, 179], "ent_id": "D010852", "tok_span": [46, 49]}, {"name": "seizures", "ent_type": "Disease", "char_span": [188, 196], "ent_id": "D012640", "tok_span": [51, 52]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [141, 149], "ent_id": "D003975", "tok_span": [40, 43]}], "relation_list": [{"subject": "picrotoxin", "object": "seizures", "sbj_char_span": [169, 179], "obj_char_span": [188, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 49], "obj_tok_span": [51, 52]}], "umls_entity_list": []}, {"text": "Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.", "entity_list": [{"name": "DOCA", "ent_type": "Chemical", "char_span": [54, 58], "ent_id": "D003900", "tok_span": [11, 13]}, {"name": "DOCA", "ent_type": "Chemical", "char_span": [194, 198], "ent_id": "D003900", "tok_span": [39, 41]}, {"name": "diabetes insipidus", "ent_type": "Disease", "char_span": [169, 187], "ent_id": "D003919", "tok_span": [33, 38]}, {"name": "Vasopressin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D014667", "tok_span": [0, 3]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [64, 76], "ent_id": "D006973", "tok_span": [15, 16]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [153, 160], "ent_id": "D008094", "tok_span": [30, 31]}], "relation_list": [{"subject": "DOCA", "object": "hypertension", "sbj_char_span": [54, 58], "obj_char_span": [64, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [15, 16]}, {"subject": "DOCA", "object": "hypertension", "sbj_char_span": [194, 198], "obj_char_span": [64, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 41], "obj_tok_span": [15, 16]}, {"subject": "lithium", "object": "diabetes insipidus", "sbj_char_span": [153, 160], "obj_char_span": [169, 187], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [33, 38]}], "umls_entity_list": []}, {"text": "Toxic hepatitis induced by disulfiram in a non-alcoholic.", "entity_list": [{"name": "disulfiram", "ent_type": "Chemical", "char_span": [27, 37], "ent_id": "D004221", "tok_span": [4, 8]}, {"name": "Toxic hepatitis", "ent_type": "Disease", "char_span": [0, 15], "ent_id": "D056486", "tok_span": [0, 2]}], "relation_list": [{"subject": "disulfiram", "object": "Toxic hepatitis", "sbj_char_span": [27, 37], "obj_char_span": [0, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "A reversible toxic liver damage was observed in a non-alcoholic woman treated with disulfiram.", "entity_list": [{"name": "disulfiram", "ent_type": "Chemical", "char_span": [83, 93], "ent_id": "D004221", "tok_span": [15, 19]}, {"name": "toxic liver damage", "ent_type": "Disease", "char_span": [13, 31], "ent_id": "D056486", "tok_span": [2, 5]}], "relation_list": [{"subject": "disulfiram", "object": "toxic liver damage", "sbj_char_span": [83, 93], "obj_char_span": [13, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Atrial thrombosis involving the heart of F-344 rats ingesting quinacrine hydrochloride.", "entity_list": [{"name": "quinacrine hydrochloride", "ent_type": "Chemical", "char_span": [62, 86], "ent_id": "D011796", "tok_span": [15, 18]}, {"name": "Atrial thrombosis", "ent_type": "Disease", "char_span": [0, 17], "ent_id": "D003328", "tok_span": [0, 4]}], "relation_list": [{"subject": "quinacrine hydrochloride", "object": "Atrial thrombosis", "sbj_char_span": [62, 86], "obj_char_span": [0, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Rats treated with 500 ppm quinacrine hydrochloride in the diet all developed a high incidence of left atrial thrombosis.", "entity_list": [{"name": "quinacrine hydrochloride", "ent_type": "Chemical", "char_span": [26, 50], "ent_id": "D011796", "tok_span": [5, 8]}, {"name": "atrial thrombosis", "ent_type": "Disease", "char_span": [102, 119], "ent_id": "D003328", "tok_span": [18, 20]}], "relation_list": [{"subject": "quinacrine hydrochloride", "object": "atrial thrombosis", "sbj_char_span": [26, 50], "obj_char_span": [102, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.", "entity_list": [{"name": "atrial thrombosis", "ent_type": "Disease", "char_span": [222, 239], "ent_id": "D003328", "tok_span": [42, 44]}, {"name": "sodium nitrite", "ent_type": "Chemical", "char_span": [77, 91], "ent_id": "D012977", "tok_span": [16, 18]}, {"name": "quinacrine hydrochloride", "ent_type": "Chemical", "char_span": [38, 62], "ent_id": "D011796", "tok_span": [8, 11]}, {"name": "thrombosis", "ent_type": "Disease", "char_span": [123, 133], "ent_id": "D013927", "tok_span": [23, 24]}], "relation_list": [{"subject": "quinacrine hydrochloride", "object": "atrial thrombosis", "sbj_char_span": [38, 62], "obj_char_span": [222, 239], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [42, 44]}], "umls_entity_list": []}, {"text": "Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol.", "entity_list": [{"name": "propranolol", "ent_type": "Chemical", "char_span": [70, 81], "ent_id": "D011433", "tok_span": [12, 16]}, {"name": "sinoatrial block", "ent_type": "Disease", "char_span": [42, 58], "ent_id": "D012848", "tok_span": [6, 10]}, {"name": "Alternating sinus rhythm", "ent_type": "Disease", "char_span": [0, 24], "ent_id": "D001146", "tok_span": [0, 4]}], "relation_list": [{"subject": "propranolol", "object": "Alternating sinus rhythm", "sbj_char_span": [70, 81], "obj_char_span": [0, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 4]}, {"subject": "propranolol", "object": "sinoatrial block", "sbj_char_span": [70, 81], "obj_char_span": [42, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily.", "entity_list": [{"name": "sinoatrial (S-A) block", "ent_type": "Disease", "char_span": [42, 64], "ent_id": "D012848", "tok_span": [6, 15]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [140, 151], "ent_id": "D011433", "tok_span": [33, 37]}, {"name": "Alternating sinus rhythm", "ent_type": "Disease", "char_span": [0, 24], "ent_id": "D001146", "tok_span": [0, 4]}, {"name": "angina", "ent_type": "Disease", "char_span": [122, 128], "ent_id": "D000787", "tok_span": [29, 30]}], "relation_list": [{"subject": "propranolol", "object": "Alternating sinus rhythm", "sbj_char_span": [140, 151], "obj_char_span": [0, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 37], "obj_tok_span": [0, 4]}, {"subject": "propranolol", "object": "sinoatrial (S-A) block", "sbj_char_span": [140, 151], "obj_char_span": [42, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 37], "obj_tok_span": [6, 15]}], "umls_entity_list": []}, {"text": "The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S-A block was seen.", "entity_list": [{"name": "propranolol", "ent_type": "Chemical", "char_span": [55, 66], "ent_id": "D011433", "tok_span": [8, 12]}, {"name": "S-A block", "ent_type": "Disease", "char_span": [105, 114], "ent_id": "D012848", "tok_span": [24, 28]}], "relation_list": [{"subject": "propranolol", "object": "S-A block", "sbj_char_span": [55, 66], "obj_char_span": [105, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Light microscopic evidence of renal damage was seen above a dose of 0.5 mg doxorubicin/kg, which resulted in albuminuria and very low serum albumin levels.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [75, 86], "ent_id": "D004317", "tok_span": [16, 17]}, {"name": "albuminuria", "ent_type": "Disease", "char_span": [109, 120], "ent_id": "D000419", "tok_span": [23, 25]}, {"name": "renal damage", "ent_type": "Disease", "char_span": [30, 42], "ent_id": "D007674", "tok_span": [4, 6]}], "relation_list": [{"subject": "doxorubicin", "object": "albuminuria", "sbj_char_span": [75, 86], "obj_char_span": [109, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.", "entity_list": [{"name": "timolol", "ent_type": "Chemical", "char_span": [59, 66], "ent_id": "D013999", "tok_span": [10, 13]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [71, 82], "ent_id": "D010862", "tok_span": [14, 17]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [31, 42], "ent_id": "D007022", "tok_span": [7, 8]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [15, 26], "ent_id": "D001919", "tok_span": [2, 6]}], "relation_list": [{"subject": "pilocarpine", "object": "hypotension", "sbj_char_span": [71, 82], "obj_char_span": [31, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [7, 8]}, {"subject": "timolol", "object": "hypotension", "sbj_char_span": [59, 66], "obj_char_span": [31, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [7, 8]}, {"subject": "pilocarpine", "object": "bradycardia", "sbj_char_span": [71, 82], "obj_char_span": [15, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [2, 6]}, {"subject": "timolol", "object": "bradycardia", "sbj_char_span": [59, 66], "obj_char_span": [15, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.", "entity_list": [{"name": "pilocarpine nitrate", "ent_type": "Chemical", "char_span": [57, 76], "ent_id": "D010862", "tok_span": [14, 18]}, {"name": "timolol maleate", "ent_type": "Chemical", "char_span": [81, 96], "ent_id": "D013999", "tok_span": [19, 24]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [162, 171], "ent_id": "D006221", "tok_span": [38, 41]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [143, 154], "ent_id": "D007022", "tok_span": [35, 37]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [120, 131], "ent_id": "D001919", "tok_span": [29, 33]}], "relation_list": [{"subject": "pilocarpine nitrate", "object": "bradycardia", "sbj_char_span": [57, 76], "obj_char_span": [120, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [29, 33]}, {"subject": "pilocarpine nitrate", "object": "hypotensive", "sbj_char_span": [57, 76], "obj_char_span": [143, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [35, 37]}, {"subject": "timolol maleate", "object": "bradycardia", "sbj_char_span": [81, 96], "obj_char_span": [120, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 24], "obj_tok_span": [29, 33]}, {"subject": "timolol maleate", "object": "hypotensive", "sbj_char_span": [81, 96], "obj_char_span": [143, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 24], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "Succinylcholine apnoea: attempted reversal with anticholinesterases.", "entity_list": [{"name": "apnoea", "ent_type": "Disease", "char_span": [16, 22], "ent_id": "D001049", "tok_span": [4, 7]}, {"name": "Succinylcholine", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D013390", "tok_span": [0, 4]}], "relation_list": [{"subject": "Succinylcholine", "object": "apnoea", "sbj_char_span": [0, 15], "obj_char_span": [16, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "It is concluded that anticholinesterases are only partially effective in restoring neuromuscular function in succinylcholine apnoea despite muscle twitch activity typical of phase II block.", "entity_list": [{"name": "apnoea", "ent_type": "Disease", "char_span": [125, 131], "ent_id": "D001049", "tok_span": [22, 25]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [109, 124], "ent_id": "D013390", "tok_span": [19, 22]}], "relation_list": [{"subject": "succinylcholine", "object": "apnoea", "sbj_char_span": [109, 124], "obj_char_span": [125, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in doxorubicin cardiotoxicity.", "entity_list": [{"name": "I-131 HA", "ent_type": "Chemical", "char_span": [98, 106], "ent_id": "C013102", "tok_span": [15, 19]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [152, 166], "ent_id": "D066126", "tok_span": [26, 28]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [140, 151], "ent_id": "D004317", "tok_span": [25, 26]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiotoxicity", "sbj_char_span": [140, 151], "obj_char_span": [152, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and trimetaphan (TMP) deliberate hypotension (20% and 40% mean pressure decrease from baseline).", "entity_list": [{"name": "TMP", "ent_type": "Chemical", "char_span": [120, 123], "ent_id": "D014294", "tok_span": [26, 28]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [136, 147], "ent_id": "D007022", "tok_span": [31, 32]}, {"name": "trimetaphan", "ent_type": "Chemical", "char_span": [107, 118], "ent_id": "D014294", "tok_span": [22, 25]}, {"name": "SNP", "ent_type": "Chemical", "char_span": [98, 101], "ent_id": "D009599", "tok_span": [19, 20]}, {"name": "sodium nitroprusside", "ent_type": "Chemical", "char_span": [76, 96], "ent_id": "D009599", "tok_span": [13, 18]}], "relation_list": [{"subject": "sodium nitroprusside", "object": "hypotension", "sbj_char_span": [76, 96], "obj_char_span": [136, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [31, 32]}, {"subject": "TMP", "object": "hypotension", "sbj_char_span": [120, 123], "obj_char_span": [136, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [31, 32]}, {"subject": "SNP", "object": "hypotension", "sbj_char_span": [98, 101], "obj_char_span": [136, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [31, 32]}, {"subject": "trimetaphan", "object": "hypotension", "sbj_char_span": [107, 118], "obj_char_span": [136, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [31, 32]}], "umls_entity_list": []}, {"text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "entity_list": [{"name": "nitroprusside", "ent_type": "Chemical", "char_span": [153, 166], "ent_id": "D009599", "tok_span": [34, 38]}, {"name": "trimetaphan", "ent_type": "Chemical", "char_span": [250, 261], "ent_id": "D014294", "tok_span": [53, 56]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [167, 178], "ent_id": "D007022", "tok_span": [38, 39]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [38, 49], "ent_id": "D007022", "tok_span": [7, 8]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [262, 273], "ent_id": "D007022", "tok_span": [56, 57]}], "relation_list": [{"subject": "trimetaphan", "object": "hypotension", "sbj_char_span": [250, 261], "obj_char_span": [262, 273], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 56], "obj_tok_span": [56, 57]}, {"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [153, 166], "obj_char_span": [167, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [38, 39]}, {"subject": "trimetaphan", "object": "hypotension", "sbj_char_span": [250, 261], "obj_char_span": [38, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 56], "obj_tok_span": [7, 8]}, {"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [153, 166], "obj_char_span": [38, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [7, 8]}, {"subject": "trimetaphan", "object": "hypotension", "sbj_char_span": [250, 261], "obj_char_span": [167, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 56], "obj_tok_span": [38, 39]}, {"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [153, 166], "obj_char_span": [262, 273], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [56, 57]}], "umls_entity_list": []}, {"text": "Cardiac work was significantly reduced during SNP hypotension.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [50, 61], "ent_id": "D007022", "tok_span": [7, 8]}, {"name": "SNP", "ent_type": "Chemical", "char_span": [46, 49], "ent_id": "D009599", "tok_span": [6, 7]}], "relation_list": [{"subject": "SNP", "object": "hypotension", "sbj_char_span": [46, 49], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "The hyperactivity induced by D-amphetamine (10 mumol/kg) was significantly reduced by DSP4 pretreatment.", "entity_list": [{"name": "hyperactivity", "ent_type": "Disease", "char_span": [4, 17], "ent_id": "D006948", "tok_span": [1, 3]}, {"name": "DSP4", "ent_type": "Chemical", "char_span": [86, 90], "ent_id": "C012102", "tok_span": [22, 24]}, {"name": "D-amphetamine", "ent_type": "Chemical", "char_span": [29, 42], "ent_id": "D003913", "tok_span": [5, 11]}], "relation_list": [{"subject": "D-amphetamine", "object": "hyperactivity", "sbj_char_span": [29, 42], "obj_char_span": [4, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 11], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "Accelerated junctional rhythms during oral verapamil therapy.", "entity_list": [{"name": "Accelerated junctional rhythms", "ent_type": "Disease", "char_span": [0, 30], "ent_id": "D001145", "tok_span": [0, 6]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "D014700", "tok_span": [8, 11]}], "relation_list": [{"subject": "verapamil", "object": "Accelerated junctional rhythms", "sbj_char_span": [43, 52], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "This study examined the frequency of atrioventricular (AV) dissociation and accelerated junctional rhythms in 59 patients receiving oral verapamil.", "entity_list": [{"name": "accelerated junctional rhythms", "ent_type": "Disease", "char_span": [76, 106], "ent_id": "D001145", "tok_span": [16, 20]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [137, 146], "ent_id": "D014700", "tok_span": [25, 28]}], "relation_list": [{"subject": "verapamil", "object": "accelerated junctional rhythms", "sbj_char_span": [137, 146], "obj_char_span": [76, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and oral contraceptives is reported in a young female patient with a locked-in syndrome.", "entity_list": [{"name": "locked-in syndrome", "ent_type": "Disease", "char_span": [175, 193], "ent_id": "D011782", "tok_span": [33, 37]}, {"name": "dissecting aneurysm", "ent_type": "Disease", "char_span": [23, 42], "ent_id": "D000784", "tok_span": [5, 8]}, {"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [110, 129], "ent_id": "D003276", "tok_span": [21, 24]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [85, 97], "ent_id": "D006973", "tok_span": [16, 17]}], "relation_list": [{"subject": "oral contraceptives", "object": "dissecting aneurysm", "sbj_char_span": [110, 129], "obj_char_span": [23, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Propylthiouracil-induced hepatic damage.", "entity_list": [{"name": "Propylthiouracil", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D011441", "tok_span": [0, 5]}, {"name": "hepatic damage", "ent_type": "Disease", "char_span": [25, 39], "ent_id": "D056486", "tok_span": [7, 9]}], "relation_list": [{"subject": "Propylthiouracil", "object": "hepatic damage", "sbj_char_span": [0, 16], "obj_char_span": [25, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Two cases of propylthiouracil-induced liver damage have been observed.", "entity_list": [{"name": "liver damage", "ent_type": "Disease", "char_span": [38, 50], "ent_id": "D056486", "tok_span": [10, 12]}, {"name": "propylthiouracil", "ent_type": "Chemical", "char_span": [13, 29], "ent_id": "D011441", "tok_span": [3, 8]}], "relation_list": [{"subject": "propylthiouracil", "object": "liver damage", "sbj_char_span": [13, 29], "obj_char_span": [38, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Studies on the bradycardia induced by bepridil.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [15, 26], "ent_id": "D001919", "tok_span": [3, 7]}, {"name": "bepridil", "ent_type": "Chemical", "char_span": [38, 46], "ent_id": "D015764", "tok_span": [9, 12]}], "relation_list": [{"subject": "bepridil", "object": "bradycardia", "sbj_char_span": [38, 46], "obj_char_span": [15, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo.", "entity_list": [{"name": "Bepridil", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D015764", "tok_span": [0, 3]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [100, 111], "ent_id": "D001919", "tok_span": [18, 22]}, {"name": "tachycardial", "ent_type": "Disease", "char_span": [136, 148], "ent_id": "D013610", "tok_span": [29, 31]}, {"name": "anginal attacks", "ent_type": "Disease", "char_span": [64, 79], "ent_id": "D000787", "tok_span": [12, 15]}], "relation_list": [{"subject": "Bepridil", "object": "bradycardia", "sbj_char_span": [0, 8], "obj_char_span": [100, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane.", "entity_list": [{"name": "renal tubular acidosis", "ent_type": "Disease", "char_span": [14, 36], "ent_id": "D000141", "tok_span": [3, 7]}, {"name": "methoxyflurane", "ent_type": "Chemical", "char_span": [59, 73], "ent_id": "D008733", "tok_span": [10, 14]}, {"name": "Hepatitis", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D056486", "tok_span": [0, 2]}], "relation_list": [{"subject": "methoxyflurane", "object": "renal tubular acidosis", "sbj_char_span": [59, 73], "obj_char_span": [14, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [3, 7]}, {"subject": "methoxyflurane", "object": "Hepatitis", "sbj_char_span": [59, 73], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "A 69-year-old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis.", "entity_list": [{"name": "acute cholecystitis", "ent_type": "Disease", "char_span": [31, 50], "ent_id": "D041881", "tok_span": [9, 13]}, {"name": "methoxyflurane", "ent_type": "Chemical", "char_span": [57, 71], "ent_id": "D008733", "tok_span": [14, 18]}, {"name": "hepatic insufficiency syndrome", "ent_type": "Disease", "char_span": [111, 141], "ent_id": "D048550", "tok_span": [22, 25]}, {"name": "renal tubular acidosis", "ent_type": "Disease", "char_span": [146, 168], "ent_id": "D000141", "tok_span": [26, 30]}], "relation_list": [{"subject": "methoxyflurane", "object": "renal tubular acidosis", "sbj_char_span": [57, 71], "obj_char_span": [146, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia.", "entity_list": [{"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [87, 105], "ent_id": "D006966", "tok_span": [17, 21]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [67, 78], "ent_id": "D006220", "tok_span": [12, 15]}], "relation_list": [{"subject": "haloperidol", "object": "hyperprolactinemia", "sbj_char_span": [67, 78], "obj_char_span": [87, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [21, 32], "ent_id": "D006220", "tok_span": [4, 7]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [56, 74], "ent_id": "D006966", "tok_span": [11, 15]}], "relation_list": [{"subject": "haloperidol", "object": "hyperprolactinemia", "sbj_char_span": [21, 32], "obj_char_span": [56, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n 5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described", "entity_list": [{"name": "hemolysis", "ent_type": "Disease", "char_span": [134, 143], "ent_id": "D006461", "tok_span": [29, 31]}, {"name": "rifampicin", "ent_type": "Chemical", "char_span": [35, 45], "ent_id": "D012293", "tok_span": [8, 11]}, {"name": "thrombopenia", "ent_type": "Disease", "char_span": [117, 129], "ent_id": "D013921", "tok_span": [25, 28]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [89, 108], "ent_id": "D058186", "tok_span": [19, 22]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [57, 70], "ent_id": "D051437", "tok_span": [13, 15]}, {"name": "rifampicin", "ent_type": "Chemical", "char_span": [178, 188], "ent_id": "D012293", "tok_span": [39, 42]}], "relation_list": [{"subject": "rifampicin", "object": "thrombopenia", "sbj_char_span": [35, 45], "obj_char_span": [117, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [25, 28]}, {"subject": "rifampicin", "object": "thrombopenia", "sbj_char_span": [178, 188], "obj_char_span": [117, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [25, 28]}, {"subject": "rifampicin", "object": "hemolysis", "sbj_char_span": [35, 45], "obj_char_span": [134, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [29, 31]}, {"subject": "rifampicin", "object": "hemolysis", "sbj_char_span": [178, 188], "obj_char_span": [134, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [26, 37], "ent_id": "D007022", "tok_span": [3, 4]}, {"name": "adenosine triphosphate", "ent_type": "Chemical", "char_span": [49, 71], "ent_id": "D000255", "tok_span": [6, 12]}, {"name": "sodium nitroprusside", "ent_type": "Chemical", "char_span": [76, 96], "ent_id": "D009599", "tok_span": [13, 18]}], "relation_list": [{"subject": "adenosine triphosphate", "object": "hypotension", "sbj_char_span": [49, 71], "obj_char_span": [26, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 12], "obj_tok_span": [3, 4]}, {"subject": "sodium nitroprusside", "object": "hypotension", "sbj_char_span": [76, 96], "obj_char_span": [26, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "Adenosine triphosphate (ATP) and sodium nitroprusside (SNP) are administered to patients to induce and control hypotension during anesthesia.", "entity_list": [{"name": "sodium nitroprusside", "ent_type": "Chemical", "char_span": [33, 53], "ent_id": "D009599", "tok_span": [11, 16]}, {"name": "ATP", "ent_type": "Chemical", "char_span": [24, 27], "ent_id": "D000255", "tok_span": [8, 9]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [111, 122], "ent_id": "D007022", "tok_span": [27, 28]}, {"name": "Adenosine triphosphate", "ent_type": "Chemical", "char_span": [0, 22], "ent_id": "D000255", "tok_span": [0, 7]}, {"name": "SNP", "ent_type": "Chemical", "char_span": [55, 58], "ent_id": "D009599", "tok_span": [17, 18]}], "relation_list": [{"subject": "SNP", "object": "hypotension", "sbj_char_span": [55, 58], "obj_char_span": [111, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [27, 28]}, {"subject": "ATP", "object": "hypotension", "sbj_char_span": [24, 27], "obj_char_span": [111, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [27, 28]}, {"subject": "sodium nitroprusside", "object": "hypotension", "sbj_char_span": [33, 53], "obj_char_span": [111, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 16], "obj_tok_span": [27, 28]}, {"subject": "Adenosine triphosphate", "object": "hypotension", "sbj_char_span": [0, 22], "obj_char_span": [111, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 7], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.", "entity_list": [{"name": "ATP", "ent_type": "Chemical", "char_span": [465, 468], "ent_id": "D000255", "tok_span": [115, 116]}, {"name": "ATP", "ent_type": "Chemical", "char_span": [23, 26], "ent_id": "D000255", "tok_span": [4, 5]}, {"name": "oxygen", "ent_type": "Chemical", "char_span": [334, 340], "ent_id": "D010100", "tok_span": [82, 83]}, {"name": "Hypotension", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D007022", "tok_span": [0, 2]}], "relation_list": [{"subject": "ATP", "object": "Hypotension", "sbj_char_span": [23, 26], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [0, 2]}, {"subject": "ATP", "object": "Hypotension", "sbj_char_span": [465, 468], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [115, 116], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased.", "entity_list": [{"name": "oxygen", "ent_type": "Chemical", "char_span": [324, 330], "ent_id": "D010100", "tok_span": [78, 79]}, {"name": "SNP", "ent_type": "Chemical", "char_span": [31, 34], "ent_id": "D009599", "tok_span": [4, 5]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [7, 18], "ent_id": "D007022", "tok_span": [1, 2]}], "relation_list": [{"subject": "SNP", "object": "hypotension", "sbj_char_span": [31, 34], "obj_char_span": [7, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "The Dimer-X group had a higher incidence of nausea and dizziness.", "entity_list": [{"name": "dizziness", "ent_type": "Disease", "char_span": [55, 64], "ent_id": "D004244", "tok_span": [13, 16]}, {"name": "nausea", "ent_type": "Disease", "char_span": [44, 50], "ent_id": "D009325", "tok_span": [11, 12]}, {"name": "Dimer-X", "ent_type": "Chemical", "char_span": [4, 11], "ent_id": "C025504", "tok_span": [1, 5]}], "relation_list": [{"subject": "Dimer-X", "object": "dizziness", "sbj_char_span": [4, 11], "obj_char_span": [55, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 5], "obj_tok_span": [13, 16]}, {"subject": "Dimer-X", "object": "nausea", "sbj_char_span": [4, 11], "obj_char_span": [44, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 5], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "The Endografine group had a higher incidence of abdominal pain.", "entity_list": [{"name": "Endografine", "ent_type": "Chemical", "char_span": [4, 15], "ent_id": "C006753", "tok_span": [1, 4]}, {"name": "abdominal pain", "ent_type": "Disease", "char_span": [48, 62], "ent_id": "D015746", "tok_span": [10, 12]}], "relation_list": [{"subject": "Endografine", "object": "abdominal pain", "sbj_char_span": [4, 15], "obj_char_span": [48, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Post-suxamethonium pains in Nigerian surgical patients.", "entity_list": [{"name": "suxamethonium", "ent_type": "Chemical", "char_span": [5, 18], "ent_id": "D013390", "tok_span": [2, 7]}, {"name": "pains", "ent_type": "Disease", "char_span": [19, 24], "ent_id": "D010146", "tok_span": [7, 9]}], "relation_list": [{"subject": "suxamethonium", "object": "pains", "sbj_char_span": [5, 18], "obj_char_span": [19, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Contrary to an earlier report by Coxon, scoline pain occurs in African negroes.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [48, 52], "ent_id": "D010146", "tok_span": [11, 12]}, {"name": "scoline", "ent_type": "Chemical", "char_span": [40, 47], "ent_id": "D013390", "tok_span": [9, 11]}], "relation_list": [{"subject": "scoline", "object": "pain", "sbj_char_span": [40, 47], "obj_char_span": [48, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "About 62% of the out-patients developed scoline pain as compared with about 26% among the in-patients.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [48, 52], "ent_id": "D010146", "tok_span": [11, 12]}, {"name": "scoline", "ent_type": "Chemical", "char_span": [40, 47], "ent_id": "D013390", "tok_span": [9, 11]}], "relation_list": [{"subject": "scoline", "object": "pain", "sbj_char_span": [40, 47], "obj_char_span": [48, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "The abolition of muscle fasciculations (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain.", "entity_list": [{"name": "Fazadinium", "ent_type": "Chemical", "char_span": [62, 72], "ent_id": "C084773", "tok_span": [19, 23]}, {"name": "pain", "ent_type": "Disease", "char_span": [118, 122], "ent_id": "D010146", "tok_span": [32, 33]}, {"name": "fasciculations", "ent_type": "Disease", "char_span": [24, 38], "ent_id": "D005207", "tok_span": [5, 8]}, {"name": "scoline", "ent_type": "Chemical", "char_span": [110, 117], "ent_id": "D013390", "tok_span": [30, 32]}], "relation_list": [{"subject": "scoline", "object": "pain", "sbj_char_span": [110, 117], "obj_char_span": [118, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 32], "obj_tok_span": [32, 33]}, {"subject": "scoline", "object": "fasciculations", "sbj_char_span": [110, 117], "obj_char_span": [24, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 32], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.", "entity_list": [{"name": "scoline", "ent_type": "Chemical", "char_span": [158, 165], "ent_id": "D013390", "tok_span": [37, 39]}, {"name": "pain", "ent_type": "Disease", "char_span": [166, 170], "ent_id": "D010146", "tok_span": [39, 40]}, {"name": "suxamethonium", "ent_type": "Chemical", "char_span": [90, 103], "ent_id": "D013390", "tok_span": [21, 26]}, {"name": "chloride", "ent_type": "Chemical", "char_span": [110, 118], "ent_id": "D002712", "tok_span": [28, 29]}, {"name": "Althesin", "ent_type": "Chemical", "char_span": [37, 45], "ent_id": "D000530", "tok_span": [7, 10]}, {"name": "Thiopentone", "ent_type": "Chemical", "char_span": [49, 60], "ent_id": "D013874", "tok_span": [11, 15]}, {"name": "bromide", "ent_type": "Chemical", "char_span": [122, 129], "ent_id": "D001965", "tok_span": [30, 31]}], "relation_list": [{"subject": "suxamethonium", "object": "pain", "sbj_char_span": [90, 103], "obj_char_span": [166, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 26], "obj_tok_span": [39, 40]}, {"subject": "scoline", "object": "pain", "sbj_char_span": [158, 165], "obj_char_span": [166, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 39], "obj_tok_span": [39, 40]}], "umls_entity_list": []}, {"text": "Medial changes in arterial spasm induced by L-norepinephrine.", "entity_list": [{"name": "L-norepinephrine", "ent_type": "Chemical", "char_span": [44, 60], "ent_id": "D009638", "tok_span": [9, 12]}, {"name": "spasm", "ent_type": "Disease", "char_span": [27, 32], "ent_id": "D013035", "tok_span": [5, 7]}], "relation_list": [{"subject": "L-norepinephrine", "object": "spasm", "sbj_char_span": [44, 60], "obj_char_span": [27, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "entity_list": [{"name": "amblyopia", "ent_type": "Disease", "char_span": [66, 75], "ent_id": "D000550", "tok_span": [13, 16]}, {"name": "quinine", "ent_type": "Chemical", "char_span": [58, 65], "ent_id": "D011803", "tok_span": [11, 13]}], "relation_list": [{"subject": "quinine", "object": "amblyopia", "sbj_char_span": [58, 65], "obj_char_span": [66, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "entity_list": [{"name": "blindness", "ent_type": "Disease", "char_span": [6, 15], "ent_id": "D001766", "tok_span": [1, 3]}, {"name": "tonic pupillary", "ent_type": "Disease", "char_span": [33, 48], "ent_id": "D015845", "tok_span": [6, 10]}, {"name": "leg cramps", "ent_type": "Disease", "char_span": [195, 205], "ent_id": "D009120", "tok_span": [40, 43]}, {"name": "quinine sulfate", "ent_type": "Chemical", "char_span": [175, 190], "ent_id": "D011803", "tok_span": [36, 39]}], "relation_list": [{"subject": "quinine sulfate", "object": "tonic pupillary", "sbj_char_span": [175, 190], "obj_char_span": [33, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [6, 10]}, {"subject": "quinine sulfate", "object": "blindness", "sbj_char_span": [175, 190], "obj_char_span": [6, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "entity_list": [{"name": "quinine", "ent_type": "Chemical", "char_span": [109, 116], "ent_id": "D011803", "tok_span": [20, 22]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [117, 125], "ent_id": "D064420", "tok_span": [22, 23]}, {"name": "tonic pupillary", "ent_type": "Disease", "char_span": [12, 27], "ent_id": "D015845", "tok_span": [2, 6]}], "relation_list": [{"subject": "quinine", "object": "tonic pupillary", "sbj_char_span": [109, 116], "obj_char_span": [12, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Suxamethonium-induced jaw stiffness and myalgia associated with atypical cholinesterase: case report.", "entity_list": [{"name": "Suxamethonium", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D013390", "tok_span": [0, 5]}, {"name": "jaw stiffness", "ent_type": "Disease", "char_span": [22, 35], "ent_id": "D014313", "tok_span": [7, 9]}, {"name": "myalgia", "ent_type": "Disease", "char_span": [40, 47], "ent_id": "D063806", "tok_span": [10, 13]}], "relation_list": [{"subject": "Suxamethonium", "object": "jaw stiffness", "sbj_char_span": [0, 13], "obj_char_span": [22, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 9]}, {"subject": "Suxamethonium", "object": "myalgia", "sbj_char_span": [0, 13], "obj_char_span": [40, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.", "entity_list": [{"name": "prolonged jaw rigidity", "ent_type": "Disease", "char_span": [20, 42], "ent_id": "D014313", "tok_span": [4, 7]}, {"name": "pancuronium", "ent_type": "Chemical", "char_span": [152, 163], "ent_id": "D010197", "tok_span": [29, 32]}, {"name": "myalgia", "ent_type": "Disease", "char_span": [47, 54], "ent_id": "D063806", "tok_span": [8, 11]}, {"name": "suxamethonium", "ent_type": "Chemical", "char_span": [71, 84], "ent_id": "D013390", "tok_span": [14, 19]}], "relation_list": [{"subject": "suxamethonium", "object": "myalgia", "sbj_char_span": [71, 84], "obj_char_span": [47, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [8, 11]}, {"subject": "suxamethonium", "object": "prolonged jaw rigidity", "sbj_char_span": [71, 84], "obj_char_span": [20, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "Indomethacin-induced hyperkalemia in three patients with gouty arthritis.", "entity_list": [{"name": "Indomethacin", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D007213", "tok_span": [0, 3]}, {"name": "gouty arthritis", "ent_type": "Disease", "char_span": [57, 72], "ent_id": "D015210", "tok_span": [13, 16]}, {"name": "hyperkalemia", "ent_type": "Disease", "char_span": [21, 33], "ent_id": "D006947", "tok_span": [5, 9]}], "relation_list": [{"subject": "Indomethacin", "object": "hyperkalemia", "sbj_char_span": [0, 12], "obj_char_span": [21, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin.", "entity_list": [{"name": "hyperkalemia", "ent_type": "Disease", "char_span": [60, 72], "ent_id": "D006947", "tok_span": [12, 16]}, {"name": "indomethacin", "ent_type": "Chemical", "char_span": [153, 165], "ent_id": "D007213", "tok_span": [28, 31]}, {"name": "gouty arthritis", "ent_type": "Disease", "char_span": [132, 147], "ent_id": "D015210", "tok_span": [24, 27]}, {"name": "renal insufficiency", "ent_type": "Disease", "char_span": [77, 96], "ent_id": "D051437", "tok_span": [17, 19]}], "relation_list": [{"subject": "indomethacin", "object": "hyperkalemia", "sbj_char_span": [153, 165], "obj_char_span": [60, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [12, 16]}, {"subject": "indomethacin", "object": "renal insufficiency", "sbj_char_span": [153, 165], "obj_char_span": [77, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Levodopa-induced dyskinesias are improved by fluoxetine.", "entity_list": [{"name": "Levodopa", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D007980", "tok_span": [0, 3]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [17, 28], "ent_id": "D004409", "tok_span": [5, 9]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [45, 55], "ent_id": "D005473", "tok_span": [12, 15]}], "relation_list": [{"subject": "fluoxetine", "object": "dyskinesias", "sbj_char_span": [45, 55], "obj_char_span": [17, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [71, 79], "ent_id": "D007980", "tok_span": [14, 17]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [165, 173], "ent_id": "D004298", "tok_span": [32, 33]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [235, 245], "ent_id": "D005473", "tok_span": [47, 50]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [50, 61], "ent_id": "D004409", "tok_span": [8, 12]}, {"name": "motor disability", "ent_type": "Disease", "char_span": [29, 45], "ent_id": "D009069", "tok_span": [5, 7]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [105, 124], "ent_id": "D010300", "tok_span": [21, 25]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [183, 194], "ent_id": "D001058", "tok_span": [35, 40]}], "relation_list": [{"subject": "apomorphine", "object": "dyskinesias", "sbj_char_span": [183, 194], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 40], "obj_tok_span": [8, 12]}, {"subject": "fluoxetine", "object": "dyskinesias", "sbj_char_span": [235, 245], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 50], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.", "entity_list": [{"name": "parkinsonian", "ent_type": "Disease", "char_span": [138, 150], "ent_id": "D010300", "tok_span": [35, 38]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [6, 16], "ent_id": "D005473", "tok_span": [1, 4]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [82, 93], "ent_id": "D001058", "tok_span": [21, 26]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [102, 113], "ent_id": "D004409", "tok_span": [28, 32]}, {"name": "motor disability", "ent_type": "Disease", "char_span": [151, 167], "ent_id": "D009069", "tok_span": [38, 40]}], "relation_list": [{"subject": "fluoxetine", "object": "dyskinesias", "sbj_char_span": [6, 16], "obj_char_span": [102, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [28, 32]}, {"subject": "apomorphine", "object": "dyskinesias", "sbj_char_span": [82, 93], "obj_char_span": [102, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 26], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.", "entity_list": [{"name": "parkinsonian", "ent_type": "Disease", "char_span": [166, 178], "ent_id": "D010300", "tok_span": [31, 34]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [109, 117], "ent_id": "D004298", "tok_span": [20, 21]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [134, 145], "ent_id": "D004409", "tok_span": [24, 28]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [96, 104], "ent_id": "D007980", "tok_span": [15, 18]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [74, 84], "ent_id": "D005473", "tok_span": [10, 13]}, {"name": "motor disability", "ent_type": "Disease", "char_span": [179, 195], "ent_id": "D009069", "tok_span": [34, 36]}], "relation_list": [{"subject": "fluoxetine", "object": "dyskinesias", "sbj_char_span": [74, 84], "obj_char_span": [134, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "The risk of clinically important idiopathic liver disease was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed trimethoprim alone (3.8/100,000).", "entity_list": [{"name": "trimethoprim", "ent_type": "Chemical", "char_span": [136, 148], "ent_id": "D014295", "tok_span": [30, 34]}, {"name": "TMP-SMZ", "ent_type": "Chemical", "char_span": [93, 100], "ent_id": "D015662", "tok_span": [13, 18]}, {"name": "liver disease", "ent_type": "Disease", "char_span": [44, 57], "ent_id": "D008107", "tok_span": [6, 8]}], "relation_list": [{"subject": "trimethoprim", "object": "liver disease", "sbj_char_span": [136, 148], "obj_char_span": [44, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [6, 8]}, {"subject": "TMP-SMZ", "object": "liver disease", "sbj_char_span": [93, 100], "obj_char_span": [44, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "entity_list": [{"name": "erythema multiforme", "ent_type": "Disease", "char_span": [98, 117], "ent_id": "D004892", "tok_span": [22, 27]}, {"name": "TMP-SMZ", "ent_type": "Chemical", "char_span": [75, 82], "ent_id": "D015662", "tok_span": [13, 18]}, {"name": "Stevens-Johnson syndrome", "ent_type": "Disease", "char_span": [122, 146], "ent_id": "D013262", "tok_span": [28, 32]}, {"name": "TMP-SMZ", "ent_type": "Chemical", "char_span": [169, 176], "ent_id": "D015662", "tok_span": [37, 42]}], "relation_list": [{"subject": "TMP-SMZ", "object": "Stevens-Johnson syndrome", "sbj_char_span": [75, 82], "obj_char_span": [122, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [28, 32]}, {"subject": "TMP-SMZ", "object": "Stevens-Johnson syndrome", "sbj_char_span": [169, 176], "obj_char_span": [122, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 42], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "The one case of toxic epidermal necrolysis occurred in a patient who took cephalexin.", "entity_list": [{"name": "cephalexin", "ent_type": "Chemical", "char_span": [74, 84], "ent_id": "D002506", "tok_span": [15, 18]}, {"name": "toxic epidermal necrolysis", "ent_type": "Disease", "char_span": [16, 42], "ent_id": "D013262", "tok_span": [4, 9]}], "relation_list": [{"subject": "cephalexin", "object": "toxic epidermal necrolysis", "sbj_char_span": [74, 84], "obj_char_span": [16, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [4, 9]}], "umls_entity_list": []}, {"text": "Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [65, 86], "ent_id": "D009203", "tok_span": [11, 13]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [19, 28], "ent_id": "D008012", "tok_span": [3, 5]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [46, 53], "ent_id": "D003042", "tok_span": [8, 9]}], "relation_list": [{"subject": "cocaine", "object": "myocardial infarction", "sbj_char_span": [46, 53], "obj_char_span": [65, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of cocaine-induced myocardial infarction (MI).", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "D008012", "tok_span": [8, 10]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [71, 78], "ent_id": "D003042", "tok_span": [14, 15]}, {"name": "MI", "ent_type": "Disease", "char_span": [110, 112], "ent_id": "D009203", "tok_span": [20, 21]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [87, 108], "ent_id": "D009203", "tok_span": [17, 19]}], "relation_list": [{"subject": "cocaine", "object": "myocardial infarction", "sbj_char_span": [71, 78], "obj_char_span": [87, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 19]}, {"subject": "cocaine", "object": "MI", "sbj_char_span": [71, 78], "obj_char_span": [110, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "PARTICIPANTS: Patients with cocaine-associated MI who received lidocaine in the emergency department.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [63, 72], "ent_id": "D008012", "tok_span": [13, 15]}, {"name": "MI", "ent_type": "Disease", "char_span": [47, 49], "ent_id": "D009203", "tok_span": [10, 11]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [28, 35], "ent_id": "D003042", "tok_span": [7, 8]}], "relation_list": [{"subject": "cocaine", "object": "MI", "sbj_char_span": [28, 35], "obj_char_span": [47, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [203, 211], "ent_id": "D012640", "tok_span": [39, 40]}, {"name": "bradydysrhythmias", "ent_type": "Disease", "char_span": [115, 132], "ent_id": "D001919", "tok_span": [23, 29]}, {"name": "MI", "ent_type": "Disease", "char_span": [84, 86], "ent_id": "D009203", "tok_span": [16, 17]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [65, 72], "ent_id": "D003042", "tok_span": [13, 14]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [134, 157], "ent_id": "D017180", "tok_span": [30, 32]}, {"name": "ventricular fibrillation", "ent_type": "Disease", "char_span": [162, 186], "ent_id": "D014693", "tok_span": [34, 36]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [236, 245], "ent_id": "D008012", "tok_span": [43, 45]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [37, 46], "ent_id": "D008012", "tok_span": [7, 9]}], "relation_list": [{"subject": "cocaine", "object": "MI", "sbj_char_span": [65, 72], "obj_char_span": [84, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity_list": [{"name": "toxicity", "ent_type": "Disease", "char_span": [76, 84], "ent_id": "D064420", "tok_span": [11, 12]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [46, 55], "ent_id": "D008012", "tok_span": [6, 8]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [124, 131], "ent_id": "D003042", "tok_span": [21, 22]}, {"name": "cardiovascular or central nervous system toxicity", "ent_type": "Disease", "char_span": [182, 231], "ent_id": "D00231", "tok_span": [30, 36]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [68, 75], "ent_id": "D003042", "tok_span": [10, 11]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [97, 106], "ent_id": "D008012", "tok_span": [16, 18]}, {"name": "MI", "ent_type": "Disease", "char_span": [143, 145], "ent_id": "D009203", "tok_span": [24, 25]}], "relation_list": [{"subject": "cocaine", "object": "MI", "sbj_char_span": [124, 131], "obj_char_span": [143, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [24, 25]}, {"subject": "cocaine", "object": "MI", "sbj_char_span": [68, 75], "obj_char_span": [143, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "Carboplatin did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks.", "entity_list": [{"name": "Carboplatin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D016190", "tok_span": [0, 3]}, {"name": "carboplatin", "ent_type": "Chemical", "char_span": [93, 104], "ent_id": "D016190", "tok_span": [19, 22]}, {"name": "paclitaxel", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D017239", "tok_span": [17, 18]}, {"name": "hematologic toxicities", "ent_type": "Disease", "char_span": [41, 63], "ent_id": "D006402", "tok_span": [10, 13]}], "relation_list": [{"subject": "paclitaxel", "object": "hematologic toxicities", "sbj_char_span": [82, 92], "obj_char_span": [41, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.", "entity_list": [{"name": "indomethacin", "ent_type": "Chemical", "char_span": [44, 56], "ent_id": "D007213", "tok_span": [10, 13]}, {"name": "renal dysfunction", "ent_type": "Disease", "char_span": [65, 82], "ent_id": "D007674", "tok_span": [15, 17]}, {"name": "cirrhosis", "ent_type": "Disease", "char_span": [103, 112], "ent_id": "D005355", "tok_span": [20, 21]}, {"name": "misoprostol", "ent_type": "Chemical", "char_span": [29, 40], "ent_id": "D016595", "tok_span": [6, 9]}], "relation_list": [{"subject": "indomethacin", "object": "renal dysfunction", "sbj_char_span": [44, 56], "obj_char_span": [65, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Misoprostol (200 micrograms) has been shown to acutely counteract the indomethacin-induced renal dysfunction in well compensated cirrhotic patients.", "entity_list": [{"name": "renal dysfunction", "ent_type": "Disease", "char_span": [91, 108], "ent_id": "D007674", "tok_span": [22, 24]}, {"name": "Misoprostol", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D016595", "tok_span": [0, 3]}, {"name": "indomethacin", "ent_type": "Chemical", "char_span": [70, 82], "ent_id": "D007213", "tok_span": [17, 20]}, {"name": "cirrhotic", "ent_type": "Disease", "char_span": [129, 138], "ent_id": "D005355", "tok_span": [27, 29]}], "relation_list": [{"subject": "indomethacin", "object": "renal dysfunction", "sbj_char_span": [70, 82], "obj_char_span": [91, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Increased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients.", "entity_list": [{"name": "angio-oedema", "ent_type": "Disease", "char_span": [36, 48], "ent_id": "D000799", "tok_span": [5, 10]}, {"name": "angiotensin-converting enzyme inhibitor", "ent_type": "Chemical", "char_span": [83, 122], "ent_id": "D000806", "tok_span": [17, 22]}], "relation_list": [{"subject": "angiotensin-converting enzyme inhibitor", "object": "angio-oedema", "sbj_char_span": [83, 122], "obj_char_span": [36, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 22], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "Soon after the introduction of ACE inhibitors, acute bouts of angio-oedema were reported in association with the use of these drugs.", "entity_list": [{"name": "angio-oedema", "ent_type": "Disease", "char_span": [62, 74], "ent_id": "D000799", "tok_span": [13, 18]}, {"name": "ACE inhibitors", "ent_type": "Chemical", "char_span": [31, 45], "ent_id": "D000806", "tok_span": [6, 8]}], "relation_list": [{"subject": "ACE inhibitors", "object": "angio-oedema", "sbj_char_span": [31, 45], "obj_char_span": [62, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [13, 18]}], "umls_entity_list": []}, {"text": "We wish to draw attention to the possibility of adverse reactions to ACE inhibitors after long-term use and in patients with pre-existing angio-oedema.", "entity_list": [{"name": "angio-oedema", "ent_type": "Disease", "char_span": [138, 150], "ent_id": "D000799", "tok_span": [26, 31]}, {"name": "ACE inhibitors", "ent_type": "Chemical", "char_span": [69, 83], "ent_id": "D000806", "tok_span": [12, 14]}], "relation_list": [{"subject": "ACE inhibitors", "object": "angio-oedema", "sbj_char_span": [69, 83], "obj_char_span": [138, 150], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [26, 31]}], "umls_entity_list": []}, {"text": "Myoclonus associated with lorazepam therapy in very-low-birth-weight infants.", "entity_list": [{"name": "lorazepam", "ent_type": "Chemical", "char_span": [26, 35], "ent_id": "D008140", "tok_span": [6, 10]}, {"name": "Myoclonus", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D009207", "tok_span": [0, 4]}], "relation_list": [{"subject": "lorazepam", "object": "Myoclonus", "sbj_char_span": [26, 35], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of lorazepam.", "entity_list": [{"name": "lorazepam", "ent_type": "Chemical", "char_span": [118, 127], "ent_id": "D008140", "tok_span": [24, 28]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [64, 73], "ent_id": "D009207", "tok_span": [15, 19]}], "relation_list": [{"subject": "lorazepam", "object": "myoclonus", "sbj_char_span": [118, 127], "obj_char_span": [64, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Three patients had acute viral myocarditis, one had a carbamazepine-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.", "entity_list": [{"name": "cardiogenic shock", "ent_type": "Disease", "char_span": [161, 178], "ent_id": "D012770", "tok_span": [33, 36]}, {"name": "eosinophilic myocarditis", "ent_type": "Disease", "char_span": [82, 106], "ent_id": "D00480", "tok_span": [18, 22]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [54, 67], "ent_id": "D002220", "tok_span": [11, 15]}, {"name": "myocarditis", "ent_type": "Disease", "char_span": [31, 42], "ent_id": "D009205", "tok_span": [5, 7]}], "relation_list": [{"subject": "carbamazepine", "object": "myocarditis", "sbj_char_span": [54, 67], "obj_char_span": [31, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.", "entity_list": [{"name": "cisplatin", "ent_type": "Chemical", "char_span": [153, 162], "ent_id": "D002945", "tok_span": [33, 34]}, {"name": "granisetron", "ent_type": "Chemical", "char_span": [23, 34], "ent_id": "D017829", "tok_span": [4, 7]}, {"name": "vomiting", "ent_type": "Disease", "char_span": [123, 131], "ent_id": "D014839", "tok_span": [27, 28]}, {"name": "nausea", "ent_type": "Disease", "char_span": [112, 118], "ent_id": "D009325", "tok_span": [25, 26]}, {"name": "5-hydroxytryptamine", "ent_type": "Chemical", "char_span": [48, 67], "ent_id": "D012701", "tok_span": [10, 16]}], "relation_list": [{"subject": "cisplatin", "object": "nausea", "sbj_char_span": [153, 162], "obj_char_span": [112, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [25, 26]}, {"subject": "cisplatin", "object": "vomiting", "sbj_char_span": [153, 162], "obj_char_span": [123, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.", "entity_list": [{"name": "Kytril", "ent_type": "Chemical", "char_span": [101, 107], "ent_id": "D017829", "tok_span": [21, 24]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [234, 243], "ent_id": "D002945", "tok_span": [50, 51]}, {"name": "vomiting", "ent_type": "Disease", "char_span": [263, 271], "ent_id": "D014839", "tok_span": [55, 56]}, {"name": "nausea", "ent_type": "Disease", "char_span": [252, 258], "ent_id": "D009325", "tok_span": [53, 54]}, {"name": "granisetron", "ent_type": "Chemical", "char_span": [88, 99], "ent_id": "D017829", "tok_span": [17, 20]}], "relation_list": [{"subject": "cisplatin", "object": "vomiting", "sbj_char_span": [234, 243], "obj_char_span": [263, 271], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 51], "obj_tok_span": [55, 56]}, {"subject": "cisplatin", "object": "nausea", "sbj_char_span": [234, 243], "obj_char_span": [252, 258], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 51], "obj_tok_span": [53, 54]}], "umls_entity_list": []}, {"text": "CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients.", "entity_list": [{"name": "vomiting", "ent_type": "Disease", "char_span": [100, 108], "ent_id": "D014839", "tok_span": [26, 27]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [148, 157], "ent_id": "D002945", "tok_span": [37, 38]}, {"name": "vomiting", "ent_type": "Disease", "char_span": [211, 219], "ent_id": "D014839", "tok_span": [50, 51]}, {"name": "granisetron", "ent_type": "Chemical", "char_span": [59, 70], "ent_id": "D017829", "tok_span": [19, 22]}], "relation_list": [{"subject": "cisplatin", "object": "vomiting", "sbj_char_span": [148, 157], "obj_char_span": [211, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [50, 51]}, {"subject": "cisplatin", "object": "vomiting", "sbj_char_span": [148, 157], "obj_char_span": [100, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.", "entity_list": [{"name": "clonidine", "ent_type": "Chemical", "char_span": [73, 82], "ent_id": "D003000", "tok_span": [12, 14]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [87, 96], "ent_id": "D014700", "tok_span": [15, 18]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [166, 177], "ent_id": "D007022", "tok_span": [34, 35]}, {"name": "atrioventricular (AV) block", "ent_type": "Disease", "char_span": [110, 137], "ent_id": "D054537", "tok_span": [20, 29]}], "relation_list": [{"subject": "verapamil", "object": "hypotension", "sbj_char_span": [87, 96], "obj_char_span": [166, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [34, 35]}, {"subject": "clonidine", "object": "hypotension", "sbj_char_span": [73, 82], "obj_char_span": [166, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [34, 35]}, {"subject": "clonidine", "object": "atrioventricular (AV) block", "sbj_char_span": [73, 82], "obj_char_span": [110, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [20, 29]}, {"subject": "verapamil", "object": "atrioventricular (AV) block", "sbj_char_span": [87, 96], "obj_char_span": [110, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [20, 29]}], "umls_entity_list": []}, {"text": "After the addition of a minimal dose of clonidine (0.15 mg bid), she developed complete AV block and severe hypotension, which resolved upon cessation of all medications.", "entity_list": [{"name": "clonidine", "ent_type": "Chemical", "char_span": [40, 49], "ent_id": "D003000", "tok_span": [8, 10]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [108, 119], "ent_id": "D007022", "tok_span": [25, 26]}, {"name": "AV block", "ent_type": "Disease", "char_span": [88, 96], "ent_id": "D054537", "tok_span": [21, 23]}], "relation_list": [{"subject": "clonidine", "object": "hypotension", "sbj_char_span": [40, 49], "obj_char_span": [108, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [25, 26]}, {"subject": "clonidine", "object": "AV block", "sbj_char_span": [40, 49], "obj_char_span": [88, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "After the addition of clonidine 0.15 mg bid she developed complete AV block, which resolved after all therapy was stopped.", "entity_list": [{"name": "clonidine", "ent_type": "Chemical", "char_span": [22, 31], "ent_id": "D003000", "tok_span": [4, 6]}, {"name": "AV block", "ent_type": "Disease", "char_span": [67, 75], "ent_id": "D054537", "tok_span": [14, 16]}], "relation_list": [{"subject": "clonidine", "object": "AV block", "sbj_char_span": [22, 31], "obj_char_span": [67, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "entity_list": [{"name": "S-312-d", "ent_type": "Chemical", "char_span": [44, 51], "ent_id": "C059447", "tok_span": [9, 14]}, {"name": "picrotoxin", "ent_type": "Chemical", "char_span": [264, 274], "ent_id": "D010852", "tok_span": [80, 83]}, {"name": "pentylenetetrazole", "ent_type": "Chemical", "char_span": [124, 142], "ent_id": "D010433", "tok_span": [28, 33]}, {"name": "N-methyl-D-aspartate", "ent_type": "Chemical", "char_span": [242, 262], "ent_id": "D016202", "tok_span": [71, 79]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [101, 112], "ent_id": "D012640", "tok_span": [23, 26]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [219, 230], "ent_id": "D012640", "tok_span": [66, 69]}, {"name": "bemegride", "ent_type": "Chemical", "char_span": [163, 172], "ent_id": "D001534", "tok_span": [45, 49]}], "relation_list": [{"subject": "pentylenetetrazole", "object": "convulsions", "sbj_char_span": [124, 142], "obj_char_span": [101, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 33], "obj_tok_span": [23, 26]}, {"subject": "picrotoxin", "object": "convulsions", "sbj_char_span": [264, 274], "obj_char_span": [101, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [80, 83], "obj_tok_span": [23, 26]}, {"subject": "pentylenetetrazole", "object": "convulsions", "sbj_char_span": [124, 142], "obj_char_span": [219, 230], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 33], "obj_tok_span": [66, 69]}, {"subject": "bemegride", "object": "convulsions", "sbj_char_span": [163, 172], "obj_char_span": [101, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 49], "obj_tok_span": [23, 26]}, {"subject": "picrotoxin", "object": "convulsions", "sbj_char_span": [264, 274], "obj_char_span": [219, 230], "rel_type": "chemical-induced disease", "sbj_tok_span": [80, 83], "obj_tok_span": [66, 69]}, {"subject": "bemegride", "object": "convulsions", "sbj_char_span": [163, 172], "obj_char_span": [219, 230], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 49], "obj_tok_span": [66, 69]}], "umls_entity_list": []}, {"text": "Transmural myocardial infarction with sumatriptan.", "entity_list": [{"name": "sumatriptan", "ent_type": "Chemical", "char_span": [38, 49], "ent_id": "D018170", "tok_span": [6, 10]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [11, 32], "ent_id": "D009203", "tok_span": [3, 5]}], "relation_list": [{"subject": "sumatriptan", "object": "myocardial infarction", "sbj_char_span": [38, 49], "obj_char_span": [11, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "We describe a 47-year-old woman with an acute myocardial infarction after administration of sumatriptan 6 mg subcutaneously for cluster headache.", "entity_list": [{"name": "cluster headache", "ent_type": "Disease", "char_span": [128, 144], "ent_id": "D003027", "tok_span": [26, 28]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [46, 67], "ent_id": "D009203", "tok_span": [12, 14]}, {"name": "sumatriptan", "ent_type": "Chemical", "char_span": [92, 103], "ent_id": "D018170", "tok_span": [17, 21]}], "relation_list": [{"subject": "sumatriptan", "object": "myocardial infarction", "sbj_char_span": [92, 103], "obj_char_span": [46, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [47, 54], "ent_id": "D003042", "tok_span": [10, 11]}, {"name": "Flumazenil", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D005442", "tok_span": [0, 4]}, {"name": "seizures", "ent_type": "Disease", "char_span": [19, 27], "ent_id": "D012640", "tok_span": [5, 6]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [55, 63], "ent_id": "D003975", "tok_span": [12, 15]}], "relation_list": [{"subject": "Flumazenil", "object": "seizures", "sbj_char_span": [0, 10], "obj_char_span": [19, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [5, 6]}, {"subject": "cocaine", "object": "seizures", "sbj_char_span": [47, 54], "obj_char_span": [19, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [5, 6]}, {"subject": "diazepam", "object": "seizures", "sbj_char_span": [55, 63], "obj_char_span": [19, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine-benzodiazepine intoxication.", "entity_list": [{"name": "flumazenil", "ent_type": "Chemical", "char_span": [66, 76], "ent_id": "D005442", "tok_span": [15, 19]}, {"name": "seizures", "ent_type": "Disease", "char_span": [88, 96], "ent_id": "D012640", "tok_span": [22, 23]}, {"name": "benzodiazepine", "ent_type": "Chemical", "char_span": [40, 54], "ent_id": "D001569", "tok_span": [10, 14]}, {"name": "benzodiazepine", "ent_type": "Chemical", "char_span": [114, 128], "ent_id": "D001569", "tok_span": [27, 31]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [106, 113], "ent_id": "D003042", "tok_span": [25, 26]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [106, 113], "obj_char_span": [88, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [22, 23]}, {"subject": "flumazenil", "object": "seizures", "sbj_char_span": [66, 76], "obj_char_span": [88, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "CONCLUSION: Flumazenil can unmask seizures and increase the incidence of death in a model of combined cocaine-diazepam intoxications.", "entity_list": [{"name": "Flumazenil", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D005442", "tok_span": [2, 6]}, {"name": "seizures", "ent_type": "Disease", "char_span": [34, 42], "ent_id": "D012640", "tok_span": [9, 10]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [110, 118], "ent_id": "D003975", "tok_span": [23, 26]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [102, 109], "ent_id": "D003042", "tok_span": [21, 22]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [102, 109], "obj_char_span": [34, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [9, 10]}, {"subject": "diazepam", "object": "seizures", "sbj_char_span": [110, 118], "obj_char_span": [34, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [9, 10]}, {"subject": "Flumazenil", "object": "seizures", "sbj_char_span": [12, 22], "obj_char_span": [34, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Mechanisms for protective effects of free radical scavengers on gentamicin-mediated nephropathy in rats.", "entity_list": [{"name": "nephropathy", "ent_type": "Disease", "char_span": [84, 95], "ent_id": "D007674", "tok_span": [14, 15]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [64, 74], "ent_id": "D005839", "tok_span": [10, 12]}], "relation_list": [{"subject": "gentamicin", "object": "nephropathy", "sbj_char_span": [64, 74], "obj_char_span": [84, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on gentamicin (GM)-mediated nephropathy.", "entity_list": [{"name": "gentamicin", "ent_type": "Chemical", "char_span": [106, 116], "ent_id": "D005839", "tok_span": [17, 19]}, {"name": "GM", "ent_type": "Chemical", "char_span": [118, 120], "ent_id": "D005839", "tok_span": [20, 21]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [131, 142], "ent_id": "D007674", "tok_span": [24, 25]}], "relation_list": [{"subject": "GM", "object": "nephropathy", "sbj_char_span": [118, 120], "obj_char_span": [131, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [24, 25]}, {"subject": "gentamicin", "object": "nephropathy", "sbj_char_span": [106, 116], "obj_char_span": [131, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "Administration of GM at 40 mg/kg sc for 13 days to rats induced a significant reduction in renal blood flow (RBF) and inulin clearance (CIn) as well as marked tubular damage.", "entity_list": [{"name": "tubular damage", "ent_type": "Disease", "char_span": [159, 173], "ent_id": "D007674", "tok_span": [37, 39]}, {"name": "GM", "ent_type": "Chemical", "char_span": [18, 20], "ent_id": "D005839", "tok_span": [2, 3]}], "relation_list": [{"subject": "GM", "object": "tubular damage", "sbj_char_span": [18, 20], "obj_char_span": [159, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated nephropathy.", "entity_list": [{"name": "cGMP", "ent_type": "Chemical", "char_span": [73, 77], "ent_id": "D006152", "tok_span": [20, 22]}, {"name": "GM", "ent_type": "Chemical", "char_span": [188, 190], "ent_id": "D005839", "tok_span": [42, 43]}, {"name": "guanosine 3',5'-cyclic monophosphate", "ent_type": "Chemical", "char_span": [35, 71], "ent_id": "D006152", "tok_span": [5, 19]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [200, 211], "ent_id": "D007674", "tok_span": [45, 46]}], "relation_list": [{"subject": "GM", "object": "nephropathy", "sbj_char_span": [188, 190], "obj_char_span": [200, 211], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 43], "obj_tok_span": [45, 46]}], "umls_entity_list": []}, {"text": "These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "entity_list": [{"name": "superoxide", "ent_type": "Chemical", "char_span": [177, 187], "ent_id": "D013481", "tok_span": [40, 41]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [87, 98], "ent_id": "D007674", "tok_span": [19, 20]}, {"name": "GM", "ent_type": "Chemical", "char_span": [219, 221], "ent_id": "D005839", "tok_span": [47, 48]}, {"name": "GM", "ent_type": "Chemical", "char_span": [75, 77], "ent_id": "D005839", "tok_span": [16, 17]}, {"name": "DMTU", "ent_type": "Chemical", "char_span": [164, 168], "ent_id": "C038983", "tok_span": [33, 36]}, {"name": "DMTU", "ent_type": "Chemical", "char_span": [43, 47], "ent_id": "C038983", "tok_span": [9, 12]}], "relation_list": [{"subject": "GM", "object": "nephropathy", "sbj_char_span": [75, 77], "obj_char_span": [87, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [19, 20]}, {"subject": "GM", "object": "nephropathy", "sbj_char_span": [219, 221], "obj_char_span": [87, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 48], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "These data indicate that adult mouse atrial and ventricular cardiomyocytes do not synthesize DNA in response to isoproterenol-induced cardiac hypertrophy.", "entity_list": [{"name": "cardiac hypertrophy", "ent_type": "Disease", "char_span": [134, 153], "ent_id": "D006332", "tok_span": [23, 25]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [112, 125], "ent_id": "D007545", "tok_span": [17, 21]}], "relation_list": [{"subject": "isoproterenol", "object": "cardiac hypertrophy", "sbj_char_span": [112, 125], "obj_char_span": [134, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Central cardiovascular effects of AVP and ANP in normotensive and spontaneously hypertensive rats.", "entity_list": [{"name": "AVP", "ent_type": "Chemical", "char_span": [34, 37], "ent_id": "D001127", "tok_span": [4, 6]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [80, 92], "ent_id": "D006973", "tok_span": [16, 17]}], "relation_list": [{"subject": "AVP", "object": "hypertensive", "sbj_char_span": [34, 37], "obj_char_span": [80, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "The purpose of the present study was to compare influence of central arginine vasopressin (AVP) and of atrial natriuretic peptide (ANP) on control of arterial blood pressure (MAP) and heart rate (HR) in normotensive (WKY) and spontaneously hypertensive (SHR) rats.", "entity_list": [{"name": "AVP", "ent_type": "Chemical", "char_span": [91, 94], "ent_id": "D001127", "tok_span": [17, 19]}, {"name": "arginine vasopressin", "ent_type": "Chemical", "char_span": [69, 89], "ent_id": "D001127", "tok_span": [12, 16]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [240, 252], "ent_id": "D006973", "tok_span": [57, 58]}], "relation_list": [{"subject": "AVP", "object": "hypertensive", "sbj_char_span": [91, 94], "obj_char_span": [240, 252], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [57, 58]}, {"subject": "arginine vasopressin", "object": "hypertensive", "sbj_char_span": [69, 89], "obj_char_span": [240, 252], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [57, 58]}], "umls_entity_list": []}, {"text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.", "entity_list": [{"name": "SN", "ent_type": "Chemical", "char_span": [267, 269], "ent_id": "D009599", "tok_span": [56, 57]}, {"name": "phenylephrine", "ent_type": "Chemical", "char_span": [200, 213], "ent_id": "D010656", "tok_span": [40, 43]}, {"name": "sodium nitroprusside", "ent_type": "Chemical", "char_span": [245, 265], "ent_id": "D009599", "tok_span": [50, 55]}, {"name": "Phe", "ent_type": "Chemical", "char_span": [215, 218], "ent_id": "D010656", "tok_span": [44, 45]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [228, 240], "ent_id": "D006973", "tok_span": [48, 49]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [279, 290], "ent_id": "D007022", "tok_span": [60, 61]}], "relation_list": [{"subject": "SN", "object": "hypotension", "sbj_char_span": [267, 269], "obj_char_span": [279, 290], "rel_type": "chemical-induced disease", "sbj_tok_span": [56, 57], "obj_tok_span": [60, 61]}, {"subject": "phenylephrine", "object": "hypertension", "sbj_char_span": [200, 213], "obj_char_span": [228, 240], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 43], "obj_tok_span": [48, 49]}, {"subject": "sodium nitroprusside", "object": "hypotension", "sbj_char_span": [245, 265], "obj_char_span": [279, 290], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 55], "obj_tok_span": [60, 61]}, {"subject": "Phe", "object": "hypertension", "sbj_char_span": [215, 218], "obj_char_span": [228, 240], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [48, 49]}], "umls_entity_list": []}, {"text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.", "entity_list": [{"name": "AVP", "ent_type": "Chemical", "char_span": [58, 61], "ent_id": "D001127", "tok_span": [13, 15]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [80, 91], "ent_id": "D007022", "tok_span": [19, 20]}, {"name": "SN", "ent_type": "Chemical", "char_span": [69, 71], "ent_id": "D009599", "tok_span": [16, 17]}], "relation_list": [{"subject": "SN", "object": "hypotension", "sbj_char_span": [69, 71], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "entity_list": [{"name": "intracerebral hemorrhage", "ent_type": "Disease", "char_span": [61, 85], "ent_id": "D002543", "tok_span": [10, 14]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [22, 30], "ent_id": "D014859", "tok_span": [4, 5]}], "relation_list": [{"subject": "warfarin", "object": "intracerebral hemorrhage", "sbj_char_span": [22, 30], "obj_char_span": [61, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [227, 238], "ent_id": "D004317", "tok_span": [53, 54]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [239, 253], "ent_id": "D009202", "tok_span": [54, 55]}, {"name": "idiopathic cardiomyopathy", "ent_type": "Disease", "char_span": [37, 62], "ent_id": "D002311", "tok_span": [5, 7]}, {"name": "valvular heart disease", "ent_type": "Disease", "char_span": [194, 216], "ent_id": "D006349", "tok_span": [42, 47]}, {"name": "hypertrophic cardiomyopathy", "ent_type": "Disease", "char_span": [160, 187], "ent_id": "D002312", "tok_span": [34, 37]}, {"name": "congenital heart disease", "ent_type": "Disease", "char_span": [70, 94], "ent_id": "D006331", "tok_span": [12, 15]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [227, 238], "obj_char_span": [239, 253], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 54], "obj_tok_span": [54, 55]}], "umls_entity_list": []}, {"text": "Delirium during fluoxetine treatment.", "entity_list": [{"name": "Delirium", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D003693", "tok_span": [0, 3]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [16, 26], "ent_id": "D005473", "tok_span": [4, 7]}], "relation_list": [{"subject": "fluoxetine", "object": "Delirium", "sbj_char_span": [16, 26], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.", "entity_list": [{"name": "fluoxetine", "ent_type": "Chemical", "char_span": [117, 127], "ent_id": "D005473", "tok_span": [27, 30]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [105, 115], "ent_id": "D005473", "tok_span": [23, 26]}, {"name": "hyperkinetic", "ent_type": "Disease", "char_span": [49, 61], "ent_id": "D006948", "tok_span": [10, 14]}, {"name": "desmethylfluoxetine", "ent_type": "Chemical", "char_span": [133, 152], "ent_id": "C036139", "tok_span": [31, 37]}, {"name": "delirium", "ent_type": "Disease", "char_span": [62, 70], "ent_id": "D003693", "tok_span": [14, 17]}], "relation_list": [{"subject": "fluoxetine", "object": "delirium", "sbj_char_span": [117, 127], "obj_char_span": [62, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [14, 17]}, {"subject": "fluoxetine", "object": "delirium", "sbj_char_span": [105, 115], "obj_char_span": [62, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [14, 17]}, {"subject": "fluoxetine", "object": "hyperkinetic", "sbj_char_span": [105, 115], "obj_char_span": [49, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [10, 14]}, {"subject": "fluoxetine", "object": "hyperkinetic", "sbj_char_span": [117, 127], "obj_char_span": [49, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.", "entity_list": [{"name": "shock", "ent_type": "Disease", "char_span": [20, 25], "ent_id": "D012769", "tok_span": [3, 4]}, {"name": "lymphoma", "ent_type": "Disease", "char_span": [58, 66], "ent_id": "D008223", "tok_span": [15, 16]}, {"name": "aracytine-C", "ent_type": "Chemical", "char_span": [42, 53], "ent_id": "D003561", "tok_span": [8, 14]}, {"name": "Pulmonary edema", "ent_type": "Disease", "char_span": [0, 15], "ent_id": "D011654", "tok_span": [0, 2]}], "relation_list": [{"subject": "aracytine-C", "object": "Pulmonary edema", "sbj_char_span": [42, 53], "obj_char_span": [0, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 14], "obj_tok_span": [0, 2]}, {"subject": "aracytine-C", "object": "shock", "sbj_char_span": [42, 53], "obj_char_span": [20, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 14], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose Ara-C may be associated with cytokine release.", "entity_list": [{"name": "Ara-C", "ent_type": "Chemical", "char_span": [148, 153], "ent_id": "D003561", "tok_span": [28, 31]}, {"name": "adult respiratory distress syndrome", "ent_type": "Disease", "char_span": [81, 116], "ent_id": "D012128", "tok_span": [17, 21]}, {"name": "shock", "ent_type": "Disease", "char_span": [71, 76], "ent_id": "D012769", "tok_span": [15, 16]}], "relation_list": [{"subject": "Ara-C", "object": "shock", "sbj_char_span": [148, 153], "obj_char_span": [71, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats.", "entity_list": [{"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [108, 122], "ent_id": "D009202", "tok_span": [28, 29]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [88, 99], "ent_id": "D004837", "tok_span": [23, 26]}, {"name": "clentiazem", "ent_type": "Chemical", "char_span": [31, 41], "ent_id": "C056595", "tok_span": [5, 9]}, {"name": "1,5-benzothiazepine", "ent_type": "Chemical", "char_span": [45, 64], "ent_id": "C106746", "tok_span": [11, 19]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [65, 72], "ent_id": "D002118", "tok_span": [19, 20]}], "relation_list": [{"subject": "epinephrine", "object": "cardiomyopathy", "sbj_char_span": [88, 99], "obj_char_span": [108, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [28, 29]}], "umls_entity_list": []}, {"text": "Cocaine induced myocardial ischemia.", "entity_list": [{"name": "Cocaine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D003042", "tok_span": [0, 3]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [16, 35], "ent_id": "D017202", "tok_span": [4, 6]}], "relation_list": [{"subject": "Cocaine", "object": "myocardial ischemia", "sbj_char_span": [0, 7], "obj_char_span": [16, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "We report a case of myocardial ischemia induced by cocaine.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [51, 58], "ent_id": "D003042", "tok_span": [9, 10]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [20, 39], "ent_id": "D017202", "tok_span": [5, 7]}], "relation_list": [{"subject": "cocaine", "object": "myocardial ischemia", "sbj_char_span": [51, 58], "obj_char_span": [20, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice.", "entity_list": [{"name": "Doxorubicin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D004317", "tok_span": [0, 3]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [20, 34], "ent_id": "D066126", "tok_span": [5, 7]}], "relation_list": [{"subject": "Doxorubicin", "object": "cardiotoxicity", "sbj_char_span": [0, 11], "obj_char_span": [20, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "In laboratory animals, histology is most commonly used to study doxorubicin-induced cardiotoxicity.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [64, 75], "ent_id": "D004317", "tok_span": [11, 12]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [84, 98], "ent_id": "D066126", "tok_span": [14, 16]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiotoxicity", "sbj_char_span": [64, 75], "obj_char_span": [84, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "These findings result in a model that allows the testing of protectors against doxorubicin-induced cardiotoxicity as demonstrated by the protection provided by ICRF-187.", "entity_list": [{"name": "ICRF-187", "ent_type": "Chemical", "char_span": [160, 168], "ent_id": "D064730", "tok_span": [26, 30]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [79, 90], "ent_id": "D004317", "tok_span": [14, 15]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [99, 113], "ent_id": "D066126", "tok_span": [17, 19]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiotoxicity", "sbj_char_span": [79, 90], "obj_char_span": [99, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.", "entity_list": [{"name": "epinephrine", "ent_type": "Chemical", "char_span": [126, 137], "ent_id": "D004837", "tok_span": [27, 30]}, {"name": "VT", "ent_type": "Disease", "char_span": [144, 146], "ent_id": "D017180", "tok_span": [31, 32]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [65, 74], "ent_id": "D006221", "tok_span": [9, 12]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [27, 48], "ent_id": "D009203", "tok_span": [4, 6]}], "relation_list": [{"subject": "epinephrine", "object": "VT", "sbj_char_span": [126, 137], "obj_char_span": [144, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [31, 32]}], "umls_entity_list": []}, {"text": "Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias.", "entity_list": [{"name": "VT", "ent_type": "Disease", "char_span": [88, 90], "ent_id": "D017180", "tok_span": [20, 21]}, {"name": "Bupivacaine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D002045", "tok_span": [0, 4]}, {"name": "dysrhythmias", "ent_type": "Disease", "char_span": [145, 157], "ent_id": "D001145", "tok_span": [31, 35]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [24, 35], "ent_id": "D004837", "tok_span": [6, 9]}], "relation_list": [{"subject": "epinephrine", "object": "VT", "sbj_char_span": [24, 35], "obj_char_span": [88, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism.", "entity_list": [{"name": "Milk-alkali syndrome", "ent_type": "Disease", "char_span": [0, 20], "ent_id": "D006934", "tok_span": [0, 6]}, {"name": "hypoparathyroidism", "ent_type": "Disease", "char_span": [61, 79], "ent_id": "D007011", "tok_span": [20, 24]}, {"name": "1,25(OH)2D", "ent_type": "Chemical", "char_span": [32, 42], "ent_id": "D002117", "tok_span": [8, 16]}], "relation_list": [{"subject": "1,25(OH)2D", "object": "Milk-alkali syndrome", "sbj_char_span": [32, 42], "obj_char_span": [0, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 16], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali.", "entity_list": [{"name": "calcium", "ent_type": "Chemical", "char_span": [132, 139], "ent_id": "D002118", "tok_span": [27, 28]}, {"name": "Milk-alkali syndrome", "ent_type": "Disease", "char_span": [0, 20], "ent_id": "D006934", "tok_span": [0, 6]}, {"name": "alkali", "ent_type": "Chemical", "char_span": [144, 150], "ent_id": "D000468", "tok_span": [29, 31]}, {"name": "peptic ulcer disease", "ent_type": "Disease", "char_span": [89, 109], "ent_id": "D010437", "tok_span": [19, 23]}], "relation_list": [{"subject": "alkali", "object": "Milk-alkali syndrome", "sbj_char_span": [144, 150], "obj_char_span": [0, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [0, 6]}, {"subject": "calcium", "object": "Milk-alkali syndrome", "sbj_char_span": [132, 139], "obj_char_span": [0, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.", "entity_list": [{"name": "milk-alkali syndrome", "ent_type": "Disease", "char_span": [158, 178], "ent_id": "D006934", "tok_span": [28, 33]}, {"name": "hypoparathyroidism", "ent_type": "Disease", "char_span": [37, 55], "ent_id": "D007011", "tok_span": [6, 10]}, {"name": "calcitriol", "ent_type": "Chemical", "char_span": [99, 109], "ent_id": "D002117", "tok_span": [17, 20]}, {"name": "calcium carbonate", "ent_type": "Chemical", "char_span": [77, 94], "ent_id": "D002119", "tok_span": [14, 16]}], "relation_list": [{"subject": "calcitriol", "object": "milk-alkali syndrome", "sbj_char_span": [99, 109], "obj_char_span": [158, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [28, 33]}, {"subject": "calcium carbonate", "object": "milk-alkali syndrome", "sbj_char_span": [77, 94], "obj_char_span": [158, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [28, 33]}], "umls_entity_list": []}, {"text": "Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?", "entity_list": [{"name": "amitriptyline", "ent_type": "Chemical", "char_span": [22, 35], "ent_id": "D000639", "tok_span": [4, 9]}, {"name": "Encephalopathy", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D001927", "tok_span": [0, 3]}, {"name": "serotonin syndrome", "ent_type": "Disease", "char_span": [84, 102], "ent_id": "D020230", "tok_span": [19, 21]}, {"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [49, 79], "ent_id": "D009459", "tok_span": [12, 18]}], "relation_list": [{"subject": "amitriptyline", "object": "Encephalopathy", "sbj_char_span": [22, 35], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 9], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression.", "entity_list": [{"name": "unipolar depression", "ent_type": "Disease", "char_span": [119, 138], "ent_id": "D003866", "tok_span": [24, 27]}, {"name": "amitriptyline", "ent_type": "Chemical", "char_span": [74, 87], "ent_id": "D000639", "tok_span": [13, 18]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [32, 46], "ent_id": "D001927", "tok_span": [6, 8]}], "relation_list": [{"subject": "amitriptyline", "object": "encephalopathy", "sbj_char_span": [74, 87], "obj_char_span": [32, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.", "entity_list": [{"name": "cystitis", "ent_type": "Disease", "char_span": [9, 17], "ent_id": "D003556", "tok_span": [1, 3]}, {"name": "CYP", "ent_type": "Chemical", "char_span": [51, 54], "ent_id": "D003520", "tok_span": [10, 11]}, {"name": "acrolein", "ent_type": "Chemical", "char_span": [80, 88], "ent_id": "D000171", "tok_span": [17, 20]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [33, 49], "ent_id": "D003520", "tok_span": [6, 9]}], "relation_list": [{"subject": "cyclophosphamide", "object": "cystitis", "sbj_char_span": [33, 49], "obj_char_span": [9, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [1, 3]}, {"subject": "CYP", "object": "cystitis", "sbj_char_span": [51, 54], "obj_char_span": [9, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.", "entity_list": [{"name": "calcium", "ent_type": "Chemical", "char_span": [17, 24], "ent_id": "D002118", "tok_span": [4, 5]}, {"name": "coronary stenosis", "ent_type": "Disease", "char_span": [111, 128], "ent_id": "D023921", "tok_span": [25, 27]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [70, 89], "ent_id": "D017202", "tok_span": [19, 21]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [48, 61], "ent_id": "D007545", "tok_span": [13, 17]}, {"name": "CD-832", "ent_type": "Chemical", "char_span": [37, 43], "ent_id": "C082828", "tok_span": [7, 11]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial ischemia", "sbj_char_span": [48, 61], "obj_char_span": [70, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "entity_list": [{"name": "CD-832", "ent_type": "Chemical", "char_span": [11, 17], "ent_id": "C082828", "tok_span": [2, 6]}, {"name": "nifedipine", "ent_type": "Chemical", "char_span": [202, 212], "ent_id": "D009543", "tok_span": [40, 43]}, {"name": "diltiazem", "ent_type": "Chemical", "char_span": [216, 225], "ent_id": "D004110", "tok_span": [44, 48]}, {"name": "ISO", "ent_type": "Chemical", "char_span": [36, 39], "ent_id": "D007545", "tok_span": [12, 13]}, {"name": "coronary stenosis", "ent_type": "Disease", "char_span": [103, 120], "ent_id": "D023921", "tok_span": [24, 26]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [49, 68], "ent_id": "D017202", "tok_span": [16, 18]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [21, 34], "ent_id": "D007545", "tok_span": [7, 11]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial ischemia", "sbj_char_span": [21, 34], "obj_char_span": [49, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [16, 18]}, {"subject": "ISO", "object": "myocardial ischemia", "sbj_char_span": [36, 39], "obj_char_span": [49, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "These data show that CD-832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832.", "entity_list": [{"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [37, 56], "ent_id": "D017202", "tok_span": [9, 11]}, {"name": "CD-832", "ent_type": "Chemical", "char_span": [146, 152], "ent_id": "C082828", "tok_span": [25, 29]}, {"name": "ISO", "ent_type": "Chemical", "char_span": [64, 67], "ent_id": "D007545", "tok_span": [12, 13]}, {"name": "CD-832", "ent_type": "Chemical", "char_span": [201, 207], "ent_id": "C082828", "tok_span": [38, 42]}, {"name": "CD-832", "ent_type": "Chemical", "char_span": [21, 27], "ent_id": "C082828", "tok_span": [4, 8]}, {"name": "stenosis", "ent_type": "Disease", "char_span": [82, 90], "ent_id": "D003251", "tok_span": [15, 16]}], "relation_list": [{"subject": "ISO", "object": "myocardial ischemia", "sbj_char_span": [64, 67], "obj_char_span": [37, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "The effect of recombinant human insulin-like growth factor-I on chronic puromycin aminonucleoside nephropathy in rats.", "entity_list": [{"name": "nephropathy", "ent_type": "Disease", "char_span": [98, 109], "ent_id": "D007674", "tok_span": [19, 20]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [72, 97], "ent_id": "D011692", "tok_span": [14, 19]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephropathy", "sbj_char_span": [72, 97], "obj_char_span": [98, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.", "entity_list": [{"name": "glomerular disease", "ent_type": "Disease", "char_span": [178, 196], "ent_id": "D007674", "tok_span": [30, 32]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [108, 133], "ent_id": "D011692", "tok_span": [16, 21]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [140, 151], "ent_id": "D007674", "tok_span": [24, 25]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [135, 138], "ent_id": "D011692", "tok_span": [22, 23]}], "relation_list": [{"subject": "PAN", "object": "nephropathy", "sbj_char_span": [135, 138], "obj_char_span": [140, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [24, 25]}, {"subject": "PAN", "object": "glomerular disease", "sbj_char_span": [135, 138], "obj_char_span": [178, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [30, 32]}, {"subject": "puromycin aminonucleoside", "object": "nephropathy", "sbj_char_span": [108, 133], "obj_char_span": [140, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 21], "obj_tok_span": [24, 25]}, {"subject": "puromycin aminonucleoside", "object": "glomerular disease", "sbj_char_span": [108, 133], "obj_char_span": [178, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 21], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy.", "entity_list": [{"name": "growth failure", "ent_type": "Disease", "char_span": [104, 118], "ent_id": "D006130", "tok_span": [22, 24]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [144, 155], "ent_id": "D007674", "tok_span": [29, 30]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [140, 143], "ent_id": "D011692", "tok_span": [28, 29]}], "relation_list": [{"subject": "PAN", "object": "nephropathy", "sbj_char_span": [140, 143], "obj_char_span": [144, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "The glomerulopathy was induced by seven serial injections of PAN over 12 wk.", "entity_list": [{"name": "glomerulopathy", "ent_type": "Disease", "char_span": [4, 18], "ent_id": "D007674", "tok_span": [1, 4]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [61, 64], "ent_id": "D011692", "tok_span": [11, 12]}], "relation_list": [{"subject": "PAN", "object": "glomerulopathy", "sbj_char_span": [61, 64], "obj_char_span": [4, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "Urinary protein excretion was unaltered by rhIGF-I treatment in rats with chronic PAN nephropathy.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [82, 85], "ent_id": "D011692", "tok_span": [18, 19]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [86, 97], "ent_id": "D007674", "tok_span": [19, 20]}], "relation_list": [{"subject": "PAN", "object": "nephropathy", "sbj_char_span": [82, 85], "obj_char_span": [86, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "After 12 wk, the inulin clearance was higher in rhIGF-I-treated rats, 0.48 +/- 0.08 versus 0.24 +/- 0.06 mL/min/100 g of body weight in untreated PAN nephropathy animals, p < 0.05.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [146, 149], "ent_id": "D011692", "tok_span": [49, 50]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [150, 161], "ent_id": "D007674", "tok_span": [50, 51]}], "relation_list": [{"subject": "PAN", "object": "nephropathy", "sbj_char_span": [146, 149], "obj_char_span": [150, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 50], "obj_tok_span": [50, 51]}], "umls_entity_list": []}, {"text": "In rats with PAN nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [13, 16], "ent_id": "D011692", "tok_span": [3, 4]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [17, 28], "ent_id": "D007674", "tok_span": [4, 5]}], "relation_list": [{"subject": "PAN", "object": "nephropathy", "sbj_char_span": [13, 16], "obj_char_span": [17, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "We conclude that: 1) administration of rhIGF-I improves growth and GFR in rats with chronic PAN nephropathy and 2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and structural injury in this disease model.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [92, 95], "ent_id": "D011692", "tok_span": [20, 21]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [96, 107], "ent_id": "D007674", "tok_span": [21, 22]}], "relation_list": [{"subject": "PAN", "object": "nephropathy", "sbj_char_span": [92, 95], "obj_char_span": [96, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.", "entity_list": [{"name": "apomorphine", "ent_type": "Chemical", "char_span": [31, 42], "ent_id": "D001058", "tok_span": [12, 17]}, {"name": "Nefiracetam", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "C058876", "tok_span": [0, 4]}, {"name": "DM-9384", "ent_type": "Chemical", "char_span": [13, 20], "ent_id": "C058876", "tok_span": [5, 9]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [51, 58], "ent_id": "D000647", "tok_span": [19, 22]}], "relation_list": [{"subject": "apomorphine", "object": "amnesia", "sbj_char_span": [31, 42], "obj_char_span": [51, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced learning and post-training consolidation deficits.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [63, 74], "ent_id": "D012601", "tok_span": [14, 17]}, {"name": "pyrrolidone", "ent_type": "Chemical", "char_span": [23, 34], "ent_id": "D011760", "tok_span": [7, 10]}, {"name": "Nefiracetam", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "C058876", "tok_span": [0, 4]}, {"name": "learning and post-training consolidation deficits", "ent_type": "Disease", "char_span": [83, 132], "ent_id": "D007859", "tok_span": [19, 26]}], "relation_list": [{"subject": "scopolamine", "object": "learning and post-training consolidation deficits", "sbj_char_span": [63, 74], "obj_char_span": [83, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [19, 26]}], "umls_entity_list": []}, {"text": "Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism.", "entity_list": [{"name": "apomorphine", "ent_type": "Chemical", "char_span": [11, 22], "ent_id": "D001058", "tok_span": [2, 7]}, {"name": "nefiracetam", "ent_type": "Chemical", "char_span": [160, 171], "ent_id": "C058876", "tok_span": [33, 37]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [185, 192], "ent_id": "D000647", "tok_span": [39, 42]}], "relation_list": [{"subject": "apomorphine", "object": "amnesia", "sbj_char_span": [11, 22], "obj_char_span": [185, 192], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [39, 42]}], "umls_entity_list": []}, {"text": "However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true.", "entity_list": [{"name": "amnesia", "ent_type": "Disease", "char_span": [79, 86], "ent_id": "D000647", "tok_span": [13, 16]}, {"name": "nefiracetam", "ent_type": "Chemical", "char_span": [27, 38], "ent_id": "C058876", "tok_span": [4, 8]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [98, 109], "ent_id": "D001058", "tok_span": [18, 23]}], "relation_list": [{"subject": "apomorphine", "object": "amnesia", "sbj_char_span": [98, 109], "obj_char_span": [79, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 23], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.", "entity_list": [{"name": "hepatitis B", "ent_type": "Disease", "char_span": [39, 50], "ent_id": "D006509", "tok_span": [8, 10]}, {"name": "hepatitis B surface antigen", "ent_type": "Chemical", "char_span": [72, 99], "ent_id": "D006514", "tok_span": [14, 18]}, {"name": "Lamivudine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D019259", "tok_span": [0, 4]}], "relation_list": [{"subject": "hepatitis B surface antigen", "object": "hepatitis B", "sbj_char_span": [72, 99], "obj_char_span": [39, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Population-based study of risk of venous thromboembolism associated with various oral contraceptives.", "entity_list": [{"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [34, 56], "ent_id": "D054556", "tok_span": [7, 10]}, {"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [81, 100], "ent_id": "D003276", "tok_span": [13, 16]}], "relation_list": [{"subject": "oral contraceptives", "object": "venous thromboembolism", "sbj_char_span": [81, 100], "obj_char_span": [34, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity_list": [{"name": "OCs", "ent_type": "Chemical", "char_span": [259, 262], "ent_id": "D003276", "tok_span": [55, 57]}, {"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [88, 110], "ent_id": "D054556", "tok_span": [15, 18]}, {"name": "progestagens", "ent_type": "Chemical", "char_span": [204, 216], "ent_id": "D011374", "tok_span": [40, 43]}, {"name": "VTE", "ent_type": "Disease", "char_span": [112, 115], "ent_id": "D054556", "tok_span": [19, 21]}, {"name": "desogestrel", "ent_type": "Chemical", "char_span": [230, 241], "ent_id": "D017135", "tok_span": [47, 51]}, {"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [146, 165], "ent_id": "D003276", "tok_span": [28, 31]}, {"name": "progestagens", "ent_type": "Chemical", "char_span": [292, 304], "ent_id": "D011374", "tok_span": [61, 64]}, {"name": "OCs", "ent_type": "Chemical", "char_span": [167, 170], "ent_id": "D003276", "tok_span": [32, 34]}, {"name": "gestodene", "ent_type": "Chemical", "char_span": [217, 226], "ent_id": "C033273", "tok_span": [43, 46]}], "relation_list": [{"subject": "OCs", "object": "VTE", "sbj_char_span": [167, 170], "obj_char_span": [112, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 34], "obj_tok_span": [19, 21]}, {"subject": "OCs", "object": "VTE", "sbj_char_span": [259, 262], "obj_char_span": [112, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 57], "obj_tok_span": [19, 21]}, {"subject": "OCs", "object": "venous thromboembolism", "sbj_char_span": [259, 262], "obj_char_span": [88, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 57], "obj_tok_span": [15, 18]}, {"subject": "OCs", "object": "venous thromboembolism", "sbj_char_span": [167, 170], "obj_char_span": [88, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 34], "obj_tok_span": [15, 18]}, {"subject": "oral contraceptives", "object": "venous thromboembolism", "sbj_char_span": [146, 165], "obj_char_span": [88, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [15, 18]}, {"subject": "oral contraceptives", "object": "VTE", "sbj_char_span": [146, 165], "obj_char_span": [112, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "The aim of our study was to re-examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies.", "entity_list": [{"name": "VTE", "ent_type": "Disease", "char_span": [71, 74], "ent_id": "D054556", "tok_span": [15, 17]}, {"name": "OC", "ent_type": "Chemical", "char_span": [79, 81], "ent_id": "D003276", "tok_span": [18, 19]}], "relation_list": [{"subject": "OC", "object": "VTE", "sbj_char_span": [79, 81], "obj_char_span": [71, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors.", "entity_list": [{"name": "OC", "ent_type": "Chemical", "char_span": [214, 216], "ent_id": "D003276", "tok_span": [43, 44]}, {"name": "VTE", "ent_type": "Disease", "char_span": [168, 171], "ent_id": "D054556", "tok_span": [34, 36]}, {"name": "OC", "ent_type": "Chemical", "char_span": [87, 89], "ent_id": "D003276", "tok_span": [18, 19]}, {"name": "VTE", "ent_type": "Disease", "char_span": [62, 65], "ent_id": "D054556", "tok_span": [11, 13]}], "relation_list": [{"subject": "OC", "object": "VTE", "sbj_char_span": [214, 216], "obj_char_span": [168, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 44], "obj_tok_span": [34, 36]}, {"subject": "OC", "object": "VTE", "sbj_char_span": [214, 216], "obj_char_span": [62, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 44], "obj_tok_span": [11, 13]}, {"subject": "OC", "object": "VTE", "sbj_char_span": [87, 89], "obj_char_span": [168, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [34, 36]}, {"subject": "OC", "object": "VTE", "sbj_char_span": [87, 89], "obj_char_span": [62, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of progestagen-only OCs.", "entity_list": [{"name": "OCs", "ent_type": "Chemical", "char_span": [98, 101], "ent_id": "D003276", "tok_span": [25, 27]}, {"name": "progestagen", "ent_type": "Chemical", "char_span": [81, 92], "ent_id": "D011372", "tok_span": [20, 23]}, {"name": "VTE", "ent_type": "Disease", "char_span": [50, 53], "ent_id": "D054556", "tok_span": [11, 13]}], "relation_list": [{"subject": "OCs", "object": "VTE", "sbj_char_span": [98, 101], "obj_char_span": [50, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 27], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.", "entity_list": [{"name": "venous thrombosis", "ent_type": "Disease", "char_span": [142, 159], "ent_id": "D020246", "tok_span": [32, 34]}, {"name": "deep-vein thrombosis", "ent_type": "Disease", "char_span": [80, 100], "ent_id": "D020246", "tok_span": [19, 23]}, {"name": "OCs", "ent_type": "Chemical", "char_span": [55, 58], "ent_id": "D003276", "tok_span": [12, 14]}, {"name": "thrombosis", "ent_type": "Disease", "char_span": [118, 128], "ent_id": "D013927", "tok_span": [27, 28]}, {"name": "VTE", "ent_type": "Disease", "char_span": [19, 22], "ent_id": "D054556", "tok_span": [5, 7]}], "relation_list": [{"subject": "OCs", "object": "VTE", "sbj_char_span": [55, 58], "obj_char_span": [19, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations.", "entity_list": [{"name": "OCs", "ent_type": "Chemical", "char_span": [117, 120], "ent_id": "D003276", "tok_span": [33, 35]}, {"name": "OC", "ent_type": "Chemical", "char_span": [78, 80], "ent_id": "D003276", "tok_span": [22, 23]}, {"name": "VTE", "ent_type": "Disease", "char_span": [18, 21], "ent_id": "D054556", "tok_span": [4, 6]}], "relation_list": [{"subject": "OC", "object": "VTE", "sbj_char_span": [78, 80], "obj_char_span": [18, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [4, 6]}, {"subject": "OCs", "object": "VTE", "sbj_char_span": [117, 120], "obj_char_span": [18, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 35], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75).", "entity_list": [{"name": "OCs", "ent_type": "Chemical", "char_span": [107, 110], "ent_id": "D003276", "tok_span": [22, 24]}, {"name": "VTE", "ent_type": "Disease", "char_span": [44, 47], "ent_id": "D054556", "tok_span": [9, 11]}], "relation_list": [{"subject": "OCs", "object": "VTE", "sbj_char_span": [107, 110], "obj_char_span": [44, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs.", "entity_list": [{"name": "OCs", "ent_type": "Chemical", "char_span": [128, 131], "ent_id": "D003276", "tok_span": [23, 25]}, {"name": "VTE", "ent_type": "Disease", "char_span": [68, 71], "ent_id": "D054556", "tok_span": [11, 13]}], "relation_list": [{"subject": "OCs", "object": "VTE", "sbj_char_span": [128, 131], "obj_char_span": [68, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.", "entity_list": [{"name": "OCs", "ent_type": "Chemical", "char_span": [27, 30], "ent_id": "D003276", "tok_span": [5, 7]}, {"name": "desogestrel", "ent_type": "Chemical", "char_span": [100, 111], "ent_id": "D017135", "tok_span": [31, 35]}, {"name": "ethinyloestradiol", "ent_type": "Chemical", "char_span": [122, 139], "ent_id": "D004997", "tok_span": [38, 44]}, {"name": "VTE", "ent_type": "Disease", "char_span": [69, 72], "ent_id": "D054556", "tok_span": [15, 17]}, {"name": "progestagens", "ent_type": "Chemical", "char_span": [192, 204], "ent_id": "D011374", "tok_span": [63, 66]}], "relation_list": [{"subject": "OCs", "object": "VTE", "sbj_char_span": [27, 30], "obj_char_span": [69, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats.\n 1", "entity_list": [{"name": "brain damage", "ent_type": "Disease", "char_span": [80, 92], "ent_id": "D001930", "tok_span": [17, 19]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [0, 6], "ent_id": "D016291", "tok_span": [0, 4]}, {"name": "seizure", "ent_type": "Disease", "char_span": [51, 58], "ent_id": "D012640", "tok_span": [13, 14]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [16, 27], "ent_id": "D010862", "tok_span": [6, 9]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [16, 27], "obj_char_span": [51, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [13, 14]}, {"subject": "MK-801", "object": "seizure", "sbj_char_span": [0, 6], "obj_char_span": [51, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "The authors examined the anticonvulsant effects of MK-801 on the pilocarpine-induced seizure model.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [65, 76], "ent_id": "D010862", "tok_span": [17, 20]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [51, 57], "ent_id": "D016291", "tok_span": [11, 15]}, {"name": "seizure", "ent_type": "Disease", "char_span": [85, 92], "ent_id": "D012640", "tok_span": [22, 23]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [65, 76], "obj_char_span": [85, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 23]}, {"subject": "MK-801", "object": "seizure", "sbj_char_span": [51, 57], "obj_char_span": [85, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "Intraperitoneal injection of pilocarpine (400 mg/kg) induced tonic and clonic seizure.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [29, 40], "ent_id": "D010862", "tok_span": [5, 8]}, {"name": "tonic and clonic seizure", "ent_type": "Disease", "char_span": [61, 85], "ent_id": "D012640", "tok_span": [15, 20]}], "relation_list": [{"subject": "pilocarpine", "object": "tonic and clonic seizure", "sbj_char_span": [29, 40], "obj_char_span": [61, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [15, 20]}], "umls_entity_list": []}, {"text": "Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0.5 mg/kg) did not. 2.", "entity_list": [{"name": "MK-801", "ent_type": "Chemical", "char_span": [119, 125], "ent_id": "D016291", "tok_span": [29, 33]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [76, 87], "ent_id": "D010862", "tok_span": [21, 24]}, {"name": "pentobarbital", "ent_type": "Chemical", "char_span": [27, 40], "ent_id": "D010424", "tok_span": [10, 12]}, {"name": "seizure", "ent_type": "Disease", "char_span": [107, 114], "ent_id": "D012640", "tok_span": [27, 28]}, {"name": "Scopolamine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D012601", "tok_span": [0, 3]}], "relation_list": [{"subject": "MK-801", "object": "seizure", "sbj_char_span": [119, 125], "obj_char_span": [107, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 33], "obj_tok_span": [27, 28]}, {"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [76, 87], "obj_char_span": [107, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "An electrical seizure measured with hippocampal EEG appeared in the pilocarpine-treated group.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [68, 79], "ent_id": "D010862", "tok_span": [10, 13]}, {"name": "seizure", "ent_type": "Disease", "char_span": [14, 21], "ent_id": "D012640", "tok_span": [2, 3]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [68, 79], "obj_char_span": [14, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine. 3.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [42, 53], "ent_id": "D010862", "tok_span": [8, 11]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [151, 162], "ent_id": "D010862", "tok_span": [29, 32]}, {"name": "seizure", "ent_type": "Disease", "char_span": [132, 139], "ent_id": "D012640", "tok_span": [26, 27]}, {"name": "pentobarbital", "ent_type": "Chemical", "char_span": [16, 29], "ent_id": "D010424", "tok_span": [4, 6]}, {"name": "Scopolamine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D012601", "tok_span": [0, 3]}, {"name": "seizure", "ent_type": "Disease", "char_span": [77, 84], "ent_id": "D012640", "tok_span": [15, 16]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [86, 92], "ent_id": "D016291", "tok_span": [17, 21]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [151, 162], "obj_char_span": [132, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [26, 27]}, {"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [151, 162], "obj_char_span": [77, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [15, 16]}, {"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [42, 53], "obj_char_span": [77, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [15, 16]}, {"subject": "MK-801", "object": "seizure", "sbj_char_span": [86, 92], "obj_char_span": [132, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [26, 27]}, {"subject": "MK-801", "object": "seizure", "sbj_char_span": [86, 92], "obj_char_span": [77, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [15, 16]}, {"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [42, 53], "obj_char_span": [132, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "Pilocarpine produced neuronal death in the hippocampus, which showed pyknotic changes.", "entity_list": [{"name": "Pilocarpine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D010862", "tok_span": [0, 3]}, {"name": "neuronal death", "ent_type": "Disease", "char_span": [21, 35], "ent_id": "D009410", "tok_span": [4, 6]}], "relation_list": [{"subject": "Pilocarpine", "object": "neuronal death", "sbj_char_span": [0, 11], "obj_char_span": [21, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [28, 46], "ent_id": "D013226", "tok_span": [4, 7]}, {"name": "brain damage", "ent_type": "Disease", "char_span": [193, 205], "ent_id": "D001930", "tok_span": [33, 35]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [58, 69], "ent_id": "D010862", "tok_span": [9, 12]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [228, 232], "ent_id": "D016202", "tok_span": [38, 39]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [58, 69], "obj_char_span": [28, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,l-sotalol for sustained ventricular tachyarrhythmias.", "entity_list": [{"name": "torsades de pointes", "ent_type": "Disease", "char_span": [132, 151], "ent_id": "D016171", "tok_span": [24, 29]}, {"name": "d,l-sotalol", "ent_type": "Chemical", "char_span": [177, 188], "ent_id": "D013015", "tok_span": [33, 40]}, {"name": "torsades de pointes", "ent_type": "Disease", "char_span": [75, 94], "ent_id": "D016171", "tok_span": [11, 16]}, {"name": "ventricular tachyarrhythmias", "ent_type": "Disease", "char_span": [203, 231], "ent_id": "D017180", "tok_span": [42, 48]}], "relation_list": [{"subject": "d,l-sotalol", "object": "torsades de pointes", "sbj_char_span": [177, 188], "obj_char_span": [75, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 40], "obj_tok_span": [11, 16]}, {"subject": "d,l-sotalol", "object": "torsades de pointes", "sbj_char_span": [177, 188], "obj_char_span": [132, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 40], "obj_tok_span": [24, 29]}], "umls_entity_list": []}, {"text": "Four (5%) patients had from torsades de pointes during the initial oral treatment with d,l-sotalol.", "entity_list": [{"name": "d,l-sotalol", "ent_type": "Chemical", "char_span": [87, 98], "ent_id": "D013015", "tok_span": [19, 26]}, {"name": "torsades de pointes", "ent_type": "Disease", "char_span": [28, 47], "ent_id": "D016171", "tok_span": [8, 13]}], "relation_list": [{"subject": "d,l-sotalol", "object": "torsades de pointes", "sbj_char_span": [87, 98], "obj_char_span": [28, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 26], "obj_tok_span": [8, 13]}], "umls_entity_list": []}, {"text": "However, the oral dose of d,l-sotalol was significantly lower in patients with torsades de pointes (200 +/- 46 vs. 328 +/- 53 mg/day; p = 0.0017).", "entity_list": [{"name": "d,l-sotalol", "ent_type": "Chemical", "char_span": [26, 37], "ent_id": "D013015", "tok_span": [6, 13]}, {"name": "torsades de pointes", "ent_type": "Disease", "char_span": [79, 98], "ent_id": "D016171", "tok_span": [19, 24]}], "relation_list": [{"subject": "d,l-sotalol", "object": "torsades de pointes", "sbj_char_span": [26, 37], "obj_char_span": [79, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 13], "obj_tok_span": [19, 24]}], "umls_entity_list": []}, {"text": "One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d,l-sotalol.", "entity_list": [{"name": "d,l-sotalol", "ent_type": "Chemical", "char_span": [124, 135], "ent_id": "D013015", "tok_span": [21, 28]}, {"name": "torsades de pointes", "ent_type": "Disease", "char_span": [61, 80], "ent_id": "D016171", "tok_span": [9, 14]}, {"name": "cardiac disease", "ent_type": "Disease", "char_span": [31, 46], "ent_id": "D006331", "tok_span": [5, 7]}], "relation_list": [{"subject": "d,l-sotalol", "object": "torsades de pointes", "sbj_char_span": [124, 135], "obj_char_span": [61, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 28], "obj_tok_span": [9, 14]}], "umls_entity_list": []}, {"text": "Torsades de pointes occurred early during treatment even with low doses of oral d,l-sotalol.", "entity_list": [{"name": "d,l-sotalol", "ent_type": "Chemical", "char_span": [80, 91], "ent_id": "D013015", "tok_span": [16, 23]}, {"name": "Torsades de pointes", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D016171", "tok_span": [0, 6]}], "relation_list": [{"subject": "d,l-sotalol", "object": "Torsades de pointes", "sbj_char_span": [80, 91], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 23], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Pronounced changes in the surface ECG (cycle length, QT, and QTc) in relation to the dose of oral d,l-sotalol might identify a subgroup of patients with an increased risk for torsades de pointes.", "entity_list": [{"name": "torsades de pointes", "ent_type": "Disease", "char_span": [175, 194], "ent_id": "D016171", "tok_span": [43, 48]}, {"name": "d,l-sotalol", "ent_type": "Chemical", "char_span": [98, 109], "ent_id": "D013015", "tok_span": [25, 32]}], "relation_list": [{"subject": "d,l-sotalol", "object": "torsades de pointes", "sbj_char_span": [98, 109], "obj_char_span": [175, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 32], "obj_tok_span": [43, 48]}], "umls_entity_list": []}, {"text": "Other ECG parameters before the application of d,l-sotalol did not identify patients at increased risk for torsades de pointes.", "entity_list": [{"name": "torsades de pointes", "ent_type": "Disease", "char_span": [107, 126], "ent_id": "D016171", "tok_span": [22, 27]}, {"name": "d,l-sotalol", "ent_type": "Chemical", "char_span": [47, 58], "ent_id": "D013015", "tok_span": [7, 14]}], "relation_list": [{"subject": "d,l-sotalol", "object": "torsades de pointes", "sbj_char_span": [47, 58], "obj_char_span": [107, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 14], "obj_tok_span": [22, 27]}], "umls_entity_list": []}, {"text": "Hyperprolactinemia was induced by treatment with haloperidol, a dopamine receptor antagonist, and Palkovits' microdissection technique in combination with high-performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain.", "entity_list": [{"name": "dopamine", "ent_type": "Chemical", "char_span": [64, 72], "ent_id": "D004298", "tok_span": [14, 15]}, {"name": "Hyperprolactinemia", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D006966", "tok_span": [0, 4]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [49, 60], "ent_id": "D006220", "tok_span": [9, 12]}], "relation_list": [{"subject": "haloperidol", "object": "Hyperprolactinemia", "sbj_char_span": [49, 60], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "However, DA response was lost if a 9-month long haloperidol-induced hyperprolactinemia was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule.", "entity_list": [{"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [68, 86], "ent_id": "D006966", "tok_span": [17, 21]}, {"name": "DA", "ent_type": "Chemical", "char_span": [9, 11], "ent_id": "D004298", "tok_span": [2, 3]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [48, 59], "ent_id": "D006220", "tok_span": [12, 15]}], "relation_list": [{"subject": "haloperidol", "object": "hyperprolactinemia", "sbj_char_span": [48, 59], "obj_char_span": [68, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose methotrexate.", "entity_list": [{"name": "acute lymphoblastic leukemia", "ent_type": "Disease", "char_span": [199, 227], "ent_id": "D054198", "tok_span": [34, 38]}, {"name": "methotrexate", "ent_type": "Chemical", "char_span": [251, 263], "ent_id": "D008727", "tok_span": [43, 45]}, {"name": "leukoencephalopathy", "ent_type": "Disease", "char_span": [157, 176], "ent_id": "D056784", "tok_span": [26, 30]}], "relation_list": [{"subject": "methotrexate", "object": "leukoencephalopathy", "sbj_char_span": [251, 263], "obj_char_span": [157, 176], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 45], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy.", "entity_list": [{"name": "acute promyelocytic leukemia", "ent_type": "Disease", "char_span": [28, 56], "ent_id": "D015473", "tok_span": [4, 9]}, {"name": "all-trans-retinoic acid", "ent_type": "Chemical", "char_span": [64, 87], "ent_id": "D014212", "tok_span": [10, 17]}, {"name": "Thrombotic", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D013927", "tok_span": [0, 2]}], "relation_list": [{"subject": "all-trans-retinoic acid", "object": "Thrombotic", "sbj_char_span": [64, 87], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 17], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity_list": [{"name": "acute renal failure", "ent_type": "Disease", "char_span": [10, 29], "ent_id": "D058186", "tok_span": [3, 6]}, {"name": "occlusion of renal vessels", "ent_type": "Disease", "char_span": [38, 64], "ent_id": "-1", "tok_span": [9, 13]}, {"name": "acute promyelocytic leukemia", "ent_type": "Disease", "char_span": [83, 111], "ent_id": "D015473", "tok_span": [17, 22]}, {"name": "tranexamic acid", "ent_type": "Chemical", "char_span": [166, 181], "ent_id": "D014148", "tok_span": [40, 44]}, {"name": "all-trans-retinoic acid", "ent_type": "Chemical", "char_span": [131, 154], "ent_id": "D014212", "tok_span": [28, 35]}, {"name": "APL", "ent_type": "Disease", "char_span": [113, 116], "ent_id": "D015473", "tok_span": [23, 25]}, {"name": "ATRA", "ent_type": "Chemical", "char_span": [156, 160], "ent_id": "D014212", "tok_span": [36, 38]}], "relation_list": [{"subject": "all-trans-retinoic acid", "object": "acute renal failure", "sbj_char_span": [131, 154], "obj_char_span": [10, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 35], "obj_tok_span": [3, 6]}, {"subject": "ATRA", "object": "acute renal failure", "sbj_char_span": [156, 160], "obj_char_span": [10, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 38], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "We report a case of acute renal failure in an APL patient treated with ATRA alone.", "entity_list": [{"name": "acute renal failure", "ent_type": "Disease", "char_span": [20, 39], "ent_id": "D058186", "tok_span": [5, 8]}, {"name": "ATRA", "ent_type": "Chemical", "char_span": [71, 75], "ent_id": "D014212", "tok_span": [15, 17]}, {"name": "APL", "ent_type": "Disease", "char_span": [46, 49], "ent_id": "D015473", "tok_span": [10, 12]}], "relation_list": [{"subject": "ATRA", "object": "acute renal failure", "sbj_char_span": [71, 75], "obj_char_span": [20, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug.", "entity_list": [{"name": "DEP", "ent_type": "Chemical", "char_span": [145, 148], "ent_id": "D004053", "tok_span": [33, 34]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [14, 21], "ent_id": "D003042", "tok_span": [6, 7]}, {"name": "diethylpropion", "ent_type": "Chemical", "char_span": [129, 143], "ent_id": "D004053", "tok_span": [28, 32]}, {"name": "manic", "ent_type": "Disease", "char_span": [157, 162], "ent_id": "D001714", "tok_span": [36, 38]}], "relation_list": [{"subject": "diethylpropion", "object": "manic", "sbj_char_span": [129, 143], "obj_char_span": [157, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 32], "obj_tok_span": [36, 38]}, {"subject": "DEP", "object": "manic", "sbj_char_span": [145, 148], "obj_char_span": [157, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "Pupillometric changes while on DEP, especially changes in the total power of pupillary oscillation, were dramatically different than those observed in the eight other study subjects who did not become manic.", "entity_list": [{"name": "pupillary oscillation", "ent_type": "Disease", "char_span": [77, 98], "ent_id": "D011681", "tok_span": [16, 20]}, {"name": "DEP", "ent_type": "Chemical", "char_span": [31, 34], "ent_id": "D004053", "tok_span": [7, 8]}, {"name": "manic", "ent_type": "Disease", "char_span": [201, 206], "ent_id": "D001714", "tok_span": [37, 39]}], "relation_list": [{"subject": "DEP", "object": "manic", "sbj_char_span": [31, 34], "obj_char_span": [201, 206], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [95, 99], "ent_id": "D010146", "tok_span": [19, 20]}, {"name": "ibuprofen", "ent_type": "Chemical", "char_span": [198, 207], "ent_id": "D007052", "tok_span": [40, 44]}, {"name": "pain", "ent_type": "Disease", "char_span": [239, 243], "ent_id": "D010146", "tok_span": [49, 50]}, {"name": "pain", "ent_type": "Disease", "char_span": [160, 164], "ent_id": "D010146", "tok_span": [33, 34]}, {"name": "ibuprofen", "ent_type": "Chemical", "char_span": [49, 58], "ent_id": "D007052", "tok_span": [8, 12]}], "relation_list": [{"subject": "ibuprofen", "object": "pain", "sbj_char_span": [198, 207], "obj_char_span": [95, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 44], "obj_tok_span": [19, 20]}, {"subject": "ibuprofen", "object": "pain", "sbj_char_span": [49, 58], "obj_char_span": [95, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [19, 20]}, {"subject": "ibuprofen", "object": "pain", "sbj_char_span": [198, 207], "obj_char_span": [160, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 44], "obj_tok_span": [33, 34]}, {"subject": "ibuprofen", "object": "pain", "sbj_char_span": [49, 58], "obj_char_span": [239, 243], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [49, 50]}, {"subject": "ibuprofen", "object": "pain", "sbj_char_span": [49, 58], "obj_char_span": [160, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [33, 34]}, {"subject": "ibuprofen", "object": "pain", "sbj_char_span": [198, 207], "obj_char_span": [239, 243], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 44], "obj_tok_span": [49, 50]}], "umls_entity_list": []}, {"text": "Hypertensive response during dobutamine stress echocardiography.", "entity_list": [{"name": "dobutamine", "ent_type": "Chemical", "char_span": [29, 39], "ent_id": "D004280", "tok_span": [4, 7]}, {"name": "Hypertensive", "ent_type": "Disease", "char_span": [0, 12], "ent_id": "D006973", "tok_span": [0, 2]}], "relation_list": [{"subject": "dobutamine", "object": "Hypertensive", "sbj_char_span": [29, 39], "obj_char_span": [0, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Among 3,129 dobutamine stress echocardiographic studies, a hypertensive response, defined as systolic blood pressure (BP) > or = 220 mm Hg and/or diastolic BP > or = 110 mm Hg, occurred in 30 patients (1%).", "entity_list": [{"name": "dobutamine", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D004280", "tok_span": [4, 7]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [59, 71], "ent_id": "D006973", "tok_span": [13, 14]}], "relation_list": [{"subject": "dobutamine", "object": "hypertensive", "sbj_char_span": [12, 22], "obj_char_span": [59, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Patients with this response more often had a history of hypertension and had higher resting systolic and diastolic BP before dobutamine infusion.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [56, 68], "ent_id": "D006973", "tok_span": [10, 11]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [125, 135], "ent_id": "D004280", "tok_span": [20, 23]}], "relation_list": [{"subject": "dobutamine", "object": "hypertension", "sbj_char_span": [125, 135], "obj_char_span": [56, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Hyperosmolar nonketotic coma precipitated by lithium-induced nephrogenic diabetes insipidus.", "entity_list": [{"name": "Hyperosmolar nonketotic coma", "ent_type": "Disease", "char_span": [0, 28], "ent_id": "D006944", "tok_span": [0, 8]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [45, 52], "ent_id": "D008094", "tok_span": [10, 11]}, {"name": "nephrogenic diabetes insipidus", "ent_type": "Disease", "char_span": [61, 91], "ent_id": "D018500", "tok_span": [13, 20]}], "relation_list": [{"subject": "lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [45, 52], "obj_char_span": [61, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 20]}, {"subject": "lithium", "object": "Hyperosmolar nonketotic coma", "sbj_char_span": [45, 52], "obj_char_span": [0, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [0, 8]}], "umls_entity_list": []}, {"text": "A 45-year-old man, with a 10-year history of manic depression treated with lithium, was admitted with hyperosmolar, nonketotic coma.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [75, 82], "ent_id": "D008094", "tok_span": [20, 21]}, {"name": "manic depression", "ent_type": "Disease", "char_span": [45, 61], "ent_id": "D001714", "tok_span": [15, 18]}, {"name": "hyperosmolar, nonketotic coma", "ent_type": "Disease", "char_span": [102, 131], "ent_id": "D006944", "tok_span": [25, 34]}], "relation_list": [{"subject": "lithium", "object": "hyperosmolar, nonketotic coma", "sbj_char_span": [75, 82], "obj_char_span": [102, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [25, 34]}], "umls_entity_list": []}, {"text": "After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced.", "entity_list": [{"name": "polyuric", "ent_type": "Disease", "char_span": [48, 56], "ent_id": "D011141", "tok_span": [9, 11]}, {"name": "nephrogenic diabetes insipidus", "ent_type": "Disease", "char_span": [138, 168], "ent_id": "D018500", "tok_span": [21, 28]}, {"name": "hyperglycaemia", "ent_type": "Disease", "char_span": [20, 34], "ent_id": "-1", "tok_span": [3, 6]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [183, 190], "ent_id": "D008094", "tok_span": [32, 33]}, {"name": "glucose", "ent_type": "Chemical", "char_span": [78, 85], "ent_id": "D005947", "tok_span": [14, 15]}], "relation_list": [{"subject": "lithium", "object": "polyuric", "sbj_char_span": [183, 190], "obj_char_span": [48, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [9, 11]}, {"subject": "lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [183, 190], "obj_char_span": [138, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [21, 28]}], "umls_entity_list": []}, {"text": "BACKGROUND: In dogs, a large amount of intravenous cocaine causes a profound deterioration of left ventricular (LV) systolic function and an increase in LV end-diastolic pressure.", "entity_list": [{"name": "deterioration of left ventricular (LV) systolic function", "ent_type": "Disease", "char_span": [77, 133], "ent_id": "D018487", "tok_span": [14, 23]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [51, 58], "ent_id": "D003042", "tok_span": [10, 11]}], "relation_list": [{"subject": "cocaine", "object": "deterioration of left ventricular (LV) systolic function", "sbj_char_span": [51, 58], "obj_char_span": [77, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [14, 23]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: In humans, the intracoronary infusion of cocaine sufficient in amount to achieve a high drug concentration in coronary sinus blood causes a deterioration of LV systolic and diastolic performance.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [54, 61], "ent_id": "D003042", "tok_span": [12, 13]}, {"name": "deterioration of LV systolic and diastolic performance", "ent_type": "Disease", "char_span": [153, 207], "ent_id": "D018487", "tok_span": [28, 35]}], "relation_list": [{"subject": "cocaine", "object": "deterioration of LV systolic and diastolic performance", "sbj_char_span": [54, 61], "obj_char_span": [153, 207], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [28, 35]}], "umls_entity_list": []}, {"text": "Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy.", "entity_list": [{"name": "thromboembolism", "ent_type": "Disease", "char_span": [46, 61], "ent_id": "D013923", "tok_span": [9, 11]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [16, 32], "ent_id": "D013921", "tok_span": [4, 6]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [89, 96], "ent_id": "D006493", "tok_span": [17, 18]}, {"name": "Heparin", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D006493", "tok_span": [0, 2]}], "relation_list": [{"subject": "heparin", "object": "thromboembolism", "sbj_char_span": [89, 96], "obj_char_span": [46, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [9, 11]}, {"subject": "Heparin", "object": "thromboembolism", "sbj_char_span": [0, 7], "obj_char_span": [46, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [9, 11]}, {"subject": "Heparin", "object": "thrombocytopenia", "sbj_char_span": [0, 7], "obj_char_span": [16, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [89, 96], "obj_char_span": [16, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity_list": [{"name": "osteoporosis", "ent_type": "Disease", "char_span": [109, 121], "ent_id": "D010024", "tok_span": [19, 20]}, {"name": "eosinophilia", "ent_type": "Disease", "char_span": [123, 135], "ent_id": "D004802", "tok_span": [21, 23]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [72, 88], "ent_id": "D013921", "tok_span": [13, 15]}, {"name": "skin reactions", "ent_type": "Disease", "char_span": [137, 151], "ent_id": "D012871", "tok_span": [24, 26]}, {"name": "allergic reactions", "ent_type": "Disease", "char_span": [153, 171], "ent_id": "D004342", "tok_span": [27, 29]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [90, 97], "ent_id": "D006493", "tok_span": [16, 17]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [56, 63], "ent_id": "D006493", "tok_span": [10, 11]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [30, 37], "ent_id": "D006493", "tok_span": [7, 8]}, {"name": "alopecia", "ent_type": "Disease", "char_span": [204, 212], "ent_id": "D000505", "tok_span": [34, 37]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [183, 199], "ent_id": "D013921", "tok_span": [31, 33]}], "relation_list": [{"subject": "heparin", "object": "osteoporosis", "sbj_char_span": [30, 37], "obj_char_span": [109, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [19, 20]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [90, 97], "obj_char_span": [183, 199], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [31, 33]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [90, 97], "obj_char_span": [72, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [13, 15]}, {"subject": "heparin", "object": "skin reactions", "sbj_char_span": [90, 97], "obj_char_span": [137, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [24, 26]}, {"subject": "heparin", "object": "allergic reactions", "sbj_char_span": [30, 37], "obj_char_span": [153, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [27, 29]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [30, 37], "obj_char_span": [183, 199], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [31, 33]}, {"subject": "heparin", "object": "eosinophilia", "sbj_char_span": [30, 37], "obj_char_span": [123, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [21, 23]}, {"subject": "heparin", "object": "alopecia", "sbj_char_span": [56, 63], "obj_char_span": [204, 212], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [34, 37]}, {"subject": "heparin", "object": "osteoporosis", "sbj_char_span": [90, 97], "obj_char_span": [109, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [19, 20]}, {"subject": "heparin", "object": "alopecia", "sbj_char_span": [90, 97], "obj_char_span": [204, 212], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [34, 37]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [30, 37], "obj_char_span": [72, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [13, 15]}, {"subject": "heparin", "object": "skin reactions", "sbj_char_span": [56, 63], "obj_char_span": [137, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [24, 26]}, {"subject": "heparin", "object": "allergic reactions", "sbj_char_span": [90, 97], "obj_char_span": [153, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [27, 29]}, {"subject": "heparin", "object": "eosinophilia", "sbj_char_span": [56, 63], "obj_char_span": [123, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [21, 23]}, {"subject": "heparin", "object": "alopecia", "sbj_char_span": [30, 37], "obj_char_span": [204, 212], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [34, 37]}, {"subject": "heparin", "object": "osteoporosis", "sbj_char_span": [56, 63], "obj_char_span": [109, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [19, 20]}, {"subject": "heparin", "object": "skin reactions", "sbj_char_span": [30, 37], "obj_char_span": [137, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [24, 26]}, {"subject": "heparin", "object": "eosinophilia", "sbj_char_span": [90, 97], "obj_char_span": [123, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [21, 23]}, {"subject": "heparin", "object": "allergic reactions", "sbj_char_span": [56, 63], "obj_char_span": [153, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [27, 29]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [56, 63], "obj_char_span": [183, 199], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [31, 33]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [56, 63], "obj_char_span": [72, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.", "entity_list": [{"name": "indinavir", "ent_type": "Chemical", "char_span": [105, 114], "ent_id": "D019469", "tok_span": [21, 24]}, {"name": "ureteric calculi", "ent_type": "Disease", "char_span": [49, 65], "ent_id": "D014514", "tok_span": [9, 14]}, {"name": "HIV-infected", "ent_type": "Disease", "char_span": [73, 85], "ent_id": "D015658", "tok_span": [16, 19]}, {"name": "urolithiasis", "ent_type": "Disease", "char_span": [214, 226], "ent_id": "D052878", "tok_span": [41, 45]}], "relation_list": [{"subject": "indinavir", "object": "ureteric calculi", "sbj_char_span": [105, 114], "obj_char_span": [49, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [9, 14]}], "umls_entity_list": []}, {"text": "Ischemic colitis and sumatriptan use.", "entity_list": [{"name": "Ischemic colitis", "ent_type": "Disease", "char_span": [0, 16], "ent_id": "D017091", "tok_span": [0, 4]}, {"name": "sumatriptan", "ent_type": "Chemical", "char_span": [21, 32], "ent_id": "D018170", "tok_span": [5, 9]}], "relation_list": [{"subject": "sumatriptan", "object": "Ischemic colitis", "sbj_char_span": [21, 32], "obj_char_span": [0, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with sumatriptan.", "entity_list": [{"name": "sumatriptan", "ent_type": "Chemical", "char_span": [107, 118], "ent_id": "D018170", "tok_span": [18, 22]}, {"name": "ischemic colitis", "ent_type": "Disease", "char_span": [51, 67], "ent_id": "D017091", "tok_span": [10, 12]}, {"name": "migraine", "ent_type": "Disease", "char_span": [85, 93], "ent_id": "D008881", "tok_span": [15, 16]}], "relation_list": [{"subject": "sumatriptan", "object": "ischemic colitis", "sbj_char_span": [107, 118], "obj_char_span": [51, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Pallidotomy with the gamma knife: a positive experience.\n 51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [263, 274], "ent_id": "D004409", "tok_span": [60, 64]}, {"name": "bradykinesia", "ent_type": "Disease", "char_span": [220, 232], "ent_id": "D018476", "tok_span": [45, 50]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [96, 115], "ent_id": "D010300", "tok_span": [20, 24]}, {"name": "L-DOPA", "ent_type": "Chemical", "char_span": [248, 254], "ent_id": "D007980", "tok_span": [54, 58]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [234, 242], "ent_id": "D009127", "tok_span": [51, 52]}], "relation_list": [{"subject": "L-DOPA", "object": "dyskinesias", "sbj_char_span": [248, 254], "obj_char_span": [263, 274], "rel_type": "chemical-induced disease", "sbj_tok_span": [54, 58], "obj_tok_span": [60, 64]}], "umls_entity_list": []}, {"text": "Neuroleptic malignant syndrome and methylphenidate.", "entity_list": [{"name": "methylphenidate", "ent_type": "Chemical", "char_span": [35, 50], "ent_id": "D008774", "tok_span": [5, 8]}, {"name": "Neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [0, 30], "ent_id": "D009459", "tok_span": [0, 4]}], "relation_list": [{"subject": "methylphenidate", "object": "Neuroleptic malignant syndrome", "sbj_char_span": [35, 50], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "A 1-year-old female presented with neuroleptic malignant syndrome probably caused by methylphenidate.", "entity_list": [{"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [35, 65], "ent_id": "D009459", "tok_span": [9, 15]}, {"name": "methylphenidate", "ent_type": "Chemical", "char_span": [85, 100], "ent_id": "D008774", "tok_span": [18, 21]}], "relation_list": [{"subject": "methylphenidate", "object": "neuroleptic malignant syndrome", "sbj_char_span": [85, 100], "obj_char_span": [35, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [9, 15]}], "umls_entity_list": []}, {"text": "This is the first reported patient with neuroleptic malignant syndrome probably caused by methylphenidate.", "entity_list": [{"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [40, 70], "ent_id": "D009459", "tok_span": [7, 13]}, {"name": "methylphenidate", "ent_type": "Chemical", "char_span": [90, 105], "ent_id": "D008774", "tok_span": [16, 19]}], "relation_list": [{"subject": "methylphenidate", "object": "neuroleptic malignant syndrome", "sbj_char_span": [90, 105], "obj_char_span": [40, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [7, 13]}], "umls_entity_list": []}, {"text": "This study shows that 17alpha-ethinylestradiol (EE)-induced intrahepatic cholestasis in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis.", "entity_list": [{"name": "bile salt", "ent_type": "Chemical", "char_span": [159, 168], "ent_id": "D001647", "tok_span": [35, 37]}, {"name": "BS", "ent_type": "Chemical", "char_span": [170, 172], "ent_id": "D001647", "tok_span": [38, 39]}, {"name": "EE", "ent_type": "Chemical", "char_span": [48, 50], "ent_id": "D004997", "tok_span": [14, 15]}, {"name": "17alpha-ethinylestradiol", "ent_type": "Chemical", "char_span": [22, 46], "ent_id": "D004997", "tok_span": [4, 13]}, {"name": "intrahepatic cholestasis", "ent_type": "Disease", "char_span": [60, 84], "ent_id": "D002780", "tok_span": [18, 23]}], "relation_list": [{"subject": "17alpha-ethinylestradiol", "object": "intrahepatic cholestasis", "sbj_char_span": [22, 46], "obj_char_span": [60, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 13], "obj_tok_span": [18, 23]}, {"subject": "EE", "object": "intrahepatic cholestasis", "sbj_char_span": [48, 50], "obj_char_span": [60, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [18, 23]}], "umls_entity_list": []}, {"text": "Glibenclamide-sensitive hypotension produced by helodermin assessed in the rat.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [24, 35], "ent_id": "D007022", "tok_span": [6, 7]}, {"name": "Glibenclamide", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D005905", "tok_span": [0, 4]}, {"name": "helodermin", "ent_type": "Chemical", "char_span": [48, 58], "ent_id": "C040442", "tok_span": [9, 12]}], "relation_list": [{"subject": "helodermin", "object": "hypotension", "sbj_char_span": [48, 58], "obj_char_span": [24, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Helodermin produced hypotension in a dose-dependent manner with approximately similar potency and duration to VIP.", "entity_list": [{"name": "Helodermin", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "C040442", "tok_span": [0, 3]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [20, 31], "ent_id": "D007022", "tok_span": [4, 5]}], "relation_list": [{"subject": "Helodermin", "object": "hypotension", "sbj_char_span": [0, 10], "obj_char_span": [20, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Hypotension induced by both peptides was significantly attenuated by glibenclamide, which abolished a levcromakalim-produced decrease in arterial blood pressure.", "entity_list": [{"name": "glibenclamide", "ent_type": "Chemical", "char_span": [69, 82], "ent_id": "D005905", "tok_span": [10, 14]}, {"name": "levcromakalim", "ent_type": "Chemical", "char_span": [102, 115], "ent_id": "D019806", "tok_span": [18, 23]}, {"name": "Hypotension", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D007022", "tok_span": [0, 2]}], "relation_list": [{"subject": "levcromakalim", "object": "Hypotension", "sbj_char_span": [102, 115], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 23], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.", "entity_list": [{"name": "acetylcholine", "ent_type": "Chemical", "char_span": [98, 111], "ent_id": "D000109", "tok_span": [20, 21]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [48, 59], "ent_id": "D007022", "tok_span": [12, 13]}, {"name": "helodermin", "ent_type": "Chemical", "char_span": [29, 39], "ent_id": "C040442", "tok_span": [7, 10]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [127, 138], "ent_id": "D007022", "tok_span": [26, 27]}, {"name": "ACh", "ent_type": "Chemical", "char_span": [113, 116], "ent_id": "D000109", "tok_span": [22, 23]}], "relation_list": [{"subject": "acetylcholine", "object": "hypotension", "sbj_char_span": [98, 111], "obj_char_span": [48, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [12, 13]}, {"subject": "helodermin", "object": "hypotension", "sbj_char_span": [29, 39], "obj_char_span": [127, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [26, 27]}, {"subject": "ACh", "object": "hypotension", "sbj_char_span": [113, 116], "obj_char_span": [48, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [12, 13]}, {"subject": "ACh", "object": "hypotension", "sbj_char_span": [113, 116], "obj_char_span": [127, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [26, 27]}, {"subject": "helodermin", "object": "hypotension", "sbj_char_span": [29, 39], "obj_char_span": [48, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 13]}, {"subject": "acetylcholine", "object": "hypotension", "sbj_char_span": [98, 111], "obj_char_span": [127, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [48, 59], "ent_id": "D007022", "tok_span": [9, 10]}, {"name": "K", "ent_type": "Chemical", "char_span": [141, 142], "ent_id": "D011188", "tok_span": [27, 28]}, {"name": "helodermin", "ent_type": "Chemical", "char_span": [28, 38], "ent_id": "C040442", "tok_span": [4, 7]}, {"name": "K", "ent_type": "Chemical", "char_span": [128, 129], "ent_id": "D011188", "tok_span": [23, 24]}, {"name": "ATP", "ent_type": "Chemical", "char_span": [143, 146], "ent_id": "D000255", "tok_span": [29, 30]}, {"name": "glibenclamide", "ent_type": "Chemical", "char_span": [104, 117], "ent_id": "D005905", "tok_span": [17, 21]}], "relation_list": [{"subject": "helodermin", "object": "hypotension", "sbj_char_span": [28, 38], "obj_char_span": [48, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.", "entity_list": [{"name": "cyclosporin A", "ent_type": "Chemical", "char_span": [81, 94], "ent_id": "D016572", "tok_span": [16, 19]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [103, 115], "ent_id": "D006973", "tok_span": [21, 22]}, {"name": "psoriasis", "ent_type": "Disease", "char_span": [133, 142], "ent_id": "D011565", "tok_span": [25, 26]}, {"name": "nifedipine", "ent_type": "Chemical", "char_span": [40, 50], "ent_id": "D009543", "tok_span": [8, 11]}], "relation_list": [{"subject": "cyclosporin A", "object": "hypertension", "sbj_char_span": [81, 94], "obj_char_span": [103, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.", "entity_list": [{"name": "calcium", "ent_type": "Chemical", "char_span": [123, 130], "ent_id": "D002118", "tok_span": [24, 25]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [33, 45], "ent_id": "D006973", "tok_span": [8, 9]}, {"name": "psoriatic", "ent_type": "Disease", "char_span": [9, 18], "ent_id": "D011565", "tok_span": [3, 6]}, {"name": "nifedipine", "ent_type": "Chemical", "char_span": [166, 176], "ent_id": "D009543", "tok_span": [31, 34]}, {"name": "cyclosporin A", "ent_type": "Chemical", "char_span": [67, 80], "ent_id": "D016572", "tok_span": [13, 16]}], "relation_list": [{"subject": "cyclosporin A", "object": "hypertension", "sbj_char_span": [67, 80], "obj_char_span": [33, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy.", "entity_list": [{"name": "hypertensive", "ent_type": "Disease", "char_span": [53, 65], "ent_id": "D006973", "tok_span": [9, 10]}, {"name": "cyclosporin A", "ent_type": "Chemical", "char_span": [79, 92], "ent_id": "D016572", "tok_span": [12, 15]}], "relation_list": [{"subject": "cyclosporin A", "object": "hypertensive", "sbj_char_span": [79, 92], "obj_char_span": [53, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients.", "entity_list": [{"name": "blood urea nitrogen", "ent_type": "Chemical", "char_span": [101, 120], "ent_id": "D001806", "tok_span": [18, 21]}, {"name": "nifedipine", "ent_type": "Chemical", "char_span": [66, 76], "ent_id": "D009543", "tok_span": [11, 14]}, {"name": "cyclosporin A", "ent_type": "Chemical", "char_span": [48, 61], "ent_id": "D016572", "tok_span": [7, 10]}, {"name": "gingival hyperplasia", "ent_type": "Disease", "char_span": [171, 191], "ent_id": "D005885", "tok_span": [31, 33]}], "relation_list": [{"subject": "nifedipine", "object": "gingival hyperplasia", "sbj_char_span": [66, 76], "obj_char_span": [171, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [31, 33]}, {"subject": "cyclosporin A", "object": "gingival hyperplasia", "sbj_char_span": [48, 61], "obj_char_span": [171, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.", "entity_list": [{"name": "cyclosporin A", "ent_type": "Chemical", "char_span": [133, 146], "ent_id": "D016572", "tok_span": [24, 27]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [70, 82], "ent_id": "D006973", "tok_span": [13, 14]}, {"name": "nifedipine", "ent_type": "Chemical", "char_span": [45, 55], "ent_id": "D009543", "tok_span": [7, 10]}, {"name": "gingival hyperplasia", "ent_type": "Disease", "char_span": [196, 216], "ent_id": "D005885", "tok_span": [36, 38]}, {"name": "psoriatic", "ent_type": "Disease", "char_span": [83, 92], "ent_id": "D011565", "tok_span": [14, 17]}], "relation_list": [{"subject": "cyclosporin A", "object": "gingival hyperplasia", "sbj_char_span": [133, 146], "obj_char_span": [196, 216], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [36, 38]}, {"subject": "nifedipine", "object": "gingival hyperplasia", "sbj_char_span": [45, 55], "obj_char_span": [196, 216], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [36, 38]}, {"subject": "cyclosporin A", "object": "hypertensive", "sbj_char_span": [133, 146], "obj_char_span": [70, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.", "entity_list": [{"name": "Torsade de pointes", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D016171", "tok_span": [0, 6]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [72, 82], "ent_id": "D004280", "tok_span": [12, 15]}, {"name": "dilated cardiomyopathy", "ent_type": "Disease", "char_span": [111, 133], "ent_id": "D002311", "tok_span": [20, 22]}, {"name": "congestive heart failure", "ent_type": "Disease", "char_span": [138, 162], "ent_id": "D006333", "tok_span": [23, 28]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [19, 42], "ent_id": "D017180", "tok_span": [6, 8]}], "relation_list": [{"subject": "dobutamine", "object": "Torsade de pointes", "sbj_char_span": [72, 82], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "entity_list": [{"name": "QT prolongation", "ent_type": "Disease", "char_span": [189, 204], "ent_id": "D008133", "tok_span": [31, 34]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [228, 251], "ent_id": "D017180", "tok_span": [40, 42]}, {"name": "dilated cardiomyopathy", "ent_type": "Disease", "char_span": [101, 123], "ent_id": "D002311", "tok_span": [21, 23]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [315, 325], "ent_id": "D004280", "tok_span": [60, 63]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [209, 227], "ent_id": "D016171", "tok_span": [35, 40]}, {"name": "ventricular arrhythmias", "ent_type": "Disease", "char_span": [151, 174], "ent_id": "D001145", "tok_span": [27, 29]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [74, 87], "ent_id": "D006333", "tok_span": [17, 19]}], "relation_list": [{"subject": "dobutamine", "object": "torsade de pointes", "sbj_char_span": [315, 325], "obj_char_span": [209, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [60, 63], "obj_tok_span": [35, 40]}], "umls_entity_list": []}, {"text": "This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.", "entity_list": [{"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [34, 57], "ent_id": "D017180", "tok_span": [8, 10]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [138, 149], "ent_id": "D001145", "tok_span": [21, 22]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [15, 33], "ent_id": "D016171", "tok_span": [3, 8]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [78, 88], "ent_id": "D004280", "tok_span": [12, 15]}], "relation_list": [{"subject": "dobutamine", "object": "torsade de pointes", "sbj_char_span": [78, 88], "obj_char_span": [15, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [3, 8]}], "umls_entity_list": []}, {"text": "Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).", "entity_list": [{"name": "hyperammonemia", "ent_type": "Disease", "char_span": [54, 68], "ent_id": "D022124", "tok_span": [9, 13]}, {"name": "bacterial infections", "ent_type": "Disease", "char_span": [99, 119], "ent_id": "D001424", "tok_span": [19, 21]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [227, 231], "ent_id": "D005472", "tok_span": [56, 59]}, {"name": "ammonium", "ent_type": "Chemical", "char_span": [14, 22], "ent_id": "D000644", "tok_span": [2, 3]}], "relation_list": [{"subject": "5-FU", "object": "hyperammonemia", "sbj_char_span": [227, 231], "obj_char_span": [54, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [56, 59], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity. 3.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [184, 192], "ent_id": "D009020", "tok_span": [40, 41]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [112, 120], "ent_id": "D009020", "tok_span": [24, 25]}, {"name": "K", "ent_type": "Chemical", "char_span": [152, 153], "ent_id": "D011188", "tok_span": [32, 33]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [211, 224], "ent_id": "D006948", "tok_span": [44, 46]}, {"name": "hypoactivity", "ent_type": "Disease", "char_span": [129, 141], "ent_id": "D009069", "tok_span": [27, 29]}, {"name": "K", "ent_type": "Chemical", "char_span": [81, 82], "ent_id": "D011188", "tok_span": [16, 17]}], "relation_list": [{"subject": "morphine", "object": "hyperactivity", "sbj_char_span": [184, 192], "obj_char_span": [211, 224], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 41], "obj_tok_span": [44, 46]}, {"subject": "morphine", "object": "hyperactivity", "sbj_char_span": [112, 120], "obj_char_span": [211, 224], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [44, 46]}], "umls_entity_list": []}, {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity_list": [{"name": "K", "ent_type": "Chemical", "char_span": [251, 252], "ent_id": "D011188", "tok_span": [51, 52]}, {"name": "hypoactivity", "ent_type": "Disease", "char_span": [130, 142], "ent_id": "D009069", "tok_span": [26, 28]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [168, 181], "ent_id": "D006948", "tok_span": [32, 34]}, {"name": "quinine", "ent_type": "Chemical", "char_span": [212, 219], "ent_id": "D011803", "tok_span": [40, 42]}, {"name": "4-aminopyridine", "ent_type": "Chemical", "char_span": [225, 240], "ent_id": "D015761", "tok_span": [44, 49]}, {"name": "K", "ent_type": "Chemical", "char_span": [42, 43], "ent_id": "D011188", "tok_span": [8, 9]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [113, 121], "ent_id": "D009020", "tok_span": [23, 24]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [151, 159], "ent_id": "D009020", "tok_span": [29, 30]}], "relation_list": [{"subject": "morphine", "object": "hyperactivity", "sbj_char_span": [113, 121], "obj_char_span": [168, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [32, 34]}, {"subject": "morphine", "object": "hyperactivity", "sbj_char_span": [151, 159], "obj_char_span": [168, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [32, 34]}], "umls_entity_list": []}, {"text": "Meloxicam-induced liver toxicity.", "entity_list": [{"name": "Meloxicam", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "C065757", "tok_span": [0, 3]}, {"name": "liver toxicity", "ent_type": "Disease", "char_span": [18, 32], "ent_id": "D056486", "tok_span": [5, 7]}], "relation_list": [{"subject": "Meloxicam", "object": "liver toxicity", "sbj_char_span": [0, 9], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to meloxicam.", "entity_list": [{"name": "rheumatoid arthritis", "ent_type": "Disease", "char_span": [44, 64], "ent_id": "D001172", "tok_span": [9, 11]}, {"name": "meloxicam", "ent_type": "Chemical", "char_span": [112, 121], "ent_id": "C065757", "tok_span": [19, 22]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [95, 104], "ent_id": "D056486", "tok_span": [16, 17]}], "relation_list": [{"subject": "meloxicam", "object": "hepatitis", "sbj_char_span": [112, 121], "obj_char_span": [95, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism.", "entity_list": [{"name": "hypersensitivity", "ent_type": "Disease", "char_span": [157, 173], "ent_id": "D004342", "tok_span": [25, 27]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [20, 29], "ent_id": "D056486", "tok_span": [4, 5]}, {"name": "meloxicam", "ent_type": "Chemical", "char_span": [53, 62], "ent_id": "C065757", "tok_span": [8, 11]}], "relation_list": [{"subject": "meloxicam", "object": "hepatitis", "sbj_char_span": [53, 62], "obj_char_span": [20, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [4, 5]}, {"subject": "meloxicam", "object": "hypersensitivity", "sbj_char_span": [53, 62], "obj_char_span": [157, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "This first case of meloxicam related liver toxicity demonstrates the potential of this drug to induce hepatic damage.", "entity_list": [{"name": "meloxicam", "ent_type": "Chemical", "char_span": [19, 28], "ent_id": "C065757", "tok_span": [4, 7]}, {"name": "liver toxicity", "ent_type": "Disease", "char_span": [37, 51], "ent_id": "D056486", "tok_span": [8, 10]}, {"name": "hepatic damage", "ent_type": "Disease", "char_span": [102, 116], "ent_id": "D056486", "tok_span": [18, 20]}], "relation_list": [{"subject": "meloxicam", "object": "liver toxicity", "sbj_char_span": [19, 28], "obj_char_span": [37, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [8, 10]}, {"subject": "meloxicam", "object": "hepatic damage", "sbj_char_span": [19, 28], "obj_char_span": [102, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to remoxipride-induced aplastic anemia.", "entity_list": [{"name": "remoxipride", "ent_type": "Chemical", "char_span": [26, 37], "ent_id": "D017330", "tok_span": [4, 9]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [153, 168], "ent_id": "D000741", "tok_span": [37, 40]}, {"name": "remoxipride", "ent_type": "Chemical", "char_span": [133, 144], "ent_id": "D017330", "tok_span": [30, 35]}], "relation_list": [{"subject": "remoxipride", "object": "aplastic anemia", "sbj_char_span": [26, 37], "obj_char_span": [153, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 9], "obj_tok_span": [37, 40]}, {"subject": "remoxipride", "object": "aplastic anemia", "sbj_char_span": [133, 144], "obj_char_span": [153, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [37, 40]}], "umls_entity_list": []}, {"text": "The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired aplastic anemia.", "entity_list": [{"name": "remoxipride", "ent_type": "Chemical", "char_span": [25, 36], "ent_id": "D017330", "tok_span": [5, 10]}, {"name": "(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide", "ent_type": "Chemical", "char_span": [38, 112], "ent_id": "D017330", "tok_span": [11, 51]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [148, 163], "ent_id": "D000741", "tok_span": [57, 60]}], "relation_list": [{"subject": "remoxipride", "object": "aplastic anemia", "sbj_char_span": [25, 36], "obj_char_span": [148, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [57, 60]}, {"subject": "(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide", "object": "aplastic anemia", "sbj_char_span": [38, 112], "obj_char_span": [148, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 51], "obj_tok_span": [57, 60]}], "umls_entity_list": []}, {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity_list": [{"name": "aplastic anemia", "ent_type": "Disease", "char_span": [242, 257], "ent_id": "D000741", "tok_span": [49, 52]}, {"name": "benzene", "ent_type": "Chemical", "char_span": [32, 39], "ent_id": "D001554", "tok_span": [9, 10]}, {"name": "NCQ344", "ent_type": "Chemical", "char_span": [149, 155], "ent_id": "C112341", "tok_span": [31, 35]}, {"name": "remoxipride", "ent_type": "Chemical", "char_span": [288, 299], "ent_id": "D017330", "tok_span": [57, 62]}, {"name": "remoxipride", "ent_type": "Chemical", "char_span": [16, 27], "ent_id": "D017330", "tok_span": [3, 8]}, {"name": "NCQ436", "ent_type": "Chemical", "char_span": [138, 144], "ent_id": "C084325", "tok_span": [26, 30]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [51, 66], "ent_id": "D000741", "tok_span": [12, 15]}], "relation_list": [{"subject": "remoxipride", "object": "aplastic anemia", "sbj_char_span": [16, 27], "obj_char_span": [51, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [12, 15]}, {"subject": "remoxipride", "object": "aplastic anemia", "sbj_char_span": [288, 299], "obj_char_span": [242, 257], "rel_type": "chemical-induced disease", "sbj_tok_span": [57, 62], "obj_tok_span": [49, 52]}, {"subject": "remoxipride", "object": "aplastic anemia", "sbj_char_span": [16, 27], "obj_char_span": [242, 257], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [49, 52]}, {"subject": "benzene", "object": "aplastic anemia", "sbj_char_span": [32, 39], "obj_char_span": [51, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [12, 15]}, {"subject": "remoxipride", "object": "aplastic anemia", "sbj_char_span": [288, 299], "obj_char_span": [51, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [57, 62], "obj_tok_span": [12, 15]}, {"subject": "benzene", "object": "aplastic anemia", "sbj_char_span": [32, 39], "obj_char_span": [242, 257], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [49, 52]}], "umls_entity_list": []}, {"text": "Compound 7e, 5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy dro-1H- indol-2-one, from this series showed significant affinities at the 5-HT1A and 5-HT2A receptors and moderate affinity at the D2 receptor. 7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [277, 288], "ent_id": "D006220", "tok_span": [96, 99]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [256, 265], "ent_id": "D002375", "tok_span": [91, 94]}, {"name": "5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy dro-1H- indol-2-one", "ent_type": "Chemical", "char_span": [13, 99], "ent_id": "-1", "tok_span": [4, 54]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [277, 288], "obj_char_span": [256, 265], "rel_type": "chemical-induced disease", "sbj_tok_span": [96, 99], "obj_tok_span": [91, 94]}], "umls_entity_list": []}, {"text": "Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [58, 69], "ent_id": "D006220", "tok_span": [10, 13]}, {"name": "nitric-oxide", "ent_type": "Chemical", "char_span": [26, 38], "ent_id": "D009569", "tok_span": [5, 8]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [78, 87], "ent_id": "D002375", "tok_span": [15, 18]}, {"name": "NADPH", "ent_type": "Chemical", "char_span": [106, 111], "ent_id": "D009249", "tok_span": [22, 23]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [58, 69], "obj_char_span": [78, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Neuroleptic drugs such as haloperidol, which block dopamine receptors, also cause catalepsy in rodents.", "entity_list": [{"name": "dopamine", "ent_type": "Chemical", "char_span": [51, 59], "ent_id": "D004298", "tok_span": [11, 12]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [26, 37], "ent_id": "D006220", "tok_span": [5, 8]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [82, 91], "ent_id": "D002375", "tok_span": [16, 19]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [26, 37], "obj_char_span": [82, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "OBJECTIVES: To investigate the effects of subchronic L-NOARG treatment in haloperidol-induced catalepsy and the number of NOS neurons in areas related to motor control.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [94, 103], "ent_id": "D002375", "tok_span": [22, 25]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [74, 85], "ent_id": "D006220", "tok_span": [17, 20]}, {"name": "L-NOARG", "ent_type": "Chemical", "char_span": [53, 60], "ent_id": "D019335", "tok_span": [10, 15]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [74, 85], "obj_char_span": [94, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "RESULTS: L-NOARG sub-chronic administration produced tolerance of L-NOARG and of haloperidol-induced catalepsy.", "entity_list": [{"name": "L-NOARG", "ent_type": "Chemical", "char_span": [9, 16], "ent_id": "D019335", "tok_span": [2, 7]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [81, 92], "ent_id": "D006220", "tok_span": [21, 24]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [101, 110], "ent_id": "D002375", "tok_span": [26, 29]}, {"name": "L-NOARG", "ent_type": "Chemical", "char_span": [66, 73], "ent_id": "D019335", "tok_span": [14, 19]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [81, 92], "obj_char_span": [101, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.", "entity_list": [{"name": "left ventricular dysfunction", "ent_type": "Disease", "char_span": [10, 38], "ent_id": "D018487", "tok_span": [3, 6]}, {"name": "myocardial ischaemia", "ent_type": "Disease", "char_span": [130, 150], "ent_id": "D017202", "tok_span": [21, 24]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [98, 108], "ent_id": "D004280", "tok_span": [15, 18]}, {"name": "coronary artery disease", "ent_type": "Disease", "char_span": [63, 86], "ent_id": "D003324", "tok_span": [10, 13]}], "relation_list": [{"subject": "dobutamine", "object": "left ventricular dysfunction", "sbj_char_span": [98, 108], "obj_char_span": [10, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.", "entity_list": [{"name": "left ventricular dysfunction", "ent_type": "Disease", "char_span": [116, 144], "ent_id": "D018487", "tok_span": [19, 22]}, {"name": "myocardial stunning", "ent_type": "Disease", "char_span": [161, 180], "ent_id": "D017682", "tok_span": [26, 29]}, {"name": "ischaemia", "ent_type": "Disease", "char_span": [74, 83], "ent_id": "D007511", "tok_span": [13, 15]}, {"name": "coronary artery disease", "ent_type": "Disease", "char_span": [30, 53], "ent_id": "D003324", "tok_span": [5, 8]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [55, 65], "ent_id": "D004280", "tok_span": [9, 12]}], "relation_list": [{"subject": "dobutamine", "object": "myocardial stunning", "sbj_char_span": [55, 65], "obj_char_span": [161, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [26, 29]}, {"subject": "dobutamine", "object": "left ventricular dysfunction", "sbj_char_span": [55, 65], "obj_char_span": [116, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "However, of the medications surveyed, only the fenfluramines had a significant preferential association with PPH as compared with SPH (adjusted odds ratio for use > 6 months, 7.5; 95% confidence interval, 1.7 to 32.4).", "entity_list": [{"name": "fenfluramines", "ent_type": "Chemical", "char_span": [47, 60], "ent_id": "D005277", "tok_span": [9, 15]}, {"name": "PPH", "ent_type": "Disease", "char_span": [109, 112], "ent_id": "D006976", "tok_span": [21, 23]}], "relation_list": [{"subject": "fenfluramines", "object": "PPH", "sbj_char_span": [47, 60], "obj_char_span": [109, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 15], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "CONCLUSION: The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH.", "entity_list": [{"name": "PPH", "ent_type": "Disease", "char_span": [245, 248], "ent_id": "D006976", "tok_span": [49, 51]}, {"name": "PPH", "ent_type": "Disease", "char_span": [50, 53], "ent_id": "D006976", "tok_span": [8, 10]}, {"name": "fenfluramines", "ent_type": "Chemical", "char_span": [140, 153], "ent_id": "D005277", "tok_span": [25, 31]}, {"name": "fenfluramines", "ent_type": "Chemical", "char_span": [207, 220], "ent_id": "D005277", "tok_span": [38, 44]}], "relation_list": [{"subject": "fenfluramines", "object": "PPH", "sbj_char_span": [207, 220], "obj_char_span": [245, 248], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 44], "obj_tok_span": [49, 51]}, {"subject": "fenfluramines", "object": "PPH", "sbj_char_span": [140, 153], "obj_char_span": [50, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 31], "obj_tok_span": [8, 10]}, {"subject": "fenfluramines", "object": "PPH", "sbj_char_span": [140, 153], "obj_char_span": [245, 248], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 31], "obj_tok_span": [49, 51]}, {"subject": "fenfluramines", "object": "PPH", "sbj_char_span": [207, 220], "obj_char_span": [50, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 44], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy.", "entity_list": [{"name": "thrombosis", "ent_type": "Disease", "char_span": [57, 67], "ent_id": "D013927", "tok_span": [9, 10]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [20, 27], "ent_id": "D006493", "tok_span": [3, 4]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [36, 52], "ent_id": "D013921", "tok_span": [6, 8]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [94, 101], "ent_id": "D006493", "tok_span": [15, 16]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [20, 27], "obj_char_span": [36, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [6, 8]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [94, 101], "obj_char_span": [36, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity_list": [{"name": "hyperkalemia", "ent_type": "Disease", "char_span": [246, 258], "ent_id": "D006947", "tok_span": [44, 48]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [108, 115], "ent_id": "D006493", "tok_span": [18, 19]}, {"name": "osteoporosis", "ent_type": "Disease", "char_span": [127, 139], "ent_id": "D010024", "tok_span": [21, 22]}, {"name": "allergic reactions", "ent_type": "Disease", "char_span": [171, 189], "ent_id": "D004342", "tok_span": [29, 31]}, {"name": "hypoaldosteronism", "ent_type": "Disease", "char_span": [260, 277], "ent_id": "D006994", "tok_span": [49, 54]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [50, 57], "ent_id": "D006493", "tok_span": [9, 10]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [74, 81], "ent_id": "D006493", "tok_span": [12, 13]}, {"name": "eosinophilia", "ent_type": "Disease", "char_span": [141, 153], "ent_id": "D004802", "tok_span": [23, 25]}, {"name": "priapism", "ent_type": "Disease", "char_span": [283, 291], "ent_id": "D011317", "tok_span": [56, 59]}, {"name": "alopecia", "ent_type": "Disease", "char_span": [219, 227], "ent_id": "D000505", "tok_span": [36, 39]}, {"name": "skin reactions", "ent_type": "Disease", "char_span": [155, 169], "ent_id": "D012871", "tok_span": [26, 28]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [90, 106], "ent_id": "D013921", "tok_span": [15, 17]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [201, 217], "ent_id": "D013921", "tok_span": [33, 35]}], "relation_list": [{"subject": "heparin", "object": "allergic reactions", "sbj_char_span": [74, 81], "obj_char_span": [171, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [29, 31]}, {"subject": "heparin", "object": "hypoaldosteronism", "sbj_char_span": [74, 81], "obj_char_span": [260, 277], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [49, 54]}, {"subject": "heparin", "object": "osteoporosis", "sbj_char_span": [108, 115], "obj_char_span": [127, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [21, 22]}, {"subject": "heparin", "object": "alopecia", "sbj_char_span": [50, 57], "obj_char_span": [219, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [36, 39]}, {"subject": "heparin", "object": "skin reactions", "sbj_char_span": [50, 57], "obj_char_span": [155, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [26, 28]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [108, 115], "obj_char_span": [201, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [33, 35]}, {"subject": "heparin", "object": "skin reactions", "sbj_char_span": [74, 81], "obj_char_span": [155, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [26, 28]}, {"subject": "heparin", "object": "hyperkalemia", "sbj_char_span": [50, 57], "obj_char_span": [246, 258], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [44, 48]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [108, 115], "obj_char_span": [90, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [15, 17]}, {"subject": "heparin", "object": "eosinophilia", "sbj_char_span": [74, 81], "obj_char_span": [141, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [23, 25]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [50, 57], "obj_char_span": [201, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [33, 35]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [74, 81], "obj_char_span": [90, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 17]}, {"subject": "heparin", "object": "osteoporosis", "sbj_char_span": [50, 57], "obj_char_span": [127, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [21, 22]}, {"subject": "heparin", "object": "priapism", "sbj_char_span": [74, 81], "obj_char_span": [283, 291], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [56, 59]}, {"subject": "heparin", "object": "hypoaldosteronism", "sbj_char_span": [108, 115], "obj_char_span": [260, 277], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [49, 54]}, {"subject": "heparin", "object": "alopecia", "sbj_char_span": [108, 115], "obj_char_span": [219, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [36, 39]}, {"subject": "heparin", "object": "priapism", "sbj_char_span": [50, 57], "obj_char_span": [283, 291], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [56, 59]}, {"subject": "heparin", "object": "allergic reactions", "sbj_char_span": [50, 57], "obj_char_span": [171, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [29, 31]}, {"subject": "heparin", "object": "hyperkalemia", "sbj_char_span": [108, 115], "obj_char_span": [246, 258], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [44, 48]}, {"subject": "heparin", "object": "eosinophilia", "sbj_char_span": [50, 57], "obj_char_span": [141, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [23, 25]}, {"subject": "heparin", "object": "allergic reactions", "sbj_char_span": [108, 115], "obj_char_span": [171, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [29, 31]}, {"subject": "heparin", "object": "osteoporosis", "sbj_char_span": [74, 81], "obj_char_span": [127, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [21, 22]}, {"subject": "heparin", "object": "alopecia", "sbj_char_span": [74, 81], "obj_char_span": [219, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [36, 39]}, {"subject": "heparin", "object": "skin reactions", "sbj_char_span": [108, 115], "obj_char_span": [155, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [26, 28]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [50, 57], "obj_char_span": [90, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [15, 17]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [74, 81], "obj_char_span": [201, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [33, 35]}, {"subject": "heparin", "object": "eosinophilia", "sbj_char_span": [108, 115], "obj_char_span": [141, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [23, 25]}, {"subject": "heparin", "object": "hypoaldosteronism", "sbj_char_span": [50, 57], "obj_char_span": [260, 277], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [49, 54]}, {"subject": "heparin", "object": "priapism", "sbj_char_span": [108, 115], "obj_char_span": [283, 291], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [56, 59]}, {"subject": "heparin", "object": "hyperkalemia", "sbj_char_span": [74, 81], "obj_char_span": [246, 258], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "These side effects are relatively rare in a given individual, but given the extremely widespread use of heparin, some are quite common, particularly HITT and osteoporosis.", "entity_list": [{"name": "HITT", "ent_type": "Disease", "char_span": [149, 153], "ent_id": "D01392", "tok_span": [26, 28]}, {"name": "osteoporosis", "ent_type": "Disease", "char_span": [158, 170], "ent_id": "D010024", "tok_span": [29, 30]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [104, 111], "ent_id": "D006493", "tok_span": [18, 19]}], "relation_list": [{"subject": "heparin", "object": "osteoporosis", "sbj_char_span": [104, 111], "obj_char_span": [158, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "A case of bilateral optic neuropathy in a patient on tacrolimus (FK506) therapy after liver transplantation.", "entity_list": [{"name": "FK506", "ent_type": "Chemical", "char_span": [65, 70], "ent_id": "D016559", "tok_span": [13, 15]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [53, 63], "ent_id": "D016559", "tok_span": [10, 12]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [20, 36], "ent_id": "D009901", "tok_span": [4, 6]}], "relation_list": [{"subject": "tacrolimus", "object": "optic neuropathy", "sbj_char_span": [53, 63], "obj_char_span": [20, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [4, 6]}, {"subject": "FK506", "object": "optic neuropathy", "sbj_char_span": [65, 70], "obj_char_span": [20, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "PURPOSE: To report a case of bilateral optic neuropathy in a patient receiving tacrolimus (FK 506, Prograf; Fujisawa USA, Inc, Deerfield, Illinois) for immunosuppression after orthotropic liver transplantation.", "entity_list": [{"name": "optic neuropathy", "ent_type": "Disease", "char_span": [39, 55], "ent_id": "D009901", "tok_span": [8, 10]}, {"name": "FK 506", "ent_type": "Chemical", "char_span": [91, 97], "ent_id": "D016559", "tok_span": [17, 20]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [79, 89], "ent_id": "D016559", "tok_span": [14, 16]}], "relation_list": [{"subject": "tacrolimus", "object": "optic neuropathy", "sbj_char_span": [79, 89], "obj_char_span": [39, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [8, 10]}, {"subject": "FK 506", "object": "optic neuropathy", "sbj_char_span": [91, 97], "obj_char_span": [39, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "CONCLUSION: Tacrolimus and other immunosuppressive agents may be associated with optic nerve toxicity.", "entity_list": [{"name": "Tacrolimus", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D016559", "tok_span": [2, 6]}, {"name": "optic nerve toxicity", "ent_type": "Disease", "char_span": [81, 101], "ent_id": "D009901", "tok_span": [15, 18]}], "relation_list": [{"subject": "Tacrolimus", "object": "optic nerve toxicity", "sbj_char_span": [12, 22], "obj_char_span": [81, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity_list": [{"name": "hypercalcemia", "ent_type": "Disease", "char_span": [228, 241], "ent_id": "D006934", "tok_span": [37, 40]}, {"name": "bradyarrhythmia", "ent_type": "Disease", "char_span": [114, 129], "ent_id": "D001919", "tok_span": [17, 22]}, {"name": "bipolar", "ent_type": "Disease", "char_span": [187, 194], "ent_id": "D001714", "tok_span": [31, 32]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [59, 66], "ent_id": "D008094", "tok_span": [8, 9]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [209, 216], "ent_id": "D008094", "tok_span": [34, 35]}, {"name": "bipolar", "ent_type": "Disease", "char_span": [21, 28], "ent_id": "D001714", "tok_span": [4, 5]}, {"name": "hypercalcemia", "ent_type": "Disease", "char_span": [89, 102], "ent_id": "D006934", "tok_span": [12, 15]}], "relation_list": [{"subject": "lithium", "object": "hypercalcemia", "sbj_char_span": [59, 66], "obj_char_span": [228, 241], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [37, 40]}, {"subject": "lithium", "object": "hypercalcemia", "sbj_char_span": [59, 66], "obj_char_span": [89, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [12, 15]}, {"subject": "lithium", "object": "hypercalcemia", "sbj_char_span": [209, 216], "obj_char_span": [89, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [12, 15]}, {"subject": "lithium", "object": "hypercalcemia", "sbj_char_span": [209, 216], "obj_char_span": [228, 241], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [37, 40]}], "umls_entity_list": []}, {"text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [117, 124], "ent_id": "D008094", "tok_span": [20, 21]}, {"name": "hypercalcemia", "ent_type": "Disease", "char_span": [265, 278], "ent_id": "D006934", "tok_span": [47, 50]}, {"name": "malignancies", "ent_type": "Disease", "char_span": [173, 185], "ent_id": "D009369", "tok_span": [31, 32]}, {"name": "hypercalcemias", "ent_type": "Disease", "char_span": [27, 41], "ent_id": "D006934", "tok_span": [3, 7]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [246, 253], "ent_id": "D008094", "tok_span": [44, 45]}, {"name": "hypercalcemias", "ent_type": "Disease", "char_span": [147, 161], "ent_id": "D006934", "tok_span": [25, 29]}], "relation_list": [{"subject": "lithium", "object": "hypercalcemias", "sbj_char_span": [246, 253], "obj_char_span": [147, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [25, 29]}, {"subject": "lithium", "object": "hypercalcemias", "sbj_char_span": [117, 124], "obj_char_span": [27, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [3, 7]}, {"subject": "lithium", "object": "hypercalcemias", "sbj_char_span": [246, 253], "obj_char_span": [27, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [3, 7]}, {"subject": "lithium", "object": "hypercalcemia", "sbj_char_span": [246, 253], "obj_char_span": [265, 278], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [47, 50]}, {"subject": "lithium", "object": "hypercalcemia", "sbj_char_span": [117, 124], "obj_char_span": [265, 278], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [47, 50]}, {"subject": "lithium", "object": "hypercalcemias", "sbj_char_span": [117, 124], "obj_char_span": [147, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Patients with hypercalcemia resulting from medical diseases and bipolar patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.", "entity_list": [{"name": "bipolar", "ent_type": "Disease", "char_span": [64, 71], "ent_id": "D001714", "tok_span": [10, 11]}, {"name": "hypercalcemia", "ent_type": "Disease", "char_span": [14, 27], "ent_id": "D006934", "tok_span": [2, 5]}, {"name": "hypercalcemia", "ent_type": "Disease", "char_span": [105, 118], "ent_id": "D006934", "tok_span": [16, 19]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [86, 93], "ent_id": "D008094", "tok_span": [13, 14]}], "relation_list": [{"subject": "lithium", "object": "hypercalcemia", "sbj_char_span": [86, 93], "obj_char_span": [105, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [16, 19]}, {"subject": "lithium", "object": "hypercalcemia", "sbj_char_span": [86, 93], "obj_char_span": [14, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Histopathological examination of the kidney showed tubular necrosis in D-AmB-treated rats but no change in NS-718-treated rats.", "entity_list": [{"name": "D-AmB", "ent_type": "Chemical", "char_span": [71, 76], "ent_id": "C059765", "tok_span": [10, 14]}, {"name": "tubular necrosis", "ent_type": "Disease", "char_span": [51, 67], "ent_id": "D007683", "tok_span": [7, 9]}], "relation_list": [{"subject": "D-AmB", "object": "tubular necrosis", "sbj_char_span": [71, 76], "obj_char_span": [51, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Patterns of sulfadiazine acute nephrotoxicity.", "entity_list": [{"name": "acute nephrotoxicity", "ent_type": "Disease", "char_span": [25, 45], "ent_id": "D058186", "tok_span": [5, 9]}, {"name": "sulfadiazine", "ent_type": "Chemical", "char_span": [12, 24], "ent_id": "D013411", "tok_span": [2, 5]}], "relation_list": [{"subject": "sulfadiazine", "object": "acute nephrotoxicity", "sbj_char_span": [12, 24], "obj_char_span": [25, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Sulfadiazine acute nephrotoxicity is reviving specially because of its use in toxoplasmosis in HIV-positive patients.", "entity_list": [{"name": "Sulfadiazine", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D013411", "tok_span": [0, 3]}, {"name": "acute nephrotoxicity", "ent_type": "Disease", "char_span": [13, 33], "ent_id": "D058186", "tok_span": [3, 7]}, {"name": "toxoplasmosis", "ent_type": "Disease", "char_span": [78, 91], "ent_id": "D014123", "tok_span": [16, 19]}], "relation_list": [{"subject": "Sulfadiazine", "object": "acute nephrotoxicity", "sbj_char_span": [0, 12], "obj_char_span": [13, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.", "entity_list": [{"name": "renal calculi", "ent_type": "Disease", "char_span": [121, 134], "ent_id": "D007669", "tok_span": [22, 25]}, {"name": "sulfadiazine", "ent_type": "Chemical", "char_span": [21, 33], "ent_id": "D013411", "tok_span": [3, 6]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [75, 88], "ent_id": "D051437", "tok_span": [14, 16]}, {"name": "oliguria", "ent_type": "Disease", "char_span": [49, 57], "ent_id": "D009846", "tok_span": [8, 10]}, {"name": "abdominal pain", "ent_type": "Disease", "char_span": [59, 73], "ent_id": "D015746", "tok_span": [11, 13]}], "relation_list": [{"subject": "sulfadiazine", "object": "renal calculi", "sbj_char_span": [21, 33], "obj_char_span": [121, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "Downbeat nystagmus associated with intravenous patient-controlled administration of morphine.", "entity_list": [{"name": "Downbeat nystagmus", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D009759", "tok_span": [0, 7]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [84, 92], "ent_id": "D009020", "tok_span": [15, 16]}], "relation_list": [{"subject": "morphine", "object": "Downbeat nystagmus", "sbj_char_span": [84, 92], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [0, 7]}], "umls_entity_list": []}, {"text": "IMPLICATIONS: This case documents a patient who developed dizziness with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia morphine.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [170, 178], "ent_id": "D009020", "tok_span": [36, 37]}, {"name": "dizziness", "ent_type": "Disease", "char_span": [58, 67], "ent_id": "D004244", "tok_span": [13, 16]}, {"name": "downbeating nystagmus", "ent_type": "Disease", "char_span": [73, 94], "ent_id": "D009759", "tok_span": [17, 24]}], "relation_list": [{"subject": "morphine", "object": "downbeating nystagmus", "sbj_char_span": [170, 178], "obj_char_span": [73, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 37], "obj_tok_span": [17, 24]}, {"subject": "morphine", "object": "dizziness", "sbj_char_span": [170, 178], "obj_char_span": [58, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 37], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.", "entity_list": [{"name": "tachycardia", "ent_type": "Disease", "char_span": [149, 160], "ent_id": "D013610", "tok_span": [32, 33]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [21, 31], "ent_id": "D000638", "tok_span": [6, 10]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [75, 86], "ent_id": "D013610", "tok_span": [16, 17]}, {"name": "dronedarone", "ent_type": "Chemical", "char_span": [5, 16], "ent_id": "C118667", "tok_span": [1, 5]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [127, 140], "ent_id": "D007545", "tok_span": [26, 30]}], "relation_list": [{"subject": "isoproterenol", "object": "tachycardia", "sbj_char_span": [127, 140], "obj_char_span": [75, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [16, 17]}, {"subject": "isoproterenol", "object": "tachycardia", "sbj_char_span": [127, 140], "obj_char_span": [149, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [32, 33]}], "umls_entity_list": []}, {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity_list": [{"name": "toxicity", "ent_type": "Disease", "char_span": [170, 178], "ent_id": "D064420", "tok_span": [32, 33]}, {"name": "hand-foot syndrome", "ent_type": "Disease", "char_span": [267, 285], "ent_id": "D060831", "tok_span": [59, 63]}, {"name": "ovarian cancer", "ent_type": "Disease", "char_span": [135, 149], "ent_id": "D010051", "tok_span": [26, 28]}, {"name": "stomatitis", "ent_type": "Disease", "char_span": [292, 302], "ent_id": "D013280", "tok_span": [66, 68]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [56, 67], "ent_id": "D004317", "tok_span": [8, 9]}, {"name": "erythrodysesthesia", "ent_type": "Disease", "char_span": [246, 264], "ent_id": "D060831", "tok_span": [52, 57]}, {"name": "Doxil", "ent_type": "Chemical", "char_span": [69, 74], "ent_id": "D004317", "tok_span": [10, 13]}, {"name": "platinum", "ent_type": "Chemical", "char_span": [116, 124], "ent_id": "D010984", "tok_span": [23, 24]}], "relation_list": [{"subject": "doxorubicin", "object": "erythrodysesthesia", "sbj_char_span": [56, 67], "obj_char_span": [246, 264], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [52, 57]}, {"subject": "Doxil", "object": "erythrodysesthesia", "sbj_char_span": [69, 74], "obj_char_span": [246, 264], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [52, 57]}, {"subject": "doxorubicin", "object": "hand-foot syndrome", "sbj_char_span": [56, 67], "obj_char_span": [267, 285], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [59, 63]}, {"subject": "doxorubicin", "object": "stomatitis", "sbj_char_span": [56, 67], "obj_char_span": [292, 302], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [66, 68]}, {"subject": "Doxil", "object": "stomatitis", "sbj_char_span": [69, 74], "obj_char_span": [292, 302], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [66, 68]}, {"subject": "Doxil", "object": "hand-foot syndrome", "sbj_char_span": [69, 74], "obj_char_span": [267, 285], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [59, 63]}], "umls_entity_list": []}, {"text": "CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.", "entity_list": [{"name": "hand-foot syndrome", "ent_type": "Disease", "char_span": [94, 112], "ent_id": "D060831", "tok_span": [16, 20]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [72, 80], "ent_id": "D064420", "tok_span": [11, 12]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [36, 47], "ent_id": "D004317", "tok_span": [6, 7]}, {"name": "stomatitis", "ent_type": "Disease", "char_span": [82, 92], "ent_id": "D013280", "tok_span": [13, 15]}], "relation_list": [{"subject": "doxorubicin", "object": "hand-foot syndrome", "sbj_char_span": [36, 47], "obj_char_span": [94, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [16, 20]}, {"subject": "doxorubicin", "object": "stomatitis", "sbj_char_span": [36, 47], "obj_char_span": [82, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "However, olanzapine-treated patients had a statistically significant greater mean (+/- SD) weight gain than placebo-treated patients (2.1 +/- 2.8 vs 0.45 +/- 2.3 kg, respectively) and also experienced more treatment-emergent somnolence (21 patients [38.2%] vs 5 [8.3% ], respectively).", "entity_list": [{"name": "somnolence", "ent_type": "Disease", "char_span": [225, 235], "ent_id": "D006970", "tok_span": [58, 62]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [9, 19], "ent_id": "C076029", "tok_span": [2, 5]}, {"name": "weight gain", "ent_type": "Disease", "char_span": [91, 102], "ent_id": "D015430", "tok_span": [20, 22]}], "relation_list": [{"subject": "olanzapine", "object": "weight gain", "sbj_char_span": [9, 19], "obj_char_span": [91, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [20, 22]}, {"subject": "olanzapine", "object": "somnolence", "sbj_char_span": [9, 19], "obj_char_span": [225, 235], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [58, 62]}], "umls_entity_list": []}, {"text": "The effect of pupil dilation with tropicamide on vision and driving simulator performance.", "entity_list": [{"name": "tropicamide", "ent_type": "Chemical", "char_span": [34, 45], "ent_id": "D014331", "tok_span": [6, 10]}, {"name": "pupil dilation", "ent_type": "Disease", "char_span": [14, 28], "ent_id": "D015878", "tok_span": [3, 5]}], "relation_list": [{"subject": "tropicamide", "object": "pupil dilation", "sbj_char_span": [34, 45], "obj_char_span": [14, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "METHODS: A series of tests on various parameters of visual function and driving simulator performance were performed on 12 healthy drivers, before and after pupil dilation using guttae tropicamide 1%.", "entity_list": [{"name": "pupil dilation", "ent_type": "Disease", "char_span": [157, 171], "ent_id": "D015878", "tok_span": [26, 28]}, {"name": "tropicamide", "ent_type": "Chemical", "char_span": [185, 196], "ent_id": "D014331", "tok_span": [32, 36]}], "relation_list": [{"subject": "tropicamide", "object": "pupil dilation", "sbj_char_span": [185, 196], "obj_char_span": [157, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 36], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester.", "entity_list": [{"name": "isotretinoin", "ent_type": "Chemical", "char_span": [120, 132], "ent_id": "D015474", "tok_span": [27, 31]}, {"name": "Taussig-Bing malformation", "ent_type": "Disease", "char_span": [74, 99], "ent_id": "D004310", "tok_span": [14, 22]}, {"name": "anotia", "ent_type": "Disease", "char_span": [63, 69], "ent_id": "D065817", "tok_span": [10, 13]}], "relation_list": [{"subject": "isotretinoin", "object": "Taussig-Bing malformation", "sbj_char_span": [120, 132], "obj_char_span": [74, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [14, 22]}, {"subject": "isotretinoin", "object": "anotia", "sbj_char_span": [120, 132], "obj_char_span": [63, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Methoxamine evoked non-significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage.", "entity_list": [{"name": "Methoxamine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D008729", "tok_span": [0, 3]}, {"name": "a significant rise in systolic blood pressure", "ent_type": "Disease", "char_span": [92, 137], "ent_id": "D006973", "tok_span": [17, 24]}], "relation_list": [{"subject": "Methoxamine", "object": "a significant rise in systolic blood pressure", "sbj_char_span": [0, 11], "obj_char_span": [92, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [17, 24]}], "umls_entity_list": []}, {"text": "Peak CE levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) decrease in cardiac output (p < 0.05), a 56% (SD +/- 23%, 95% CI = 32% to 80%) decrease in dP/dt(max) (p <.006), and a 23% (SD +/- 15%, 95% CI = 7% to 49%) decrease in SVO(2) (p < 0.025).", "entity_list": [{"name": "decrease in cardiac output", "ent_type": "Disease", "char_span": [76, 102], "ent_id": "D002303", "tok_span": [27, 31]}, {"name": "CE", "ent_type": "Chemical", "char_span": [5, 7], "ent_id": "C066444", "tok_span": [1, 2]}], "relation_list": [{"subject": "CE", "object": "decrease in cardiac output", "sbj_char_span": [5, 7], "obj_char_span": [76, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report.", "entity_list": [{"name": "veralipride", "ent_type": "Chemical", "char_span": [43, 54], "ent_id": "C027429", "tok_span": [10, 14]}, {"name": "Parkinsonism", "ent_type": "Disease", "char_span": [13, 25], "ent_id": "D010302", "tok_span": [4, 6]}], "relation_list": [{"subject": "veralipride", "object": "Parkinsonism", "sbj_char_span": [43, 54], "obj_char_span": [13, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "We describe a female patient with stable Parkinson's disease who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with veralipride, as well as the improvement of her symptoms back to baseline after discontinuation of the drug.", "entity_list": [{"name": "veralipride", "ent_type": "Chemical", "char_span": [170, 181], "ent_id": "C027429", "tok_span": [29, 33]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [41, 60], "ent_id": "D010302", "tok_span": [7, 11]}], "relation_list": [{"subject": "veralipride", "object": "Parkinson's disease", "sbj_char_span": [170, 181], "obj_char_span": [41, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 33], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "A group of doctors in Boston warn that the protease inhibitor Viracept may cause an irregular heart beat, known as bradycardia, in people with HIV.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [115, 126], "ent_id": "D001919", "tok_span": [24, 28]}, {"name": "irregular heart beat", "ent_type": "Disease", "char_span": [84, 104], "ent_id": "D001145", "tok_span": [18, 21]}, {"name": "Viracept", "ent_type": "Chemical", "char_span": [62, 70], "ent_id": "D019888", "tok_span": [12, 15]}], "relation_list": [{"subject": "Viracept", "object": "bradycardia", "sbj_char_span": [62, 70], "obj_char_span": [115, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Bradycardia occurred in a 45-year-old male patient who was Viracept in combination with other anti-HIV drugs.", "entity_list": [{"name": "Viracept", "ent_type": "Chemical", "char_span": [59, 67], "ent_id": "D019888", "tok_span": [14, 17]}, {"name": "Bradycardia", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D001919", "tok_span": [0, 2]}], "relation_list": [{"subject": "Viracept", "object": "Bradycardia", "sbj_char_span": [59, 67], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "entity_list": [{"name": "PTU", "ent_type": "Chemical", "char_span": [269, 272], "ent_id": "D011441", "tok_span": [69, 71]}, {"name": "oral ulcers", "ent_type": "Disease", "char_span": [97, 108], "ent_id": "D019226", "tok_span": [26, 28]}, {"name": "polyarthralgia", "ent_type": "Disease", "char_span": [113, 127], "ent_id": "D018771", "tok_span": [29, 33]}, {"name": "PTU", "ent_type": "Chemical", "char_span": [178, 181], "ent_id": "D011441", "tok_span": [42, 44]}, {"name": "fever", "ent_type": "Disease", "char_span": [90, 95], "ent_id": "D005334", "tok_span": [24, 25]}], "relation_list": [{"subject": "PTU", "object": "polyarthralgia", "sbj_char_span": [178, 181], "obj_char_span": [113, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 44], "obj_tok_span": [29, 33]}, {"subject": "PTU", "object": "oral ulcers", "sbj_char_span": [178, 181], "obj_char_span": [97, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 44], "obj_tok_span": [26, 28]}, {"subject": "PTU", "object": "fever", "sbj_char_span": [178, 181], "obj_char_span": [90, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 44], "obj_tok_span": [24, 25]}, {"subject": "PTU", "object": "polyarthralgia", "sbj_char_span": [269, 272], "obj_char_span": [113, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [69, 71], "obj_tok_span": [29, 33]}, {"subject": "PTU", "object": "fever", "sbj_char_span": [269, 272], "obj_char_span": [90, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [69, 71], "obj_tok_span": [24, 25]}, {"subject": "PTU", "object": "oral ulcers", "sbj_char_span": [269, 272], "obj_char_span": [97, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [69, 71], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol-induced myocardial infarction in rats with respect to lipid metabolism in serum and heart tissue has been investigated.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [122, 143], "ent_id": "D009203", "tok_span": [30, 32]}, {"name": "ethanol", "ent_type": "Chemical", "char_span": [35, 42], "ent_id": "D000431", "tok_span": [6, 7]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [100, 113], "ent_id": "D007545", "tok_span": [24, 28]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [100, 113], "obj_char_span": [122, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Oral pre-treatment with PK (80 mg kg(-1) day(-1) for 15 days) significantly prevented the isoproterenol-induced myocardial infarction and maintained the rats at near normal status.", "entity_list": [{"name": "isoproterenol", "ent_type": "Chemical", "char_span": [90, 103], "ent_id": "D007545", "tok_span": [26, 30]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [112, 133], "ent_id": "D009203", "tok_span": [32, 34]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [90, 103], "obj_char_span": [112, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [32, 34]}], "umls_entity_list": []}, {"text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.", "entity_list": [{"name": "TdP", "ent_type": "Disease", "char_span": [139, 142], "ent_id": "D016171", "tok_span": [31, 34]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [119, 137], "ent_id": "D016171", "tok_span": [25, 30]}, {"name": "azimilide", "ent_type": "Chemical", "char_span": [191, 200], "ent_id": "C086123", "tok_span": [47, 51]}, {"name": "QT prolongation", "ent_type": "Disease", "char_span": [149, 164], "ent_id": "D008133", "tok_span": [36, 39]}, {"name": "sotalol", "ent_type": "Chemical", "char_span": [179, 186], "ent_id": "D013015", "tok_span": [43, 46]}], "relation_list": [{"subject": "sotalol", "object": "torsade de pointes", "sbj_char_span": [179, 186], "obj_char_span": [119, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [25, 30]}, {"subject": "sotalol", "object": "TdP", "sbj_char_span": [179, 186], "obj_char_span": [139, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [31, 34]}, {"subject": "sotalol", "object": "QT prolongation", "sbj_char_span": [179, 186], "obj_char_span": [149, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [36, 39]}], "umls_entity_list": []}, {"text": "METHODS AND RESULTS: Transmembrane action potentials from epicardium, midmyocardium, and endocardium were recorded simultaneously, together with a transmural ECG, in arterially perfused canine and rabbit left ventricular preparations. dl-Sotalol preferentially prolonged action potential duration (APD) in M cells dose-dependently (1 to 100 micromol/L), leading to QT prolongation and an increase in TDR.", "entity_list": [{"name": "Sotalol", "ent_type": "Chemical", "char_span": [238, 245], "ent_id": "D013015", "tok_span": [46, 49]}, {"name": "QT prolongation", "ent_type": "Disease", "char_span": [365, 380], "ent_id": "D008133", "tok_span": [77, 80]}], "relation_list": [{"subject": "Sotalol", "object": "QT prolongation", "sbj_char_span": [238, 245], "obj_char_span": [365, 380], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 49], "obj_tok_span": [77, 80]}], "umls_entity_list": []}, {"text": "Although both dl-sotalol and azimilide rarely induced EADs in canine left ventricles, they produced frequent EADs in rabbits, in which more pronounced QT prolongation was seen.", "entity_list": [{"name": "sotalol", "ent_type": "Chemical", "char_span": [17, 24], "ent_id": "D013015", "tok_span": [4, 7]}, {"name": "azimilide", "ent_type": "Chemical", "char_span": [29, 38], "ent_id": "C086123", "tok_span": [8, 12]}, {"name": "QT prolongation", "ent_type": "Disease", "char_span": [151, 166], "ent_id": "D008133", "tok_span": [34, 37]}], "relation_list": [{"subject": "sotalol", "object": "QT prolongation", "sbj_char_span": [17, 24], "obj_char_span": [151, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [34, 37]}], "umls_entity_list": []}, {"text": "An increase in TDR by dl-sotalol facilitated transmural propagation of EADs that initiated multiple episodes of spontaneous TdP in 3 of 6 rabbit left ventricles.", "entity_list": [{"name": "TdP", "ent_type": "Disease", "char_span": [124, 127], "ent_id": "D016171", "tok_span": [24, 27]}, {"name": "sotalol", "ent_type": "Chemical", "char_span": [25, 32], "ent_id": "D013015", "tok_span": [8, 11]}], "relation_list": [{"subject": "sotalol", "object": "TdP", "sbj_char_span": [25, 32], "obj_char_span": [124, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Prenatal cocaine exposure and cranial sonographic findings in preterm infants.", "entity_list": [{"name": "preterm infants", "ent_type": "Disease", "char_span": [62, 77], "ent_id": "D007235", "tok_span": [10, 12]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [9, 16], "ent_id": "D003042", "tok_span": [2, 3]}], "relation_list": [{"subject": "cocaine", "object": "preterm infants", "sbj_char_span": [9, 16], "obj_char_span": [62, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "PURPOSE: Prenatal cocaine exposure has been linked with subependymal hemorrhage and the formation of cysts that are detectable on cranial sonography in neonates born at term.", "entity_list": [{"name": "cysts", "ent_type": "Disease", "char_span": [101, 106], "ent_id": "D003560", "tok_span": [18, 19]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [18, 25], "ent_id": "D003042", "tok_span": [4, 5]}, {"name": "hemorrhage", "ent_type": "Disease", "char_span": [69, 79], "ent_id": "D006470", "tok_span": [13, 14]}], "relation_list": [{"subject": "cocaine", "object": "cysts", "sbj_char_span": [18, 25], "obj_char_span": [101, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "We sought to determine if prenatal cocaine exposure increases the incidence of subependymal cysts in preterm infants.", "entity_list": [{"name": "subependymal cysts", "ent_type": "Disease", "char_span": [79, 97], "ent_id": "D00192", "tok_span": [12, 16]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [35, 42], "ent_id": "D003042", "tok_span": [6, 7]}, {"name": "preterm infants", "ent_type": "Disease", "char_span": [101, 116], "ent_id": "D007235", "tok_span": [17, 19]}], "relation_list": [{"subject": "cocaine", "object": "preterm infants", "sbj_char_span": [35, 42], "obj_char_span": [101, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: We found an increased incidence of subependymal cyst formation in preterm infants who were exposed to cocaine prenatally.", "entity_list": [{"name": "subependymal cyst", "ent_type": "Disease", "char_span": [48, 65], "ent_id": "D00192", "tok_span": [8, 12]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [115, 122], "ent_id": "D003042", "tok_span": [20, 21]}, {"name": "preterm infants", "ent_type": "Disease", "char_span": [79, 94], "ent_id": "D007235", "tok_span": [14, 16]}], "relation_list": [{"subject": "cocaine", "object": "preterm infants", "sbj_char_span": [115, 122], "obj_char_span": [79, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced hearing loss.", "entity_list": [{"name": "superoxide", "ent_type": "Chemical", "char_span": [30, 40], "ent_id": "D013481", "tok_span": [6, 7]}, {"name": "zinc", "ent_type": "Chemical", "char_span": [25, 29], "ent_id": "D015032", "tok_span": [4, 5]}, {"name": "copper", "ent_type": "Chemical", "char_span": [18, 24], "ent_id": "D003300", "tok_span": [2, 3]}, {"name": "kanamycin", "ent_type": "Chemical", "char_span": [65, 74], "ent_id": "D007612", "tok_span": [10, 12]}, {"name": "hearing loss", "ent_type": "Disease", "char_span": [83, 95], "ent_id": "D034381", "tok_span": [14, 16]}], "relation_list": [{"subject": "kanamycin", "object": "hearing loss", "sbj_char_span": [65, 74], "obj_char_span": [83, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Prednisone induces anxiety and glial cerebral changes in rats.", "entity_list": [{"name": "Prednisone", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D011241", "tok_span": [0, 3]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [19, 26], "ent_id": "D001008", "tok_span": [4, 5]}], "relation_list": [{"subject": "Prednisone", "object": "anxiety", "sbj_char_span": [0, 10], "obj_char_span": [19, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To assess whether prednisone (PDN) produces anxiety and/or cerebral glial changes in rats.", "entity_list": [{"name": "PDN", "ent_type": "Chemical", "char_span": [41, 44], "ent_id": "D011241", "tok_span": [8, 10]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [55, 62], "ent_id": "D001008", "tok_span": [12, 13]}, {"name": "prednisone", "ent_type": "Chemical", "char_span": [29, 39], "ent_id": "D011241", "tok_span": [5, 7]}], "relation_list": [{"subject": "PDN", "object": "anxiety", "sbj_char_span": [41, 44], "obj_char_span": [55, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [12, 13]}, {"subject": "prednisone", "object": "anxiety", "sbj_char_span": [29, 39], "obj_char_span": [55, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "RESULTS: Anxiety was documented in both groups of PDN treated rats compared with controls.", "entity_list": [{"name": "PDN", "ent_type": "Chemical", "char_span": [50, 53], "ent_id": "D011241", "tok_span": [9, 11]}, {"name": "Anxiety", "ent_type": "Disease", "char_span": [9, 16], "ent_id": "D001008", "tok_span": [2, 3]}], "relation_list": [{"subject": "PDN", "object": "Anxiety", "sbj_char_span": [50, 53], "obj_char_span": [9, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "CONCLUSION: Subacute exposure to PDN induced anxiety and reactivity of microglia.", "entity_list": [{"name": "anxiety", "ent_type": "Disease", "char_span": [45, 52], "ent_id": "D001008", "tok_span": [9, 10]}, {"name": "PDN", "ent_type": "Chemical", "char_span": [33, 36], "ent_id": "D011241", "tok_span": [6, 8]}], "relation_list": [{"subject": "PDN", "object": "anxiety", "sbj_char_span": [33, 36], "obj_char_span": [45, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported manic episodes.", "entity_list": [{"name": "metronidazole", "ent_type": "Chemical", "char_span": [15, 28], "ent_id": "D008795", "tok_span": [5, 10]}, {"name": "manic", "ent_type": "Disease", "char_span": [76, 81], "ent_id": "D001714", "tok_span": [19, 21]}, {"name": "erythromycin", "ent_type": "Chemical", "char_span": [34, 46], "ent_id": "D004917", "tok_span": [12, 14]}, {"name": "Cotrimoxazole", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D015662", "tok_span": [0, 4]}], "relation_list": [{"subject": "erythromycin", "object": "manic", "sbj_char_span": [34, 46], "obj_char_span": [76, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [19, 21]}, {"subject": "metronidazole", "object": "manic", "sbj_char_span": [15, 28], "obj_char_span": [76, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [19, 21]}, {"subject": "Cotrimoxazole", "object": "manic", "sbj_char_span": [0, 13], "obj_char_span": [76, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania.", "entity_list": [{"name": "mania", "ent_type": "Disease", "char_span": [127, 132], "ent_id": "D001714", "tok_span": [25, 27]}, {"name": "ciprofloxacin", "ent_type": "Chemical", "char_span": [52, 65], "ent_id": "D002939", "tok_span": [10, 15]}, {"name": "clarithromycin", "ent_type": "Chemical", "char_span": [33, 47], "ent_id": "D017291", "tok_span": [6, 9]}], "relation_list": [{"subject": "ciprofloxacin", "object": "mania", "sbj_char_span": [52, 65], "obj_char_span": [127, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [25, 27]}, {"subject": "clarithromycin", "object": "mania", "sbj_char_span": [33, 47], "obj_char_span": [127, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Levodopa-induced ocular dyskinesias in Parkinson's disease.", "entity_list": [{"name": "Levodopa", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D007980", "tok_span": [0, 3]}, {"name": "ocular dyskinesias", "ent_type": "Disease", "char_span": [17, 35], "ent_id": "D015835", "tok_span": [5, 10]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [39, 58], "ent_id": "D010300", "tok_span": [11, 15]}], "relation_list": [{"subject": "Levodopa", "object": "ocular dyskinesias", "sbj_char_span": [0, 8], "obj_char_span": [17, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "Levodopa-induced ocular dyskinesias are very uncommon.", "entity_list": [{"name": "Levodopa", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D007980", "tok_span": [0, 3]}, {"name": "ocular dyskinesias", "ent_type": "Disease", "char_span": [17, 35], "ent_id": "D015835", "tok_span": [5, 10]}], "relation_list": [{"subject": "Levodopa", "object": "ocular dyskinesias", "sbj_char_span": [0, 8], "obj_char_span": [17, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [93, 101], "ent_id": "D007980", "tok_span": [18, 21]}, {"name": "ocular dyskinesias", "ent_type": "Disease", "char_span": [235, 253], "ent_id": "D015835", "tok_span": [47, 52]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [219, 227], "ent_id": "D007980", "tok_span": [42, 45]}], "relation_list": [{"subject": "levodopa", "object": "ocular dyskinesias", "sbj_char_span": [219, 227], "obj_char_span": [235, 253], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 45], "obj_tok_span": [47, 52]}, {"subject": "levodopa", "object": "ocular dyskinesias", "sbj_char_span": [93, 101], "obj_char_span": [235, 253], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [47, 52]}], "umls_entity_list": []}, {"text": "Headache was significantly increased by GTN but not by DCF.", "entity_list": [{"name": "DCF", "ent_type": "Chemical", "char_span": [55, 58], "ent_id": "D004008", "tok_span": [11, 13]}, {"name": "GTN", "ent_type": "Chemical", "char_span": [40, 43], "ent_id": "D005996", "tok_span": [6, 8]}, {"name": "Headache", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D006261", "tok_span": [0, 2]}], "relation_list": [{"subject": "GTN", "object": "Headache", "sbj_char_span": [40, 43], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Eight patients stopped using GTN because headache--attributed to its use--became intolerable.", "entity_list": [{"name": "GTN", "ent_type": "Chemical", "char_span": [29, 32], "ent_id": "D005996", "tok_span": [4, 6]}, {"name": "headache", "ent_type": "Disease", "char_span": [41, 49], "ent_id": "D006261", "tok_span": [7, 8]}], "relation_list": [{"subject": "GTN", "object": "headache", "sbj_char_span": [29, 32], "obj_char_span": [41, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.", "entity_list": [{"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [119, 144], "ent_id": "D011692", "tok_span": [23, 28]}, {"name": "nephrosis", "ent_type": "Disease", "char_span": [145, 154], "ent_id": "D009401", "tok_span": [28, 30]}, {"name": "glomerular injury", "ent_type": "Disease", "char_span": [90, 107], "ent_id": "D007674", "tok_span": [19, 21]}, {"name": "angiotensin", "ent_type": "Chemical", "char_span": [39, 50], "ent_id": "D000809", "tok_span": [13, 14]}, {"name": "Temocapril", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "C055603", "tok_span": [0, 4]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrosis", "sbj_char_span": [119, 144], "obj_char_span": [145, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 28], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity_list": [{"name": "hypertrophy", "ent_type": "Disease", "char_span": [212, 223], "ent_id": "D006984", "tok_span": [39, 40]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [178, 189], "ent_id": "D011507", "tok_span": [35, 36]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [295, 298], "ent_id": "D011692", "tok_span": [54, 55]}, {"name": "temocapril", "ent_type": "Chemical", "char_span": [84, 94], "ent_id": "C055603", "tok_span": [13, 17]}, {"name": "nephrotic", "ent_type": "Disease", "char_span": [310, 319], "ent_id": "D009404", "tok_span": [58, 60]}, {"name": "glomerulosclerosis", "ent_type": "Disease", "char_span": [238, 256], "ent_id": "D005921", "tok_span": [42, 46]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [268, 293], "ent_id": "D011692", "tok_span": [48, 53]}, {"name": "angiotensin", "ent_type": "Chemical", "char_span": [123, 134], "ent_id": "D000809", "tok_span": [26, 27]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "proteinuria", "sbj_char_span": [268, 293], "obj_char_span": [178, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 53], "obj_tok_span": [35, 36]}, {"subject": "PAN", "object": "proteinuria", "sbj_char_span": [295, 298], "obj_char_span": [178, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [54, 55], "obj_tok_span": [35, 36]}], "umls_entity_list": []}, {"text": "Nephrosis was induced by injection of PAN (15mg/100g body weight) in male Sprague-Dawley (SD) rats.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [38, 41], "ent_id": "D011692", "tok_span": [7, 8]}, {"name": "Nephrosis", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D009401", "tok_span": [0, 2]}], "relation_list": [{"subject": "PAN", "object": "Nephrosis", "sbj_char_span": [38, 41], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "It appears that temocapril was effective in retarding renal progression and protected renal function in PAN neprotic rats.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [104, 107], "ent_id": "D011692", "tok_span": [19, 20]}, {"name": "neprotic", "ent_type": "Disease", "char_span": [108, 116], "ent_id": "D009401", "tok_span": [20, 23]}, {"name": "temocapril", "ent_type": "Chemical", "char_span": [16, 26], "ent_id": "C055603", "tok_span": [3, 7]}], "relation_list": [{"subject": "PAN", "object": "neprotic", "sbj_char_span": [104, 107], "obj_char_span": [108, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.", "entity_list": [{"name": "ibuprofen", "ent_type": "Chemical", "char_span": [29, 38], "ent_id": "D007052", "tok_span": [3, 7]}, {"name": "Pulmonary hypertension", "ent_type": "Disease", "char_span": [0, 22], "ent_id": "D006976", "tok_span": [0, 2]}], "relation_list": [{"subject": "ibuprofen", "object": "Pulmonary hypertension", "sbj_char_span": [29, 38], "obj_char_span": [0, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.", "entity_list": [{"name": "patent ductus arteriosus", "ent_type": "Disease", "char_span": [140, 164], "ent_id": "D004374", "tok_span": [24, 29]}, {"name": "ibuprofen", "ent_type": "Chemical", "char_span": [170, 179], "ent_id": "D007052", "tok_span": [30, 34]}, {"name": "ibuprofen", "ent_type": "Chemical", "char_span": [49, 58], "ent_id": "D007052", "tok_span": [10, 14]}, {"name": "hypoxaemia", "ent_type": "Disease", "char_span": [32, 42], "ent_id": "D000860", "tok_span": [6, 9]}], "relation_list": [{"subject": "ibuprofen", "object": "hypoxaemia", "sbj_char_span": [170, 179], "obj_char_span": [32, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [6, 9]}, {"subject": "ibuprofen", "object": "hypoxaemia", "sbj_char_span": [49, 58], "obj_char_span": [32, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "We suggest that investigators involved in similar trials pay close attention to pulmonary pressure if hypoxaemia occurs after prophylactic administration of ibuprofen.", "entity_list": [{"name": "ibuprofen", "ent_type": "Chemical", "char_span": [157, 166], "ent_id": "D007052", "tok_span": [23, 27]}, {"name": "hypoxaemia", "ent_type": "Disease", "char_span": [102, 112], "ent_id": "D000860", "tok_span": [15, 18]}], "relation_list": [{"subject": "ibuprofen", "object": "hypoxaemia", "sbj_char_span": [157, 166], "obj_char_span": [102, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?", "entity_list": [{"name": "syndrome of inappropriate anti-diuretic hormone", "ent_type": "Disease", "char_span": [17, 64], "ent_id": "D007177", "tok_span": [5, 13]}, {"name": "Vincristine", "ent_type": "Chemical", "char_span": [90, 101], "ent_id": "D014750", "tok_span": [18, 22]}, {"name": "Hyponatremia", "ent_type": "Disease", "char_span": [0, 12], "ent_id": "D007010", "tok_span": [0, 4]}], "relation_list": [{"subject": "Vincristine", "object": "syndrome of inappropriate anti-diuretic hormone", "sbj_char_span": [90, 101], "obj_char_span": [17, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [5, 13]}, {"subject": "Vincristine", "object": "Hyponatremia", "sbj_char_span": [90, 101], "obj_char_span": [0, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "PURPOSE: This retrospective study used a pharmaceutical company's global safety database to determine the reporting rate of hyponatremia and/or syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) among vincristine-treated patients and to explore the possibility of at-risk population subgroups.", "entity_list": [{"name": "vincristine", "ent_type": "Chemical", "char_span": [219, 230], "ent_id": "D014750", "tok_span": [43, 47]}, {"name": "SIADH", "ent_type": "Disease", "char_span": [206, 211], "ent_id": "D007177", "tok_span": [38, 41]}, {"name": "hyponatremia", "ent_type": "Disease", "char_span": [124, 136], "ent_id": "D007010", "tok_span": [20, 24]}, {"name": "syndrome of inappropriate secretion of anti-diuretic hormone", "ent_type": "Disease", "char_span": [144, 204], "ent_id": "D007177", "tok_span": [27, 37]}], "relation_list": [{"subject": "vincristine", "object": "syndrome of inappropriate secretion of anti-diuretic hormone", "sbj_char_span": [219, 230], "obj_char_span": [144, 204], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 47], "obj_tok_span": [27, 37]}, {"subject": "vincristine", "object": "hyponatremia", "sbj_char_span": [219, 230], "obj_char_span": [124, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 47], "obj_tok_span": [20, 24]}, {"subject": "vincristine", "object": "SIADH", "sbj_char_span": [219, 230], "obj_char_span": [206, 211], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 47], "obj_tok_span": [38, 41]}], "umls_entity_list": []}, {"text": "METHOD: We searched the Eli Lilly and Company's computerized adverse event database for all reported cases of hyponatremia and/or SIADH as of 1 November 1999 that had been reported during the use of vincristine.", "entity_list": [{"name": "hyponatremia", "ent_type": "Disease", "char_span": [110, 122], "ent_id": "D007010", "tok_span": [23, 27]}, {"name": "vincristine", "ent_type": "Chemical", "char_span": [199, 210], "ent_id": "D014750", "tok_span": [46, 50]}, {"name": "SIADH", "ent_type": "Disease", "char_span": [130, 135], "ent_id": "D007177", "tok_span": [30, 33]}], "relation_list": [{"subject": "vincristine", "object": "hyponatremia", "sbj_char_span": [199, 210], "obj_char_span": [110, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 50], "obj_tok_span": [23, 27]}, {"subject": "vincristine", "object": "SIADH", "sbj_char_span": [199, 210], "obj_char_span": [130, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 50], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "RESULTS: A total of 76 cases of hyponatremia and/or SIADH associated with vincristine use were identified.", "entity_list": [{"name": "hyponatremia", "ent_type": "Disease", "char_span": [32, 44], "ent_id": "D007010", "tok_span": [8, 12]}, {"name": "SIADH", "ent_type": "Disease", "char_span": [52, 57], "ent_id": "D007177", "tok_span": [15, 18]}, {"name": "vincristine", "ent_type": "Chemical", "char_span": [74, 85], "ent_id": "D014750", "tok_span": [20, 24]}], "relation_list": [{"subject": "vincristine", "object": "SIADH", "sbj_char_span": [74, 85], "obj_char_span": [52, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [15, 18]}, {"subject": "vincristine", "object": "hyponatremia", "sbj_char_span": [74, 85], "obj_char_span": [32, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "CONCLUSION: Our data suggest that Asian patients may be at increased risk of hyponatremia and/or SIADH associated with vincristine use.", "entity_list": [{"name": "vincristine", "ent_type": "Chemical", "char_span": [119, 130], "ent_id": "D014750", "tok_span": [26, 30]}, {"name": "hyponatremia", "ent_type": "Disease", "char_span": [77, 89], "ent_id": "D007010", "tok_span": [14, 18]}, {"name": "SIADH", "ent_type": "Disease", "char_span": [97, 102], "ent_id": "D007177", "tok_span": [21, 24]}], "relation_list": [{"subject": "vincristine", "object": "hyponatremia", "sbj_char_span": [119, 130], "obj_char_span": [77, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [14, 18]}, {"subject": "vincristine", "object": "SIADH", "sbj_char_span": [119, 130], "obj_char_span": [97, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "Although the overall reported rate of SIADH associated with vincristine is very low, physicians caring for Asian oncology patients should be aware of this potential serious but reversible adverse event.", "entity_list": [{"name": "vincristine", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "D014750", "tok_span": [11, 15]}, {"name": "SIADH", "ent_type": "Disease", "char_span": [38, 43], "ent_id": "D007177", "tok_span": [6, 9]}], "relation_list": [{"subject": "vincristine", "object": "SIADH", "sbj_char_span": [60, 71], "obj_char_span": [38, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "Early CY toxicity caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7-10 days.", "entity_list": [{"name": "cystitis", "ent_type": "Disease", "char_span": [48, 56], "ent_id": "D003556", "tok_span": [8, 10]}, {"name": "haemorrhagic", "ent_type": "Disease", "char_span": [35, 47], "ent_id": "D006470", "tok_span": [6, 8]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [9, 17], "ent_id": "D064420", "tok_span": [2, 3]}, {"name": "CY", "ent_type": "Chemical", "char_span": [6, 8], "ent_id": "D003520", "tok_span": [1, 2]}], "relation_list": [{"subject": "CY", "object": "cystitis", "sbj_char_span": [6, 8], "obj_char_span": [48, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [8, 10]}, {"subject": "CY", "object": "haemorrhagic", "sbj_char_span": [6, 8], "obj_char_span": [35, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "After 30 days of CY injection ulcerous and non-ulcerous forms of chronic cystitis appeared in 86% of DBA/2 mice but only in 4% of C57BL/6 mice.", "entity_list": [{"name": "cystitis", "ent_type": "Disease", "char_span": [73, 81], "ent_id": "D003556", "tok_span": [16, 18]}, {"name": "CY", "ent_type": "Chemical", "char_span": [17, 19], "ent_id": "D003520", "tok_span": [4, 5]}], "relation_list": [{"subject": "CY", "object": "cystitis", "sbj_char_span": [17, 19], "obj_char_span": [73, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.", "entity_list": [{"name": "leukocyturia", "ent_type": "Disease", "char_span": [19, 31], "ent_id": "-1", "tok_span": [3, 6]}, {"name": "human immunodeficiency virus type 1-infected", "ent_type": "Disease", "char_span": [78, 122], "ent_id": "D015658", "tok_span": [13, 21]}, {"name": "indinavir", "ent_type": "Chemical", "char_span": [145, 154], "ent_id": "D019469", "tok_span": [24, 27]}, {"name": "impaired renal function", "ent_type": "Disease", "char_span": [51, 74], "ent_id": "D007674", "tok_span": [9, 12]}], "relation_list": [{"subject": "indinavir", "object": "impaired renal function", "sbj_char_span": [145, 154], "obj_char_span": [51, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.", "entity_list": [{"name": "human immunodeficiency virus type 1-infected", "ent_type": "Disease", "char_span": [90, 134], "ent_id": "D015658", "tok_span": [20, 28]}, {"name": "indinavir", "ent_type": "Chemical", "char_span": [39, 48], "ent_id": "D019469", "tok_span": [7, 10]}, {"name": "indinavir", "ent_type": "Chemical", "char_span": [157, 166], "ent_id": "D019469", "tok_span": [31, 34]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [57, 71], "ent_id": "D007674", "tok_span": [12, 15]}], "relation_list": [{"subject": "indinavir", "object": "nephrotoxicity", "sbj_char_span": [39, 48], "obj_char_span": [57, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 15]}, {"subject": "indinavir", "object": "nephrotoxicity", "sbj_char_span": [157, 166], "obj_char_span": [57, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "In 4 children, indinavir was discontinued because of nephrotoxicity.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [53, 67], "ent_id": "D007674", "tok_span": [11, 14]}, {"name": "indinavir", "ent_type": "Chemical", "char_span": [15, 24], "ent_id": "D019469", "tok_span": [4, 7]}], "relation_list": [{"subject": "indinavir", "object": "nephrotoxicity", "sbj_char_span": [15, 24], "obj_char_span": [53, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.", "entity_list": [{"name": "Indinavir", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D019469", "tok_span": [0, 3]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [21, 35], "ent_id": "D007674", "tok_span": [5, 8]}, {"name": "leukocyturia", "ent_type": "Disease", "char_span": [131, 143], "ent_id": "-1", "tok_span": [23, 26]}, {"name": "indinavir", "ent_type": "Chemical", "char_span": [188, 197], "ent_id": "D019469", "tok_span": [40, 43]}], "relation_list": [{"subject": "Indinavir", "object": "nephrotoxicity", "sbj_char_span": [0, 9], "obj_char_span": [21, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 8]}, {"subject": "indinavir", "object": "nephrotoxicity", "sbj_char_span": [188, 197], "obj_char_span": [21, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 43], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.", "entity_list": [{"name": "myocardial necrosis", "ent_type": "Disease", "char_span": [83, 102], "ent_id": "D009202", "tok_span": [10, 12]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [203, 213], "ent_id": "D002637", "tok_span": [28, 30]}, {"name": "MI", "ent_type": "Disease", "char_span": [153, 155], "ent_id": "D009203", "tok_span": [19, 20]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [130, 151], "ent_id": "D009203", "tok_span": [16, 18]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [184, 191], "ent_id": "D003042", "tok_span": [25, 26]}], "relation_list": [{"subject": "cocaine", "object": "myocardial infarction", "sbj_char_span": [184, 191], "obj_char_span": [130, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [16, 18]}, {"subject": "cocaine", "object": "MI", "sbj_char_span": [184, 191], "obj_char_span": [153, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI.", "entity_list": [{"name": "MI", "ent_type": "Disease", "char_span": [121, 123], "ent_id": "D009203", "tok_span": [20, 21]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [84, 94], "ent_id": "D002637", "tok_span": [14, 16]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [76, 83], "ent_id": "D003042", "tok_span": [13, 14]}], "relation_list": [{"subject": "cocaine", "object": "MI", "sbj_char_span": [76, 83], "obj_char_span": [121, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "METHODS: Outcomes were examined in patients admitted for possible MI after cocaine use.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [75, 82], "ent_id": "D003042", "tok_span": [12, 13]}, {"name": "MI", "ent_type": "Disease", "char_span": [66, 68], "ent_id": "D009203", "tok_span": [10, 11]}], "relation_list": [{"subject": "cocaine", "object": "MI", "sbj_char_span": [75, 82], "obj_char_span": [66, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Troponin appears to have an equivalent diagnostic accuracy compared with CK-MB for diagnosing necrosis in patients with cocaine-associated chest pain and suspected MI.", "entity_list": [{"name": "chest pain", "ent_type": "Disease", "char_span": [139, 149], "ent_id": "D002637", "tok_span": [23, 25]}, {"name": "MI", "ent_type": "Disease", "char_span": [164, 166], "ent_id": "D009203", "tok_span": [27, 28]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [120, 127], "ent_id": "D003042", "tok_span": [20, 21]}, {"name": "necrosis", "ent_type": "Disease", "char_span": [94, 102], "ent_id": "D009336", "tok_span": [16, 17]}], "relation_list": [{"subject": "cocaine", "object": "MI", "sbj_char_span": [120, 127], "obj_char_span": [164, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "Acute interstitial nephritis due to nicergoline (Sermion).", "entity_list": [{"name": "interstitial nephritis", "ent_type": "Disease", "char_span": [6, 28], "ent_id": "D009395", "tok_span": [1, 4]}, {"name": "nicergoline", "ent_type": "Chemical", "char_span": [36, 47], "ent_id": "D009530", "tok_span": [6, 10]}, {"name": "Sermion", "ent_type": "Chemical", "char_span": [49, 56], "ent_id": "D009530", "tok_span": [11, 14]}], "relation_list": [{"subject": "nicergoline", "object": "interstitial nephritis", "sbj_char_span": [36, 47], "obj_char_span": [6, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [1, 4]}, {"subject": "Sermion", "object": "interstitial nephritis", "sbj_char_span": [49, 56], "obj_char_span": [6, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "We report a case of acute interstitial nephritis (AIN) due to nicergoline (Sermion).", "entity_list": [{"name": "nicergoline", "ent_type": "Chemical", "char_span": [62, 73], "ent_id": "D009530", "tok_span": [15, 19]}, {"name": "Sermion", "ent_type": "Chemical", "char_span": [75, 82], "ent_id": "D009530", "tok_span": [20, 23]}, {"name": "AIN", "ent_type": "Disease", "char_span": [50, 53], "ent_id": "D009395", "tok_span": [10, 12]}, {"name": "interstitial nephritis", "ent_type": "Disease", "char_span": [26, 48], "ent_id": "D009395", "tok_span": [6, 9]}], "relation_list": [{"subject": "nicergoline", "object": "AIN", "sbj_char_span": [62, 73], "obj_char_span": [50, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [10, 12]}, {"subject": "nicergoline", "object": "interstitial nephritis", "sbj_char_span": [62, 73], "obj_char_span": [26, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [6, 9]}, {"subject": "Sermion", "object": "AIN", "sbj_char_span": [75, 82], "obj_char_span": [50, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [10, 12]}, {"subject": "Sermion", "object": "interstitial nephritis", "sbj_char_span": [75, 82], "obj_char_span": [26, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "To our knowledge, this is the first report of nicergoline-associated AIN.", "entity_list": [{"name": "AIN", "ent_type": "Disease", "char_span": [69, 72], "ent_id": "D009395", "tok_span": [16, 18]}, {"name": "nicergoline", "ent_type": "Chemical", "char_span": [46, 57], "ent_id": "D009530", "tok_span": [10, 14]}], "relation_list": [{"subject": "nicergoline", "object": "AIN", "sbj_char_span": [46, 57], "obj_char_span": [69, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "entity_list": [{"name": "risperidone", "ent_type": "Chemical", "char_span": [114, 125], "ent_id": "D018967", "tok_span": [23, 26]}, {"name": "chronic renal failure", "ent_type": "Disease", "char_span": [15, 36], "ent_id": "D007676", "tok_span": [3, 6]}, {"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [53, 83], "ent_id": "D009459", "tok_span": [10, 16]}, {"name": "CRF", "ent_type": "Disease", "char_span": [38, 41], "ent_id": "D007676", "tok_span": [7, 8]}, {"name": "levomepromazine", "ent_type": "Chemical", "char_span": [130, 145], "ent_id": "D008728", "tok_span": [27, 31]}, {"name": "NMS", "ent_type": "Disease", "char_span": [85, 88], "ent_id": "D009459", "tok_span": [17, 19]}], "relation_list": [{"subject": "levomepromazine", "object": "NMS", "sbj_char_span": [130, 145], "obj_char_span": [85, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [17, 19]}, {"subject": "risperidone", "object": "NMS", "sbj_char_span": [114, 125], "obj_char_span": [85, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [17, 19]}, {"subject": "risperidone", "object": "neuroleptic malignant syndrome", "sbj_char_span": [114, 125], "obj_char_span": [53, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [10, 16]}, {"subject": "levomepromazine", "object": "neuroleptic malignant syndrome", "sbj_char_span": [130, 145], "obj_char_span": [53, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [10, 16]}], "umls_entity_list": []}, {"text": "Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s. In normal rats, the whole brain sections exhibited complete staining with TTC.", "entity_list": [{"name": "TTC", "ent_type": "Chemical", "char_span": [256, 259], "ent_id": "C009591", "tok_span": [52, 54]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [161, 171], "ent_id": "D004837", "tok_span": [34, 36]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [19, 31], "ent_id": "D006973", "tok_span": [5, 6]}, {"name": "Adrenaline", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D004837", "tok_span": [0, 3]}, {"name": "triphenyltetrazolium", "ent_type": "Chemical", "char_span": [87, 107], "ent_id": "C009591", "tok_span": [17, 22]}, {"name": "TTC", "ent_type": "Chemical", "char_span": [109, 112], "ent_id": "C009591", "tok_span": [23, 25]}], "relation_list": [{"subject": "adrenaline", "object": "hypertension", "sbj_char_span": [161, 171], "obj_char_span": [19, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [5, 6]}, {"subject": "Adrenaline", "object": "hypertension", "sbj_char_span": [0, 10], "obj_char_span": [19, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.", "entity_list": [{"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [62, 76], "ent_id": "D009202", "tok_span": [10, 11]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [28, 39], "ent_id": "D004317", "tok_span": [6, 7]}, {"name": "Carvedilol", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "C043211", "tok_span": [0, 4]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [28, 39], "obj_char_span": [62, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible cardiomyopathy caused by doxorubicin.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [132, 143], "ent_id": "D004317", "tok_span": [19, 20]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [107, 121], "ent_id": "D009202", "tok_span": [16, 17]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [132, 143], "obj_char_span": [107, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.", "entity_list": [{"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [220, 234], "ent_id": "D009202", "tok_span": [34, 35]}, {"name": "cancer", "ent_type": "Disease", "char_span": [285, 291], "ent_id": "D009369", "tok_span": [44, 45]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [262, 273], "ent_id": "D004317", "tok_span": [41, 42]}, {"name": "carvedilol", "ent_type": "Chemical", "char_span": [40, 50], "ent_id": "C043211", "tok_span": [7, 11]}, {"name": "mitochondrial dysfunction", "ent_type": "Disease", "char_span": [190, 215], "ent_id": "D028361", "tok_span": [31, 33]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [262, 273], "obj_char_span": [220, 234], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 42], "obj_tok_span": [34, 35]}], "umls_entity_list": []}, {"text": "Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [128, 149], "ent_id": "D009203", "tok_span": [26, 28]}, {"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [98, 117], "ent_id": "D001281", "tok_span": [22, 24]}, {"name": "bradyarrhythmia", "ent_type": "Disease", "char_span": [27, 42], "ent_id": "D001919", "tok_span": [8, 13]}, {"name": "Amiodarone", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D000638", "tok_span": [0, 4]}], "relation_list": [{"subject": "Amiodarone", "object": "bradyarrhythmia", "sbj_char_span": [0, 10], "obj_char_span": [27, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [8, 13]}], "umls_entity_list": []}, {"text": "OBJECTIVES: The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "entity_list": [{"name": "bradyarrhythmia", "ent_type": "Disease", "char_span": [145, 160], "ent_id": "D001919", "tok_span": [30, 35]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [70, 80], "ent_id": "D000638", "tok_span": [14, 18]}, {"name": "AF", "ent_type": "Disease", "char_span": [119, 121], "ent_id": "D001281", "tok_span": [24, 25]}, {"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [98, 117], "ent_id": "D001281", "tok_span": [21, 23]}], "relation_list": [{"subject": "amiodarone", "object": "bradyarrhythmia", "sbj_char_span": [70, 80], "obj_char_span": [145, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [30, 35]}], "umls_entity_list": []}, {"text": "BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias.", "entity_list": [{"name": "bradyarrhythmia", "ent_type": "Disease", "char_span": [30, 45], "ent_id": "D001919", "tok_span": [5, 10]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [53, 63], "ent_id": "D000638", "tok_span": [11, 15]}, {"name": "ventricular arrhythmias", "ent_type": "Disease", "char_span": [173, 196], "ent_id": "D001145", "tok_span": [35, 37]}], "relation_list": [{"subject": "amiodarone", "object": "bradyarrhythmia", "sbj_char_span": [53, 63], "obj_char_span": [30, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "entity_list": [{"name": "bradyarrhythmia", "ent_type": "Disease", "char_span": [128, 143], "ent_id": "D001919", "tok_span": [26, 31]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [49, 59], "ent_id": "D000638", "tok_span": [9, 13]}, {"name": "MI", "ent_type": "Disease", "char_span": [103, 105], "ent_id": "D009203", "tok_span": [21, 22]}, {"name": "AF", "ent_type": "Disease", "char_span": [85, 87], "ent_id": "D001281", "tok_span": [17, 18]}], "relation_list": [{"subject": "amiodarone", "object": "bradyarrhythmia", "sbj_char_span": [49, 59], "obj_char_span": [128, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [26, 31]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal mastocytosis.", "entity_list": [{"name": "mastocytosis", "ent_type": "Disease", "char_span": [142, 154], "ent_id": "D008415", "tok_span": [24, 26]}, {"name": "Indomethacin", "ent_type": "Chemical", "char_span": [13, 25], "ent_id": "D007213", "tok_span": [2, 5]}, {"name": "interstitial cystitis", "ent_type": "Disease", "char_span": [74, 95], "ent_id": "D018856", "tok_span": [12, 15]}], "relation_list": [{"subject": "Indomethacin", "object": "interstitial cystitis", "sbj_char_span": [13, 25], "obj_char_span": [74, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [12, 15]}, {"subject": "Indomethacin", "object": "mastocytosis", "sbj_char_span": [13, 25], "obj_char_span": [142, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "In the seven men who completed six months on thalidomide, subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing.", "entity_list": [{"name": "peripheral neuropathy", "ent_type": "Disease", "char_span": [82, 103], "ent_id": "D010523", "tok_span": [16, 18]}, {"name": "thalidomide", "ent_type": "Chemical", "char_span": [45, 56], "ent_id": "D013792", "tok_span": [9, 12]}], "relation_list": [{"subject": "thalidomide", "object": "peripheral neuropathy", "sbj_char_span": [45, 56], "obj_char_span": [82, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "The findings indicate that thalidomide may be an option for patients who have failed other forms of therapy, provided close follow-up is maintained for development of peripheral neuropathy.", "entity_list": [{"name": "thalidomide", "ent_type": "Chemical", "char_span": [27, 38], "ent_id": "D013792", "tok_span": [4, 7]}, {"name": "peripheral neuropathy", "ent_type": "Disease", "char_span": [167, 188], "ent_id": "D010523", "tok_span": [31, 33]}], "relation_list": [{"subject": "thalidomide", "object": "peripheral neuropathy", "sbj_char_span": [27, 38], "obj_char_span": [167, 188], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "We describe 2 cases of grand mal seizures following accidental intravascular injection of levobupivacaine.", "entity_list": [{"name": "grand mal seizures", "ent_type": "Disease", "char_span": [23, 41], "ent_id": "D004830", "tok_span": [5, 8]}, {"name": "levobupivacaine", "ent_type": "Chemical", "char_span": [90, 105], "ent_id": "C476513", "tok_span": [15, 21]}], "relation_list": [{"subject": "levobupivacaine", "object": "grand mal seizures", "sbj_char_span": [90, 105], "obj_char_span": [23, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 21], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Immediately after the administration of levobupivacaine 0.5% with epinephrine 2.5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration.", "entity_list": [{"name": "grand mal seizures", "ent_type": "Disease", "char_span": [119, 137], "ent_id": "D004830", "tok_span": [33, 36]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [214, 225], "ent_id": "D004837", "tok_span": [48, 51]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [66, 77], "ent_id": "D004837", "tok_span": [19, 22]}, {"name": "levobupivacaine", "ent_type": "Chemical", "char_span": [40, 55], "ent_id": "C476513", "tok_span": [8, 14]}], "relation_list": [{"subject": "levobupivacaine", "object": "grand mal seizures", "sbj_char_span": [40, 55], "obj_char_span": [119, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 14], "obj_tok_span": [33, 36]}], "umls_entity_list": []}, {"text": "We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of suxamethonium.", "entity_list": [{"name": "suxamethonium", "ent_type": "Chemical", "char_span": [174, 187], "ent_id": "D013390", "tok_span": [30, 35]}, {"name": "muscle spasm", "ent_type": "Disease", "char_span": [84, 96], "ent_id": "D013035", "tok_span": [18, 21]}], "relation_list": [{"subject": "suxamethonium", "object": "muscle spasm", "sbj_char_span": [174, 187], "obj_char_span": [84, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Here we sought to generate information with regard to the interictal period in animals with pilocarpine-induced epilepsy.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [92, 103], "ent_id": "D010862", "tok_span": [17, 20]}, {"name": "epilepsy", "ent_type": "Disease", "char_span": [112, 120], "ent_id": "D004827", "tok_span": [22, 23]}], "relation_list": [{"subject": "pilocarpine", "object": "epilepsy", "sbj_char_span": [92, 103], "obj_char_span": [112, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.", "entity_list": [{"name": "acute liver failure", "ent_type": "Disease", "char_span": [45, 64], "ent_id": "D017114", "tok_span": [7, 10]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D000082", "tok_span": [12, 16]}, {"name": "overdose", "ent_type": "Disease", "char_span": [84, 92], "ent_id": "D062787", "tok_span": [16, 18]}], "relation_list": [{"subject": "paracetamol", "object": "acute liver failure", "sbj_char_span": [72, 83], "obj_char_span": [45, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Levels were significantly greater in patients with acute liver failure due to paracetamol overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [179, 188], "ent_id": "D056486", "tok_span": [54, 55]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [51, 70], "ent_id": "D017114", "tok_span": [7, 10]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [78, 89], "ent_id": "D000082", "tok_span": [12, 16]}, {"name": "overdose", "ent_type": "Disease", "char_span": [90, 98], "ent_id": "D062787", "tok_span": [16, 18]}], "relation_list": [{"subject": "paracetamol", "object": "acute liver failure", "sbj_char_span": [78, 89], "obj_char_span": [51, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.", "entity_list": [{"name": "bradykinesia", "ent_type": "Disease", "char_span": [129, 141], "ent_id": "D018476", "tok_span": [31, 36]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [157, 165], "ent_id": "D007980", "tok_span": [40, 43]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [52, 71], "ent_id": "D010300", "tok_span": [9, 13]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [143, 151], "ent_id": "D009127", "tok_span": [37, 38]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [174, 185], "ent_id": "D004409", "tok_span": [45, 49]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [157, 165], "obj_char_span": [174, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 43], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "The reduction in the levodopa dose is useful in controlling drug-induced dyskinesias.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [21, 29], "ent_id": "D007980", "tok_span": [4, 7]}, {"name": "drug-induced dyskinesias", "ent_type": "Disease", "char_span": [60, 84], "ent_id": "D004409", "tok_span": [12, 19]}], "relation_list": [{"subject": "levodopa", "object": "drug-induced dyskinesias", "sbj_char_span": [21, 29], "obj_char_span": [60, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [12, 19]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "entity_list": [{"name": "carboplatin", "ent_type": "Chemical", "char_span": [109, 120], "ent_id": "D016190", "tok_span": [18, 21]}, {"name": "abnormal ocular motility", "ent_type": "Disease", "char_span": [50, 74], "ent_id": "D015835", "tok_span": [8, 11]}], "relation_list": [{"subject": "carboplatin", "object": "abnormal ocular motility", "sbj_char_span": [109, 120], "obj_char_span": [50, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "METHODS: We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin.", "entity_list": [{"name": "abnormal ocular motility", "ent_type": "Disease", "char_span": [18, 42], "ent_id": "D015835", "tok_span": [4, 7]}, {"name": "retinoblastoma", "ent_type": "Disease", "char_span": [75, 89], "ent_id": "D012175", "tok_span": [12, 14]}, {"name": "carboplatin", "ent_type": "Chemical", "char_span": [116, 127], "ent_id": "D016190", "tok_span": [20, 23]}], "relation_list": [{"subject": "carboplatin", "object": "abnormal ocular motility", "sbj_char_span": [116, 127], "obj_char_span": [18, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult.", "entity_list": [{"name": "carboplatin", "ent_type": "Chemical", "char_span": [22, 33], "ent_id": "D016190", "tok_span": [5, 8]}, {"name": "fibrosis", "ent_type": "Disease", "char_span": [78, 86], "ent_id": "D005355", "tok_span": [13, 14]}], "relation_list": [{"subject": "carboplatin", "object": "fibrosis", "sbj_char_span": [22, 33], "obj_char_span": [78, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Ethambutol and optic neuropathy.", "entity_list": [{"name": "Ethambutol", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D004977", "tok_span": [0, 4]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [15, 31], "ent_id": "D009901", "tok_span": [5, 7]}], "relation_list": [{"subject": "Ethambutol", "object": "optic neuropathy", "sbj_char_span": [0, 10], "obj_char_span": [15, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "PURPOSE: To demonstrate the association between ethambutol and optic neuropathy.", "entity_list": [{"name": "optic neuropathy", "ent_type": "Disease", "char_span": [63, 79], "ent_id": "D009901", "tok_span": [12, 14]}, {"name": "ethambutol", "ent_type": "Chemical", "char_span": [48, 58], "ent_id": "D004977", "tok_span": [7, 11]}], "relation_list": [{"subject": "ethambutol", "object": "optic neuropathy", "sbj_char_span": [48, 58], "obj_char_span": [63, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "METHOD: Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed.", "entity_list": [{"name": "tuberculosis of the lung or lymph node", "ent_type": "Disease", "char_span": [97, 135], "ent_id": "D01439", "tok_span": [19, 26]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [40, 56], "ent_id": "D009901", "tok_span": [8, 10]}, {"name": "ethambutol", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D004977", "tok_span": [14, 18]}], "relation_list": [{"subject": "ethambutol", "object": "optic neuropathy", "sbj_char_span": [82, 92], "obj_char_span": [40, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "RESULTS: All patients had optic neuropathy between 1 to 6 months (mean = 2.9 months) after starting ethambutol therapy at a dosage ranging from 13 to 20 mg/kg/day (mean = 17 mg/kg/day).", "entity_list": [{"name": "ethambutol", "ent_type": "Chemical", "char_span": [100, 110], "ent_id": "D004977", "tok_span": [22, 26]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [26, 42], "ent_id": "D009901", "tok_span": [5, 7]}], "relation_list": [{"subject": "ethambutol", "object": "optic neuropathy", "sbj_char_span": [100, 110], "obj_char_span": [26, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ethambutol therapy.", "entity_list": [{"name": "ethambutol", "ent_type": "Chemical", "char_span": [88, 98], "ent_id": "D004977", "tok_span": [13, 17]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [33, 49], "ent_id": "D009901", "tok_span": [5, 7]}], "relation_list": [{"subject": "ethambutol", "object": "optic neuropathy", "sbj_char_span": [88, 98], "obj_char_span": [33, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).", "entity_list": [{"name": "headache", "ent_type": "Disease", "char_span": [105, 113], "ent_id": "D006261", "tok_span": [28, 29]}, {"name": "sore throat", "ent_type": "Disease", "char_span": [50, 61], "ent_id": "D010612", "tok_span": [10, 14]}, {"name": "glycopyrrolate", "ent_type": "Chemical", "char_span": [133, 147], "ent_id": "D006024", "tok_span": [37, 41]}, {"name": "dry mouth", "ent_type": "Disease", "char_span": [34, 43], "ent_id": "D014987", "tok_span": [6, 8]}, {"name": "glycopyrrolate", "ent_type": "Chemical", "char_span": [80, 94], "ent_id": "D006024", "tok_span": [20, 24]}], "relation_list": [{"subject": "glycopyrrolate", "object": "sore throat", "sbj_char_span": [80, 94], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [10, 14]}, {"subject": "glycopyrrolate", "object": "headache", "sbj_char_span": [133, 147], "obj_char_span": [105, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 41], "obj_tok_span": [28, 29]}, {"subject": "glycopyrrolate", "object": "headache", "sbj_char_span": [80, 94], "obj_char_span": [105, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [28, 29]}, {"subject": "glycopyrrolate", "object": "sore throat", "sbj_char_span": [133, 147], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 41], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Pain on injection (80 vs. 20%, p < 0.01) and thrombophlebitis (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with Disoprivan.", "entity_list": [{"name": "Disoprivan", "ent_type": "Chemical", "char_span": [135, 145], "ent_id": "D015742", "tok_span": [47, 51]}, {"name": "Pain", "ent_type": "Disease", "char_span": [0, 4], "ent_id": "D010146", "tok_span": [0, 1]}, {"name": "thrombophlebitis", "ent_type": "Disease", "char_span": [45, 61], "ent_id": "D013924", "tok_span": [17, 21]}], "relation_list": [{"subject": "Disoprivan", "object": "Pain", "sbj_char_span": [135, 145], "obj_char_span": [0, 4], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 51], "obj_tok_span": [0, 1]}, {"subject": "Disoprivan", "object": "thrombophlebitis", "sbj_char_span": [135, 145], "obj_char_span": [45, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 51], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "entity_list": [{"name": "anthracyclines", "ent_type": "Chemical", "char_span": [105, 119], "ent_id": "D018943", "tok_span": [27, 30]}, {"name": "fluorouracil", "ent_type": "Chemical", "char_span": [91, 103], "ent_id": "D005472", "tok_span": [23, 26]}, {"name": "cardiotoxic", "ent_type": "Disease", "char_span": [72, 83], "ent_id": "D066126", "tok_span": [19, 21]}, {"name": "gemcitabine", "ent_type": "Chemical", "char_span": [121, 132], "ent_id": "C056507", "tok_span": [31, 34]}, {"name": "VNR", "ent_type": "Chemical", "char_span": [12, 15], "ent_id": "C030852", "tok_span": [3, 5]}, {"name": "GEM", "ent_type": "Chemical", "char_span": [134, 137], "ent_id": "C056507", "tok_span": [35, 37]}, {"name": "vindesine", "ent_type": "Chemical", "char_span": [46, 55], "ent_id": "D014751", "tok_span": [10, 13]}, {"name": "VDS", "ent_type": "Chemical", "char_span": [57, 60], "ent_id": "D014751", "tok_span": [14, 16]}], "relation_list": [{"subject": "VNR", "object": "cardiotoxic", "sbj_char_span": [12, 15], "obj_char_span": [72, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by trimethoprim-sulfomethoxazole, resulting in cerebral anoxia leading to permanent damage.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [97, 113], "ent_id": "D000743", "tok_span": [20, 23]}, {"name": "cerebral anoxia", "ent_type": "Disease", "char_span": [176, 191], "ent_id": "D002534", "tok_span": [38, 41]}, {"name": "trimethoprim-sulfomethoxazole", "ent_type": "Chemical", "char_span": [132, 161], "ent_id": "D015662", "tok_span": [26, 35]}], "relation_list": [{"subject": "trimethoprim-sulfomethoxazole", "object": "hemolytic anemia", "sbj_char_span": [132, 161], "obj_char_span": [97, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 35], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.", "entity_list": [{"name": "visual field defects", "ent_type": "Disease", "char_span": [45, 65], "ent_id": "D014786", "tok_span": [9, 12]}, {"name": "Vigabatrin", "ent_type": "Chemical", "char_span": [23, 33], "ent_id": "D020888", "tok_span": [4, 8]}], "relation_list": [{"subject": "Vigabatrin", "object": "visual field defects", "sbj_char_span": [23, 33], "obj_char_span": [45, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "PURPOSE: To determine the natural history of visual field defects in a group of patients known to have Vigabatrin-associated changes who elected to continue the medication because of good seizure control.", "entity_list": [{"name": "Vigabatrin", "ent_type": "Chemical", "char_span": [103, 113], "ent_id": "D020888", "tok_span": [19, 23]}, {"name": "seizure", "ent_type": "Disease", "char_span": [188, 195], "ent_id": "D012640", "tok_span": [35, 36]}, {"name": "visual field defects", "ent_type": "Disease", "char_span": [45, 65], "ent_id": "D014786", "tok_span": [8, 11]}], "relation_list": [{"subject": "Vigabatrin", "object": "visual field defects", "sbj_char_span": [103, 113], "obj_char_span": [45, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "CONCLUSION: Established visual field defects presumed to be due to Vigabatrin therapy did not usually progress in spite of continuing use of the medication.", "entity_list": [{"name": "visual field defects", "ent_type": "Disease", "char_span": [24, 44], "ent_id": "D014786", "tok_span": [4, 7]}, {"name": "Vigabatrin", "ent_type": "Chemical", "char_span": [67, 77], "ent_id": "D020888", "tok_span": [12, 16]}], "relation_list": [{"subject": "Vigabatrin", "object": "visual field defects", "sbj_char_span": [67, 77], "obj_char_span": [24, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "These data give support to the hypothesis that the pathogenesis of Vigabatrin-associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose-dependent toxicity.", "entity_list": [{"name": "visual field defects", "ent_type": "Disease", "char_span": [89, 109], "ent_id": "D014786", "tok_span": [17, 20]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [183, 191], "ent_id": "D064420", "tok_span": [35, 36]}, {"name": "Vigabatrin", "ent_type": "Chemical", "char_span": [67, 77], "ent_id": "D020888", "tok_span": [11, 15]}], "relation_list": [{"subject": "Vigabatrin", "object": "visual field defects", "sbj_char_span": [67, 77], "obj_char_span": [89, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.", "entity_list": [{"name": "Tacrolimus", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D016559", "tok_span": [2, 6]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [190, 197], "ent_id": "D013256", "tok_span": [35, 36]}, {"name": "perioral dermatitis", "ent_type": "Disease", "char_span": [221, 240], "ent_id": "D019557", "tok_span": [44, 47]}, {"name": "rosacea", "ent_type": "Disease", "char_span": [209, 216], "ent_id": "D012393", "tok_span": [39, 43]}], "relation_list": [{"subject": "Tacrolimus", "object": "rosacea", "sbj_char_span": [12, 22], "obj_char_span": [209, 216], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "We visualize, for the first time, the profile of structural deficits in the human brain associated with chronic methamphetamine (MA) abuse.", "entity_list": [{"name": "structural deficits in the human brain", "ent_type": "Disease", "char_span": [49, 87], "ent_id": "D001930", "tok_span": [11, 17]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [112, 127], "ent_id": "D008694", "tok_span": [20, 23]}, {"name": "MA", "ent_type": "Chemical", "char_span": [129, 131], "ent_id": "D008694", "tok_span": [24, 25]}], "relation_list": [{"subject": "methamphetamine", "object": "structural deficits in the human brain", "sbj_char_span": [112, 127], "obj_char_span": [49, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [11, 17]}, {"subject": "MA", "object": "structural deficits in the human brain", "sbj_char_span": [129, 131], "obj_char_span": [49, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [11, 17]}], "umls_entity_list": []}, {"text": "We used high-resolution MRI and surface-based computational image analyses to map regional abnormalities in the cortex, hippocampus, white matter, and ventricles in 22 human subjects who used MA and 21 age-matched, healthy controls.", "entity_list": [{"name": "MA", "ent_type": "Chemical", "char_span": [192, 194], "ent_id": "D008694", "tok_span": [35, 36]}, {"name": "abnormalities in the cortex, hippocampus, white matter, and ventricles", "ent_type": "Disease", "char_span": [91, 161], "ent_id": "D001930", "tok_span": [16, 29]}], "relation_list": [{"subject": "MA", "object": "abnormalities in the cortex, hippocampus, white matter, and ventricles", "sbj_char_span": [192, 194], "obj_char_span": [91, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 36], "obj_tok_span": [16, 29]}], "umls_entity_list": []}, {"text": "MRI-based maps suggest that chronic methamphetamine abuse causes a selective pattern of cerebral deterioration that contributes to impaired memory performance.", "entity_list": [{"name": "methamphetamine", "ent_type": "Chemical", "char_span": [36, 51], "ent_id": "D008694", "tok_span": [7, 10]}, {"name": "impaired memory performance", "ent_type": "Disease", "char_span": [131, 158], "ent_id": "D008569", "tok_span": [21, 24]}], "relation_list": [{"subject": "methamphetamine", "object": "impaired memory performance", "sbj_char_span": [36, 51], "obj_char_span": [131, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "These brain substrates may help account for the symptoms of MA abuse, providing therapeutic targets for drug-induced brain injury.", "entity_list": [{"name": "MA", "ent_type": "Chemical", "char_span": [60, 62], "ent_id": "D008694", "tok_span": [10, 11]}, {"name": "brain injury", "ent_type": "Disease", "char_span": [117, 129], "ent_id": "D001930", "tok_span": [20, 22]}], "relation_list": [{"subject": "MA", "object": "brain injury", "sbj_char_span": [60, 62], "obj_char_span": [117, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Amiodarone, an efficacious and widely used antiarrhythmic agent, has been reported to cause hepatotoxicity in some patients.", "entity_list": [{"name": "Amiodarone", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D000638", "tok_span": [0, 4]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [92, 106], "ent_id": "D056486", "tok_span": [21, 23]}], "relation_list": [{"subject": "Amiodarone", "object": "hepatotoxicity", "sbj_char_span": [0, 10], "obj_char_span": [92, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.", "entity_list": [{"name": "triglycerides", "ent_type": "Chemical", "char_span": [115, 128], "ent_id": "D014280", "tok_span": [23, 24]}, {"name": "hepatomegaly", "ent_type": "Disease", "char_span": [19, 31], "ent_id": "D006529", "tok_span": [5, 8]}, {"name": "Amiodarone", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D000638", "tok_span": [0, 4]}, {"name": "glucose", "ent_type": "Chemical", "char_span": [133, 140], "ent_id": "D005947", "tok_span": [25, 26]}], "relation_list": [{"subject": "Amiodarone", "object": "hepatomegaly", "sbj_char_span": [0, 10], "obj_char_span": [19, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene.", "entity_list": [{"name": "amiodarone", "ent_type": "Chemical", "char_span": [136, 146], "ent_id": "D000638", "tok_span": [30, 34]}, {"name": "hepatomegaly", "ent_type": "Disease", "char_span": [51, 63], "ent_id": "D006529", "tok_span": [10, 13]}], "relation_list": [{"subject": "amiodarone", "object": "hepatomegaly", "sbj_char_span": [136, 146], "obj_char_span": [51, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.", "entity_list": [{"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [172, 186], "ent_id": "D056486", "tok_span": [30, 32]}, {"name": "hepatotoxic", "ent_type": "Disease", "char_span": [74, 85], "ent_id": "D056486", "tok_span": [9, 11]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [153, 163], "ent_id": "D000638", "tok_span": [24, 28]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [97, 107], "ent_id": "D000638", "tok_span": [13, 17]}], "relation_list": [{"subject": "amiodarone", "object": "hepatotoxic", "sbj_char_span": [153, 163], "obj_char_span": [74, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [9, 11]}, {"subject": "amiodarone", "object": "hepatotoxicity", "sbj_char_span": [153, 163], "obj_char_span": [172, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [30, 32]}, {"subject": "amiodarone", "object": "hepatotoxic", "sbj_char_span": [97, 107], "obj_char_span": [74, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [9, 11]}, {"subject": "amiodarone", "object": "hepatotoxicity", "sbj_char_span": [97, 107], "obj_char_span": [172, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol.", "entity_list": [{"name": "Terminalia chebula", "ent_type": "Chemical", "char_span": [21, 39], "ent_id": "D010936", "tok_span": [5, 11]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [90, 103], "ent_id": "D007545", "tok_span": [17, 21]}, {"name": "myocardial injury", "ent_type": "Disease", "char_span": [61, 78], "ent_id": "D009202", "tok_span": [13, 15]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial injury", "sbj_char_span": [90, 103], "obj_char_span": [61, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Cardioprotective effect of ethanolic extract of Terminalia chebula fruits (500 mg/kg body wt) was examined in isoproterenol (200 mg/kg body wt) induced myocardial damage in rats.", "entity_list": [{"name": "isoproterenol", "ent_type": "Chemical", "char_span": [110, 123], "ent_id": "D007545", "tok_span": [26, 30]}, {"name": "ethanolic extract of Terminalia chebula fruits", "ent_type": "Chemical", "char_span": [27, 73], "ent_id": "D010936", "tok_span": [4, 15]}, {"name": "myocardial damage", "ent_type": "Disease", "char_span": [152, 169], "ent_id": "D009202", "tok_span": [39, 41]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial damage", "sbj_char_span": [110, 123], "obj_char_span": [152, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [39, 41]}], "umls_entity_list": []}, {"text": "A case of postoperative anxiety due to low dose droperidol used with patient-controlled analgesia.", "entity_list": [{"name": "droperidol", "ent_type": "Chemical", "char_span": [48, 58], "ent_id": "D004329", "tok_span": [9, 13]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [24, 31], "ent_id": "D001008", "tok_span": [4, 5]}], "relation_list": [{"subject": "droperidol", "object": "anxiety", "sbj_char_span": [48, 58], "obj_char_span": [24, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "The diagnosis of droperidol-induced psychological disturbance was not made straight away although on subsequent close questioning the patient gave a very clear history.", "entity_list": [{"name": "psychological disturbance", "ent_type": "Disease", "char_span": [36, 61], "ent_id": "D001008", "tok_span": [9, 11]}, {"name": "droperidol", "ent_type": "Chemical", "char_span": [17, 27], "ent_id": "D004329", "tok_span": [3, 7]}], "relation_list": [{"subject": "droperidol", "object": "psychological disturbance", "sbj_char_span": [17, 27], "obj_char_span": [36, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Lithium is implicated in drug-induced nephrogenic DI, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic DI.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [95, 102], "ent_id": "D008094", "tok_span": [19, 20]}, {"name": "nephrogenic DI", "ent_type": "Disease", "char_span": [175, 189], "ent_id": "D018500", "tok_span": [33, 36]}, {"name": "nephrogenic DI", "ent_type": "Disease", "char_span": [38, 52], "ent_id": "D018500", "tok_span": [8, 11]}, {"name": "Lithium", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D008094", "tok_span": [0, 2]}], "relation_list": [{"subject": "Lithium", "object": "nephrogenic DI", "sbj_char_span": [0, 7], "obj_char_span": [38, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [8, 11]}, {"subject": "lithium", "object": "nephrogenic DI", "sbj_char_span": [95, 102], "obj_char_span": [175, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [33, 36]}, {"subject": "Lithium", "object": "nephrogenic DI", "sbj_char_span": [0, 7], "obj_char_span": [175, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [33, 36]}, {"subject": "lithium", "object": "nephrogenic DI", "sbj_char_span": [95, 102], "obj_char_span": [38, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his lithium-induced nephrogenic DI and developed neurogenic DI secondary to brain trauma.", "entity_list": [{"name": "nephrogenic DI", "ent_type": "Disease", "char_span": [212, 226], "ent_id": "D018500", "tok_span": [37, 40]}, {"name": "brain trauma", "ent_type": "Disease", "char_span": [268, 280], "ent_id": "D001930", "tok_span": [47, 49]}, {"name": "neurogenic DI", "ent_type": "Disease", "char_span": [241, 254], "ent_id": "D018500", "tok_span": [42, 45]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [196, 203], "ent_id": "D008094", "tok_span": [34, 35]}], "relation_list": [{"subject": "lithium", "object": "neurogenic DI", "sbj_char_span": [196, 203], "obj_char_span": [241, 254], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [42, 45]}, {"subject": "lithium", "object": "nephrogenic DI", "sbj_char_span": [196, 203], "obj_char_span": [212, 226], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [37, 40]}], "umls_entity_list": []}, {"text": "BACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "entity_list": [{"name": "Interferon", "ent_type": "Chemical", "char_span": [20, 30], "ent_id": "D016898", "tok_span": [4, 7]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [98, 114], "ent_id": "D000743", "tok_span": [18, 21]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [35, 44], "ent_id": "D012254", "tok_span": [8, 11]}, {"name": "chronic hepatitis C", "ent_type": "Disease", "char_span": [69, 88], "ent_id": "D019698", "tok_span": [14, 17]}], "relation_list": [{"subject": "ribavirin", "object": "hemolytic anemia", "sbj_char_span": [35, 44], "obj_char_span": [98, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [18, 21]}, {"subject": "Interferon", "object": "hemolytic anemia", "sbj_char_span": [20, 30], "obj_char_span": [98, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury.", "entity_list": [{"name": "mitochondrial injury", "ent_type": "Disease", "char_span": [73, 93], "ent_id": "D028361", "tok_span": [16, 18]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [46, 56], "ent_id": "D004317", "tok_span": [9, 13]}], "relation_list": [{"subject": "adriamycin", "object": "mitochondrial injury", "sbj_char_span": [46, 56], "obj_char_span": [73, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Our data showed ADR induced 4HNE-protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared.", "entity_list": [{"name": "mitochondrial injury", "ent_type": "Disease", "char_span": [96, 116], "ent_id": "D028361", "tok_span": [21, 23]}, {"name": "ADR", "ent_type": "Chemical", "char_span": [16, 19], "ent_id": "D004317", "tok_span": [3, 5]}, {"name": "4HNE", "ent_type": "Chemical", "char_span": [28, 32], "ent_id": "C027576", "tok_span": [6, 9]}], "relation_list": [{"subject": "ADR", "object": "mitochondrial injury", "sbj_char_span": [16, 19], "obj_char_span": [96, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.", "entity_list": [{"name": "Sotalol", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D013015", "tok_span": [0, 3]}, {"name": "coronary spasm", "ent_type": "Disease", "char_span": [16, 30], "ent_id": "D003329", "tok_span": [5, 8]}, {"name": "dilated cardiomyopathy", "ent_type": "Disease", "char_span": [49, 71], "ent_id": "D002311", "tok_span": [12, 14]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [98, 121], "ent_id": "D017180", "tok_span": [17, 19]}], "relation_list": [{"subject": "Sotalol", "object": "coronary spasm", "sbj_char_span": [0, 7], "obj_char_span": [16, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Coronary vasospasm may be induced by the non-selective beta-blocking properties of sotalol.", "entity_list": [{"name": "sotalol", "ent_type": "Chemical", "char_span": [83, 90], "ent_id": "D013015", "tok_span": [17, 20]}, {"name": "Coronary vasospasm", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D003329", "tok_span": [0, 4]}], "relation_list": [{"subject": "sotalol", "object": "Coronary vasospasm", "sbj_char_span": [83, 90], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "entity_list": [{"name": "fluoxetine", "ent_type": "Chemical", "char_span": [241, 251], "ent_id": "D005473", "tok_span": [74, 77]}, {"name": "oral stereotypies", "ent_type": "Disease", "char_span": [94, 111], "ent_id": "D009062", "tok_span": [24, 28]}, {"name": "dexamphetamine", "ent_type": "Chemical", "char_span": [54, 68], "ent_id": "D003913", "tok_span": [12, 15]}, {"name": "ergometrine", "ent_type": "Chemical", "char_span": [188, 199], "ent_id": "D004874", "tok_span": [59, 62]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [116, 125], "ent_id": "D002375", "tok_span": [30, 33]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [137, 148], "ent_id": "D006220", "tok_span": [35, 38]}, {"name": "trazodone", "ent_type": "Chemical", "char_span": [41, 50], "ent_id": "D014196", "tok_span": [7, 11]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [74, 85], "ent_id": "D001058", "tok_span": [17, 22]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [153, 164], "ent_id": "D001058", "tok_span": [39, 44]}], "relation_list": [{"subject": "apomorphine", "object": "catalepsy", "sbj_char_span": [74, 85], "obj_char_span": [116, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 22], "obj_tok_span": [30, 33]}, {"subject": "apomorphine", "object": "catalepsy", "sbj_char_span": [153, 164], "obj_char_span": [116, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 44], "obj_tok_span": [30, 33]}, {"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [137, 148], "obj_char_span": [116, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.", "entity_list": [{"name": "Trazodone", "ent_type": "Chemical", "char_span": [9, 18], "ent_id": "D014196", "tok_span": [2, 6]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [55, 64], "ent_id": "D002375", "tok_span": [22, 25]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [134, 145], "ent_id": "D001058", "tok_span": [50, 55]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [89, 100], "ent_id": "D001058", "tok_span": [31, 36]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [167, 176], "ent_id": "D002375", "tok_span": [65, 68]}], "relation_list": [{"subject": "apomorphine", "object": "catalepsy", "sbj_char_span": [134, 145], "obj_char_span": [55, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 55], "obj_tok_span": [22, 25]}, {"subject": "apomorphine", "object": "catalepsy", "sbj_char_span": [89, 100], "obj_char_span": [55, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 36], "obj_tok_span": [22, 25]}, {"subject": "apomorphine", "object": "catalepsy", "sbj_char_span": [89, 100], "obj_char_span": [167, 176], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 36], "obj_tok_span": [65, 68]}, {"subject": "apomorphine", "object": "catalepsy", "sbj_char_span": [134, 145], "obj_char_span": [167, 176], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 55], "obj_tok_span": [65, 68]}], "umls_entity_list": []}, {"text": "However, pretreatment with 5, 10 and 20 mg/kg i.p. trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "entity_list": [{"name": "dexamphetamine", "ent_type": "Chemical", "char_span": [70, 84], "ent_id": "D003913", "tok_span": [21, 24]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [113, 124], "ent_id": "D006220", "tok_span": [31, 34]}, {"name": "ergometrine", "ent_type": "Chemical", "char_span": [136, 147], "ent_id": "D004874", "tok_span": [38, 41]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [173, 183], "ent_id": "D005473", "tok_span": [47, 50]}, {"name": "trazodone", "ent_type": "Chemical", "char_span": [51, 60], "ent_id": "D014196", "tok_span": [16, 20]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [125, 134], "ent_id": "D002375", "tok_span": [34, 37]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [113, 124], "obj_char_span": [125, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [34, 37]}], "umls_entity_list": []}, {"text": "Trazodone at 30, 40 and 50 mg/kg i.p. induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies.", "entity_list": [{"name": "apomorphine", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D001058", "tok_span": [24, 29]}, {"name": "Trazodone", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D014196", "tok_span": [0, 4]}, {"name": "dexamphetamine", "ent_type": "Chemical", "char_span": [88, 102], "ent_id": "D003913", "tok_span": [30, 33]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [46, 55], "ent_id": "D002375", "tok_span": [18, 21]}], "relation_list": [{"subject": "apomorphine", "object": "catalepsy", "sbj_char_span": [72, 83], "obj_char_span": [46, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 29], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.", "entity_list": [{"name": "5-HT", "ent_type": "Chemical", "char_span": [64, 68], "ent_id": "D012701", "tok_span": [21, 24]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [230, 241], "ent_id": "D006220", "tok_span": [59, 62]}, {"name": "dexamphetamine", "ent_type": "Chemical", "char_span": [188, 202], "ent_id": "D003913", "tok_span": [50, 53]}, {"name": "trazodone", "ent_type": "Chemical", "char_span": [16, 25], "ent_id": "D014196", "tok_span": [3, 7]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [242, 251], "ent_id": "D002375", "tok_span": [62, 65]}, {"name": "5-HT", "ent_type": "Chemical", "char_span": [158, 162], "ent_id": "D012701", "tok_span": [42, 45]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [230, 241], "obj_char_span": [242, 251], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 62], "obj_tok_span": [62, 65]}], "umls_entity_list": []}, {"text": "The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa-induced dyskinesia.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [101, 109], "ent_id": "D007980", "tok_span": [18, 21]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [118, 128], "ent_id": "D004409", "tok_span": [23, 27]}, {"name": "PD", "ent_type": "Disease", "char_span": [72, 74], "ent_id": "D010300", "tok_span": [13, 14]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [101, 109], "obj_char_span": [118, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "In the current study, dyskinetic patients performed better in swallowing function, which could be explained on the basis of a greater levodopa dose.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [134, 142], "ent_id": "D007980", "tok_span": [27, 30]}, {"name": "dyskinetic", "ent_type": "Disease", "char_span": [22, 32], "ent_id": "D004409", "tok_span": [5, 9]}], "relation_list": [{"subject": "levodopa", "object": "dyskinetic", "sbj_char_span": [134, 142], "obj_char_span": [22, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Inhibition of nuclear factor-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin.", "entity_list": [{"name": "gentamicin", "ent_type": "Chemical", "char_span": [98, 108], "ent_id": "D005839", "tok_span": [19, 21]}, {"name": "tubulointerstitial nephritis", "ent_type": "Disease", "char_span": [58, 86], "ent_id": "D009395", "tok_span": [10, 17]}], "relation_list": [{"subject": "gentamicin", "object": "tubulointerstitial nephritis", "sbj_char_span": [98, 108], "obj_char_span": [58, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [10, 17]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: These data show that inhibition of NF-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin.", "entity_list": [{"name": "tubulointerstitial nephritis", "ent_type": "Disease", "char_span": [80, 108], "ent_id": "D009395", "tok_span": [15, 22]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [120, 130], "ent_id": "D005839", "tok_span": [24, 26]}], "relation_list": [{"subject": "gentamicin", "object": "tubulointerstitial nephritis", "sbj_char_span": [120, 130], "obj_char_span": [80, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [15, 22]}], "umls_entity_list": []}, {"text": "There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).", "entity_list": [{"name": "olanzapine", "ent_type": "Chemical", "char_span": [338, 348], "ent_id": "C076029", "tok_span": [91, 94]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [302, 313], "ent_id": "D018967", "tok_span": [71, 74]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [178, 188], "ent_id": "C076029", "tok_span": [49, 52]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [102, 111], "ent_id": "D003024", "tok_span": [28, 31]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [352, 363], "ent_id": "D018967", "tok_span": [95, 98]}, {"name": "insulin resistance", "ent_type": "Disease", "char_span": [212, 230], "ent_id": "D007333", "tok_span": [54, 56]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [112, 122], "ent_id": "C076029", "tok_span": [32, 35]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [289, 298], "ent_id": "D003024", "tok_span": [67, 70]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [164, 173], "ent_id": "D003024", "tok_span": [45, 48]}, {"name": "insulin sensitivity", "ent_type": "Disease", "char_span": [38, 57], "ent_id": "D007333", "tok_span": [6, 8]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [276, 287], "ent_id": "D018967", "tok_span": [63, 66]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [123, 134], "ent_id": "D018967", "tok_span": [36, 39]}], "relation_list": [{"subject": "olanzapine", "object": "insulin resistance", "sbj_char_span": [112, 122], "obj_char_span": [212, 230], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [54, 56]}, {"subject": "clozapine", "object": "insulin sensitivity", "sbj_char_span": [164, 173], "obj_char_span": [38, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 48], "obj_tok_span": [6, 8]}, {"subject": "clozapine", "object": "insulin sensitivity", "sbj_char_span": [289, 298], "obj_char_span": [38, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [67, 70], "obj_tok_span": [6, 8]}, {"subject": "clozapine", "object": "insulin resistance", "sbj_char_span": [102, 111], "obj_char_span": [212, 230], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [54, 56]}, {"subject": "olanzapine", "object": "insulin resistance", "sbj_char_span": [338, 348], "obj_char_span": [212, 230], "rel_type": "chemical-induced disease", "sbj_tok_span": [91, 94], "obj_tok_span": [54, 56]}, {"subject": "clozapine", "object": "insulin resistance", "sbj_char_span": [289, 298], "obj_char_span": [212, 230], "rel_type": "chemical-induced disease", "sbj_tok_span": [67, 70], "obj_tok_span": [54, 56]}, {"subject": "olanzapine", "object": "insulin resistance", "sbj_char_span": [178, 188], "obj_char_span": [212, 230], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 52], "obj_tok_span": [54, 56]}, {"subject": "olanzapine", "object": "insulin sensitivity", "sbj_char_span": [178, 188], "obj_char_span": [38, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 52], "obj_tok_span": [6, 8]}, {"subject": "clozapine", "object": "insulin resistance", "sbj_char_span": [164, 173], "obj_char_span": [212, 230], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 48], "obj_tok_span": [54, 56]}, {"subject": "olanzapine", "object": "insulin sensitivity", "sbj_char_span": [338, 348], "obj_char_span": [38, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [91, 94], "obj_tok_span": [6, 8]}, {"subject": "olanzapine", "object": "insulin sensitivity", "sbj_char_span": [112, 122], "obj_char_span": [38, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [6, 8]}, {"subject": "clozapine", "object": "insulin sensitivity", "sbj_char_span": [102, 111], "obj_char_span": [38, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).", "entity_list": [{"name": "risperidone", "ent_type": "Chemical", "char_span": [220, 231], "ent_id": "D018967", "tok_span": [68, 71]}, {"name": "insulin resistance", "ent_type": "Disease", "char_span": [36, 54], "ent_id": "D007333", "tok_span": [5, 7]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [121, 130], "ent_id": "D003024", "tok_span": [28, 31]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [156, 165], "ent_id": "D003024", "tok_span": [41, 44]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [131, 141], "ent_id": "C076029", "tok_span": [32, 35]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [206, 216], "ent_id": "C076029", "tok_span": [64, 67]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [169, 180], "ent_id": "D018967", "tok_span": [45, 48]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [142, 153], "ent_id": "D018967", "tok_span": [36, 39]}], "relation_list": [{"subject": "olanzapine", "object": "insulin resistance", "sbj_char_span": [206, 216], "obj_char_span": [36, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [64, 67], "obj_tok_span": [5, 7]}, {"subject": "clozapine", "object": "insulin resistance", "sbj_char_span": [156, 165], "obj_char_span": [36, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 44], "obj_tok_span": [5, 7]}, {"subject": "olanzapine", "object": "insulin resistance", "sbj_char_span": [131, 141], "obj_char_span": [36, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [5, 7]}, {"subject": "clozapine", "object": "insulin resistance", "sbj_char_span": [121, 130], "obj_char_span": [36, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.", "entity_list": [{"name": "glucose", "ent_type": "Chemical", "char_span": [127, 134], "ent_id": "D005947", "tok_span": [24, 25]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [42, 52], "ent_id": "C076029", "tok_span": [11, 14]}, {"name": "insulin resistance", "ent_type": "Disease", "char_span": [90, 108], "ent_id": "D007333", "tok_span": [19, 21]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [163, 174], "ent_id": "D018967", "tok_span": [28, 31]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [27, 36], "ent_id": "D003024", "tok_span": [6, 9]}], "relation_list": [{"subject": "clozapine", "object": "insulin resistance", "sbj_char_span": [27, 36], "obj_char_span": [90, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [19, 21]}, {"subject": "olanzapine", "object": "insulin resistance", "sbj_char_span": [42, 52], "obj_char_span": [90, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.", "entity_list": [{"name": "insulin resistance", "ent_type": "Disease", "char_span": [62, 80], "ent_id": "D007333", "tok_span": [13, 15]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [16, 25], "ent_id": "D003024", "tok_span": [2, 5]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [30, 40], "ent_id": "C076029", "tok_span": [6, 9]}], "relation_list": [{"subject": "clozapine", "object": "insulin resistance", "sbj_char_span": [16, 25], "obj_char_span": [62, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [13, 15]}, {"subject": "olanzapine", "object": "insulin resistance", "sbj_char_span": [30, 40], "obj_char_span": [62, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Focal cerebral ischemia in rats: effect of phenylephrine-induced hypertension during reperfusion.", "entity_list": [{"name": "cerebral ischemia", "ent_type": "Disease", "char_span": [6, 23], "ent_id": "D002545", "tok_span": [2, 4]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [65, 77], "ent_id": "D006973", "tok_span": [14, 15]}, {"name": "phenylephrine", "ent_type": "Chemical", "char_span": [43, 56], "ent_id": "D010656", "tok_span": [9, 12]}], "relation_list": [{"subject": "phenylephrine", "object": "hypertension", "sbj_char_span": [43, 56], "obj_char_span": [65, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.", "entity_list": [{"name": "ischemic brain injury", "ent_type": "Disease", "char_span": [148, 169], "ent_id": "D001930", "tok_span": [24, 27]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [77, 89], "ent_id": "D006973", "tok_span": [11, 12]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [132, 144], "ent_id": "D006973", "tok_span": [22, 23]}, {"name": "phenylephrine", "ent_type": "Chemical", "char_span": [110, 123], "ent_id": "D010656", "tok_span": [17, 20]}, {"name": "middle cerebral artery occlusion", "ent_type": "Disease", "char_span": [27, 59], "ent_id": "D020244", "tok_span": [5, 9]}], "relation_list": [{"subject": "phenylephrine", "object": "hypertension", "sbj_char_span": [110, 123], "obj_char_span": [132, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 23]}, {"subject": "phenylephrine", "object": "hypertensive", "sbj_char_span": [110, 123], "obj_char_span": [77, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.", "entity_list": [{"name": "stroke", "ent_type": "Disease", "char_span": [89, 95], "ent_id": "D020521", "tok_span": [16, 17]}, {"name": "hemorrhage", "ent_type": "Disease", "char_span": [74, 84], "ent_id": "D006470", "tok_span": [14, 15]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [46, 54], "ent_id": "D014859", "tok_span": [8, 9]}, {"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [23, 42], "ent_id": "D001281", "tok_span": [5, 7]}], "relation_list": [{"subject": "warfarin", "object": "hemorrhage", "sbj_char_span": [46, 54], "obj_char_span": [74, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.", "entity_list": [{"name": "stroke", "ent_type": "Disease", "char_span": [63, 69], "ent_id": "D020521", "tok_span": [10, 11]}, {"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [103, 122], "ent_id": "D001281", "tok_span": [18, 20]}, {"name": "hemorrhage", "ent_type": "Disease", "char_span": [48, 58], "ent_id": "D006470", "tok_span": [8, 9]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [140, 148], "ent_id": "D014859", "tok_span": [24, 25]}], "relation_list": [{"subject": "warfarin", "object": "hemorrhage", "sbj_char_span": [140, 148], "obj_char_span": [48, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "MEASUREMENTS: Information regarding major bleeding episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.", "entity_list": [{"name": "strokes", "ent_type": "Disease", "char_span": [61, 68], "ent_id": "D020521", "tok_span": [11, 12]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [74, 82], "ent_id": "D014859", "tok_span": [14, 15]}, {"name": "bleeding", "ent_type": "Disease", "char_span": [42, 50], "ent_id": "D006470", "tok_span": [8, 9]}], "relation_list": [{"subject": "warfarin", "object": "bleeding", "sbj_char_span": [74, 82], "obj_char_span": [42, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.", "entity_list": [{"name": "warfarin", "ent_type": "Chemical", "char_span": [160, 168], "ent_id": "D014859", "tok_span": [36, 37]}, {"name": "stroke", "ent_type": "Disease", "char_span": [145, 151], "ent_id": "D020521", "tok_span": [33, 34]}, {"name": "hemorrhage", "ent_type": "Disease", "char_span": [30, 40], "ent_id": "D006470", "tok_span": [6, 7]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [206, 214], "ent_id": "D014859", "tok_span": [43, 44]}], "relation_list": [{"subject": "warfarin", "object": "hemorrhage", "sbj_char_span": [160, 168], "obj_char_span": [30, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 37], "obj_tok_span": [6, 7]}, {"subject": "warfarin", "object": "hemorrhage", "sbj_char_span": [206, 214], "obj_char_span": [30, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 44], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.", "entity_list": [{"name": "celecoxib", "ent_type": "Chemical", "char_span": [10, 19], "ent_id": "C105934", "tok_span": [2, 6]}, {"name": "nimesulide", "ent_type": "Chemical", "char_span": [95, 105], "ent_id": "C012655", "tok_span": [23, 27]}, {"name": "skin reactions", "ent_type": "Disease", "char_span": [45, 59], "ent_id": "D003875", "tok_span": [10, 12]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [63, 76], "ent_id": "D000082", "tok_span": [13, 16]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [78, 89], "ent_id": "D000082", "tok_span": [17, 21]}], "relation_list": [{"subject": "nimesulide", "object": "skin reactions", "sbj_char_span": [95, 105], "obj_char_span": [45, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [10, 12]}, {"subject": "acetaminophen", "object": "skin reactions", "sbj_char_span": [63, 76], "obj_char_span": [45, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [10, 12]}, {"subject": "paracetamol", "object": "skin reactions", "sbj_char_span": [78, 89], "obj_char_span": [45, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.", "entity_list": [{"name": "cutaneous reactions", "ent_type": "Disease", "char_span": [105, 124], "ent_id": "D003875", "tok_span": [19, 21]}, {"name": "N", "ent_type": "Chemical", "char_span": [134, 135], "ent_id": "C012655", "tok_span": [24, 25]}, {"name": "P", "ent_type": "Chemical", "char_span": [128, 129], "ent_id": "D000082", "tok_span": [22, 23]}, {"name": "CE", "ent_type": "Chemical", "char_span": [44, 46], "ent_id": "C105934", "tok_span": [8, 9]}], "relation_list": [{"subject": "N", "object": "cutaneous reactions", "sbj_char_span": [134, 135], "obj_char_span": [105, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [19, 21]}, {"subject": "P", "object": "cutaneous reactions", "sbj_char_span": [128, 129], "obj_char_span": [105, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "The diagnosis of P and N-induced skin reactions was based in vivo challenge.", "entity_list": [{"name": "skin reactions", "ent_type": "Disease", "char_span": [33, 47], "ent_id": "D003875", "tok_span": [8, 10]}, {"name": "P", "ent_type": "Chemical", "char_span": [17, 18], "ent_id": "D000082", "tok_span": [3, 4]}, {"name": "N", "ent_type": "Chemical", "char_span": [23, 24], "ent_id": "C012655", "tok_span": [5, 6]}], "relation_list": [{"subject": "P", "object": "skin reactions", "sbj_char_span": [17, 18], "obj_char_span": [33, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [8, 10]}, {"subject": "N", "object": "skin reactions", "sbj_char_span": [23, 24], "obj_char_span": [33, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "BACKGROUND: Studies on the association between the long-term use of aspirin and other analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs) and end-stage renal disease (ESRD) have given conflicting results.", "entity_list": [{"name": "end-stage renal disease", "ent_type": "Disease", "char_span": [150, 173], "ent_id": "D007676", "tok_span": [30, 35]}, {"name": "ESRD", "ent_type": "Disease", "char_span": [175, 179], "ent_id": "D007676", "tok_span": [36, 38]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [68, 75], "ent_id": "D001241", "tok_span": [13, 14]}], "relation_list": [{"subject": "aspirin", "object": "end-stage renal disease", "sbj_char_span": [68, 75], "obj_char_span": [150, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [30, 35]}, {"subject": "aspirin", "object": "ESRD", "sbj_char_span": [68, 75], "obj_char_span": [175, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2.35 (1.17-4.72)].", "entity_list": [{"name": "nephropathy", "ent_type": "Disease", "char_span": [168, 179], "ent_id": "D007674", "tok_span": [32, 33]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [33, 40], "ent_id": "D001241", "tok_span": [7, 8]}, {"name": "ESRD", "ent_type": "Disease", "char_span": [12, 16], "ent_id": "D007676", "tok_span": [3, 5]}], "relation_list": [{"subject": "aspirin", "object": "ESRD", "sbj_char_span": [33, 40], "obj_char_span": [12, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "However, the chronic use of aspirin may increase the risk of ESRD.", "entity_list": [{"name": "ESRD", "ent_type": "Disease", "char_span": [61, 65], "ent_id": "D007676", "tok_span": [12, 14]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [28, 35], "ent_id": "D001241", "tok_span": [6, 7]}], "relation_list": [{"subject": "aspirin", "object": "ESRD", "sbj_char_span": [28, 35], "obj_char_span": [61, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Two cases of amisulpride overdose: a cause for prolonged QT syndrome.", "entity_list": [{"name": "overdose", "ent_type": "Disease", "char_span": [25, 33], "ent_id": "D062787", "tok_span": [8, 10]}, {"name": "amisulpride", "ent_type": "Chemical", "char_span": [13, 24], "ent_id": "C012052", "tok_span": [3, 8]}, {"name": "prolonged QT syndrome", "ent_type": "Disease", "char_span": [47, 68], "ent_id": "D008133", "tok_span": [14, 17]}], "relation_list": [{"subject": "amisulpride", "object": "prolonged QT syndrome", "sbj_char_span": [13, 24], "obj_char_span": [47, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [248, 259], "ent_id": "D010862", "tok_span": [59, 62]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [218, 236], "ent_id": "D013226", "tok_span": [54, 57]}, {"name": "CHX", "ent_type": "Chemical", "char_span": [315, 318], "ent_id": "D003513", "tok_span": [76, 78]}, {"name": "Pilo", "ent_type": "Chemical", "char_span": [261, 265], "ent_id": "D010862", "tok_span": [63, 65]}, {"name": "cycloheximide", "ent_type": "Chemical", "char_span": [300, 313], "ent_id": "D003513", "tok_span": [72, 75]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [248, 259], "obj_char_span": [218, 236], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 62], "obj_tok_span": [54, 57]}, {"subject": "Pilo", "object": "status epilepticus", "sbj_char_span": [261, 265], "obj_char_span": [218, 236], "rel_type": "chemical-induced disease", "sbj_tok_span": [63, 65], "obj_tok_span": [54, 57]}], "umls_entity_list": []}, {"text": "OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [58, 66], "ent_id": "D009538", "tok_span": [9, 10]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [89, 97], "ent_id": "D002110", "tok_span": [14, 15]}, {"name": "pentylenetetrazole", "ent_type": "Chemical", "char_span": [127, 145], "ent_id": "D010433", "tok_span": [22, 27]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [70, 77], "ent_id": "D001008", "tok_span": [11, 12]}], "relation_list": [{"subject": "caffeine", "object": "anxiety", "sbj_char_span": [89, 97], "obj_char_span": [70, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [11, 12]}, {"subject": "pentylenetetrazole", "object": "anxiety", "sbj_char_span": [127, 145], "obj_char_span": [70, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.", "entity_list": [{"name": "pentylenetetrazole", "ent_type": "Chemical", "char_span": [65, 83], "ent_id": "D010433", "tok_span": [17, 22]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [92, 99], "ent_id": "D001008", "tok_span": [24, 25]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [47, 55], "ent_id": "D002110", "tok_span": [13, 14]}, {"name": "Nicotine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D009538", "tok_span": [0, 2]}], "relation_list": [{"subject": "caffeine", "object": "anxiety", "sbj_char_span": [47, 55], "obj_char_span": [92, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [24, 25]}, {"subject": "pentylenetetrazole", "object": "anxiety", "sbj_char_span": [65, 83], "obj_char_span": [92, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 22], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [65, 73], "ent_id": "D009538", "tok_span": [11, 12]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [117, 125], "ent_id": "D002110", "tok_span": [20, 21]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [77, 85], "ent_id": "D002110", "tok_span": [13, 14]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [94, 101], "ent_id": "D001008", "tok_span": [16, 17]}], "relation_list": [{"subject": "caffeine", "object": "anxiety", "sbj_char_span": [77, 85], "obj_char_span": [94, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [16, 17]}, {"subject": "caffeine", "object": "anxiety", "sbj_char_span": [117, 125], "obj_char_span": [94, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "Long-term oestrogen-only HT also significantly increased the risk of stroke and gallbladder disease.", "entity_list": [{"name": "oestrogen", "ent_type": "Chemical", "char_span": [10, 19], "ent_id": "D004967", "tok_span": [3, 6]}, {"name": "gallbladder disease", "ent_type": "Disease", "char_span": [80, 99], "ent_id": "D005705", "tok_span": [17, 20]}, {"name": "stroke", "ent_type": "Disease", "char_span": [69, 75], "ent_id": "D020521", "tok_span": [15, 16]}], "relation_list": [{"subject": "oestrogen", "object": "gallbladder disease", "sbj_char_span": [10, 19], "obj_char_span": [80, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [17, 20]}, {"subject": "oestrogen", "object": "stroke", "sbj_char_span": [10, 19], "obj_char_span": [69, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Amoxicillin-clavulanate stands out as the most common drug related to DILI.", "entity_list": [{"name": "Amoxicillin-clavulanate", "ent_type": "Chemical", "char_span": [0, 23], "ent_id": "D019980", "tok_span": [0, 9]}, {"name": "DILI", "ent_type": "Disease", "char_span": [70, 74], "ent_id": "D056486", "tok_span": [18, 20]}], "relation_list": [{"subject": "Amoxicillin-clavulanate", "object": "DILI", "sbj_char_span": [0, 23], "obj_char_span": [70, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 9], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "The influence of d-ribose on adriamycin-induced myocardiopathy in rats was studied.", "entity_list": [{"name": "adriamycin", "ent_type": "Chemical", "char_span": [29, 39], "ent_id": "D004317", "tok_span": [8, 12]}, {"name": "d-ribose", "ent_type": "Chemical", "char_span": [17, 25], "ent_id": "D012266", "tok_span": [3, 7]}, {"name": "myocardiopathy", "ent_type": "Disease", "char_span": [48, 62], "ent_id": "D009202", "tok_span": [14, 17]}], "relation_list": [{"subject": "adriamycin", "object": "myocardiopathy", "sbj_char_span": [29, 39], "obj_char_span": [48, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine.", "entity_list": [{"name": "vancomycin", "ent_type": "Chemical", "char_span": [77, 87], "ent_id": "D014640", "tok_span": [12, 13]}, {"name": "erdosteine", "ent_type": "Chemical", "char_span": [126, 136], "ent_id": "C048498", "tok_span": [21, 24]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [96, 110], "ent_id": "D007674", "tok_span": [15, 18]}], "relation_list": [{"subject": "vancomycin", "object": "nephrotoxicity", "sbj_char_span": [77, 87], "obj_char_span": [96, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.", "entity_list": [{"name": "VCM", "ent_type": "Chemical", "char_span": [51, 54], "ent_id": "D014640", "tok_span": [10, 12]}, {"name": "vancomycin", "ent_type": "Chemical", "char_span": [39, 49], "ent_id": "D014640", "tok_span": [8, 9]}, {"name": "oxygen", "ent_type": "Chemical", "char_span": [118, 124], "ent_id": "D010100", "tok_span": [22, 23]}, {"name": "erdosteine", "ent_type": "Chemical", "char_span": [170, 180], "ent_id": "C048498", "tok_span": [33, 36]}, {"name": "renal impairment", "ent_type": "Disease", "char_span": [293, 309], "ent_id": "D007674", "tok_span": [59, 61]}, {"name": "VCM", "ent_type": "Chemical", "char_span": [281, 284], "ent_id": "D014640", "tok_span": [55, 57]}], "relation_list": [{"subject": "VCM", "object": "renal impairment", "sbj_char_span": [51, 54], "obj_char_span": [293, 309], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [59, 61]}, {"subject": "VCM", "object": "renal impairment", "sbj_char_span": [281, 284], "obj_char_span": [293, 309], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 57], "obj_tok_span": [59, 61]}, {"subject": "vancomycin", "object": "renal impairment", "sbj_char_span": [39, 49], "obj_char_span": [293, 309], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [59, 61]}], "umls_entity_list": []}, {"text": "VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.", "entity_list": [{"name": "renal tubular injury", "ent_type": "Disease", "char_span": [149, 169], "ent_id": "D007674", "tok_span": [37, 40]}, {"name": "superoxide", "ent_type": "Chemical", "char_span": [195, 205], "ent_id": "D013481", "tok_span": [44, 45]}, {"name": "malondialdehyde", "ent_type": "Chemical", "char_span": [65, 80], "ent_id": "D008315", "tok_span": [9, 13]}, {"name": "VCM", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D014640", "tok_span": [0, 2]}, {"name": "MDA", "ent_type": "Chemical", "char_span": [82, 85], "ent_id": "D008315", "tok_span": [14, 15]}], "relation_list": [{"subject": "VCM", "object": "renal tubular injury", "sbj_char_span": [0, 3], "obj_char_span": [149, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [37, 40]}], "umls_entity_list": []}, {"text": "Erdosteine showed histopathological protection against VCM-induced nephrotoxicity.", "entity_list": [{"name": "Erdosteine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "C048498", "tok_span": [0, 3]}, {"name": "VCM", "ent_type": "Chemical", "char_span": [55, 58], "ent_id": "D014640", "tok_span": [8, 10]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [67, 81], "ent_id": "D007674", "tok_span": [12, 15]}], "relation_list": [{"subject": "VCM", "object": "nephrotoxicity", "sbj_char_span": [55, 58], "obj_char_span": [67, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.", "entity_list": [{"name": "erdosteine", "ent_type": "Chemical", "char_span": [148, 158], "ent_id": "C048498", "tok_span": [27, 30]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [89, 103], "ent_id": "D007674", "tok_span": [17, 20]}, {"name": "VCM", "ent_type": "Chemical", "char_span": [171, 174], "ent_id": "D014640", "tok_span": [32, 34]}, {"name": "kidney damage", "ent_type": "Disease", "char_span": [183, 196], "ent_id": "D007674", "tok_span": [36, 38]}, {"name": "VCM", "ent_type": "Chemical", "char_span": [77, 80], "ent_id": "D014640", "tok_span": [13, 15]}], "relation_list": [{"subject": "VCM", "object": "nephrotoxicity", "sbj_char_span": [77, 80], "obj_char_span": [89, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [17, 20]}, {"subject": "VCM", "object": "kidney damage", "sbj_char_span": [77, 80], "obj_char_span": [183, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [36, 38]}, {"subject": "VCM", "object": "nephrotoxicity", "sbj_char_span": [171, 174], "obj_char_span": [89, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 34], "obj_tok_span": [17, 20]}, {"subject": "VCM", "object": "kidney damage", "sbj_char_span": [171, 174], "obj_char_span": [183, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 34], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "Does domperidone potentiate mirtazapine-associated restless legs syndrome?", "entity_list": [{"name": "restless legs syndrome", "ent_type": "Disease", "char_span": [51, 73], "ent_id": "D012148", "tok_span": [12, 16]}, {"name": "domperidone", "ent_type": "Chemical", "char_span": [5, 16], "ent_id": "D004294", "tok_span": [1, 4]}, {"name": "mirtazapine", "ent_type": "Chemical", "char_span": [28, 39], "ent_id": "C035133", "tok_span": [6, 10]}], "relation_list": [{"subject": "mirtazapine", "object": "restless legs syndrome", "sbj_char_span": [28, 39], "obj_char_span": [51, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications.", "entity_list": [{"name": "RLS", "ent_type": "Disease", "char_span": [112, 115], "ent_id": "D012148", "tok_span": [24, 26]}, {"name": "Mirtazapine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "C035133", "tok_span": [0, 4]}], "relation_list": [{"subject": "Mirtazapine", "object": "RLS", "sbj_char_span": [0, 11], "obj_char_span": [112, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.", "entity_list": [{"name": "postprandial dyspepsia", "ent_type": "Disease", "char_span": [58, 80], "ent_id": "D004415", "tok_span": [9, 15]}, {"name": "domperidone", "ent_type": "Chemical", "char_span": [139, 150], "ent_id": "D004294", "tok_span": [29, 32]}, {"name": "mirtazapine", "ent_type": "Chemical", "char_span": [105, 116], "ent_id": "C035133", "tok_span": [20, 24]}, {"name": "RLS", "ent_type": "Disease", "char_span": [95, 98], "ent_id": "D012148", "tok_span": [17, 19]}], "relation_list": [{"subject": "mirtazapine", "object": "RLS", "sbj_char_span": [105, 116], "obj_char_span": [95, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.", "entity_list": [{"name": "mirtazapine", "ent_type": "Chemical", "char_span": [80, 91], "ent_id": "C035133", "tok_span": [16, 20]}, {"name": "mirtazapine", "ent_type": "Chemical", "char_span": [162, 173], "ent_id": "C035133", "tok_span": [32, 36]}, {"name": "RLS", "ent_type": "Disease", "char_span": [40, 43], "ent_id": "D012148", "tok_span": [7, 9]}, {"name": "RLS", "ent_type": "Disease", "char_span": [101, 104], "ent_id": "D012148", "tok_span": [23, 25]}], "relation_list": [{"subject": "mirtazapine", "object": "RLS", "sbj_char_span": [80, 91], "obj_char_span": [40, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [7, 9]}, {"subject": "mirtazapine", "object": "RLS", "sbj_char_span": [80, 91], "obj_char_span": [101, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [23, 25]}, {"subject": "mirtazapine", "object": "RLS", "sbj_char_span": [162, 173], "obj_char_span": [101, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 36], "obj_tok_span": [23, 25]}, {"subject": "mirtazapine", "object": "RLS", "sbj_char_span": [162, 173], "obj_char_span": [40, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 36], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.", "entity_list": [{"name": "mirtazapine", "ent_type": "Chemical", "char_span": [154, 165], "ent_id": "C035133", "tok_span": [33, 37]}, {"name": "RLS", "ent_type": "Disease", "char_span": [177, 180], "ent_id": "D012148", "tok_span": [39, 41]}, {"name": "domperione", "ent_type": "Chemical", "char_span": [140, 150], "ent_id": "D004294", "tok_span": [29, 32]}, {"name": "RLS", "ent_type": "Disease", "char_span": [80, 83], "ent_id": "D012148", "tok_span": [16, 18]}, {"name": "mirtazapine", "ent_type": "Chemical", "char_span": [48, 59], "ent_id": "C035133", "tok_span": [8, 12]}], "relation_list": [{"subject": "mirtazapine", "object": "RLS", "sbj_char_span": [154, 165], "obj_char_span": [80, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 37], "obj_tok_span": [16, 18]}, {"subject": "mirtazapine", "object": "RLS", "sbj_char_span": [48, 59], "obj_char_span": [80, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [16, 18]}, {"subject": "mirtazapine", "object": "RLS", "sbj_char_span": [154, 165], "obj_char_span": [177, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 37], "obj_tok_span": [39, 41]}, {"subject": "mirtazapine", "object": "RLS", "sbj_char_span": [48, 59], "obj_char_span": [177, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [39, 41]}], "umls_entity_list": []}, {"text": "However, physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.", "entity_list": [{"name": "dopamine", "ent_type": "Chemical", "char_span": [159, 167], "ent_id": "D004298", "tok_span": [28, 29]}, {"name": "mirtazapine", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "C035133", "tok_span": [10, 14]}, {"name": "RLS", "ent_type": "Disease", "char_span": [95, 98], "ent_id": "D012148", "tok_span": [18, 20]}], "relation_list": [{"subject": "mirtazapine", "object": "RLS", "sbj_char_span": [60, 71], "obj_char_span": [95, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.", "entity_list": [{"name": "estrogen", "ent_type": "Chemical", "char_span": [258, 266], "ent_id": "D004967", "tok_span": [62, 63]}, {"name": "cholesterol", "ent_type": "Chemical", "char_span": [151, 162], "ent_id": "D002784", "tok_span": [32, 33]}, {"name": "hyperglyceridemic effect", "ent_type": "Disease", "char_span": [223, 247], "ent_id": "D050171", "tok_span": [55, 60]}, {"name": "coronary arteriosclerosis", "ent_type": "Disease", "char_span": [23, 48], "ent_id": "D003324", "tok_span": [5, 10]}, {"name": "CPA", "ent_type": "Chemical", "char_span": [104, 107], "ent_id": "D017373", "tok_span": [23, 25]}], "relation_list": [{"subject": "CPA", "object": "hyperglyceridemic effect", "sbj_char_span": [104, 107], "obj_char_span": [223, 247], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [55, 60]}, {"subject": "CPA", "object": "coronary arteriosclerosis", "sbj_char_span": [104, 107], "obj_char_span": [23, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.", "entity_list": [{"name": "precordial pain", "ent_type": "Disease", "char_span": [108, 123], "ent_id": "D002637", "tok_span": [23, 27]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [75, 79], "ent_id": "D005472", "tok_span": [11, 14]}, {"name": "right bundle branch block", "ent_type": "Disease", "char_span": [129, 154], "ent_id": "D002037", "tok_span": [28, 32]}, {"name": "FBAL", "ent_type": "Chemical", "char_span": [196, 200], "ent_id": "C032348", "tok_span": [39, 41]}], "relation_list": [{"subject": "5-FU", "object": "right bundle branch block", "sbj_char_span": [75, 79], "obj_char_span": [129, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [28, 32]}, {"subject": "5-FU", "object": "precordial pain", "sbj_char_span": [75, 79], "obj_char_span": [108, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU.", "entity_list": [{"name": "5-FU", "ent_type": "Chemical", "char_span": [117, 121], "ent_id": "D005472", "tok_span": [17, 20]}, {"name": "precordial pain", "ent_type": "Disease", "char_span": [9, 24], "ent_id": "D002637", "tok_span": [2, 6]}], "relation_list": [{"subject": "5-FU", "object": "precordial pain", "sbj_char_span": [117, 121], "obj_char_span": [9, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.", "entity_list": [{"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [87, 101], "ent_id": "D066126", "tok_span": [21, 23]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [125, 129], "ent_id": "D005472", "tok_span": [27, 30]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [74, 78], "ent_id": "D005472", "tok_span": [16, 19]}, {"name": "precordial pain", "ent_type": "Disease", "char_span": [7, 22], "ent_id": "D002637", "tok_span": [2, 6]}], "relation_list": [{"subject": "5-FU", "object": "precordial pain", "sbj_char_span": [125, 129], "obj_char_span": [7, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [2, 6]}, {"subject": "5-FU", "object": "precordial pain", "sbj_char_span": [74, 78], "obj_char_span": [7, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.", "entity_list": [{"name": "cardiac hypertrophy", "ent_type": "Disease", "char_span": [31, 50], "ent_id": "D006332", "tok_span": [7, 9]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [9, 22], "ent_id": "D007545", "tok_span": [1, 5]}], "relation_list": [{"subject": "isoproterenol", "object": "cardiac hypertrophy", "sbj_char_span": [9, 22], "obj_char_span": [31, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively).", "entity_list": [{"name": "Iso", "ent_type": "Chemical", "char_span": [26, 29], "ent_id": "D007545", "tok_span": [4, 5]}, {"name": "LV hypertrophy", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D006332", "tok_span": [0, 2]}], "relation_list": [{"subject": "Iso", "object": "LV hypertrophy", "sbj_char_span": [26, 29], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.", "entity_list": [{"name": "long QT syndrome", "ent_type": "Disease", "char_span": [13, 29], "ent_id": "D008133", "tok_span": [3, 6]}, {"name": "methadone", "ent_type": "Chemical", "char_span": [64, 73], "ent_id": "D008691", "tok_span": [11, 14]}], "relation_list": [{"subject": "methadone", "object": "long QT syndrome", "sbj_char_span": [64, 73], "obj_char_span": [13, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.", "entity_list": [{"name": "QT interval prolongation", "ent_type": "Disease", "char_span": [43, 67], "ent_id": "D008133", "tok_span": [8, 12]}, {"name": "methadone", "ent_type": "Chemical", "char_span": [73, 82], "ent_id": "D008691", "tok_span": [13, 16]}], "relation_list": [{"subject": "methadone", "object": "QT interval prolongation", "sbj_char_span": [73, 82], "obj_char_span": [43, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.", "entity_list": [{"name": "methadone", "ent_type": "Chemical", "char_span": [15, 24], "ent_id": "D008691", "tok_span": [3, 6]}, {"name": "QT prolongation", "ent_type": "Disease", "char_span": [135, 150], "ent_id": "D008133", "tok_span": [23, 26]}], "relation_list": [{"subject": "methadone", "object": "QT prolongation", "sbj_char_span": [15, 24], "obj_char_span": [135, 150], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding.", "entity_list": [{"name": "methadone", "ent_type": "Chemical", "char_span": [41, 50], "ent_id": "D008691", "tok_span": [7, 10]}, {"name": "QT interval prolongation", "ent_type": "Disease", "char_span": [13, 37], "ent_id": "D008133", "tok_span": [2, 6]}], "relation_list": [{"subject": "methadone", "object": "QT interval prolongation", "sbj_char_span": [41, 50], "obj_char_span": [13, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation.", "entity_list": [{"name": "potassium", "ent_type": "Chemical", "char_span": [61, 70], "ent_id": "D011188", "tok_span": [16, 17]}, {"name": "Methadone", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D008691", "tok_span": [0, 3]}, {"name": "QT prolongation", "ent_type": "Disease", "char_span": [111, 126], "ent_id": "D008133", "tok_span": [24, 27]}], "relation_list": [{"subject": "Methadone", "object": "QT prolongation", "sbj_char_span": [0, 9], "obj_char_span": [111, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Long QT syndrome can occur with low doses of methadone.", "entity_list": [{"name": "Long QT syndrome", "ent_type": "Disease", "char_span": [0, 16], "ent_id": "D008133", "tok_span": [0, 3]}, {"name": "methadone", "ent_type": "Chemical", "char_span": [45, 54], "ent_id": "D008691", "tok_span": [9, 12]}], "relation_list": [{"subject": "methadone", "object": "Long QT syndrome", "sbj_char_span": [45, 54], "obj_char_span": [0, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Mechanisms of hypertension induced by nitric oxide (NO) deficiency: focus on venous function.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [14, 26], "ent_id": "D006973", "tok_span": [2, 3]}, {"name": "NO", "ent_type": "Chemical", "char_span": [52, 54], "ent_id": "D009569", "tok_span": [8, 9]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [38, 50], "ent_id": "D009569", "tok_span": [5, 7]}], "relation_list": [{"subject": "NO", "object": "hypertension", "sbj_char_span": [52, 54], "obj_char_span": [14, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [2, 3]}, {"subject": "nitric oxide", "object": "hypertension", "sbj_char_span": [38, 50], "obj_char_span": [14, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.", "entity_list": [{"name": "NO", "ent_type": "Chemical", "char_span": [47, 49], "ent_id": "D009569", "tok_span": [9, 10]}, {"name": "arterial dysfunction", "ent_type": "Disease", "char_span": [84, 104], "ent_id": "D018754", "tok_span": [17, 19]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [33, 45], "ent_id": "D009569", "tok_span": [6, 8]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [54, 66], "ent_id": "D006973", "tok_span": [12, 13]}], "relation_list": [{"subject": "NO", "object": "hypertension", "sbj_char_span": [47, 49], "obj_char_span": [54, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [12, 13]}, {"subject": "nitric oxide", "object": "hypertension", "sbj_char_span": [33, 45], "obj_char_span": [54, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "Experimental hypertension created by the removal of NO, however, involves mechanisms in addition to decreased arterial vasodilator activity.", "entity_list": [{"name": "NO", "ent_type": "Chemical", "char_span": [52, 54], "ent_id": "D009569", "tok_span": [7, 8]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [13, 25], "ent_id": "D006973", "tok_span": [1, 2]}], "relation_list": [{"subject": "NO", "object": "hypertension", "sbj_char_span": [52, 54], "obj_char_span": [13, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "These data suggest that while NO deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels, the impact on veins does not make a major contribution to this form of hypertension.", "entity_list": [{"name": "NO", "ent_type": "Chemical", "char_span": [30, 32], "ent_id": "D009569", "tok_span": [5, 6]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [204, 216], "ent_id": "D006973", "tok_span": [34, 35]}], "relation_list": [{"subject": "NO", "object": "hypertension", "sbj_char_span": [30, 32], "obj_char_span": [204, 216], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [34, 35]}], "umls_entity_list": []}, {"text": "Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.", "entity_list": [{"name": "schizophrenic", "ent_type": "Disease", "char_span": [96, 109], "ent_id": "D012559", "tok_span": [19, 21]}, {"name": "chlorpromazine", "ent_type": "Chemical", "char_span": [38, 52], "ent_id": "D002746", "tok_span": [7, 10]}, {"name": "extrapyramidal syndrome", "ent_type": "Disease", "char_span": [61, 84], "ent_id": "D001480", "tok_span": [12, 17]}], "relation_list": [{"subject": "chlorpromazine", "object": "extrapyramidal syndrome", "sbj_char_span": [38, 52], "obj_char_span": [61, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 17]}], "umls_entity_list": []}, {"text": "In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.", "entity_list": [{"name": "EPS", "ent_type": "Disease", "char_span": [73, 76], "ent_id": "D001480", "tok_span": [18, 19]}, {"name": "chlorpromazine", "ent_type": "Chemical", "char_span": [50, 64], "ent_id": "D002746", "tok_span": [13, 16]}, {"name": "schizophrenic", "ent_type": "Disease", "char_span": [80, 93], "ent_id": "D012559", "tok_span": [20, 22]}], "relation_list": [{"subject": "chlorpromazine", "object": "EPS", "sbj_char_span": [50, 64], "obj_char_span": [73, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "entity_list": [{"name": "EPS", "ent_type": "Disease", "char_span": [189, 192], "ent_id": "D001480", "tok_span": [57, 58]}, {"name": "chlorpromazine", "ent_type": "Chemical", "char_span": [263, 277], "ent_id": "D002746", "tok_span": [73, 76]}, {"name": "schizophrenic", "ent_type": "Disease", "char_span": [155, 168], "ent_id": "D012559", "tok_span": [50, 52]}, {"name": "EPS", "ent_type": "Disease", "char_span": [208, 211], "ent_id": "D001480", "tok_span": [61, 62]}], "relation_list": [{"subject": "chlorpromazine", "object": "EPS", "sbj_char_span": [263, 277], "obj_char_span": [189, 192], "rel_type": "chemical-induced disease", "sbj_tok_span": [73, 76], "obj_tok_span": [57, 58]}, {"subject": "chlorpromazine", "object": "EPS", "sbj_char_span": [263, 277], "obj_char_span": [208, 211], "rel_type": "chemical-induced disease", "sbj_tok_span": [73, 76], "obj_tok_span": [61, 62]}], "umls_entity_list": []}, {"text": "Physical training decreases susceptibility to subsequent pilocarpine-induced seizures in the rat.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [77, 85], "ent_id": "D012640", "tok_span": [11, 12]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [57, 68], "ent_id": "D010862", "tok_span": [6, 9]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [57, 68], "obj_char_span": [77, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Thereafter, seizures were induced by pilocarpine injections in trained and non-trained control groups.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [12, 20], "ent_id": "D012640", "tok_span": [2, 3]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [37, 48], "ent_id": "D010862", "tok_span": [6, 9]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [37, 48], "obj_char_span": [12, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa.", "entity_list": [{"name": "polyarteritis nodosa", "ent_type": "Disease", "char_span": [58, 78], "ent_id": "D010488", "tok_span": [13, 18]}, {"name": "Minocycline", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D008911", "tok_span": [0, 4]}, {"name": "vasculitis", "ent_type": "Disease", "char_span": [20, 30], "ent_id": "D014657", "tok_span": [6, 8]}], "relation_list": [{"subject": "Minocycline", "object": "polyarteritis nodosa", "sbj_char_span": [0, 11], "obj_char_span": [58, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 18]}], "umls_entity_list": []}, {"text": "Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.", "entity_list": [{"name": "picrotoxin", "ent_type": "Chemical", "char_span": [102, 112], "ent_id": "D010852", "tok_span": [29, 32]}, {"name": "eslicarbazepine acetate", "ent_type": "Chemical", "char_span": [25, 48], "ent_id": "C416835", "tok_span": [7, 13]}, {"name": "BIA 2-093", "ent_type": "Chemical", "char_span": [50, 59], "ent_id": "C416835", "tok_span": [14, 20]}, {"name": "seizures", "ent_type": "Disease", "char_span": [64, 72], "ent_id": "D012640", "tok_span": [22, 23]}], "relation_list": [{"subject": "picrotoxin", "object": "seizures", "sbj_char_span": [102, 112], "obj_char_span": [64, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "In the animals treated with threshold doses of picrotoxin, the average number of seizures was 2.3+/-1.2, and average seizure duration was 39.5+/-8.4s.", "entity_list": [{"name": "seizure", "ent_type": "Disease", "char_span": [117, 124], "ent_id": "D012640", "tok_span": [30, 31]}, {"name": "picrotoxin", "ent_type": "Chemical", "char_span": [47, 57], "ent_id": "D010852", "tok_span": [8, 11]}, {"name": "seizures", "ent_type": "Disease", "char_span": [81, 89], "ent_id": "D012640", "tok_span": [16, 17]}], "relation_list": [{"subject": "picrotoxin", "object": "seizures", "sbj_char_span": [47, 57], "obj_char_span": [81, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [16, 17]}, {"subject": "picrotoxin", "object": "seizure", "sbj_char_span": [47, 57], "obj_char_span": [117, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [30, 31]}], "umls_entity_list": []}, {"text": "Pre-treatment with a dose of 30 mg/kg 2h before picrotoxin microperfusion prevented seizures in the 75% of the rats.", "entity_list": [{"name": "picrotoxin", "ent_type": "Chemical", "char_span": [48, 58], "ent_id": "D010852", "tok_span": [14, 17]}, {"name": "seizures", "ent_type": "Disease", "char_span": [84, 92], "ent_id": "D012640", "tok_span": [21, 22]}], "relation_list": [{"subject": "picrotoxin", "object": "seizures", "sbj_char_span": [48, 58], "obj_char_span": [84, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb).", "entity_list": [{"name": "acute renal failure", "ent_type": "Disease", "char_span": [44, 63], "ent_id": "D058186", "tok_span": [11, 14]}, {"name": "Chinese herbal", "ent_type": "Chemical", "char_span": [105, 119], "ent_id": "D004365", "tok_span": [20, 22]}, {"name": "anthraquinone", "ent_type": "Chemical", "char_span": [149, 162], "ent_id": "D000880", "tok_span": [27, 31]}], "relation_list": [{"subject": "Chinese herbal", "object": "acute renal failure", "sbj_char_span": [105, 119], "obj_char_span": [44, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac.", "entity_list": [{"name": "renal injury", "ent_type": "Disease", "char_span": [4, 16], "ent_id": "D058186", "tok_span": [1, 3]}, {"name": "diclofenac", "ent_type": "Chemical", "char_span": [110, 120], "ent_id": "D004008", "tok_span": [22, 26]}], "relation_list": [{"subject": "diclofenac", "object": "renal injury", "sbj_char_span": [110, 120], "obj_char_span": [4, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.", "entity_list": [{"name": "thiol", "ent_type": "Chemical", "char_span": [65, 70], "ent_id": "D013438", "tok_span": [16, 17]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [81, 91], "ent_id": "D007069", "tok_span": [19, 24]}, {"name": "sulfhydryl", "ent_type": "Chemical", "char_span": [24, 34], "ent_id": "-1", "tok_span": [7, 10]}, {"name": "Chloroacetaldehyde", "ent_type": "Chemical", "char_span": [0, 18], "ent_id": "C004656", "tok_span": [0, 5]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [92, 103], "ent_id": "D007674", "tok_span": [24, 25]}], "relation_list": [{"subject": "ifosfamide", "object": "nephropathy", "sbj_char_span": [81, 91], "obj_char_span": [92, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 24], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity_list": [{"name": "CAA", "ent_type": "Chemical", "char_span": [20, 23], "ent_id": "C004656", "tok_span": [6, 8]}, {"name": "tumor", "ent_type": "Disease", "char_span": [141, 146], "ent_id": "D009369", "tok_span": [36, 37]}, {"name": "IFO", "ent_type": "Chemical", "char_span": [160, 163], "ent_id": "D007069", "tok_span": [39, 41]}, {"name": "Chloroacetaldehyde", "ent_type": "Chemical", "char_span": [0, 18], "ent_id": "C004656", "tok_span": [0, 5]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [65, 75], "ent_id": "D007069", "tok_span": [17, 22]}, {"name": "IFO", "ent_type": "Chemical", "char_span": [77, 80], "ent_id": "D007069", "tok_span": [23, 25]}, {"name": "renal damage", "ent_type": "Disease", "char_span": [113, 125], "ent_id": "D007674", "tok_span": [31, 33]}], "relation_list": [{"subject": "IFO", "object": "renal damage", "sbj_char_span": [160, 163], "obj_char_span": [113, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 41], "obj_tok_span": [31, 33]}, {"subject": "IFO", "object": "renal damage", "sbj_char_span": [77, 80], "obj_char_span": [113, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [31, 33]}, {"subject": "ifosfamide", "object": "renal damage", "sbj_char_span": [65, 75], "obj_char_span": [113, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 22], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "Therefore, urinary acidification could be an option to prevent IFO nephropathy in patients.", "entity_list": [{"name": "nephropathy", "ent_type": "Disease", "char_span": [67, 78], "ent_id": "D007674", "tok_span": [13, 14]}, {"name": "IFO", "ent_type": "Chemical", "char_span": [63, 66], "ent_id": "D007069", "tok_span": [11, 13]}], "relation_list": [{"subject": "IFO", "object": "nephropathy", "sbj_char_span": [63, 66], "obj_char_span": [67, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Stereological methods reveal the robust size and stability of ectopic hilar granule cells after pilocarpine-induced status epilepticus in the adult rat.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [116, 134], "ent_id": "D013226", "tok_span": [22, 25]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [96, 107], "ent_id": "D010862", "tok_span": [17, 20]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [96, 107], "obj_char_span": [116, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "To quantify this population, the total number of ectopic hilar granule cells was estimated using unbiased stereology at different times after pilocarpine-induced status epilepticus.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [142, 153], "ent_id": "D010862", "tok_span": [25, 28]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [162, 180], "ent_id": "D013226", "tok_span": [30, 33]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [142, 153], "obj_char_span": [162, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "The results provide new insight into the potential role of ectopic hilar granule cells in the pilocarpine model of temporal lobe epilepsy.", "entity_list": [{"name": "temporal lobe epilepsy", "ent_type": "Disease", "char_span": [115, 137], "ent_id": "D004833", "tok_span": [22, 25]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [94, 105], "ent_id": "D010862", "tok_span": [17, 20]}], "relation_list": [{"subject": "pilocarpine", "object": "temporal lobe epilepsy", "sbj_char_span": [94, 105], "obj_char_span": [115, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "Overall, galantamine was well-tolerated, with no significant adverse effects apart from headaches in one patient.", "entity_list": [{"name": "galantamine", "ent_type": "Chemical", "char_span": [9, 20], "ent_id": "D005702", "tok_span": [2, 6]}, {"name": "headaches", "ent_type": "Disease", "char_span": [88, 97], "ent_id": "D006261", "tok_span": [18, 20]}], "relation_list": [{"subject": "galantamine", "object": "headaches", "sbj_char_span": [9, 20], "obj_char_span": [88, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine.", "entity_list": [{"name": "olanzapine", "ent_type": "Chemical", "char_span": [112, 122], "ent_id": "C076029", "tok_span": [46, 49]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [70, 81], "ent_id": "D018967", "tok_span": [25, 28]}, {"name": "Extrapyramidal symptom", "ent_type": "Disease", "char_span": [0, 22], "ent_id": "D001480", "tok_span": [0, 5]}], "relation_list": [{"subject": "risperidone", "object": "Extrapyramidal symptom", "sbj_char_span": [70, 81], "obj_char_span": [0, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [0, 5]}, {"subject": "olanzapine", "object": "Extrapyramidal symptom", "sbj_char_span": [112, 122], "obj_char_span": [0, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 49], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.", "entity_list": [{"name": "weight gain", "ent_type": "Disease", "char_span": [19, 30], "ent_id": "D015430", "tok_span": [2, 4]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [66, 77], "ent_id": "D018967", "tok_span": [11, 14]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [178, 188], "ent_id": "C076029", "tok_span": [47, 50]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [45, 55], "ent_id": "C076029", "tok_span": [6, 9]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [224, 235], "ent_id": "D018967", "tok_span": [71, 74]}], "relation_list": [{"subject": "risperidone", "object": "weight gain", "sbj_char_span": [224, 235], "obj_char_span": [19, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [71, 74], "obj_tok_span": [2, 4]}, {"subject": "olanzapine", "object": "weight gain", "sbj_char_span": [178, 188], "obj_char_span": [19, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 50], "obj_tok_span": [2, 4]}, {"subject": "risperidone", "object": "weight gain", "sbj_char_span": [66, 77], "obj_char_span": [19, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [2, 4]}, {"subject": "olanzapine", "object": "weight gain", "sbj_char_span": [45, 55], "obj_char_span": [19, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.", "entity_list": [{"name": "olanzapine", "ent_type": "Chemical", "char_span": [88, 98], "ent_id": "C076029", "tok_span": [14, 17]}, {"name": "weight gain", "ent_type": "Disease", "char_span": [59, 70], "ent_id": "D015430", "tok_span": [9, 11]}, {"name": "weight gain", "ent_type": "Disease", "char_span": [42, 53], "ent_id": "D015430", "tok_span": [5, 7]}], "relation_list": [{"subject": "olanzapine", "object": "weight gain", "sbj_char_span": [88, 98], "obj_char_span": [59, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [9, 11]}, {"subject": "olanzapine", "object": "weight gain", "sbj_char_span": [88, 98], "obj_char_span": [42, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Early paracentral visual field loss in patients taking hydroxychloroquine.", "entity_list": [{"name": "visual field loss", "ent_type": "Disease", "char_span": [18, 35], "ent_id": "D014786", "tok_span": [3, 6]}, {"name": "hydroxychloroquine", "ent_type": "Chemical", "char_span": [55, 73], "ent_id": "D006886", "tok_span": [9, 13]}], "relation_list": [{"subject": "hydroxychloroquine", "object": "visual field loss", "sbj_char_span": [55, 73], "obj_char_span": [18, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Thirty-five patients (13.4%) had visual field abnormalities, which were attributed to hydroxychloroquine treatment in 4 patients (1.5%).", "entity_list": [{"name": "visual field abnormalities", "ent_type": "Disease", "char_span": [33, 59], "ent_id": "D014786", "tok_span": [11, 14]}, {"name": "hydroxychloroquine", "ent_type": "Chemical", "char_span": [86, 104], "ent_id": "D006886", "tok_span": [19, 23]}], "relation_list": [{"subject": "hydroxychloroquine", "object": "visual field abnormalities", "sbj_char_span": [86, 104], "obj_char_span": [33, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.", "entity_list": [{"name": "atrioventricular block", "ent_type": "Disease", "char_span": [15, 37], "ent_id": "D054537", "tok_span": [4, 10]}, {"name": "paclitaxel", "ent_type": "Chemical", "char_span": [86, 96], "ent_id": "D017239", "tok_span": [20, 21]}, {"name": "epirubicin", "ent_type": "Chemical", "char_span": [71, 81], "ent_id": "D015251", "tok_span": [16, 19]}], "relation_list": [{"subject": "epirubicin", "object": "atrioventricular block", "sbj_char_span": [71, 81], "obj_char_span": [15, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [4, 10]}, {"subject": "paclitaxel", "object": "atrioventricular block", "sbj_char_span": [86, 96], "obj_char_span": [15, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [4, 10]}], "umls_entity_list": []}, {"text": "OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).", "entity_list": [{"name": "COX-2 inhibitors", "ent_type": "Chemical", "char_span": [63, 79], "ent_id": "D052246", "tok_span": [12, 16]}, {"name": "AMI", "ent_type": "Disease", "char_span": [53, 56], "ent_id": "D009203", "tok_span": [9, 10]}, {"name": "acute myocardial infarction", "ent_type": "Disease", "char_span": [24, 51], "ent_id": "D009203", "tok_span": [5, 8]}, {"name": "non-steroidal anti-inflammatory drugs", "ent_type": "Chemical", "char_span": [160, 197], "ent_id": "D000894", "tok_span": [33, 41]}], "relation_list": [{"subject": "non-steroidal anti-inflammatory drugs", "object": "acute myocardial infarction", "sbj_char_span": [160, 197], "obj_char_span": [24, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 41], "obj_tok_span": [5, 8]}, {"subject": "COX-2 inhibitors", "object": "acute myocardial infarction", "sbj_char_span": [63, 79], "obj_char_span": [24, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [5, 8]}, {"subject": "non-steroidal anti-inflammatory drugs", "object": "AMI", "sbj_char_span": [160, 197], "obj_char_span": [53, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 41], "obj_tok_span": [9, 10]}, {"subject": "COX-2 inhibitors", "object": "AMI", "sbj_char_span": [63, 79], "obj_char_span": [53, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.", "entity_list": [{"name": "AMI", "ent_type": "Disease", "char_span": [53, 56], "ent_id": "D009203", "tok_span": [9, 10]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [134, 147], "ent_id": "D000082", "tok_span": [27, 30]}, {"name": "GI bleeding", "ent_type": "Disease", "char_span": [61, 72], "ent_id": "D006471", "tok_span": [11, 13]}, {"name": "COX-2 inhibitors", "ent_type": "Chemical", "char_span": [102, 118], "ent_id": "D052246", "tok_span": [17, 21]}], "relation_list": [{"subject": "COX-2 inhibitors", "object": "AMI", "sbj_char_span": [102, 118], "obj_char_span": [53, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "entity_list": [{"name": "naproxen", "ent_type": "Chemical", "char_span": [220, 228], "ent_id": "D009288", "tok_span": [70, 74]}, {"name": "diclofenac", "ent_type": "Chemical", "char_span": [248, 258], "ent_id": "D004008", "tok_span": [87, 91]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [19, 26], "ent_id": "D001241", "tok_span": [5, 6]}, {"name": "celecoxib", "ent_type": "Chemical", "char_span": [191, 200], "ent_id": "C105934", "tok_span": [53, 57]}, {"name": "ibuprofen", "ent_type": "Chemical", "char_span": [281, 290], "ent_id": "D007052", "tok_span": [104, 108]}, {"name": "rofecoxib", "ent_type": "Chemical", "char_span": [162, 171], "ent_id": "C116926", "tok_span": [36, 40]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [141, 148], "ent_id": "D001241", "tok_span": [31, 32]}, {"name": "AMI", "ent_type": "Disease", "char_span": [104, 107], "ent_id": "D009203", "tok_span": [20, 21]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [118, 131], "ent_id": "D000082", "tok_span": [25, 28]}], "relation_list": [{"subject": "naproxen", "object": "AMI", "sbj_char_span": [220, 228], "obj_char_span": [104, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [70, 74], "obj_tok_span": [20, 21]}, {"subject": "rofecoxib", "object": "AMI", "sbj_char_span": [162, 171], "obj_char_span": [104, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 40], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity_list": [{"name": "GI bleeding", "ent_type": "Disease", "char_span": [90, 101], "ent_id": "D006471", "tok_span": [22, 24]}, {"name": "naproxen", "ent_type": "Chemical", "char_span": [40, 48], "ent_id": "D009288", "tok_span": [9, 13]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [31, 38], "ent_id": "D001241", "tok_span": [7, 8]}, {"name": "AMI", "ent_type": "Disease", "char_span": [86, 89], "ent_id": "D009203", "tok_span": [20, 21]}], "relation_list": [{"subject": "naproxen", "object": "AMI", "sbj_char_span": [40, 48], "obj_char_span": [86, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [20, 21]}, {"subject": "naproxen", "object": "GI bleeding", "sbj_char_span": [40, 48], "obj_char_span": [90, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.", "entity_list": [{"name": "AMI", "ent_type": "Disease", "char_span": [4, 7], "ent_id": "D009203", "tok_span": [1, 2]}, {"name": "celecoxib", "ent_type": "Chemical", "char_span": [23, 32], "ent_id": "C105934", "tok_span": [6, 10]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [56, 69], "ent_id": "D000082", "tok_span": [15, 18]}, {"name": "rofecoxib", "ent_type": "Chemical", "char_span": [108, 117], "ent_id": "C116926", "tok_span": [26, 30]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [11, 19], "ent_id": "D064420", "tok_span": [4, 5]}], "relation_list": [{"subject": "rofecoxib", "object": "AMI", "sbj_char_span": [108, 117], "obj_char_span": [4, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.", "entity_list": [{"name": "premature ventricular contraction", "ent_type": "Disease", "char_span": [109, 142], "ent_id": "D018879", "tok_span": [22, 25]}, {"name": "severe malaria", "ent_type": "Disease", "char_span": [41, 55], "ent_id": "D016778", "tok_span": [9, 11]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [97, 107], "ent_id": "D001145", "tok_span": [19, 21]}, {"name": "quinine", "ent_type": "Chemical", "char_span": [158, 165], "ent_id": "D011803", "tok_span": [28, 30]}, {"name": "jaundice", "ent_type": "Disease", "char_span": [69, 77], "ent_id": "D007565", "tok_span": [13, 16]}], "relation_list": [{"subject": "quinine", "object": "premature ventricular contraction", "sbj_char_span": [158, 165], "obj_char_span": [109, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.", "entity_list": [{"name": "palpitation", "ent_type": "Disease", "char_span": [52, 63], "ent_id": "-1", "tok_span": [10, 12]}, {"name": "PVC", "ent_type": "Disease", "char_span": [146, 149], "ent_id": "D018879", "tok_span": [24, 26]}, {"name": "premature ventricular contraction", "ent_type": "Disease", "char_span": [111, 144], "ent_id": "D018879", "tok_span": [20, 23]}, {"name": "quinine", "ent_type": "Chemical", "char_span": [18, 25], "ent_id": "D011803", "tok_span": [4, 6]}, {"name": "sinoatrial block", "ent_type": "Disease", "char_span": [191, 207], "ent_id": "D012848", "tok_span": [41, 45]}], "relation_list": [{"subject": "quinine", "object": "premature ventricular contraction", "sbj_char_span": [18, 25], "obj_char_span": [111, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [20, 23]}, {"subject": "quinine", "object": "PVC", "sbj_char_span": [18, 25], "obj_char_span": [146, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.", "entity_list": [{"name": "PVC", "ent_type": "Disease", "char_span": [196, 199], "ent_id": "D018879", "tok_span": [42, 44]}, {"name": "arrhythmic", "ent_type": "Disease", "char_span": [104, 114], "ent_id": "D001145", "tok_span": [27, 29]}, {"name": "Quinine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D011803", "tok_span": [0, 2]}, {"name": "quinidine", "ent_type": "Chemical", "char_span": [14, 23], "ent_id": "D011802", "tok_span": [4, 6]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [138, 149], "ent_id": "D001145", "tok_span": [33, 34]}, {"name": "arrhythmic", "ent_type": "Disease", "char_span": [62, 72], "ent_id": "D001145", "tok_span": [18, 20]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [168, 178], "ent_id": "D001145", "tok_span": [37, 39]}], "relation_list": [{"subject": "Quinine", "object": "PVC", "sbj_char_span": [0, 7], "obj_char_span": [196, 199], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [42, 44]}], "umls_entity_list": []}, {"text": "Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.", "entity_list": [{"name": "lichenoid dermatitis", "ent_type": "Disease", "char_span": [22, 42], "ent_id": "D017512", "tok_span": [7, 11]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [126, 133], "ent_id": "D001008", "tok_span": [25, 26]}, {"name": "Penicillamine", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D010396", "tok_span": [0, 5]}, {"name": "Wilson disease", "ent_type": "Disease", "char_span": [76, 90], "ent_id": "D006527", "tok_span": [18, 20]}, {"name": "zinc acetate", "ent_type": "Chemical", "char_span": [58, 70], "ent_id": "D019345", "tok_span": [14, 16]}], "relation_list": [{"subject": "Penicillamine", "object": "lichenoid dermatitis", "sbj_char_span": [0, 13], "obj_char_span": [22, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects.", "entity_list": [{"name": "penicillamine", "ent_type": "Chemical", "char_span": [37, 50], "ent_id": "D010396", "tok_span": [9, 14]}, {"name": "lichenoid dermatitis", "ent_type": "Disease", "char_span": [93, 113], "ent_id": "D017512", "tok_span": [21, 25]}, {"name": "zinc acetate", "ent_type": "Chemical", "char_span": [119, 131], "ent_id": "D019345", "tok_span": [27, 29]}], "relation_list": [{"subject": "penicillamine", "object": "lichenoid dermatitis", "sbj_char_span": [37, 50], "obj_char_span": [93, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "A dramatic drop in blood pressure following prehospital GTN administration.", "entity_list": [{"name": "GTN", "ent_type": "Chemical", "char_span": [56, 59], "ent_id": "D005996", "tok_span": [9, 11]}, {"name": "drop in blood pressure", "ent_type": "Disease", "char_span": [11, 33], "ent_id": "D007022", "tok_span": [2, 6]}], "relation_list": [{"subject": "GTN", "object": "drop in blood pressure", "sbj_char_span": [56, 59], "obj_char_span": [11, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge.", "entity_list": [{"name": "GTN", "ent_type": "Chemical", "char_span": [26, 29], "ent_id": "D005996", "tok_span": [4, 6]}, {"name": "drop in blood pressure", "ent_type": "Disease", "char_span": [63, 85], "ent_id": "D007022", "tok_span": [11, 15]}, {"name": "atropine sulphate", "ent_type": "Chemical", "char_span": [124, 141], "ent_id": "D001285", "tok_span": [24, 28]}], "relation_list": [{"subject": "GTN", "object": "drop in blood pressure", "sbj_char_span": [26, 29], "obj_char_span": [63, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.", "entity_list": [{"name": "acute lymphoblastic leukemia", "ent_type": "Disease", "char_span": [149, 177], "ent_id": "D054198", "tok_span": [32, 36]}, {"name": "Acute encephalopathy", "ent_type": "Disease", "char_span": [0, 20], "ent_id": "D020803", "tok_span": [0, 3]}, {"name": "cytarabine", "ent_type": "Chemical", "char_span": [117, 127], "ent_id": "D003561", "tok_span": [24, 28]}, {"name": "cerebral vasospasm", "ent_type": "Disease", "char_span": [25, 43], "ent_id": "D020301", "tok_span": [4, 8]}, {"name": "PEG-asparaginase", "ent_type": "Chemical", "char_span": [84, 100], "ent_id": "C042705", "tok_span": [13, 20]}], "relation_list": [{"subject": "cytarabine", "object": "cerebral vasospasm", "sbj_char_span": [117, 127], "obj_char_span": [25, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [4, 8]}, {"subject": "PEG-asparaginase", "object": "cerebral vasospasm", "sbj_char_span": [84, 100], "obj_char_span": [25, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 20], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "entity_list": [{"name": "acute encephalopathy", "ent_type": "Disease", "char_span": [22, 42], "ent_id": "D020803", "tok_span": [3, 6]}, {"name": "visual hallucinations", "ent_type": "Disease", "char_span": [99, 120], "ent_id": "D006212", "tok_span": [16, 20]}, {"name": "cytarabine", "ent_type": "Chemical", "char_span": [253, 263], "ent_id": "D003561", "tok_span": [44, 48]}, {"name": "incontinence", "ent_type": "Disease", "char_span": [85, 97], "ent_id": "D014549", "tok_span": [14, 15]}, {"name": "weakness", "ent_type": "Disease", "char_span": [138, 146], "ent_id": "D018908", "tok_span": [26, 27]}, {"name": "cerebral vasospasm", "ent_type": "Disease", "char_span": [160, 178], "ent_id": "D020301", "tok_span": [29, 33]}, {"name": "aphasia", "ent_type": "Disease", "char_span": [76, 83], "ent_id": "D001037", "tok_span": [11, 13]}], "relation_list": [{"subject": "cytarabine", "object": "incontinence", "sbj_char_span": [253, 263], "obj_char_span": [85, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 48], "obj_tok_span": [14, 15]}, {"subject": "cytarabine", "object": "cerebral vasospasm", "sbj_char_span": [253, 263], "obj_char_span": [160, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 48], "obj_tok_span": [29, 33]}, {"subject": "cytarabine", "object": "aphasia", "sbj_char_span": [253, 263], "obj_char_span": [76, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 48], "obj_tok_span": [11, 13]}, {"subject": "cytarabine", "object": "visual hallucinations", "sbj_char_span": [253, 263], "obj_char_span": [99, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 48], "obj_tok_span": [16, 20]}, {"subject": "cytarabine", "object": "weakness", "sbj_char_span": [253, 263], "obj_char_span": [138, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 48], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).", "entity_list": [{"name": "HCTZ", "ent_type": "Chemical", "char_span": [48, 52], "ent_id": "D006852", "tok_span": [13, 15]}, {"name": "hypokalemia", "ent_type": "Disease", "char_span": [17, 28], "ent_id": "D007008", "tok_span": [3, 7]}, {"name": "VAL", "ent_type": "Chemical", "char_span": [44, 47], "ent_id": "C081489", "tok_span": [10, 12]}, {"name": "HCTZ", "ent_type": "Chemical", "char_span": [88, 92], "ent_id": "D006852", "tok_span": [29, 31]}], "relation_list": [{"subject": "HCTZ", "object": "hypokalemia", "sbj_char_span": [48, 52], "obj_char_span": [17, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [3, 7]}, {"subject": "HCTZ", "object": "hypokalemia", "sbj_char_span": [88, 92], "obj_char_span": [17, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than HCTZ alone.", "entity_list": [{"name": "HCTZ", "ent_type": "Chemical", "char_span": [70, 74], "ent_id": "D006852", "tok_span": [13, 15]}, {"name": "HCTZ", "ent_type": "Chemical", "char_span": [234, 238], "ent_id": "D006852", "tok_span": [41, 43]}, {"name": "hypokalemia", "ent_type": "Disease", "char_span": [217, 228], "ent_id": "D007008", "tok_span": [36, 40]}, {"name": "VAL", "ent_type": "Chemical", "char_span": [66, 69], "ent_id": "C081489", "tok_span": [10, 12]}], "relation_list": [{"subject": "HCTZ", "object": "hypokalemia", "sbj_char_span": [234, 238], "obj_char_span": [217, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 43], "obj_tok_span": [36, 40]}, {"subject": "HCTZ", "object": "hypokalemia", "sbj_char_span": [70, 74], "obj_char_span": [217, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.", "entity_list": [{"name": "Succimer", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D004113", "tok_span": [0, 3]}, {"name": "lead", "ent_type": "Chemical", "char_span": [153, 157], "ent_id": "D007854", "tok_span": [27, 28]}, {"name": "lead", "ent_type": "Chemical", "char_span": [75, 79], "ent_id": "D007854", "tok_span": [14, 15]}, {"name": "cognitive impairment", "ent_type": "Disease", "char_span": [114, 134], "ent_id": "D003072", "tok_span": [21, 23]}], "relation_list": [{"subject": "Succimer", "object": "cognitive impairment", "sbj_char_span": [0, 8], "obj_char_span": [114, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Caffeine challenge test in panic disorder and depression with panic attacks.", "entity_list": [{"name": "panic attacks", "ent_type": "Disease", "char_span": [62, 75], "ent_id": "D016584", "tok_span": [13, 16]}, {"name": "panic disorder", "ent_type": "Disease", "char_span": [27, 41], "ent_id": "D016584", "tok_span": [7, 10]}, {"name": "depression", "ent_type": "Disease", "char_span": [46, 56], "ent_id": "D003866", "tok_span": [11, 12]}, {"name": "Caffeine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D002110", "tok_span": [0, 4]}], "relation_list": [{"subject": "Caffeine", "object": "panic disorder", "sbj_char_span": [0, 8], "obj_char_span": [27, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [7, 10]}, {"subject": "Caffeine", "object": "panic attacks", "sbj_char_span": [0, 8], "obj_char_span": [62, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "entity_list": [{"name": "panic attacks", "ent_type": "Disease", "char_span": [246, 259], "ent_id": "D016584", "tok_span": [49, 52]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [271, 279], "ent_id": "D002110", "tok_span": [55, 56]}, {"name": "PD", "ent_type": "Disease", "char_span": [56, 58], "ent_id": "D016584", "tok_span": [12, 13]}, {"name": "MDP", "ent_type": "Disease", "char_span": [115, 118], "ent_id": "D00386", "tok_span": [24, 26]}, {"name": "panic attacks", "ent_type": "Disease", "char_span": [100, 113], "ent_id": "D016584", "tok_span": [20, 23]}, {"name": "Mental Disorders", "ent_type": "Disease", "char_span": [158, 174], "ent_id": "D001523", "tok_span": [33, 35]}, {"name": "panic disorder", "ent_type": "Disease", "char_span": [40, 54], "ent_id": "D016584", "tok_span": [8, 11]}, {"name": "major depression", "ent_type": "Disease", "char_span": [78, 94], "ent_id": "D003865", "tok_span": [17, 19]}], "relation_list": [{"subject": "caffeine", "object": "panic attacks", "sbj_char_span": [271, 279], "obj_char_span": [100, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 56], "obj_tok_span": [20, 23]}, {"subject": "caffeine", "object": "panic attacks", "sbj_char_span": [271, 279], "obj_char_span": [246, 259], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 56], "obj_tok_span": [49, 52]}, {"subject": "caffeine", "object": "panic disorder", "sbj_char_span": [271, 279], "obj_char_span": [40, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 56], "obj_tok_span": [8, 11]}, {"subject": "caffeine", "object": "PD", "sbj_char_span": [271, 279], "obj_char_span": [56, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 56], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).", "entity_list": [{"name": "MDP", "ent_type": "Disease", "char_span": [79, 82], "ent_id": "D00386", "tok_span": [29, 31]}, {"name": "MD", "ent_type": "Disease", "char_span": [115, 117], "ent_id": "D003865", "tok_span": [44, 45]}, {"name": "panic attack", "ent_type": "Disease", "char_span": [161, 173], "ent_id": "D016584", "tok_span": [61, 64]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [191, 199], "ent_id": "D002110", "tok_span": [69, 70]}, {"name": "PD", "ent_type": "Disease", "char_span": [43, 45], "ent_id": "D016584", "tok_span": [15, 16]}], "relation_list": [{"subject": "caffeine", "object": "PD", "sbj_char_span": [191, 199], "obj_char_span": [43, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [69, 70], "obj_tok_span": [15, 16]}, {"subject": "caffeine", "object": "panic attack", "sbj_char_span": [191, 199], "obj_char_span": [161, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [69, 70], "obj_tok_span": [61, 64]}], "umls_entity_list": []}, {"text": "The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.", "entity_list": [{"name": "MD", "ent_type": "Disease", "char_span": [85, 87], "ent_id": "D003865", "tok_span": [16, 17]}, {"name": "PD", "ent_type": "Disease", "char_span": [18, 20], "ent_id": "D016584", "tok_span": [3, 4]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [52, 60], "ent_id": "D002110", "tok_span": [11, 12]}, {"name": "MDP", "ent_type": "Disease", "char_span": [25, 28], "ent_id": "D00386", "tok_span": [5, 7]}], "relation_list": [{"subject": "caffeine", "object": "PD", "sbj_char_span": [52, 60], "obj_char_span": [18, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "No panic attack was observed after the caffeine-free solution intake.", "entity_list": [{"name": "panic attack", "ent_type": "Disease", "char_span": [3, 15], "ent_id": "D016584", "tok_span": [1, 4]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [39, 47], "ent_id": "D002110", "tok_span": [8, 9]}], "relation_list": [{"subject": "caffeine", "object": "panic attack", "sbj_char_span": [39, 47], "obj_char_span": [3, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral caffeine challenge test.", "entity_list": [{"name": "PD", "ent_type": "Disease", "char_span": [98, 100], "ent_id": "D016584", "tok_span": [18, 19]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [140, 148], "ent_id": "D002110", "tok_span": [31, 32]}, {"name": "panic attacks", "ent_type": "Disease", "char_span": [54, 67], "ent_id": "D016584", "tok_span": [9, 12]}, {"name": "MDP", "ent_type": "Disease", "char_span": [104, 107], "ent_id": "D00386", "tok_span": [20, 22]}], "relation_list": [{"subject": "caffeine", "object": "PD", "sbj_char_span": [140, 148], "obj_char_span": [98, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [18, 19]}, {"subject": "caffeine", "object": "panic attacks", "sbj_char_span": [140, 148], "obj_char_span": [54, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Acute heart failure was induced by propranolol and volume loading after weaning from cardiopulmonary bypass; an absence of MR was confirmed by echocardiography.", "entity_list": [{"name": "heart failure", "ent_type": "Disease", "char_span": [6, 19], "ent_id": "D006333", "tok_span": [1, 3]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [35, 46], "ent_id": "D011433", "tok_span": [6, 10]}, {"name": "MR", "ent_type": "Disease", "char_span": [123, 125], "ent_id": "D008944", "tok_span": [22, 23]}], "relation_list": [{"subject": "propranolol", "object": "heart failure", "sbj_char_span": [35, 46], "obj_char_span": [6, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "entity_list": [{"name": "end-stage renal disease", "ent_type": "Disease", "char_span": [35, 58], "ent_id": "D007676", "tok_span": [10, 15]}, {"name": "piperacillin/tazobactam", "ent_type": "Chemical", "char_span": [280, 303], "ent_id": "C085143", "tok_span": [62, 71]}, {"name": "secondary infection", "ent_type": "Disease", "char_span": [352, 371], "ent_id": "D060085", "tok_span": [86, 88]}, {"name": "bronchiectasis", "ent_type": "Disease", "char_span": [332, 346], "ent_id": "D001987", "tok_span": [81, 85]}, {"name": "GTCS", "ent_type": "Disease", "char_span": [257, 261], "ent_id": "D004830", "tok_span": [55, 57]}, {"name": "confusion", "ent_type": "Disease", "char_span": [194, 203], "ent_id": "D003221", "tok_span": [42, 43]}, {"name": "tonic-clonic seizure", "ent_type": "Disease", "char_span": [235, 255], "ent_id": "D004830", "tok_span": [49, 54]}, {"name": "tremor", "ent_type": "Disease", "char_span": [149, 155], "ent_id": "D014202", "tok_span": [31, 33]}], "relation_list": [{"subject": "piperacillin/tazobactam", "object": "confusion", "sbj_char_span": [280, 303], "obj_char_span": [194, 203], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 71], "obj_tok_span": [42, 43]}, {"subject": "piperacillin/tazobactam", "object": "GTCS", "sbj_char_span": [280, 303], "obj_char_span": [257, 261], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 71], "obj_tok_span": [55, 57]}, {"subject": "piperacillin/tazobactam", "object": "tremor", "sbj_char_span": [280, 303], "obj_char_span": [149, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 71], "obj_tok_span": [31, 33]}, {"subject": "piperacillin/tazobactam", "object": "tonic-clonic seizure", "sbj_char_span": [280, 303], "obj_char_span": [235, 255], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 71], "obj_tok_span": [49, 54]}], "umls_entity_list": []}, {"text": "Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of piperacillin/tazobactam.", "entity_list": [{"name": "GTCS", "ent_type": "Disease", "char_span": [49, 53], "ent_id": "D004830", "tok_span": [11, 13]}, {"name": "piperacillin/tazobactam", "ent_type": "Chemical", "char_span": [95, 118], "ent_id": "C085143", "tok_span": [21, 30]}], "relation_list": [{"subject": "piperacillin/tazobactam", "object": "GTCS", "sbj_char_span": [95, 118], "obj_char_span": [49, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 30], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia.", "entity_list": [{"name": "cortical dysplasia", "ent_type": "Disease", "char_span": [107, 125], "ent_id": "D054220", "tok_span": [22, 24]}, {"name": "melatonin", "ent_type": "Chemical", "char_span": [27, 36], "ent_id": "D008550", "tok_span": [6, 7]}, {"name": "BCNU", "ent_type": "Chemical", "char_span": [94, 98], "ent_id": "D002330", "tok_span": [17, 20]}], "relation_list": [{"subject": "BCNU", "object": "cortical dysplasia", "sbj_char_span": [94, 98], "obj_char_span": [107, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.", "entity_list": [{"name": "1,3-bis (2-chloroethyl)-1-nitrosoure", "ent_type": "Chemical", "char_span": [124, 160], "ent_id": "D002330", "tok_span": [23, 42]}, {"name": "cortical dysplasia", "ent_type": "Disease", "char_span": [252, 270], "ent_id": "D054220", "tok_span": [63, 65]}, {"name": "BCNU", "ent_type": "Chemical", "char_span": [163, 167], "ent_id": "D002330", "tok_span": [44, 47]}, {"name": "melatonin", "ent_type": "Chemical", "char_span": [213, 222], "ent_id": "D008550", "tok_span": [55, 56]}, {"name": "BCNU", "ent_type": "Chemical", "char_span": [239, 243], "ent_id": "D002330", "tok_span": [58, 61]}, {"name": "carmustine", "ent_type": "Chemical", "char_span": [112, 122], "ent_id": "D002330", "tok_span": [17, 21]}], "relation_list": [{"subject": "1,3-bis (2-chloroethyl)-1-nitrosoure", "object": "cortical dysplasia", "sbj_char_span": [124, 160], "obj_char_span": [252, 270], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 42], "obj_tok_span": [63, 65]}, {"subject": "carmustine", "object": "cortical dysplasia", "sbj_char_span": [112, 122], "obj_char_span": [252, 270], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [63, 65]}, {"subject": "BCNU", "object": "cortical dysplasia", "sbj_char_span": [163, 167], "obj_char_span": [252, 270], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 47], "obj_tok_span": [63, 65]}, {"subject": "BCNU", "object": "cortical dysplasia", "sbj_char_span": [239, 243], "obj_char_span": [252, 270], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 61], "obj_tok_span": [63, 65]}], "umls_entity_list": []}, {"text": "Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed cortical dysplasia group.", "entity_list": [{"name": "BCNU", "ent_type": "Chemical", "char_span": [169, 173], "ent_id": "D002330", "tok_span": [28, 31]}, {"name": "cortical dysplasia", "ent_type": "Disease", "char_span": [182, 200], "ent_id": "D054220", "tok_span": [33, 35]}], "relation_list": [{"subject": "BCNU", "object": "cortical dysplasia", "sbj_char_span": [169, 173], "obj_char_span": [182, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced seizures model.", "entity_list": [{"name": "MIP", "ent_type": "Chemical", "char_span": [22, 25], "ent_id": "C002647", "tok_span": [4, 5]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [125, 136], "ent_id": "D010862", "tok_span": [22, 25]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [91, 98], "ent_id": "D008094", "tok_span": [15, 16]}, {"name": "inositol", "ent_type": "Chemical", "char_span": [106, 114], "ent_id": "D007294", "tok_span": [18, 21]}, {"name": "seizures", "ent_type": "Disease", "char_span": [145, 153], "ent_id": "D012640", "tok_span": [27, 28]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [125, 136], "obj_char_span": [145, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "Rifampicin-associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis.", "entity_list": [{"name": "staphylococcal endocarditis", "ent_type": "Disease", "char_span": [66, 93], "ent_id": "D01320", "tok_span": [16, 22]}, {"name": "Rifampicin", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D012293", "tok_span": [0, 4]}, {"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [44, 62], "ent_id": "D005921", "tok_span": [10, 15]}], "relation_list": [{"subject": "Rifampicin", "object": "glomerulonephritis", "sbj_char_span": [0, 10], "obj_char_span": [44, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 15]}], "umls_entity_list": []}, {"text": "Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis.", "entity_list": [{"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [22, 40], "ent_id": "D005921", "tok_span": [5, 10]}, {"name": "tuberculosis", "ent_type": "Disease", "char_span": [133, 145], "ent_id": "D014376", "tok_span": [25, 26]}, {"name": "rifampicin", "ent_type": "Chemical", "char_span": [78, 88], "ent_id": "D012293", "tok_span": [16, 19]}], "relation_list": [{"subject": "rifampicin", "object": "glomerulonephritis", "sbj_char_span": [78, 88], "obj_char_span": [22, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "entity_list": [{"name": "rifampicin", "ent_type": "Chemical", "char_span": [170, 180], "ent_id": "D012293", "tok_span": [32, 35]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [69, 88], "ent_id": "D058186", "tok_span": [13, 16]}, {"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [126, 144], "ent_id": "D005921", "tok_span": [23, 28]}, {"name": "rifampicin", "ent_type": "Chemical", "char_span": [239, 249], "ent_id": "D012293", "tok_span": [44, 47]}, {"name": "Staphylococcal IE", "ent_type": "Disease", "char_span": [37, 54], "ent_id": "D01320", "tok_span": [8, 11]}], "relation_list": [{"subject": "rifampicin", "object": "glomerulonephritis", "sbj_char_span": [239, 249], "obj_char_span": [126, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 47], "obj_tok_span": [23, 28]}, {"subject": "rifampicin", "object": "acute renal failure", "sbj_char_span": [170, 180], "obj_char_span": [69, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [13, 16]}, {"subject": "rifampicin", "object": "glomerulonephritis", "sbj_char_span": [170, 180], "obj_char_span": [126, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [23, 28]}, {"subject": "rifampicin", "object": "acute renal failure", "sbj_char_span": [239, 249], "obj_char_span": [69, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 47], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Branch retinal vein occlusion and fluoxetine.", "entity_list": [{"name": "retinal vein occlusion", "ent_type": "Disease", "char_span": [7, 29], "ent_id": "D012170", "tok_span": [1, 4]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [34, 44], "ent_id": "D005473", "tok_span": [5, 8]}], "relation_list": [{"subject": "fluoxetine", "object": "retinal vein occlusion", "sbj_char_span": [34, 44], "obj_char_span": [7, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "A case of branch retinal vein occlusion associated with fluoxetine-induced secondary hypertension is described.", "entity_list": [{"name": "retinal vein occlusion", "ent_type": "Disease", "char_span": [17, 39], "ent_id": "D012170", "tok_span": [4, 7]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [56, 66], "ent_id": "D005473", "tok_span": [9, 12]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [85, 97], "ent_id": "D006973", "tok_span": [15, 16]}], "relation_list": [{"subject": "fluoxetine", "object": "retinal vein occlusion", "sbj_char_span": [56, 66], "obj_char_span": [17, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [4, 7]}, {"subject": "fluoxetine", "object": "hypertension", "sbj_char_span": [56, 66], "obj_char_span": [85, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.", "entity_list": [{"name": "PGE2", "ent_type": "Chemical", "char_span": [104, 108], "ent_id": "D015232", "tok_span": [21, 23]}, {"name": "prostaglandin E2", "ent_type": "Chemical", "char_span": [86, 102], "ent_id": "D015232", "tok_span": [17, 20]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [65, 76], "ent_id": "D002045", "tok_span": [11, 15]}, {"name": "postoperative pain", "ent_type": "Disease", "char_span": [177, 195], "ent_id": "D010149", "tok_span": [35, 37]}], "relation_list": [{"subject": "bupivacaine", "object": "postoperative pain", "sbj_char_span": [65, 76], "obj_char_span": [177, 195], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "p75NTR expression in rat urinary bladder sensory neurons and spinal cord with cyclophosphamide-induced cystitis.", "entity_list": [{"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [78, 94], "ent_id": "D003520", "tok_span": [15, 18]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [103, 111], "ent_id": "D003556", "tok_span": [20, 22]}], "relation_list": [{"subject": "cyclophosphamide", "object": "cystitis", "sbj_char_span": [78, 94], "obj_char_span": [103, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "The present studies examine the expression and regulation of another receptor known to bind NGF, p75(NTR), after various durations of bladder inflammation induced by cyclophosphamide (CYP).", "entity_list": [{"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [166, 182], "ent_id": "D003520", "tok_span": [31, 34]}, {"name": "CYP", "ent_type": "Chemical", "char_span": [184, 187], "ent_id": "D003520", "tok_span": [35, 36]}, {"name": "bladder inflammation", "ent_type": "Disease", "char_span": [134, 154], "ent_id": "D003556", "tok_span": [27, 29]}], "relation_list": [{"subject": "CYP", "object": "bladder inflammation", "sbj_char_span": [184, 187], "obj_char_span": [134, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 36], "obj_tok_span": [27, 29]}, {"subject": "cyclophosphamide", "object": "bladder inflammation", "sbj_char_span": [166, 182], "obj_char_span": [134, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "CYP-induced cystitis increased (P < or = 0.001) p75(NTR) expression in the superficial lateral and medial dorsal horn in L1-L2 and L6-S1 spinal segments.", "entity_list": [{"name": "CYP", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D003520", "tok_span": [0, 1]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [12, 20], "ent_id": "D003556", "tok_span": [3, 5]}], "relation_list": [{"subject": "CYP", "object": "cystitis", "sbj_char_span": [0, 3], "obj_char_span": [12, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "The number of p75(NTR)-immunoreactive (-IR) cells in the lumbosacral dorsal root ganglia (DRG) also increased (P < or = 0.05) with CYP-induced cystitis (acute, intermediate, and chronic).", "entity_list": [{"name": "CYP", "ent_type": "Chemical", "char_span": [131, 134], "ent_id": "D003520", "tok_span": [43, 44]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [143, 151], "ent_id": "D003556", "tok_span": [46, 48]}], "relation_list": [{"subject": "CYP", "object": "cystitis", "sbj_char_span": [131, 134], "obj_char_span": [143, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 44], "obj_tok_span": [46, 48]}], "umls_entity_list": []}, {"text": "Quantitative, real-time polymerase chain reaction also demonstrated significant increases (P < or = 0.01) in p75(NTR) mRNA in DRG with intermediate and chronic CYP-induced cystitis.", "entity_list": [{"name": "CYP", "ent_type": "Chemical", "char_span": [160, 163], "ent_id": "D003520", "tok_span": [36, 37]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [172, 180], "ent_id": "D003556", "tok_span": [39, 41]}], "relation_list": [{"subject": "CYP", "object": "cystitis", "sbj_char_span": [160, 163], "obj_char_span": [172, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 37], "obj_tok_span": [39, 41]}], "umls_entity_list": []}, {"text": "The side effects of azathioprine include anemia, which has been attributed to bone marrow suppression.", "entity_list": [{"name": "anemia", "ent_type": "Disease", "char_span": [41, 47], "ent_id": "D000740", "tok_span": [9, 10]}, {"name": "azathioprine", "ent_type": "Chemical", "char_span": [20, 32], "ent_id": "D001379", "tok_span": [4, 8]}], "relation_list": [{"subject": "azathioprine", "object": "anemia", "sbj_char_span": [20, 32], "obj_char_span": [41, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced anemia.", "entity_list": [{"name": "Azathioprine", "ent_type": "Chemical", "char_span": [13, 25], "ent_id": "D001379", "tok_span": [2, 6]}, {"name": "azathioprine", "ent_type": "Chemical", "char_span": [100, 112], "ent_id": "D001379", "tok_span": [16, 20]}, {"name": "anemia", "ent_type": "Disease", "char_span": [121, 127], "ent_id": "D000740", "tok_span": [22, 23]}], "relation_list": [{"subject": "azathioprine", "object": "anemia", "sbj_char_span": [100, 112], "obj_char_span": [121, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [22, 23]}, {"subject": "Azathioprine", "object": "anemia", "sbj_char_span": [13, 25], "obj_char_span": [121, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).", "entity_list": [{"name": "rash", "ent_type": "Disease", "char_span": [102, 106], "ent_id": "D005076", "tok_span": [19, 21]}, {"name": "d4T", "ent_type": "Chemical", "char_span": [111, 114], "ent_id": "D018119", "tok_span": [22, 25]}, {"name": "NVP", "ent_type": "Chemical", "char_span": [45, 48], "ent_id": "D019829", "tok_span": [11, 13]}, {"name": "peripheral neuropathy", "ent_type": "Disease", "char_span": [139, 160], "ent_id": "D010523", "tok_span": [28, 30]}], "relation_list": [{"subject": "NVP", "object": "rash", "sbj_char_span": [45, 48], "obj_char_span": [102, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [19, 21]}, {"subject": "d4T", "object": "peripheral neuropathy", "sbj_char_span": [111, 114], "obj_char_span": [139, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "Thalidomide and sensory neurotoxicity: a neurophysiological study.", "entity_list": [{"name": "sensory neurotoxicity", "ent_type": "Disease", "char_span": [16, 37], "ent_id": "D010523", "tok_span": [4, 7]}, {"name": "Thalidomide", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D013792", "tok_span": [0, 3]}], "relation_list": [{"subject": "Thalidomide", "object": "sensory neurotoxicity", "sbj_char_span": [0, 11], "obj_char_span": [16, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "BACKGROUND: Recent studies confirmed a high incidence of sensory axonal neuropathy in patients treated with different doses of thalidomide.", "entity_list": [{"name": "sensory axonal neuropathy", "ent_type": "Disease", "char_span": [57, 82], "ent_id": "D010523", "tok_span": [9, 12]}, {"name": "thalidomide", "ent_type": "Chemical", "char_span": [127, 138], "ent_id": "D013792", "tok_span": [19, 22]}], "relation_list": [{"subject": "thalidomide", "object": "sensory axonal neuropathy", "sbj_char_span": [127, 138], "obj_char_span": [57, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings.", "entity_list": [{"name": "valvular heart disease", "ent_type": "Disease", "char_span": [93, 115], "ent_id": "D006349", "tok_span": [22, 27]}, {"name": "Amiodarone", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D000638", "tok_span": [0, 4]}, {"name": "pulmonary mass", "ent_type": "Disease", "char_span": [19, 33], "ent_id": "D055370", "tok_span": [6, 8]}, {"name": "membranous glomerulonephritis", "ent_type": "Disease", "char_span": [45, 74], "ent_id": "D015433", "tok_span": [10, 18]}], "relation_list": [{"subject": "Amiodarone", "object": "pulmonary mass", "sbj_char_span": [0, 10], "obj_char_span": [19, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 8]}, {"subject": "Amiodarone", "object": "membranous glomerulonephritis", "sbj_char_span": [0, 10], "obj_char_span": [45, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 18]}], "umls_entity_list": []}, {"text": "Reported herein is an autopsy case of valvular heart disease, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with amiodarone for a long time.", "entity_list": [{"name": "amiodarone", "ent_type": "Chemical", "char_span": [172, 182], "ent_id": "D000638", "tok_span": [43, 47]}, {"name": "valvular heart disease", "ent_type": "Disease", "char_span": [38, 60], "ent_id": "D006349", "tok_span": [8, 13]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [126, 137], "ent_id": "D011507", "tok_span": [31, 32]}, {"name": "lung mass", "ent_type": "Disease", "char_span": [91, 100], "ent_id": "D055370", "tok_span": [20, 22]}], "relation_list": [{"subject": "amiodarone", "object": "lung mass", "sbj_char_span": [172, 182], "obj_char_span": [91, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 47], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "The lung mass was highly suspected to be lung cancer on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an amiodarone-related lesion.", "entity_list": [{"name": "lung mass", "ent_type": "Disease", "char_span": [4, 13], "ent_id": "D055370", "tok_span": [1, 3]}, {"name": "lung cancer", "ent_type": "Disease", "char_span": [41, 52], "ent_id": "D008175", "tok_span": [8, 10]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [310, 320], "ent_id": "D000638", "tok_span": [53, 57]}], "relation_list": [{"subject": "amiodarone", "object": "lung mass", "sbj_char_span": [310, 320], "obj_char_span": [4, 13], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 57], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.", "entity_list": [{"name": "neoplasm", "ent_type": "Disease", "char_span": [125, 133], "ent_id": "D009369", "tok_span": [21, 23]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [83, 93], "ent_id": "D000638", "tok_span": [11, 15]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [262, 272], "ent_id": "D000638", "tok_span": [47, 51]}, {"name": "membranous glomerulonephritis", "ent_type": "Disease", "char_span": [190, 219], "ent_id": "D015433", "tok_span": [33, 41]}, {"name": "pulmonary lesion", "ent_type": "Disease", "char_span": [102, 118], "ent_id": "D055370", "tok_span": [17, 19]}], "relation_list": [{"subject": "amiodarone", "object": "pulmonary lesion", "sbj_char_span": [262, 272], "obj_char_span": [102, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 51], "obj_tok_span": [17, 19]}, {"subject": "amiodarone", "object": "membranous glomerulonephritis", "sbj_char_span": [83, 93], "obj_char_span": [190, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [33, 41]}, {"subject": "amiodarone", "object": "membranous glomerulonephritis", "sbj_char_span": [262, 272], "obj_char_span": [190, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 51], "obj_tok_span": [33, 41]}, {"subject": "amiodarone", "object": "pulmonary lesion", "sbj_char_span": [83, 93], "obj_char_span": [102, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.", "entity_list": [{"name": "glipizide", "ent_type": "Chemical", "char_span": [164, 173], "ent_id": "D005913", "tok_span": [63, 67]}, {"name": "CAD", "ent_type": "Disease", "char_span": [25, 28], "ent_id": "D003324", "tok_span": [4, 5]}, {"name": "metformin", "ent_type": "Chemical", "char_span": [239, 248], "ent_id": "D008687", "tok_span": [95, 96]}, {"name": "glibenclamide", "ent_type": "Chemical", "char_span": [118, 131], "ent_id": "D005905", "tok_span": [38, 42]}], "relation_list": [{"subject": "glibenclamide", "object": "CAD", "sbj_char_span": [118, 131], "obj_char_span": [25, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 42], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "entity_list": [{"name": "gliclazide", "ent_type": "Chemical", "char_span": [143, 153], "ent_id": "D005907", "tok_span": [29, 33]}, {"name": "glipizide", "ent_type": "Chemical", "char_span": [75, 84], "ent_id": "D005913", "tok_span": [15, 19]}, {"name": "glimepiride", "ent_type": "Chemical", "char_span": [157, 168], "ent_id": "C057619", "tok_span": [34, 38]}, {"name": "type 2 diabetes", "ent_type": "Disease", "char_span": [37, 52], "ent_id": "D003924", "tok_span": [6, 9]}, {"name": "glibenclamide", "ent_type": "Chemical", "char_span": [58, 71], "ent_id": "D005905", "tok_span": [10, 14]}, {"name": "CAD", "ent_type": "Disease", "char_span": [122, 125], "ent_id": "D003324", "tok_span": [25, 26]}], "relation_list": [{"subject": "glibenclamide", "object": "CAD", "sbj_char_span": [58, 71], "obj_char_span": [122, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.", "entity_list": [{"name": "uraemia", "ent_type": "Disease", "char_span": [17, 24], "ent_id": "D014511", "tok_span": [3, 5]}, {"name": "ADR", "ent_type": "Chemical", "char_span": [66, 69], "ent_id": "D004317", "tok_span": [11, 13]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [70, 81], "ent_id": "D007674", "tok_span": [13, 14]}, {"name": "Losartan", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D019808", "tok_span": [0, 2]}, {"name": "urea", "ent_type": "Chemical", "char_span": [39, 43], "ent_id": "D014508", "tok_span": [7, 8]}], "relation_list": [{"subject": "ADR", "object": "uraemia", "sbj_char_span": [66, 69], "obj_char_span": [17, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.", "entity_list": [{"name": "Losartan", "ent_type": "Chemical", "char_span": [12, 20], "ent_id": "D019808", "tok_span": [2, 4]}, {"name": "focal segmental glomerulosclerosis", "ent_type": "Disease", "char_span": [68, 102], "ent_id": "D005923", "tok_span": [14, 20]}, {"name": "end-stage renal disease", "ent_type": "Disease", "char_span": [106, 129], "ent_id": "D007676", "tok_span": [21, 26]}, {"name": "ADR", "ent_type": "Chemical", "char_span": [56, 59], "ent_id": "D004317", "tok_span": [10, 12]}], "relation_list": [{"subject": "ADR", "object": "focal segmental glomerulosclerosis", "sbj_char_span": [56, 59], "obj_char_span": [68, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [14, 20]}], "umls_entity_list": []}, {"text": "Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "entity_list": [{"name": "adrenaline", "ent_type": "Chemical", "char_span": [55, 65], "ent_id": "D004837", "tok_span": [11, 13]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [211, 222], "ent_id": "D011433", "tok_span": [59, 63]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [121, 130], "ent_id": "D006221", "tok_span": [22, 25]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [16, 27], "ent_id": "D011433", "tok_span": [3, 7]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [157, 168], "ent_id": "D011433", "tok_span": [35, 39]}, {"name": "cardiac arrhythmias", "ent_type": "Disease", "char_span": [74, 93], "ent_id": "D001145", "tok_span": [15, 17]}], "relation_list": [{"subject": "halothane", "object": "cardiac arrhythmias", "sbj_char_span": [121, 130], "obj_char_span": [74, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [15, 17]}, {"subject": "adrenaline", "object": "cardiac arrhythmias", "sbj_char_span": [55, 65], "obj_char_span": [74, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.7.", "entity_list": [{"name": "adrenaline", "ent_type": "Chemical", "char_span": [85, 95], "ent_id": "D004837", "tok_span": [17, 19]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [12, 23], "ent_id": "D001145", "tok_span": [3, 4]}], "relation_list": [{"subject": "adrenaline", "object": "arrhythmias", "sbj_char_span": [85, 95], "obj_char_span": [12, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.", "entity_list": [{"name": "ouabain", "ent_type": "Chemical", "char_span": [93, 100], "ent_id": "D010042", "tok_span": [17, 20]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [16, 27], "ent_id": "D011433", "tok_span": [3, 7]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [59, 82], "ent_id": "D017180", "tok_span": [13, 15]}], "relation_list": [{"subject": "ouabain", "object": "ventricular tachycardia", "sbj_char_span": [93, 100], "obj_char_span": [59, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Long-term lithium therapy leading to hyperparathyroidism: a case report.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [10, 17], "ent_id": "D008094", "tok_span": [3, 4]}, {"name": "hyperparathyroidism", "ent_type": "Disease", "char_span": [37, 56], "ent_id": "D006961", "tok_span": [7, 11]}], "relation_list": [{"subject": "lithium", "object": "hyperparathyroidism", "sbj_char_span": [10, 17], "obj_char_span": [37, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "We examined the case of a lithium-treated patient who had recurrent hypercalcemia to better understand the disease process.", "entity_list": [{"name": "hypercalcemia", "ent_type": "Disease", "char_span": [68, 81], "ent_id": "D006934", "tok_span": [13, 16]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [26, 33], "ent_id": "D008094", "tok_span": [6, 7]}], "relation_list": [{"subject": "lithium", "object": "hypercalcemia", "sbj_char_span": [26, 33], "obj_char_span": [68, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "PRACTICAL IMPLICATIONS: As much as 15% of lithium-treated patients become hypercalcemic.", "entity_list": [{"name": "hypercalcemic", "ent_type": "Disease", "char_span": [74, 87], "ent_id": "D006934", "tok_span": [20, 23]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [42, 49], "ent_id": "D008094", "tok_span": [15, 16]}], "relation_list": [{"subject": "lithium", "object": "hypercalcemic", "sbj_char_span": [42, 49], "obj_char_span": [74, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-remifentanil total i.v. anesthesia (TIVA).", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [327, 338], "ent_id": "D007022", "tok_span": [59, 60]}, {"name": "bleeding", "ent_type": "Disease", "char_span": [113, 121], "ent_id": "D006470", "tok_span": [18, 19]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [361, 369], "ent_id": "D015742", "tok_span": [63, 65]}, {"name": "remifentanil", "ent_type": "Chemical", "char_span": [370, 382], "ent_id": "C071741", "tok_span": [66, 70]}], "relation_list": [{"subject": "propofol", "object": "hypotension", "sbj_char_span": [361, 369], "obj_char_span": [327, 338], "rel_type": "chemical-induced disease", "sbj_tok_span": [63, 65], "obj_tok_span": [59, 60]}, {"subject": "remifentanil", "object": "hypotension", "sbj_char_span": [370, 382], "obj_char_span": [327, 338], "rel_type": "chemical-induced disease", "sbj_tok_span": [66, 70], "obj_tok_span": [59, 60]}], "umls_entity_list": []}, {"text": "METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol-remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT.", "entity_list": [{"name": "remifentanil", "ent_type": "Chemical", "char_span": [161, 173], "ent_id": "C071741", "tok_span": [30, 34]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [152, 160], "ent_id": "D015742", "tok_span": [27, 29]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [119, 130], "ent_id": "D007022", "tok_span": [23, 24]}], "relation_list": [{"subject": "remifentanil", "object": "hypotension", "sbj_char_span": [161, 173], "obj_char_span": [119, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [23, 24]}, {"subject": "propofol", "object": "hypotension", "sbj_char_span": [152, 160], "obj_char_span": [119, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "RESULTS: Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [20, 31], "ent_id": "D007022", "tok_span": [3, 4]}, {"name": "remifentanil", "ent_type": "Chemical", "char_span": [157, 169], "ent_id": "C071741", "tok_span": [27, 31]}, {"name": "remifentanil", "ent_type": "Chemical", "char_span": [111, 123], "ent_id": "C071741", "tok_span": [17, 21]}], "relation_list": [{"subject": "remifentanil", "object": "hypotension", "sbj_char_span": [157, 169], "obj_char_span": [20, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [3, 4]}, {"subject": "remifentanil", "object": "hypotension", "sbj_char_span": [111, 123], "obj_char_span": [20, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS.", "entity_list": [{"name": "remifentanil", "ent_type": "Chemical", "char_span": [276, 288], "ent_id": "C071741", "tok_span": [43, 47]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [98, 109], "ent_id": "D007022", "tok_span": [17, 18]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [246, 257], "ent_id": "D007022", "tok_span": [38, 39]}], "relation_list": [{"subject": "remifentanil", "object": "hypotension", "sbj_char_span": [276, 288], "obj_char_span": [98, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 47], "obj_tok_span": [17, 18]}, {"subject": "remifentanil", "object": "hypotension", "sbj_char_span": [276, 288], "obj_char_span": [246, 257], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 47], "obj_tok_span": [38, 39]}], "umls_entity_list": []}, {"text": "Nonalcoholic fatty liver disease during valproate therapy.", "entity_list": [{"name": "Nonalcoholic fatty liver disease", "ent_type": "Disease", "char_span": [0, 32], "ent_id": "D065626", "tok_span": [0, 7]}, {"name": "valproate", "ent_type": "Chemical", "char_span": [40, 49], "ent_id": "D014635", "tok_span": [8, 11]}], "relation_list": [{"subject": "valproate", "object": "Nonalcoholic fatty liver disease", "sbj_char_span": [40, 49], "obj_char_span": [0, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [0, 7]}], "umls_entity_list": []}, {"text": "We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during VPA treatment.", "entity_list": [{"name": "VPA", "ent_type": "Chemical", "char_span": [109, 112], "ent_id": "D014635", "tok_span": [24, 26]}, {"name": "obesity", "ent_type": "Disease", "char_span": [94, 101], "ent_id": "D009765", "tok_span": [22, 23]}, {"name": "nonalcoholic fatty liver disease", "ent_type": "Disease", "char_span": [20, 52], "ent_id": "D065626", "tok_span": [5, 12]}, {"name": "NAFLD", "ent_type": "Disease", "char_span": [54, 59], "ent_id": "D065626", "tok_span": [13, 15]}], "relation_list": [{"subject": "VPA", "object": "obesity", "sbj_char_span": [109, 112], "obj_char_span": [94, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [22, 23]}, {"subject": "VPA", "object": "nonalcoholic fatty liver disease", "sbj_char_span": [109, 112], "obj_char_span": [20, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [5, 12]}, {"subject": "VPA", "object": "NAFLD", "sbj_char_span": [109, 112], "obj_char_span": [54, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "entity_list": [{"name": "hyperinsulinemia", "ent_type": "Disease", "char_span": [40, 56], "ent_id": "D006946", "tok_span": [7, 10]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [201, 204], "ent_id": "D014635", "tok_span": [39, 41]}, {"name": "obesity", "ent_type": "Disease", "char_span": [31, 38], "ent_id": "D009765", "tok_span": [5, 6]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [107, 110], "ent_id": "D014635", "tok_span": [20, 22]}, {"name": "NAFLD", "ent_type": "Disease", "char_span": [157, 162], "ent_id": "D065626", "tok_span": [30, 32]}, {"name": "insulin resistance", "ent_type": "Disease", "char_span": [58, 76], "ent_id": "D007333", "tok_span": [11, 13]}], "relation_list": [{"subject": "VPA", "object": "NAFLD", "sbj_char_span": [201, 204], "obj_char_span": [157, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 41], "obj_tok_span": [30, 32]}, {"subject": "VPA", "object": "insulin resistance", "sbj_char_span": [107, 110], "obj_char_span": [58, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [11, 13]}, {"subject": "VPA", "object": "hyperinsulinemia", "sbj_char_span": [107, 110], "obj_char_span": [40, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [7, 10]}, {"subject": "VPA", "object": "insulin resistance", "sbj_char_span": [201, 204], "obj_char_span": [58, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 41], "obj_tok_span": [11, 13]}, {"subject": "VPA", "object": "obesity", "sbj_char_span": [107, 110], "obj_char_span": [31, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [5, 6]}, {"subject": "VPA", "object": "obesity", "sbj_char_span": [201, 204], "obj_char_span": [31, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 41], "obj_tok_span": [5, 6]}, {"subject": "VPA", "object": "NAFLD", "sbj_char_span": [107, 110], "obj_char_span": [157, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [30, 32]}, {"subject": "VPA", "object": "hyperinsulinemia", "sbj_char_span": [201, 204], "obj_char_span": [40, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 41], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Carbimazole induced ANCA positive vasculitis.", "entity_list": [{"name": "ANCA positive vasculitis", "ent_type": "Disease", "char_span": [20, 44], "ent_id": "D056648", "tok_span": [5, 10]}, {"name": "Carbimazole", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D002231", "tok_span": [0, 4]}], "relation_list": [{"subject": "Carbimazole", "object": "ANCA positive vasculitis", "sbj_char_span": [0, 11], "obj_char_span": [20, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications.", "entity_list": [{"name": "antithyroidmedications", "ent_type": "Chemical", "char_span": [118, 140], "ent_id": "D013956", "tok_span": [25, 30]}, {"name": "Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis", "ent_type": "Disease", "char_span": [0, 65], "ent_id": "D056648", "tok_span": [0, 15]}], "relation_list": [{"subject": "antithyroidmedications", "object": "Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis", "sbj_char_span": [118, 140], "obj_char_span": [0, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 30], "obj_tok_span": [0, 15]}], "umls_entity_list": []}, {"text": "PURPOSE: To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions, strokes, and death.", "entity_list": [{"name": "aspirin", "ent_type": "Chemical", "char_span": [55, 62], "ent_id": "D001241", "tok_span": [11, 12]}, {"name": "myocardial infarctions", "ent_type": "Disease", "char_span": [93, 115], "ent_id": "D009203", "tok_span": [17, 20]}, {"name": "strokes", "ent_type": "Disease", "char_span": [117, 124], "ent_id": "D020521", "tok_span": [21, 22]}], "relation_list": [{"subject": "aspirin", "object": "strokes", "sbj_char_span": [55, 62], "obj_char_span": [117, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity_list": [{"name": "aspirin", "ent_type": "Chemical", "char_span": [271, 278], "ent_id": "D001241", "tok_span": [51, 52]}, {"name": "strokes", "ent_type": "Disease", "char_span": [311, 318], "ent_id": "D020521", "tok_span": [57, 58]}, {"name": "CVD", "ent_type": "Disease", "char_span": [411, 414], "ent_id": "D002318", "tok_span": [76, 77]}, {"name": "stroke", "ent_type": "Disease", "char_span": [356, 362], "ent_id": "D020521", "tok_span": [65, 66]}, {"name": "CVD", "ent_type": "Disease", "char_span": [212, 215], "ent_id": "D002318", "tok_span": [40, 41]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [135, 142], "ent_id": "D001241", "tok_span": [29, 30]}, {"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [188, 210], "ent_id": "D002318", "tok_span": [37, 39]}], "relation_list": [{"subject": "aspirin", "object": "strokes", "sbj_char_span": [135, 142], "obj_char_span": [311, 318], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [57, 58]}, {"subject": "aspirin", "object": "strokes", "sbj_char_span": [271, 278], "obj_char_span": [311, 318], "rel_type": "chemical-induced disease", "sbj_tok_span": [51, 52], "obj_tok_span": [57, 58]}, {"subject": "aspirin", "object": "stroke", "sbj_char_span": [271, 278], "obj_char_span": [356, 362], "rel_type": "chemical-induced disease", "sbj_tok_span": [51, 52], "obj_tok_span": [65, 66]}, {"subject": "aspirin", "object": "stroke", "sbj_char_span": [135, 142], "obj_char_span": [356, 362], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [65, 66]}], "umls_entity_list": []}, {"text": "Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes?", "entity_list": [{"name": "gastrointestinal bleeding", "ent_type": "Disease", "char_span": [22, 47], "ent_id": "D006471", "tok_span": [3, 6]}, {"name": "hemorrhagic strokes", "ent_type": "Disease", "char_span": [51, 70], "ent_id": "D02030", "tok_span": [7, 9]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [5, 12], "ent_id": "D001241", "tok_span": [1, 2]}], "relation_list": [{"subject": "aspirin", "object": "gastrointestinal bleeding", "sbj_char_span": [5, 12], "obj_char_span": [22, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "The use of aspirin for primary prevention increases the risk for major bleeding events, primarily gastrointestinal bleeding events, in both men and women.", "entity_list": [{"name": "aspirin", "ent_type": "Chemical", "char_span": [11, 18], "ent_id": "D001241", "tok_span": [3, 4]}, {"name": "gastrointestinal bleeding", "ent_type": "Disease", "char_span": [98, 123], "ent_id": "D006471", "tok_span": [16, 19]}, {"name": "bleeding", "ent_type": "Disease", "char_span": [71, 79], "ent_id": "D006470", "tok_span": [12, 13]}], "relation_list": [{"subject": "aspirin", "object": "gastrointestinal bleeding", "sbj_char_span": [11, 18], "obj_char_span": [98, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "CONCLUSION: Aspirin reduces the risk for myocardial infarction in men and strokes in women.", "entity_list": [{"name": "strokes", "ent_type": "Disease", "char_span": [74, 81], "ent_id": "D020521", "tok_span": [14, 15]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [41, 62], "ent_id": "D009203", "tok_span": [9, 11]}, {"name": "Aspirin", "ent_type": "Chemical", "char_span": [12, 19], "ent_id": "D001241", "tok_span": [2, 5]}], "relation_list": [{"subject": "Aspirin", "object": "strokes", "sbj_char_span": [12, 19], "obj_char_span": [74, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Major bleeding with argatroban is 0-10% in the non-interventional setting and 0-5.8% periprocedurally.", "entity_list": [{"name": "argatroban", "ent_type": "Chemical", "char_span": [20, 30], "ent_id": "C031942", "tok_span": [3, 7]}, {"name": "bleeding", "ent_type": "Disease", "char_span": [6, 14], "ent_id": "D006470", "tok_span": [1, 2]}], "relation_list": [{"subject": "argatroban", "object": "bleeding", "sbj_char_span": [20, 30], "obj_char_span": [6, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.", "entity_list": [{"name": "methadone", "ent_type": "Chemical", "char_span": [74, 83], "ent_id": "D008691", "tok_span": [16, 19]}, {"name": "Rhabdomyolysis", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D012206", "tok_span": [0, 4]}, {"name": "ischemic stroke", "ent_type": "Disease", "char_span": [25, 40], "ent_id": "D002544", "tok_span": [6, 8]}, {"name": "heroin", "ent_type": "Chemical", "char_span": [46, 52], "ent_id": "D003932", "tok_span": [10, 12]}], "relation_list": [{"subject": "heroin", "object": "Rhabdomyolysis", "sbj_char_span": [46, 52], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [0, 4]}, {"subject": "methadone", "object": "Rhabdomyolysis", "sbj_char_span": [74, 83], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "RESULTS: A 33-year-old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin.", "entity_list": [{"name": "heroin", "ent_type": "Chemical", "char_span": [104, 110], "ent_id": "D003932", "tok_span": [21, 23]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [42, 56], "ent_id": "D012206", "tok_span": [11, 15]}, {"name": "ischemic stroke", "ent_type": "Disease", "char_span": [70, 85], "ent_id": "D002544", "tok_span": [17, 19]}], "relation_list": [{"subject": "heroin", "object": "rhabdomyolysis", "sbj_char_span": [104, 110], "obj_char_span": [42, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.", "entity_list": [{"name": "methadone", "ent_type": "Chemical", "char_span": [24, 33], "ent_id": "D008691", "tok_span": [4, 7]}, {"name": "heroin", "ent_type": "Chemical", "char_span": [38, 44], "ent_id": "D003932", "tok_span": [8, 10]}, {"name": "ischemic stroke", "ent_type": "Disease", "char_span": [100, 115], "ent_id": "D002544", "tok_span": [20, 22]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [81, 95], "ent_id": "D012206", "tok_span": [15, 19]}], "relation_list": [{"subject": "heroin", "object": "rhabdomyolysis", "sbj_char_span": [38, 44], "obj_char_span": [81, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [15, 19]}, {"subject": "methadone", "object": "rhabdomyolysis", "sbj_char_span": [24, 33], "obj_char_span": [81, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Hypotheses of heroin-related rhabdomyolysis and stroke in heroin abusers are discussed.", "entity_list": [{"name": "heroin", "ent_type": "Chemical", "char_span": [58, 64], "ent_id": "D003932", "tok_span": [14, 16]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [29, 43], "ent_id": "D012206", "tok_span": [7, 11]}, {"name": "heroin", "ent_type": "Chemical", "char_span": [14, 20], "ent_id": "D003932", "tok_span": [3, 5]}, {"name": "stroke", "ent_type": "Disease", "char_span": [48, 54], "ent_id": "D020521", "tok_span": [12, 13]}], "relation_list": [{"subject": "heroin", "object": "rhabdomyolysis", "sbj_char_span": [14, 20], "obj_char_span": [29, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [7, 11]}, {"subject": "heroin", "object": "stroke", "sbj_char_span": [58, 64], "obj_char_span": [48, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [12, 13]}, {"subject": "heroin", "object": "stroke", "sbj_char_span": [14, 20], "obj_char_span": [48, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [12, 13]}, {"subject": "heroin", "object": "rhabdomyolysis", "sbj_char_span": [58, 64], "obj_char_span": [29, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced L-DOPA-induced dyskinesias.", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [149, 160], "ent_id": "D004409", "tok_span": [31, 35]}, {"name": "DA", "ent_type": "Chemical", "char_span": [111, 113], "ent_id": "D004298", "tok_span": [20, 21]}, {"name": "L-DOPA", "ent_type": "Chemical", "char_span": [134, 140], "ent_id": "D007980", "tok_span": [25, 29]}], "relation_list": [{"subject": "L-DOPA", "object": "dyskinesias", "sbj_char_span": [134, 140], "obj_char_span": [149, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "These results suggest that activation of CB1 receptors offers neuroprotection against dopaminergic lesion and the development of L-DOPA-induced dyskinesias.", "entity_list": [{"name": "L-DOPA", "ent_type": "Chemical", "char_span": [129, 135], "ent_id": "D007980", "tok_span": [19, 23]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [144, 155], "ent_id": "D004409", "tok_span": [25, 29]}], "relation_list": [{"subject": "L-DOPA", "object": "dyskinesias", "sbj_char_span": [129, 135], "obj_char_span": [144, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Animal model of mania induced by ouabain: Evidence of oxidative stress in submitochondrial particles of the rat brain.", "entity_list": [{"name": "ouabain", "ent_type": "Chemical", "char_span": [33, 40], "ent_id": "D010042", "tok_span": [7, 10]}, {"name": "mania", "ent_type": "Disease", "char_span": [16, 21], "ent_id": "D001714", "tok_span": [3, 5]}], "relation_list": [{"subject": "ouabain", "object": "mania", "sbj_char_span": [33, 40], "obj_char_span": [16, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "The intracerebroventricular (ICV) administration of ouabain (a Na(+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania.", "entity_list": [{"name": "Na", "ent_type": "Chemical", "char_span": [63, 65], "ent_id": "D012964", "tok_span": [18, 19]}, {"name": "ouabain", "ent_type": "Chemical", "char_span": [52, 59], "ent_id": "D010042", "tok_span": [13, 16]}, {"name": "K", "ent_type": "Chemical", "char_span": [69, 70], "ent_id": "D011188", "tok_span": [23, 24]}, {"name": "bipolar mania", "ent_type": "Disease", "char_span": [151, 164], "ent_id": "D001714", "tok_span": [42, 45]}], "relation_list": [{"subject": "ouabain", "object": "bipolar mania", "sbj_char_span": [52, 59], "obj_char_span": [151, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [42, 45]}], "umls_entity_list": []}, {"text": "In conclusion, ouabain-induced mania-like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder.", "entity_list": [{"name": "ouabain", "ent_type": "Chemical", "char_span": [15, 22], "ent_id": "D010042", "tok_span": [3, 6]}, {"name": "mania", "ent_type": "Disease", "char_span": [31, 36], "ent_id": "D001714", "tok_span": [8, 10]}, {"name": "bipolar disorder", "ent_type": "Disease", "char_span": [150, 166], "ent_id": "D001714", "tok_span": [30, 32]}], "relation_list": [{"subject": "ouabain", "object": "bipolar disorder", "sbj_char_span": [15, 22], "obj_char_span": [150, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [30, 32]}, {"subject": "ouabain", "object": "mania", "sbj_char_span": [15, 22], "obj_char_span": [31, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.", "entity_list": [{"name": "acetaminophen", "ent_type": "Chemical", "char_span": [46, 59], "ent_id": "D000082", "tok_span": [13, 16]}, {"name": "AKI", "ent_type": "Disease", "char_span": [108, 111], "ent_id": "D058186", "tok_span": [25, 26]}, {"name": "fulminant liver failure", "ent_type": "Disease", "char_span": [68, 91], "ent_id": "D017114", "tok_span": [18, 23]}, {"name": "citrate", "ent_type": "Chemical", "char_span": [207, 214], "ent_id": "D019343", "tok_span": [38, 39]}], "relation_list": [{"subject": "acetaminophen", "object": "AKI", "sbj_char_span": [46, 59], "obj_char_span": [108, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [25, 26]}, {"subject": "acetaminophen", "object": "fulminant liver failure", "sbj_char_span": [46, 59], "obj_char_span": [68, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 23]}], "umls_entity_list": []}, {"text": "Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.", "entity_list": [{"name": "Delirium", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D003693", "tok_span": [0, 3]}, {"name": "flecainide", "ent_type": "Chemical", "char_span": [33, 43], "ent_id": "D005424", "tok_span": [8, 12]}, {"name": "paroxetine", "ent_type": "Chemical", "char_span": [119, 129], "ent_id": "D017374", "tok_span": [23, 26]}], "relation_list": [{"subject": "flecainide", "object": "Delirium", "sbj_char_span": [33, 43], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [0, 3]}, {"subject": "paroxetine", "object": "Delirium", "sbj_char_span": [119, 129], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine.", "entity_list": [{"name": "delirium", "ent_type": "Disease", "char_span": [52, 60], "ent_id": "D003693", "tok_span": [13, 16]}, {"name": "paroxetine", "ent_type": "Chemical", "char_span": [117, 127], "ent_id": "D017374", "tok_span": [23, 26]}, {"name": "flecainide", "ent_type": "Chemical", "char_span": [33, 43], "ent_id": "D005424", "tok_span": [7, 11]}], "relation_list": [{"subject": "flecainide", "object": "delirium", "sbj_char_span": [33, 43], "obj_char_span": [52, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 16]}, {"subject": "paroxetine", "object": "delirium", "sbj_char_span": [117, 127], "obj_char_span": [52, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "DISCUSSION: Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients.", "entity_list": [{"name": "Flecainide", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D005424", "tok_span": [2, 6]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [79, 85], "ent_id": "D012964", "tok_span": [14, 15]}, {"name": "delirium", "ent_type": "Disease", "char_span": [105, 113], "ent_id": "D003693", "tok_span": [18, 21]}], "relation_list": [{"subject": "Flecainide", "object": "delirium", "sbj_char_span": [12, 22], "obj_char_span": [105, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.", "entity_list": [{"name": "flecainide", "ent_type": "Chemical", "char_span": [204, 214], "ent_id": "D005424", "tok_span": [52, 56]}, {"name": "delirium", "ent_type": "Disease", "char_span": [223, 231], "ent_id": "D003693", "tok_span": [58, 61]}, {"name": "paroxetine", "ent_type": "Chemical", "char_span": [143, 153], "ent_id": "D017374", "tok_span": [34, 37]}, {"name": "flecainide", "ent_type": "Chemical", "char_span": [107, 117], "ent_id": "D005424", "tok_span": [21, 25]}], "relation_list": [{"subject": "paroxetine", "object": "delirium", "sbj_char_span": [143, 153], "obj_char_span": [223, 231], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 37], "obj_tok_span": [58, 61]}, {"subject": "flecainide", "object": "delirium", "sbj_char_span": [107, 117], "obj_char_span": [223, 231], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [58, 61]}, {"subject": "flecainide", "object": "delirium", "sbj_char_span": [204, 214], "obj_char_span": [223, 231], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 56], "obj_tok_span": [58, 61]}], "umls_entity_list": []}, {"text": "According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.", "entity_list": [{"name": "flecainide", "ent_type": "Chemical", "char_span": [211, 221], "ent_id": "D005424", "tok_span": [39, 43]}, {"name": "flecainide", "ent_type": "Chemical", "char_span": [44, 54], "ent_id": "D005424", "tok_span": [9, 13]}, {"name": "delirium", "ent_type": "Disease", "char_span": [95, 103], "ent_id": "D003693", "tok_span": [22, 25]}, {"name": "paroxetine", "ent_type": "Chemical", "char_span": [226, 236], "ent_id": "D017374", "tok_span": [44, 47]}], "relation_list": [{"subject": "flecainide", "object": "delirium", "sbj_char_span": [44, 54], "obj_char_span": [95, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [22, 25]}, {"subject": "paroxetine", "object": "delirium", "sbj_char_span": [226, 236], "obj_char_span": [95, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 47], "obj_tok_span": [22, 25]}, {"subject": "flecainide", "object": "delirium", "sbj_char_span": [211, 221], "obj_char_span": [95, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 43], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Supratherapeutic flecainide plasma concentrations may cause delirium.", "entity_list": [{"name": "flecainide", "ent_type": "Chemical", "char_span": [30, 40], "ent_id": "D005424", "tok_span": [6, 10]}, {"name": "delirium", "ent_type": "Disease", "char_span": [73, 81], "ent_id": "D003693", "tok_span": [14, 17]}], "relation_list": [{"subject": "flecainide", "object": "delirium", "sbj_char_span": [30, 40], "obj_char_span": [73, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Posttransplant anemia: the role of sirolimus.", "entity_list": [{"name": "anemia", "ent_type": "Disease", "char_span": [15, 21], "ent_id": "D000740", "tok_span": [2, 3]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [35, 44], "ent_id": "D020123", "tok_span": [7, 9]}], "relation_list": [{"subject": "sirolimus", "object": "anemia", "sbj_char_span": [35, 44], "obj_char_span": [15, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia.", "entity_list": [{"name": "Sirolimus", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D020123", "tok_span": [0, 3]}, {"name": "anemia", "ent_type": "Disease", "char_span": [118, 124], "ent_id": "D000740", "tok_span": [22, 23]}, {"name": "rapamycin", "ent_type": "Chemical", "char_span": [33, 42], "ent_id": "D020123", "tok_span": [8, 9]}], "relation_list": [{"subject": "Sirolimus", "object": "anemia", "sbj_char_span": [0, 9], "obj_char_span": [118, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [22, 23]}, {"subject": "rapamycin", "object": "anemia", "sbj_char_span": [33, 42], "obj_char_span": [118, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.", "entity_list": [{"name": "anemia", "ent_type": "Disease", "char_span": [22, 28], "ent_id": "D000740", "tok_span": [3, 4]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [45, 54], "ent_id": "D020123", "tok_span": [6, 8]}], "relation_list": [{"subject": "sirolimus", "object": "anemia", "sbj_char_span": [45, 54], "obj_char_span": [22, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "Coronary computerized tomography angiography for rapid discharge of low-risk patients with cocaine-associated chest pain.", "entity_list": [{"name": "chest pain", "ent_type": "Disease", "char_span": [110, 120], "ent_id": "D002637", "tok_span": [16, 18]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [91, 98], "ent_id": "D003042", "tok_span": [13, 14]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [91, 98], "obj_char_span": [110, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "BACKGROUND: Most patients presenting to emergency departments (EDs) with cocaine-associated chest pain are admitted for at least 12 hours and receive a \"rule out acute coronary syndrome\" protocol, often with noninvasive testing prior to discharge.", "entity_list": [{"name": "acute coronary syndrome", "ent_type": "Disease", "char_span": [162, 185], "ent_id": "D054058", "tok_span": [31, 34]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [92, 102], "ent_id": "D002637", "tok_span": [16, 18]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [73, 80], "ent_id": "D003042", "tok_span": [13, 14]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [73, 80], "obj_char_span": [92, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "It is unclear whether a coronary CTA strategy would be efficacious in cocaine-associated chest pain, as coronary vasospasm may account for some of the ischemia.", "entity_list": [{"name": "ischemia", "ent_type": "Disease", "char_span": [151, 159], "ent_id": "D007511", "tok_span": [30, 31]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [89, 99], "ent_id": "D002637", "tok_span": [16, 18]}, {"name": "coronary vasospasm", "ent_type": "Disease", "char_span": [104, 122], "ent_id": "D003329", "tok_span": [20, 24]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [70, 77], "ent_id": "D003042", "tok_span": [13, 14]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [70, 77], "obj_char_span": [89, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "We studied whether a negative coronary CTA in patients with cocaine-associated chest pain could identify a subset safe for discharge.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [60, 67], "ent_id": "D003042", "tok_span": [11, 12]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [79, 89], "ent_id": "D002637", "tok_span": [14, 16]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [60, 67], "obj_char_span": [79, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "RESULTS: A total of 59 patients with cocaine-associated chest pain were evaluated.", "entity_list": [{"name": "chest pain", "ent_type": "Disease", "char_span": [56, 66], "ent_id": "D002637", "tok_span": [11, 13]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [37, 44], "ent_id": "D003042", "tok_span": [8, 9]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [37, 44], "obj_char_span": [56, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "entity_list": [{"name": "chest pain", "ent_type": "Disease", "char_span": [137, 147], "ent_id": "D002637", "tok_span": [19, 21]}, {"name": "ischemic", "ent_type": "Disease", "char_span": [155, 163], "ent_id": "D007511", "tok_span": [25, 26]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [22, 29], "ent_id": "D003042", "tok_span": [3, 4]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [41, 60], "ent_id": "D017202", "tok_span": [6, 8]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [118, 125], "ent_id": "D003042", "tok_span": [17, 18]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [118, 125], "obj_char_span": [137, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [19, 21]}, {"subject": "cocaine", "object": "myocardial ischemia", "sbj_char_span": [22, 29], "obj_char_span": [41, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [6, 8]}, {"subject": "cocaine", "object": "myocardial ischemia", "sbj_char_span": [118, 125], "obj_char_span": [41, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [6, 8]}, {"subject": "cocaine", "object": "chest pain", "sbj_char_span": [22, 29], "obj_char_span": [137, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema.", "entity_list": [{"name": "cerebral edema", "ent_type": "Disease", "char_span": [168, 182], "ent_id": "D001929", "tok_span": [38, 40]}, {"name": "FHF", "ent_type": "Disease", "char_span": [131, 134], "ent_id": "D017114", "tok_span": [30, 32]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [140, 153], "ent_id": "D000082", "tok_span": [33, 36]}], "relation_list": [{"subject": "acetaminophen", "object": "cerebral edema", "sbj_char_span": [140, 153], "obj_char_span": [168, 182], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [38, 40]}, {"subject": "acetaminophen", "object": "FHF", "sbj_char_span": [140, 153], "obj_char_span": [131, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Initial evaluation confirmed FHF from acetaminophen and cerebral edema.", "entity_list": [{"name": "cerebral edema", "ent_type": "Disease", "char_span": [56, 70], "ent_id": "D001929", "tok_span": [10, 12]}, {"name": "FHF", "ent_type": "Disease", "char_span": [29, 32], "ent_id": "D017114", "tok_span": [3, 5]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [38, 51], "ent_id": "D000082", "tok_span": [6, 9]}], "relation_list": [{"subject": "acetaminophen", "object": "cerebral edema", "sbj_char_span": [38, 51], "obj_char_span": [56, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [10, 12]}, {"subject": "acetaminophen", "object": "FHF", "sbj_char_span": [38, 51], "obj_char_span": [29, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.", "entity_list": [{"name": "acetaminophen", "ent_type": "Chemical", "char_span": [57, 70], "ent_id": "D000082", "tok_span": [11, 14]}, {"name": "hypothermia", "ent_type": "Disease", "char_span": [103, 114], "ent_id": "D007035", "tok_span": [19, 21]}, {"name": "overdose", "ent_type": "Disease", "char_span": [71, 79], "ent_id": "D062787", "tok_span": [14, 16]}, {"name": "FHF", "ent_type": "Disease", "char_span": [29, 32], "ent_id": "D017114", "tok_span": [5, 7]}, {"name": "cerebral edema", "ent_type": "Disease", "char_span": [37, 51], "ent_id": "D001929", "tok_span": [8, 10]}], "relation_list": [{"subject": "acetaminophen", "object": "FHF", "sbj_char_span": [57, 70], "obj_char_span": [29, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [5, 7]}, {"subject": "acetaminophen", "object": "cerebral edema", "sbj_char_span": [57, 70], "obj_char_span": [37, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Binasal visual field defects are not specific to vigabatrin.", "entity_list": [{"name": "vigabatrin", "ent_type": "Chemical", "char_span": [49, 59], "ent_id": "D020888", "tok_span": [9, 12]}, {"name": "Binasal visual field defects", "ent_type": "Disease", "char_span": [0, 28], "ent_id": "D014786", "tok_span": [0, 5]}], "relation_list": [{"subject": "vigabatrin", "object": "Binasal visual field defects", "sbj_char_span": [49, 59], "obj_char_span": [0, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "This study investigated the visual defects associated with the antiepileptic drug vigabatrin (VGB).", "entity_list": [{"name": "vigabatrin", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D020888", "tok_span": [14, 17]}, {"name": "VGB", "ent_type": "Chemical", "char_span": [94, 97], "ent_id": "D020888", "tok_span": [18, 20]}, {"name": "visual defects", "ent_type": "Disease", "char_span": [28, 42], "ent_id": "D014786", "tok_span": [4, 6]}], "relation_list": [{"subject": "VGB", "object": "visual defects", "sbj_char_span": [94, 97], "obj_char_span": [28, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [4, 6]}, {"subject": "vigabatrin", "object": "visual defects", "sbj_char_span": [82, 92], "obj_char_span": [28, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Assessment by conventional static perimetry may neither be sufficiently sensitive nor specific to reliably identify retinal toxicity associated with VGB.", "entity_list": [{"name": "VGB", "ent_type": "Chemical", "char_span": [149, 152], "ent_id": "D020888", "tok_span": [20, 22]}, {"name": "retinal toxicity", "ent_type": "Disease", "char_span": [116, 132], "ent_id": "D012164", "tok_span": [16, 18]}], "relation_list": [{"subject": "VGB", "object": "retinal toxicity", "sbj_char_span": [149, 152], "obj_char_span": [116, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "To determine whether the risk of HIV seroconversion among daily smokers of crack cocaine changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov. 30, 1999 (period 1), Dec. 1, 1999-Nov. 30, 2002 (period 2), and Dec. 1, 2002-Dec. 30, 2005 (period 3).", "entity_list": [{"name": "HIV seroconversion", "ent_type": "Disease", "char_span": [33, 51], "ent_id": "D006679", "tok_span": [6, 10]}, {"name": "crack cocaine", "ent_type": "Chemical", "char_span": [75, 88], "ent_id": "D016578", "tok_span": [14, 16]}], "relation_list": [{"subject": "crack cocaine", "object": "HIV seroconversion", "sbj_char_span": [75, 88], "obj_char_span": [33, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "After adjusting for potential confounders, we found that the risk of HIV seroconversion among participants who were daily smokers of crack cocaine increased over time (period 1: hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.57-1.85; period 2: HR 1.68, 95% CI 1.01-2.80; and period 3: HR 2.74, 95% CI 1.06-7.11).", "entity_list": [{"name": "HIV seroconversion", "ent_type": "Disease", "char_span": [69, 87], "ent_id": "D006679", "tok_span": [12, 16]}, {"name": "crack cocaine", "ent_type": "Chemical", "char_span": [133, 146], "ent_id": "D016578", "tok_span": [23, 25]}], "relation_list": [{"subject": "crack cocaine", "object": "HIV seroconversion", "sbj_char_span": [133, 146], "obj_char_span": [69, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "INTERPRETATION: Smoking of crack cocaine was found to be an independent risk factor for HIV seroconversion among people who were injection drug users.", "entity_list": [{"name": "crack cocaine", "ent_type": "Chemical", "char_span": [27, 40], "ent_id": "D016578", "tok_span": [8, 10]}, {"name": "HIV seroconversion", "ent_type": "Disease", "char_span": [88, 106], "ent_id": "D006679", "tok_span": [19, 23]}], "relation_list": [{"subject": "crack cocaine", "object": "HIV seroconversion", "sbj_char_span": [27, 40], "obj_char_span": [88, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.", "entity_list": [{"name": "Fluoxetine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D005473", "tok_span": [0, 3]}, {"name": "5-fluorouracil", "ent_type": "Chemical", "char_span": [73, 87], "ent_id": "D005472", "tok_span": [12, 17]}, {"name": "memory deficits", "ent_type": "Disease", "char_span": [24, 39], "ent_id": "D008569", "tok_span": [5, 7]}], "relation_list": [{"subject": "5-fluorouracil", "object": "memory deficits", "sbj_char_span": [73, 87], "obj_char_span": [24, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration.", "entity_list": [{"name": "phenobarbital", "ent_type": "Chemical", "char_span": [134, 147], "ent_id": "D010634", "tok_span": [23, 25]}, {"name": "hepatomegaly", "ent_type": "Disease", "char_span": [115, 127], "ent_id": "D006529", "tok_span": [19, 22]}], "relation_list": [{"subject": "phenobarbital", "object": "hepatomegaly", "sbj_char_span": [134, 147], "obj_char_span": [115, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.", "entity_list": [{"name": "Nephropathy", "ent_type": "Disease", "char_span": [84, 95], "ent_id": "D007674", "tok_span": [30, 32]}, {"name": "K", "ent_type": "Chemical", "char_span": [27, 28], "ent_id": "D011188", "tok_span": [6, 7]}, {"name": "Na", "ent_type": "Chemical", "char_span": [24, 26], "ent_id": "D012964", "tok_span": [4, 5]}, {"name": "Gentamicin", "ent_type": "Chemical", "char_span": [65, 75], "ent_id": "D005839", "tok_span": [24, 28]}], "relation_list": [{"subject": "Gentamicin", "object": "Nephropathy", "sbj_char_span": [65, 75], "obj_char_span": [84, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "The present study was aimed to determine whether there is an altered regulation of tubular transporters in gentamicin-induced nephropathy.", "entity_list": [{"name": "gentamicin", "ent_type": "Chemical", "char_span": [107, 117], "ent_id": "D005839", "tok_span": [17, 19]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [126, 137], "ent_id": "D007674", "tok_span": [21, 22]}], "relation_list": [{"subject": "gentamicin", "object": "nephropathy", "sbj_char_span": [107, 117], "obj_char_span": [126, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.", "entity_list": [{"name": "nephropathy", "ent_type": "Disease", "char_span": [19, 30], "ent_id": "D007674", "tok_span": [6, 7]}, {"name": "Gentamicin", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D005839", "tok_span": [0, 4]}, {"name": "Na", "ent_type": "Chemical", "char_span": [103, 105], "ent_id": "D012964", "tok_span": [21, 22]}, {"name": "K", "ent_type": "Chemical", "char_span": [109, 110], "ent_id": "D011188", "tok_span": [26, 27]}], "relation_list": [{"subject": "Gentamicin", "object": "nephropathy", "sbj_char_span": [0, 10], "obj_char_span": [19, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "We evaluated the association of alcohol consumption and depression, and their effects on HIV disease progression among women with HIV.", "entity_list": [{"name": "HIV disease", "ent_type": "Disease", "char_span": [89, 100], "ent_id": "D015658", "tok_span": [14, 16]}, {"name": "alcohol", "ent_type": "Chemical", "char_span": [32, 39], "ent_id": "D000431", "tok_span": [5, 6]}, {"name": "depression", "ent_type": "Disease", "char_span": [56, 66], "ent_id": "D003866", "tok_span": [8, 9]}], "relation_list": [{"subject": "alcohol", "object": "depression", "sbj_char_span": [32, 39], "obj_char_span": [56, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "The participants had physical examination, medical record extraction, and venipuncture, CD4+T-cell counts determination, measurement of depression symptoms (using the self-report Center for Epidemiological Studies-Depression Scale), and alcohol use assessment at enrollment, and semiannually until March 2000.", "entity_list": [{"name": "alcohol", "ent_type": "Chemical", "char_span": [237, 244], "ent_id": "D000431", "tok_span": [46, 47]}, {"name": "depression", "ent_type": "Disease", "char_span": [136, 146], "ent_id": "D003866", "tok_span": [26, 27]}, {"name": "Depression", "ent_type": "Disease", "char_span": [214, 224], "ent_id": "D003866", "tok_span": [41, 42]}], "relation_list": [{"subject": "alcohol", "object": "depression", "sbj_char_span": [237, 244], "obj_char_span": [136, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 47], "obj_tok_span": [26, 27]}, {"subject": "alcohol", "object": "Depression", "sbj_char_span": [237, 244], "obj_char_span": [214, 224], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 47], "obj_tok_span": [41, 42]}], "umls_entity_list": []}, {"text": "The association between alcohol consumption and depression was significant (p<0.001).", "entity_list": [{"name": "alcohol", "ent_type": "Chemical", "char_span": [24, 31], "ent_id": "D000431", "tok_span": [3, 4]}, {"name": "depression", "ent_type": "Disease", "char_span": [48, 58], "ent_id": "D003866", "tok_span": [6, 7]}], "relation_list": [{"subject": "alcohol", "object": "depression", "sbj_char_span": [24, 31], "obj_char_span": [48, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Our findings suggest that alcohol consumption has a direct association with depression.", "entity_list": [{"name": "depression", "ent_type": "Disease", "char_span": [76, 86], "ent_id": "D003866", "tok_span": [11, 12]}, {"name": "alcohol", "ent_type": "Chemical", "char_span": [26, 33], "ent_id": "D000431", "tok_span": [4, 5]}], "relation_list": [{"subject": "alcohol", "object": "depression", "sbj_char_span": [26, 33], "obj_char_span": [76, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [100, 118], "ent_id": "D013226", "tok_span": [20, 23]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [80, 91], "ent_id": "D010862", "tok_span": [15, 18]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [80, 91], "obj_char_span": [100, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [97, 108], "ent_id": "D010862", "tok_span": [20, 23]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [62, 80], "ent_id": "D013226", "tok_span": [12, 15]}, {"name": "SE", "ent_type": "Disease", "char_span": [82, 84], "ent_id": "D013226", "tok_span": [16, 17]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [97, 108], "obj_char_span": [62, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [12, 15]}, {"subject": "pilocarpine", "object": "SE", "sbj_char_span": [97, 108], "obj_char_span": [82, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "METHODS: SE was induced by pilocarpine injection.", "entity_list": [{"name": "SE", "ent_type": "Disease", "char_span": [9, 11], "ent_id": "D013226", "tok_span": [2, 3]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [27, 38], "ent_id": "D010862", "tok_span": [6, 9]}], "relation_list": [{"subject": "pilocarpine", "object": "SE", "sbj_char_span": [27, 38], "obj_char_span": [9, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after pilocarpine-induced SE.", "entity_list": [{"name": "SE", "ent_type": "Disease", "char_span": [107, 109], "ent_id": "D013226", "tok_span": [24, 25]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [87, 98], "ent_id": "D010862", "tok_span": [19, 22]}], "relation_list": [{"subject": "pilocarpine", "object": "SE", "sbj_char_span": [87, 98], "obj_char_span": [107, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.", "entity_list": [{"name": "carmustine", "ent_type": "Chemical", "char_span": [65, 75], "ent_id": "D002330", "tok_span": [12, 16]}, {"name": "MT", "ent_type": "Chemical", "char_span": [49, 51], "ent_id": "D008668", "tok_span": [9, 10]}, {"name": "BCNU", "ent_type": "Chemical", "char_span": [77, 81], "ent_id": "D002330", "tok_span": [17, 20]}, {"name": "cognitive dysfunction", "ent_type": "Disease", "char_span": [103, 124], "ent_id": "D003072", "tok_span": [24, 26]}], "relation_list": [{"subject": "carmustine", "object": "cognitive dysfunction", "sbj_char_span": [65, 75], "obj_char_span": [103, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [24, 26]}, {"subject": "BCNU", "object": "cognitive dysfunction", "sbj_char_span": [77, 81], "obj_char_span": [103, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.", "entity_list": [{"name": "carbamazepine", "ent_type": "Chemical", "char_span": [6, 19], "ent_id": "D002220", "tok_span": [2, 6]}, {"name": "drug hypersensitivity", "ent_type": "Disease", "char_span": [167, 188], "ent_id": "D004342", "tok_span": [30, 33]}, {"name": "fulminant eosinophilic", "ent_type": "Disease", "char_span": [28, 50], "ent_id": "D004802", "tok_span": [7, 12]}, {"name": "hypersensitivity", "ent_type": "Disease", "char_span": [52, 68], "ent_id": "D004342", "tok_span": [13, 15]}, {"name": "myocarditis", "ent_type": "Disease", "char_span": [70, 81], "ent_id": "D009205", "tok_span": [16, 18]}], "relation_list": [{"subject": "carbamazepine", "object": "myocarditis", "sbj_char_span": [6, 19], "obj_char_span": [70, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [16, 18]}, {"subject": "carbamazepine", "object": "drug hypersensitivity", "sbj_char_span": [6, 19], "obj_char_span": [167, 188], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [30, 33]}, {"subject": "carbamazepine", "object": "fulminant eosinophilic", "sbj_char_span": [6, 19], "obj_char_span": [28, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [7, 12]}, {"subject": "carbamazepine", "object": "hypersensitivity", "sbj_char_span": [6, 19], "obj_char_span": [52, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "A frequently fatal, although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic (hypersensitivity) myocarditis.", "entity_list": [{"name": "myocarditis", "ent_type": "Disease", "char_span": [124, 135], "ent_id": "D009205", "tok_span": [25, 27]}, {"name": "hypersensitivity", "ent_type": "Disease", "char_span": [106, 122], "ent_id": "D004342", "tok_span": [22, 24]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [63, 76], "ent_id": "D002220", "tok_span": [11, 15]}], "relation_list": [{"subject": "carbamazepine", "object": "hypersensitivity", "sbj_char_span": [63, 76], "obj_char_span": [106, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [22, 24]}, {"subject": "carbamazepine", "object": "myocarditis", "sbj_char_span": [63, 76], "obj_char_span": [124, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine.", "entity_list": [{"name": "carbamazepine", "ent_type": "Chemical", "char_span": [80, 93], "ent_id": "D002220", "tok_span": [13, 17]}, {"name": "myocarditis", "ent_type": "Disease", "char_span": [37, 48], "ent_id": "D009205", "tok_span": [7, 9]}, {"name": "hypersensitivity", "ent_type": "Disease", "char_span": [20, 36], "ent_id": "D004342", "tok_span": [5, 7]}], "relation_list": [{"subject": "carbamazepine", "object": "hypersensitivity", "sbj_char_span": [80, 93], "obj_char_span": [20, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [5, 7]}, {"subject": "carbamazepine", "object": "myocarditis", "sbj_char_span": [80, 93], "obj_char_span": [37, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "To best of our knowledge this is the second case of fatal carbamazepine induced myocarditis reported in English literature.", "entity_list": [{"name": "carbamazepine", "ent_type": "Chemical", "char_span": [58, 71], "ent_id": "D002220", "tok_span": [12, 16]}, {"name": "myocarditis", "ent_type": "Disease", "char_span": [80, 91], "ent_id": "D009205", "tok_span": [17, 19]}], "relation_list": [{"subject": "carbamazepine", "object": "myocarditis", "sbj_char_span": [58, 71], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [52, 62], "ent_id": "D004409", "tok_span": [9, 13]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [151, 159], "ent_id": "D007980", "tok_span": [33, 36]}, {"name": "parkinsonian disability", "ent_type": "Disease", "char_span": [27, 50], "ent_id": "D020734", "tok_span": [4, 8]}, {"name": "neuropsychiatric-like behaviors", "ent_type": "Disease", "char_span": [100, 131], "ent_id": "D001523", "tok_span": [22, 27]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [151, 159], "obj_char_span": [52, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "As anticipated, animals exhibited a progressive increase in levodopa-induced motor fluctuations, dyskinesia and wearing-off, that correlated with the duration of levodopa therapy.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [97, 107], "ent_id": "D004409", "tok_span": [17, 21]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [162, 170], "ent_id": "D007980", "tok_span": [33, 36]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [60, 68], "ent_id": "D007980", "tok_span": [9, 12]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [60, 68], "obj_char_span": [97, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [17, 21]}, {"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [162, 170], "obj_char_span": [97, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Contrast medium nephrotoxicity after renal artery and coronary angioplasty.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [16, 30], "ent_id": "D007674", "tok_span": [2, 5]}, {"name": "Contrast medium", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D003287", "tok_span": [0, 2]}], "relation_list": [{"subject": "Contrast medium", "object": "nephrotoxicity", "sbj_char_span": [0, 15], "obj_char_span": [16, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "BACKGROUND: Renal dysfunction induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (PTRA).", "entity_list": [{"name": "Renal dysfunction", "ent_type": "Disease", "char_span": [12, 29], "ent_id": "D007674", "tok_span": [2, 4]}, {"name": "CM", "ent_type": "Chemical", "char_span": [68, 70], "ent_id": "D003287", "tok_span": [11, 12]}, {"name": "contrast medium", "ent_type": "Chemical", "char_span": [51, 66], "ent_id": "D003287", "tok_span": [8, 10]}], "relation_list": [{"subject": "CM", "object": "Renal dysfunction", "sbj_char_span": [68, 70], "obj_char_span": [12, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [2, 4]}, {"subject": "contrast medium", "object": "Renal dysfunction", "sbj_char_span": [51, 66], "obj_char_span": [12, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "PURPOSE: To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI).", "entity_list": [{"name": "CM", "ent_type": "Chemical", "char_span": [64, 66], "ent_id": "D003287", "tok_span": [12, 13]}, {"name": "nephrotoxic", "ent_type": "Disease", "char_span": [42, 53], "ent_id": "D007674", "tok_span": [7, 10]}], "relation_list": [{"subject": "CM", "object": "nephrotoxic", "sbj_char_span": [64, 66], "obj_char_span": [42, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "CONCLUSION: In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients.", "entity_list": [{"name": "renal damage", "ent_type": "Disease", "char_span": [98, 110], "ent_id": "D007674", "tok_span": [16, 18]}, {"name": "CM", "ent_type": "Chemical", "char_span": [122, 124], "ent_id": "D003287", "tok_span": [20, 21]}], "relation_list": [{"subject": "CM", "object": "renal damage", "sbj_char_span": [122, 124], "obj_char_span": [98, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Medical and psychiatric outcomes for patients transplanted for acetaminophen-induced acute liver failure: a case-control study.", "entity_list": [{"name": "acute liver failure", "ent_type": "Disease", "char_span": [85, 104], "ent_id": "D017114", "tok_span": [13, 16]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [63, 76], "ent_id": "D000082", "tok_span": [8, 11]}], "relation_list": [{"subject": "acetaminophen", "object": "acute liver failure", "sbj_char_span": [63, 76], "obj_char_span": [85, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "BACKGROUND: Acetaminophen-induced hepatotoxicity is the most common cause of acute liver failure (ALF) in the UK.", "entity_list": [{"name": "ALF", "ent_type": "Disease", "char_span": [98, 101], "ent_id": "D017114", "tok_span": [19, 21]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [77, 96], "ent_id": "D017114", "tok_span": [15, 18]}, {"name": "Acetaminophen", "ent_type": "Chemical", "char_span": [12, 25], "ent_id": "D000082", "tok_span": [2, 5]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [34, 48], "ent_id": "D056486", "tok_span": [7, 9]}], "relation_list": [{"subject": "Acetaminophen", "object": "ALF", "sbj_char_span": [12, 25], "obj_char_span": [98, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [19, 21]}, {"subject": "Acetaminophen", "object": "acute liver failure", "sbj_char_span": [12, 25], "obj_char_span": [77, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [15, 18]}, {"subject": "Acetaminophen", "object": "hepatotoxicity", "sbj_char_span": [12, 25], "obj_char_span": [34, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity_list": [{"name": "chronic liver disease", "ent_type": "Disease", "char_span": [375, 396], "ent_id": "D008107", "tok_span": [85, 88]}, {"name": "ALF", "ent_type": "Disease", "char_span": [245, 248], "ent_id": "D017114", "tok_span": [48, 50]}, {"name": "ALF", "ent_type": "Disease", "char_span": [344, 347], "ent_id": "D017114", "tok_span": [74, 76]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [322, 335], "ent_id": "D000082", "tok_span": [69, 72]}, {"name": "CLD", "ent_type": "Disease", "char_span": [398, 401], "ent_id": "D008107", "tok_span": [89, 91]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [223, 236], "ent_id": "D000082", "tok_span": [43, 46]}], "relation_list": [{"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [223, 236], "obj_char_span": [245, 248], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [48, 50]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [322, 335], "obj_char_span": [245, 248], "rel_type": "chemical-induced disease", "sbj_tok_span": [69, 72], "obj_tok_span": [48, 50]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [223, 236], "obj_char_span": [344, 347], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [74, 76]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [322, 335], "obj_char_span": [344, 347], "rel_type": "chemical-induced disease", "sbj_tok_span": [69, 72], "obj_tok_span": [74, 76]}], "umls_entity_list": []}, {"text": "RESULTS: Acetaminophen-induced ALF patients undergoing LT had a greater severity of pre-LT illness reflected by higher Acute Physiology and Chronic Health Evaluation II scores and requirement for organ support compared with the other two groups.", "entity_list": [{"name": "Acetaminophen", "ent_type": "Chemical", "char_span": [9, 22], "ent_id": "D000082", "tok_span": [2, 5]}, {"name": "ALF", "ent_type": "Disease", "char_span": [31, 34], "ent_id": "D017114", "tok_span": [7, 9]}], "relation_list": [{"subject": "Acetaminophen", "object": "ALF", "sbj_char_span": [9, 22], "obj_char_span": [31, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "entity_list": [{"name": "acetaminophen", "ent_type": "Chemical", "char_span": [13, 26], "ent_id": "D000082", "tok_span": [5, 8]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [98, 111], "ent_id": "D000082", "tok_span": [23, 26]}, {"name": "ALF", "ent_type": "Disease", "char_span": [35, 38], "ent_id": "D017114", "tok_span": [10, 12]}, {"name": "ALF", "ent_type": "Disease", "char_span": [120, 123], "ent_id": "D017114", "tok_span": [28, 30]}, {"name": "CLD", "ent_type": "Disease", "char_span": [130, 133], "ent_id": "D008107", "tok_span": [35, 37]}], "relation_list": [{"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [98, 111], "obj_char_span": [35, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [10, 12]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [98, 111], "obj_char_span": [120, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [28, 30]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [13, 26], "obj_char_span": [35, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 12]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [13, 26], "obj_char_span": [120, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "entity_list": [{"name": "CLD", "ent_type": "Disease", "char_span": [244, 247], "ent_id": "D008107", "tok_span": [63, 65]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [153, 166], "ent_id": "D000082", "tok_span": [31, 34]}, {"name": "ALF", "ent_type": "Disease", "char_span": [230, 233], "ent_id": "D017114", "tok_span": [55, 57]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [208, 221], "ent_id": "D000082", "tok_span": [50, 53]}, {"name": "ALF", "ent_type": "Disease", "char_span": [175, 178], "ent_id": "D017114", "tok_span": [36, 38]}], "relation_list": [{"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [153, 166], "obj_char_span": [230, 233], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [55, 57]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [208, 221], "obj_char_span": [230, 233], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 53], "obj_tok_span": [55, 57]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [153, 166], "obj_char_span": [175, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [36, 38]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [208, 221], "obj_char_span": [175, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 53], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "Two acetaminophen-induced ALF patients reattempted suicide post-LT (one died 8 years post-LT).", "entity_list": [{"name": "acetaminophen", "ent_type": "Chemical", "char_span": [4, 17], "ent_id": "D000082", "tok_span": [1, 4]}, {"name": "ALF", "ent_type": "Disease", "char_span": [26, 29], "ent_id": "D017114", "tok_span": [6, 8]}], "relation_list": [{"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [4, 17], "obj_char_span": [26, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "entity_list": [{"name": "ALF", "ent_type": "Disease", "char_span": [139, 142], "ent_id": "D017114", "tok_span": [22, 24]}, {"name": "CLD", "ent_type": "Disease", "char_span": [234, 237], "ent_id": "D008107", "tok_span": [43, 45]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [189, 202], "ent_id": "D000082", "tok_span": [32, 35]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [117, 130], "ent_id": "D000082", "tok_span": [17, 20]}, {"name": "ALF", "ent_type": "Disease", "char_span": [211, 214], "ent_id": "D017114", "tok_span": [37, 39]}], "relation_list": [{"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [117, 130], "obj_char_span": [211, 214], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [37, 39]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [189, 202], "obj_char_span": [139, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [22, 24]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [189, 202], "obj_char_span": [211, 214], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [37, 39]}, {"subject": "acetaminophen", "object": "ALF", "sbj_char_span": [117, 130], "obj_char_span": [139, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity_list": [{"name": "carrageenan", "ent_type": "Chemical", "char_span": [242, 253], "ent_id": "D002351", "tok_span": [47, 52]}, {"name": "pain", "ent_type": "Disease", "char_span": [229, 233], "ent_id": "D010146", "tok_span": [44, 45]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [299, 302], "ent_id": "D013311", "tok_span": [63, 65]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [54, 62], "ent_id": "D009020", "tok_span": [11, 12]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [283, 297], "ent_id": "D013311", "tok_span": [58, 62]}, {"name": "CNSB002", "ent_type": "Chemical", "char_span": [67, 74], "ent_id": "C401121", "tok_span": [13, 16]}, {"name": "diabetic neuropathy", "ent_type": "Disease", "char_span": [312, 331], "ent_id": "D003929", "tok_span": [68, 70]}, {"name": "inflammation", "ent_type": "Disease", "char_span": [266, 278], "ent_id": "D007249", "tok_span": [56, 57]}], "relation_list": [{"subject": "STZ", "object": "diabetic neuropathy", "sbj_char_span": [299, 302], "obj_char_span": [312, 331], "rel_type": "chemical-induced disease", "sbj_tok_span": [63, 65], "obj_tok_span": [68, 70]}, {"subject": "carrageenan", "object": "inflammation", "sbj_char_span": [242, 253], "obj_char_span": [266, 278], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 52], "obj_tok_span": [56, 57]}, {"subject": "streptozotocin", "object": "diabetic neuropathy", "sbj_char_span": [283, 297], "obj_char_span": [312, 331], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 62], "obj_tok_span": [68, 70]}], "umls_entity_list": []}, {"text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "entity_list": [{"name": "hyperalgesia", "ent_type": "Disease", "char_span": [46, 58], "ent_id": "D006930", "tok_span": [9, 13]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [164, 167], "ent_id": "D013311", "tok_span": [63, 65]}, {"name": "carrageenan", "ent_type": "Chemical", "char_span": [106, 117], "ent_id": "D002351", "tok_span": [37, 42]}, {"name": "neuropathy", "ent_type": "Disease", "char_span": [176, 186], "ent_id": "D009422", "tok_span": [67, 68]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [209, 217], "ent_id": "D009020", "tok_span": [74, 75]}, {"name": "CNSB002", "ent_type": "Chemical", "char_span": [197, 204], "ent_id": "C401121", "tok_span": [70, 73]}], "relation_list": [{"subject": "carrageenan", "object": "hyperalgesia", "sbj_char_span": [106, 117], "obj_char_span": [46, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 42], "obj_tok_span": [9, 13]}, {"subject": "STZ", "object": "hyperalgesia", "sbj_char_span": [164, 167], "obj_char_span": [46, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [63, 65], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Heparin-induced thrombocytopenia: a practical review.", "entity_list": [{"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [16, 32], "ent_id": "D013921", "tok_span": [4, 6]}, {"name": "Heparin", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D006493", "tok_span": [0, 2]}], "relation_list": [{"subject": "Heparin", "object": "thrombocytopenia", "sbj_char_span": [0, 7], "obj_char_span": [16, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Heparin-induced thrombocytopenia (HIT) remains under-recognized despite its potentially devastating outcomes.", "entity_list": [{"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [16, 32], "ent_id": "D013921", "tok_span": [4, 6]}, {"name": "HIT", "ent_type": "Disease", "char_span": [34, 37], "ent_id": "D013921", "tok_span": [7, 9]}, {"name": "Heparin", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D006493", "tok_span": [0, 2]}], "relation_list": [{"subject": "Heparin", "object": "HIT", "sbj_char_span": [0, 7], "obj_char_span": [34, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [7, 9]}, {"subject": "Heparin", "object": "thrombocytopenia", "sbj_char_span": [0, 7], "obj_char_span": [16, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after heparin exposure.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [116, 123], "ent_id": "D006493", "tok_span": [20, 21]}, {"name": "thrombosis", "ent_type": "Disease", "char_span": [58, 68], "ent_id": "D013927", "tok_span": [13, 14]}, {"name": "thrombosis", "ent_type": "Disease", "char_span": [92, 102], "ent_id": "D013927", "tok_span": [17, 18]}, {"name": "HIT", "ent_type": "Disease", "char_span": [0, 3], "ent_id": "D013921", "tok_span": [0, 2]}], "relation_list": [{"subject": "heparin", "object": "thrombosis", "sbj_char_span": [116, 123], "obj_char_span": [58, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [13, 14]}, {"subject": "heparin", "object": "HIT", "sbj_char_span": [116, 123], "obj_char_span": [0, 3], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [0, 2]}, {"subject": "heparin", "object": "thrombosis", "sbj_char_span": [116, 123], "obj_char_span": [92, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "The treatment of HIT mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy, most commonly using a direct thrombin inhibitor.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [60, 67], "ent_id": "D006493", "tok_span": [12, 13]}, {"name": "direct thrombin inhibitor", "ent_type": "Chemical", "char_span": [149, 174], "ent_id": "D000991", "tok_span": [29, 32]}, {"name": "HIT", "ent_type": "Disease", "char_span": [17, 20], "ent_id": "D013921", "tok_span": [3, 5]}], "relation_list": [{"subject": "heparin", "object": "HIT", "sbj_char_span": [60, 67], "obj_char_span": [17, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Direct thrombin inhibitors are appropriate, evidence-based alternatives to heparin in patients with a history of HIT, who need to undergo percutaneous coronary intervention.", "entity_list": [{"name": "Direct thrombin inhibitors", "ent_type": "Chemical", "char_span": [0, 26], "ent_id": "D000991", "tok_span": [0, 3]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [75, 82], "ent_id": "D006493", "tok_span": [11, 12]}, {"name": "HIT", "ent_type": "Disease", "char_span": [113, 116], "ent_id": "D013921", "tok_span": [18, 20]}], "relation_list": [{"subject": "heparin", "object": "HIT", "sbj_char_span": [75, 82], "obj_char_span": [113, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "As heparin remains one of the most frequently used medications today with potential for HIT with every heparin exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [103, 110], "ent_id": "D006493", "tok_span": [18, 19]}, {"name": "HIT", "ent_type": "Disease", "char_span": [88, 91], "ent_id": "D013921", "tok_span": [14, 16]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [3, 10], "ent_id": "D006493", "tok_span": [1, 2]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [185, 192], "ent_id": "D006493", "tok_span": [34, 35]}], "relation_list": [{"subject": "heparin", "object": "HIT", "sbj_char_span": [185, 192], "obj_char_span": [88, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [14, 16]}, {"subject": "heparin", "object": "HIT", "sbj_char_span": [3, 10], "obj_char_span": [88, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [14, 16]}, {"subject": "heparin", "object": "HIT", "sbj_char_span": [103, 110], "obj_char_span": [88, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Abductor paralysis after botox injection for adductor spasmodic dysphonia.", "entity_list": [{"name": "paralysis", "ent_type": "Disease", "char_span": [9, 18], "ent_id": "D010243", "tok_span": [3, 5]}, {"name": "botox", "ent_type": "Chemical", "char_span": [25, 30], "ent_id": "C542870", "tok_span": [6, 8]}, {"name": "adductor spasmodic dysphonia", "ent_type": "Disease", "char_span": [45, 73], "ent_id": "D014826", "tok_span": [10, 18]}], "relation_list": [{"subject": "botox", "object": "adductor spasmodic dysphonia", "sbj_char_span": [25, 30], "obj_char_span": [45, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [10, 18]}], "umls_entity_list": []}, {"text": "OBJECTIVES/HYPOTHESIS: Botulinum toxin (Botox) injections into the thyroarytenoid muscles are the current standard of care for adductor spasmodic dysphonia (ADSD).", "entity_list": [{"name": "Botox", "ent_type": "Chemical", "char_span": [40, 45], "ent_id": "C542870", "tok_span": [13, 15]}, {"name": "ADSD", "ent_type": "Disease", "char_span": [157, 161], "ent_id": "D014826", "tok_span": [41, 43]}, {"name": "adductor spasmodic dysphonia", "ent_type": "Disease", "char_span": [127, 155], "ent_id": "D014826", "tok_span": [32, 40]}], "relation_list": [{"subject": "Botox", "object": "ADSD", "sbj_char_span": [40, 45], "obj_char_span": [157, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [41, 43]}, {"subject": "Botox", "object": "adductor spasmodic dysphonia", "sbj_char_span": [40, 45], "obj_char_span": [127, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [32, 40]}], "umls_entity_list": []}, {"text": "Here we report multiple cases of bilateral abductor paralysis following Botox injections for ADSD, a complication previously unreported.", "entity_list": [{"name": "ADSD", "ent_type": "Disease", "char_span": [93, 97], "ent_id": "D014826", "tok_span": [16, 18]}, {"name": "Botox", "ent_type": "Chemical", "char_span": [72, 77], "ent_id": "C542870", "tok_span": [12, 14]}, {"name": "paralysis", "ent_type": "Disease", "char_span": [52, 61], "ent_id": "D010243", "tok_span": [9, 11]}], "relation_list": [{"subject": "Botox", "object": "ADSD", "sbj_char_span": [72, 77], "obj_char_span": [93, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "RESULTS: From a database of 452 patients receiving Botox, 352 patients had been diagnosed with ADSD.", "entity_list": [{"name": "Botox", "ent_type": "Chemical", "char_span": [51, 56], "ent_id": "C542870", "tok_span": [10, 12]}, {"name": "ADSD", "ent_type": "Disease", "char_span": [95, 99], "ent_id": "D014826", "tok_span": [20, 22]}], "relation_list": [{"subject": "Botox", "object": "ADSD", "sbj_char_span": [51, 56], "obj_char_span": [95, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "The incidence of abductor paralysis after Botox injection for ADSD was 0.34%.", "entity_list": [{"name": "ADSD", "ent_type": "Disease", "char_span": [62, 66], "ent_id": "D014826", "tok_span": [12, 14]}, {"name": "Botox", "ent_type": "Chemical", "char_span": [42, 47], "ent_id": "C542870", "tok_span": [8, 10]}, {"name": "paralysis", "ent_type": "Disease", "char_span": [26, 35], "ent_id": "D010243", "tok_span": [5, 7]}], "relation_list": [{"subject": "Botox", "object": "ADSD", "sbj_char_span": [42, 47], "obj_char_span": [62, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Bilateral abductor paralysis is a rare complication of Botox injections for ADSD, causing difficulty with breathing upon exertion.", "entity_list": [{"name": "Botox", "ent_type": "Chemical", "char_span": [68, 73], "ent_id": "C542870", "tok_span": [13, 15]}, {"name": "paralysis", "ent_type": "Disease", "char_span": [32, 41], "ent_id": "D010243", "tok_span": [6, 8]}, {"name": "ADSD", "ent_type": "Disease", "char_span": [89, 93], "ent_id": "D014826", "tok_span": [17, 19]}], "relation_list": [{"subject": "Botox", "object": "ADSD", "sbj_char_span": [68, 73], "obj_char_span": [89, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.", "entity_list": [{"name": "MitoQ", "ent_type": "Chemical", "char_span": [116, 121], "ent_id": "C476756", "tok_span": [15, 18]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [40, 47], "ent_id": "D003042", "tok_span": [4, 5]}, {"name": "cardiac dysfunction", "ent_type": "Disease", "char_span": [56, 75], "ent_id": "D006331", "tok_span": [7, 9]}, {"name": "Mitochondrial impairment", "ent_type": "Disease", "char_span": [0, 24], "ent_id": "D028361", "tok_span": [0, 2]}], "relation_list": [{"subject": "cocaine", "object": "cardiac dysfunction", "sbj_char_span": [40, 47], "obj_char_span": [56, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [107, 114], "ent_id": "D003042", "tok_span": [18, 19]}, {"name": "cardiac dysfunction", "ent_type": "Disease", "char_span": [123, 142], "ent_id": "D006331", "tok_span": [21, 23]}], "relation_list": [{"subject": "cocaine", "object": "cardiac dysfunction", "sbj_char_span": [107, 114], "obj_char_span": [123, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Taken together, these results extend previous studies and demonstrate that cocaine-induced cardiac dysfunction may be due to a mitochondrial defect.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [75, 82], "ent_id": "D003042", "tok_span": [11, 12]}, {"name": "cardiac dysfunction", "ent_type": "Disease", "char_span": [91, 110], "ent_id": "D006331", "tok_span": [14, 16]}, {"name": "mitochondrial defect", "ent_type": "Disease", "char_span": [127, 147], "ent_id": "D028361", "tok_span": [21, 23]}], "relation_list": [{"subject": "cocaine", "object": "cardiac dysfunction", "sbj_char_span": [75, 82], "obj_char_span": [91, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Trimethoprim-induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [28, 44], "ent_id": "D000743", "tok_span": [7, 10]}, {"name": "Trimethoprim", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D014295", "tok_span": [0, 4]}], "relation_list": [{"subject": "Trimethoprim", "object": "hemolytic anemia", "sbj_char_span": [0, 12], "obj_char_span": [28, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy.", "entity_list": [{"name": "diabetic nephropathy", "ent_type": "Disease", "char_span": [123, 143], "ent_id": "D003928", "tok_span": [23, 25]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [100, 114], "ent_id": "D013311", "tok_span": [17, 21]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetic nephropathy", "sbj_char_span": [100, 114], "obj_char_span": [123, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 (SIS3) were performed in MMECs and in STZ-induced diabetic nephropathy in Tie2-Cre;Loxp-EGFP mice.", "entity_list": [{"name": "STZ", "ent_type": "Chemical", "char_span": [118, 121], "ent_id": "D013311", "tok_span": [28, 30]}, {"name": "diabetic nephropathy", "ent_type": "Disease", "char_span": [130, 150], "ent_id": "D003928", "tok_span": [32, 34]}], "relation_list": [{"subject": "STZ", "object": "diabetic nephropathy", "sbj_char_span": [118, 121], "obj_char_span": [130, 150], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [32, 34]}], "umls_entity_list": []}, {"text": "Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ-induced diabetic nephropathy.", "entity_list": [{"name": "diabetic nephropathy", "ent_type": "Disease", "char_span": [131, 151], "ent_id": "D003928", "tok_span": [31, 33]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [119, 122], "ent_id": "D013311", "tok_span": [27, 29]}], "relation_list": [{"subject": "STZ", "object": "diabetic nephropathy", "sbj_char_span": [119, 122], "obj_char_span": [131, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.", "entity_list": [{"name": "temsirolimus", "ent_type": "Chemical", "char_span": [126, 138], "ent_id": "C401859", "tok_span": [27, 30]}, {"name": "necrotic", "ent_type": "Disease", "char_span": [77, 85], "ent_id": "D009336", "tok_span": [17, 18]}], "relation_list": [{"subject": "temsirolimus", "object": "necrotic", "sbj_char_span": [126, 138], "obj_char_span": [77, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.", "entity_list": [{"name": "angiotensin", "ent_type": "Chemical", "char_span": [73, 84], "ent_id": "D000809", "tok_span": [16, 17]}, {"name": "spironolactone", "ent_type": "Chemical", "char_span": [117, 131], "ent_id": "D013148", "tok_span": [22, 26]}, {"name": "hyperkalemia", "ent_type": "Disease", "char_span": [18, 30], "ent_id": "D006947", "tok_span": [4, 8]}, {"name": "Syncope", "ent_type": "Disease", "char_span": [0, 7], "ent_id": "D013575", "tok_span": [0, 2]}], "relation_list": [{"subject": "spironolactone", "object": "hyperkalemia", "sbj_char_span": [117, 131], "obj_char_span": [18, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.", "entity_list": [{"name": "aldosterone", "ent_type": "Chemical", "char_span": [83, 94], "ent_id": "D000450", "tok_span": [20, 22]}, {"name": "ramipril", "ent_type": "Chemical", "char_span": [146, 154], "ent_id": "D017257", "tok_span": [33, 36]}, {"name": "spiranolactone", "ent_type": "Chemical", "char_span": [64, 78], "ent_id": "D013148", "tok_span": [14, 18]}, {"name": "hyperkalemia", "ent_type": "Disease", "char_span": [13, 25], "ent_id": "D006947", "tok_span": [3, 7]}], "relation_list": [{"subject": "spiranolactone", "object": "hyperkalemia", "sbj_char_span": [64, 78], "obj_char_span": [13, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [3, 7]}, {"subject": "ramipril", "object": "hyperkalemia", "sbj_char_span": [146, 154], "obj_char_span": [13, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Diffuse skeletal pain after administration of alendronate.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [17, 21], "ent_id": "D010146", "tok_span": [3, 4]}, {"name": "alendronate", "ent_type": "Chemical", "char_span": [46, 57], "ent_id": "D019386", "tok_span": [7, 11]}], "relation_list": [{"subject": "alendronate", "object": "pain", "sbj_char_span": [46, 57], "obj_char_span": [17, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "We presented a patient admitted to our out-patient clinic with diffuse skeletal pain after three consecutive administration of alendronate.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [80, 84], "ent_id": "D010146", "tok_span": [14, 15]}, {"name": "alendronate", "ent_type": "Chemical", "char_span": [127, 138], "ent_id": "D019386", "tok_span": [20, 24]}], "relation_list": [{"subject": "alendronate", "object": "pain", "sbj_char_span": [127, 138], "obj_char_span": [80, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.", "entity_list": [{"name": "bacteremia", "ent_type": "Disease", "char_span": [135, 145], "ent_id": "D016470", "tok_span": [25, 27]}, {"name": "nafcillin", "ent_type": "Chemical", "char_span": [74, 83], "ent_id": "D009254", "tok_span": [13, 16]}, {"name": "interstitial nephritis", "ent_type": "Disease", "char_span": [98, 120], "ent_id": "D009395", "tok_span": [19, 22]}, {"name": "Daptomycin", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D017576", "tok_span": [2, 5]}], "relation_list": [{"subject": "nafcillin", "object": "interstitial nephritis", "sbj_char_span": [74, 83], "obj_char_span": [98, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "The role of nitric oxide in convulsions induced by lindane in rats.", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [28, 39], "ent_id": "D012640", "tok_span": [6, 9]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [51, 58], "ent_id": "D001556", "tok_span": [11, 14]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [12, 24], "ent_id": "D009569", "tok_span": [3, 5]}], "relation_list": [{"subject": "lindane", "object": "convulsions", "sbj_char_span": [51, 58], "obj_char_span": [28, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).", "entity_list": [{"name": "L-arginine", "ent_type": "Chemical", "char_span": [22, 32], "ent_id": "D001120", "tok_span": [3, 6]}, {"name": "convulsion", "ent_type": "Disease", "char_span": [184, 194], "ent_id": "D012640", "tok_span": [39, 41]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [213, 220], "ent_id": "D001556", "tok_span": [44, 47]}, {"name": "convulsion", "ent_type": "Disease", "char_span": [114, 124], "ent_id": "D012640", "tok_span": [28, 30]}], "relation_list": [{"subject": "lindane", "object": "convulsion", "sbj_char_span": [213, 220], "obj_char_span": [184, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 47], "obj_tok_span": [39, 41]}, {"subject": "lindane", "object": "convulsion", "sbj_char_span": [213, 220], "obj_char_span": [114, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 47], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).", "entity_list": [{"name": "lindane", "ent_type": "Chemical", "char_span": [204, 211], "ent_id": "D001556", "tok_span": [46, 49]}, {"name": "L-NAME", "ent_type": "Chemical", "char_span": [35, 41], "ent_id": "D019331", "tok_span": [6, 10]}, {"name": "convulsive", "ent_type": "Disease", "char_span": [185, 195], "ent_id": "D012640", "tok_span": [42, 44]}, {"name": "convulsion", "ent_type": "Disease", "char_span": [147, 157], "ent_id": "D012640", "tok_span": [36, 38]}, {"name": "convulsion", "ent_type": "Disease", "char_span": [83, 93], "ent_id": "D012640", "tok_span": [26, 28]}], "relation_list": [{"subject": "lindane", "object": "convulsion", "sbj_char_span": [204, 211], "obj_char_span": [83, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 49], "obj_tok_span": [26, 28]}, {"subject": "lindane", "object": "convulsive", "sbj_char_span": [204, 211], "obj_char_span": [185, 195], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 49], "obj_tok_span": [42, 44]}, {"subject": "lindane", "object": "convulsion", "sbj_char_span": [204, 211], "obj_char_span": [147, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 49], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures.", "entity_list": [{"name": "NO", "ent_type": "Chemical", "char_span": [42, 44], "ent_id": "D009569", "tok_span": [6, 7]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [99, 106], "ent_id": "D001556", "tok_span": [19, 22]}, {"name": "seizures", "ent_type": "Disease", "char_span": [107, 115], "ent_id": "D012640", "tok_span": [22, 23]}], "relation_list": [{"subject": "lindane", "object": "seizures", "sbj_char_span": [99, 106], "obj_char_span": [107, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.", "entity_list": [{"name": "galactose", "ent_type": "Chemical", "char_span": [15, 24], "ent_id": "D005690", "tok_span": [4, 6]}, {"name": "cognitive deficits", "ent_type": "Disease", "char_span": [44, 62], "ent_id": "D003072", "tok_span": [8, 10]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [122, 136], "ent_id": "D013311", "tok_span": [23, 27]}], "relation_list": [{"subject": "galactose", "object": "cognitive deficits", "sbj_char_span": [15, 24], "obj_char_span": [44, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [8, 10]}, {"subject": "streptozotocin", "object": "cognitive deficits", "sbj_char_span": [122, 136], "obj_char_span": [44, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "entity_list": [{"name": "Alzheimer's disease", "ent_type": "Disease", "char_span": [71, 90], "ent_id": "D000544", "tok_span": [10, 14]}, {"name": "glucose", "ent_type": "Chemical", "char_span": [253, 260], "ent_id": "D005947", "tok_span": [44, 45]}, {"name": "dementia", "ent_type": "Disease", "char_span": [50, 58], "ent_id": "D003704", "tok_span": [7, 8]}, {"name": "glucose", "ent_type": "Chemical", "char_span": [191, 198], "ent_id": "D005947", "tok_span": [35, 36]}, {"name": "glucose", "ent_type": "Chemical", "char_span": [213, 220], "ent_id": "D005947", "tok_span": [38, 39]}], "relation_list": [{"subject": "glucose", "object": "Alzheimer's disease", "sbj_char_span": [213, 220], "obj_char_span": [71, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 39], "obj_tok_span": [10, 14]}, {"subject": "glucose", "object": "Alzheimer's disease", "sbj_char_span": [191, 198], "obj_char_span": [71, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 36], "obj_tok_span": [10, 14]}, {"subject": "glucose", "object": "Alzheimer's disease", "sbj_char_span": [253, 260], "obj_char_span": [71, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.", "entity_list": [{"name": "streptozotocin", "ent_type": "Chemical", "char_span": [119, 133], "ent_id": "D013311", "tok_span": [24, 28]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [143, 146], "ent_id": "D013311", "tok_span": [31, 33]}, {"name": "galactose", "ent_type": "Chemical", "char_span": [58, 67], "ent_id": "D005690", "tok_span": [9, 11]}, {"name": "cognitive deficits", "ent_type": "Disease", "char_span": [97, 115], "ent_id": "D003072", "tok_span": [21, 23]}], "relation_list": [{"subject": "streptozotocin", "object": "cognitive deficits", "sbj_char_span": [119, 133], "obj_char_span": [97, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [21, 23]}, {"subject": "STZ", "object": "cognitive deficits", "sbj_char_span": [143, 146], "obj_char_span": [97, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [21, 23]}, {"subject": "galactose", "object": "cognitive deficits", "sbj_char_span": [58, 67], "obj_char_span": [97, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits.", "entity_list": [{"name": "galactose", "ent_type": "Chemical", "char_span": [18, 27], "ent_id": "D005690", "tok_span": [4, 6]}, {"name": "cognitive deficits", "ent_type": "Disease", "char_span": [152, 170], "ent_id": "D003072", "tok_span": [30, 32]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [136, 139], "ent_id": "D013311", "tok_span": [23, 25]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [70, 73], "ent_id": "D013311", "tok_span": [11, 13]}], "relation_list": [{"subject": "STZ", "object": "cognitive deficits", "sbj_char_span": [70, 73], "obj_char_span": [152, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [30, 32]}, {"subject": "galactose", "object": "cognitive deficits", "sbj_char_span": [18, 27], "obj_char_span": [152, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [30, 32]}, {"subject": "STZ", "object": "cognitive deficits", "sbj_char_span": [136, 139], "obj_char_span": [152, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.", "entity_list": [{"name": "galactose", "ent_type": "Chemical", "char_span": [5, 14], "ent_id": "D005690", "tok_span": [1, 3]}, {"name": "glucose hypometabolism", "ent_type": "Disease", "char_span": [172, 194], "ent_id": "D018149", "tok_span": [25, 29]}, {"name": "AD", "ent_type": "Disease", "char_span": [198, 200], "ent_id": "D000544", "tok_span": [30, 31]}, {"name": "cognitive deficits", "ent_type": "Disease", "char_span": [137, 155], "ent_id": "D003072", "tok_span": [21, 23]}], "relation_list": [{"subject": "galactose", "object": "cognitive deficits", "sbj_char_span": [5, 14], "obj_char_span": [137, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 3], "obj_tok_span": [21, 23]}], "umls_entity_list": []}]